

TRANSLATION FROM GERMAN

(12) WORLD ORGANIZATION OF INTELLECTUAL PROPERTY INTERNATIONAL APPLICATION PUBLISHED PURSUANT TO THE PATENT COOPERATION TREATY (PCT)

(19) World Organization for Intellectual Property			
International Office			
(43) International Publication Date:	PCT	(10) International Publication Number:	
18 July 2002		WO 02/055693 A2	
(51) International Patent Classification ⁷ : C12N 15/11		LIMMER,	Stephan
(21) International Application Number: PCT/EP02/00152		[GERMANY/GERMANY];	
(22) International filing date: 9 January 2002		Universitätsstrasse 30, 95447 Bayreuth	
(25) Submission language German		(GERMANY). ROST, Sylvia	
(26) Publication language German		[GERMANY/GERMANY];	
(30) Priority data:		Universitätsstrasse 30, 95447 Bayreuth	
101 00 586.5 9 January 2001 GERMANY		(GERMANY). HADWIGER, Philipp	
101 55 280.7 26 October 2001 GERMANY		[GERMANY/GERMANY; Universitätsstrasse	
101 58 411.3 29 November 2001 GERMANY	(74)	30, 95447 Bayreuth (GERMANY).	
101 60 151.4 7 December 2001 GERMANY		Attorneys: GASSNER, Rolfgang;	
(71) Applicant: <i>(for all designated states, except US):</i>		Nägelsbachstrasse 49a, 91052 Erlangen	
RIBOPHARMA AG		(GERMANY).	
[GERMANY/GERMANY]; Universitätsstrasse		(81) Designated states <i>(national)</i> : AE, AG,	
30, 95447 Bayreuth (GERMANY).		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,	
(72) Inventor and		BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,	
(75) Inventor/Applicant <i>(for US only)</i> : KREUTZER,		DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
Roland [GERMANY/GERMANY];		GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,	
Universitätsstrasse 30, 95447 Bayreuth		KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,	
(GERMANY).		MD, MG, MK, MN, MW, MX, MZ, NO, NZ,	
		OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,	
		SK, SL, TJ, TM, TRADENAME, TR, TT, TZ,	
		UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.	

BEST AVAILABLE COPY

(84) Regional states (*regional*): ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR). OAPI Patent (BR, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


– without International Search Report and republished on receipt of the report

Refer to the "Guidance Notes on Codes and Abbreviations" at the beginning of each regular issue of the PCT Gazette for explanation of the two-letter codes and other abbreviations..

(54) Title: **METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE**

(57) Abstract

The invention relates to a method for inhibiting the expression of a target gene in a cell, comprising the following steps: introduction of an amount of at least one dual-stranded ribonucleic acid (dsRNA I) which is sufficient to inhibit the expression of the target gene. The dsRNA I has a dual-stranded structure formed by a maximum of 49 successive nucleotide pairs. One strand (as1) or at least one section of the one strand (as1) of the dual-stranded structure is complementary to the sense strand of the target gene. The dsRNA has an overhang on the end (E1) of dsRNA I formed by 1 – 4 nucleotides.



Variant 1

Variant 2

METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE

The invention concerns a method, an application and a medicament for inhibition of expression of a target gene.

Methods to inhibit expression of genes of medical or biotechnological interest by means of a double-strand ribonucleic acid (dsRNA) are known from WO 99/32619 and WO 00/44895. The known methods are highly effective. But there is also a requirement to further increase their efficiency.

The task of the present invention is to eliminate the shortcomings according to the prior art. In particular, a method, an application and a medicament are to be offered, with which even more efficient inhibition of expression of the target gene is attainable.

This task is solved by the features of Claims 1, 41 and 81. Advantageous embodiments are apparent from the features of Claims 2 to 40, 42 to 80 and 82 to 120.

With the features claimed according to the invention, a drastic increase in the effectiveness of inhibition of expression of the target gene in vitro and in vivo is surprisingly achieved. By the special design of the ends of the dsRNA, both their efficiency in mediating the inhibiting effect on expression of the target gene and their stability can be deliberately influenced. By increasing the stability, the effective concentration in the cell is increased.

Target gene according to the invention is understood to mean the DNA strand of the double-strand DNA in the cell that is complementary to a DNA strand, including all transcribed regions that serve for transcription as matrix. The target gene is therefore generally the "sense" strand. The one strand or anti-sense strand (as1) can be complementary to an RNA transcript formed during expression of the target gene or its processing product, for example, an mRNA. Insertion is understood to mean uptake in the cell. Uptake can occur by the cell itself; it also can be mediated by auxiliaries or aids. "Overhang" is understood to mean a terminal single-strand overhang that does not have paired nucleotides, according to Watson and Crick. "Double-strand

structure” is understood to mean a structure, in which the nucleotides of the individual strands are essentially paired according to Watson and Crick. A double-strand structure in the context of the present invention can also have individual mismatches.

According to a particularly advantageous embodiment, the dsRNA I has the overhang on the 3' end of one strand or the anti-sense strand as1 and/or on the 3' end of the other end or sense strand ss1. The dsRNA I can also be formed smoothly on one end. In this case, the smooth end is advantageously situated on the side of dsRNA I that has the 5' end of one strand (anti-sense strand; as1). In this form, the dsRNA I, on the one hand, has very good efficiency and, on the other hand, high stability in a living organism. The overall in vivo efficiency is excellent. The overhang is expediently formed from 1 to 4 nucleotides, preferably from 1 or 2 nucleotides.

According to another embodying feature, the efficiency of the method can be further increased if at least one additional dsRNA II, formed according to the dsRNA I according to the invention, is inserted into the cell, in which the one strand or at least a section of one strand of the double-strand structure of dsRNA I is complementary to a first region of the sense strand of the target gene, and in which an additional strand or at least a section of the additional strand of the double-strand structure of the additional dsRNA II is complementary to a second region of sense strand of the target gene. Inhibition of expression of the target gene is significantly increased in this case. The first and second region can overlap in sections, abut each other, or also be spaced from each other.

It has also proven advantageous if the dsRNA I and/or the additional dsRNA II have a length of less than 25 consecutive nucleotide pairs. A length in the range between 19 and 23 nucleotide pairs has proven to be particularly effective. The efficiency can be further increased if single-strand overhangs of 1 to 4 nucleotides are present on the double strands preferably formed from 19 to 23 nucleotide pairs.

The target gene, according to an additional embodying feature, can have the sequences SQ001 to SQ140, given in the enclosed sequence protocol. It can also be chosen from the following groups: oncogene, cytokine gene, id-protein gene, prion gene, genes for expression of

angiogenesis-inducing molecules, adhesion molecules and cell surface receptors. genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules, as well as genes for expression of the EGF receptors. The target gene can be the MDR1 gene, in particular. In this context, one of the existing sequences SQ141-173 or a combined dsRNA I/II from antisense (as) and sense sequences (ss) that go together can be used.

According to an additional advantageous embodying feature, expression is inhibited according to the principle of RNA interference.

The target gene is expediently expressed in pathogenic organisms, preferably in plasmodia. It can be a component of a virus or viroid, especially a human pathogenic virus or viroid. The virus or viroid can also be an animal or plant pathogenic virus or viroid.

According to another embodying feature, it is prescribed that the unpaired nucleotides be substituted by nucleoside thiophosphates.

At least one end of the dsRNA I/II can be modified, in order to counteract degradation in the cell or dissociation in the individual strand. Advantageously, cohesion caused by the complementary nucleotide pairs of the double-strand structure is increased by at least one chemical length. The chemical length can be formed by a covalent or ionic bond, a hydrogen bridge bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal ion coordination. It has also proven expedient and to increase stability if the chemical link is formed in the vicinity of one end. Additional advantageous embodiments with respect to chemical linking can be deduced from the features of Claims 24 to 30, without requiring a further explanation for this.

The dsRNA I/II can be incorporated particularly easily in the cell if it is enclosed in micellar structures, advantageously in liposomes. It has also proven advantageous for transport of dsRNA I/II into the cell that it is bonded to at least a viral sheath protein, originating from a virus, derived from a virus or synthetically produced, associated with the sheath protein or

enclosed by it. The sheath protein can be derived from polyoma virus. The sheath protein can contain, in particular, the virus protein 1 and/or the virus protein 2 of polyoma virus. According to another embodiment, it is prescribed that, during formation of a capsid or capsid-like structure from the sheath protein, one side face the interior of the capsid or capsid-like structure. It is also advantageous that the one strand of dsRNA I/II (as1/2) is complementary to the primary or processed RNA transcript of the target gene. The cell can be a vertebrate cell or a human cell.

It has also been found that the dsRNA I/II can advantageously be administered already in an amount of, at most, 5 mg/kg of body weight per day to a mammal, preferably a human. Even in this low dose, an excellent efficiency is achieved.

It has surprisingly been found that the dsRNA I/II can be taken up in a buffer solution for administration and then administered orally or by injection or infusion intravenously, intratumorally, by inhalation or intraperitoneally.

The use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in the cell is also proposed according to the invention, in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (anti-sense strand; as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of the target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

According to an additional stipulation of the invention, a medicament for inhibiting the expression of a target gene in a cell is proposed, containing a double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of a target gene, in which the dsRNA I has a double-strand structure from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

The preceding comments are referred to for the further advantageous embodiment of dsRNA I/II.

The invention is further explained on an example below, with reference to the drawings and practical examples. In the drawings:

- Fig. 1a, b schematically depicts a first and second double-strand RNA and
- Fig. 2 schematically depicts a target gene,
- Fig. 3 depicts relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (first experiment),
- Fig. 4 shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (second experiment),
- Fig. 5 shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (third experiment),
- Fig. 6 shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (fourth experiment),
- Fig. 7 shows relative YFP fluorescence after application of different dsRNA in HeLa-S3 cells (fifth experiment),
- Fig. 8 shows fluorescence micrographs of NIH/3T3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 9 shows fluorescence micrographs of HeLa-S3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 10 shows gel electrophoretic separation of S1 after incubation in mouse serum,

- Fig. 11 shows gel electrophoretic separation of S1 after incubation in human serum,
- Fig. 12 shows gel electrophoretic separation of S7 after incubation in mouse serum,
- Fig. 13 shows gel electrophoretic separation of S7 after incubation in human serum,
- Fig. 14 shows gel electrophoretic separation of K3 after incubation in mouse serum,
- Fig. 15 shows gel electrophoretic separation of PKC1/2 after incubation in mouse serum,
- Fig. 16 shows gel electrophoretic separation of S1A/S4B after incubation in human serum,
- Fig. 17 shows gel electrophoretic separation of K2 after incubation in human serum and
- Fig. 18 shows GFP-specific immunoperoxidase staining on kidney paraffin sections of transgenic GFP mice,
- Fig. 19 shows GFP-specific immunoperoxidase staining on heart paraffin sections of transgenic GFP mice,
- Fig. 20 shows GFP-specific immunoperoxidase staining on pancreas paraffin sections transgenic GFP mice,
- Fig. 21 shows Western blot analysis of GFP expression in plasma,
- Fig. 22 shows Western blot analysis of GFP expression in the kidneys,
- Fig. 23 shows Western blot analysis of GFP expression in the heart,
- Fig. 24 shows Western blot analysis of EGFR expression in U-87 MG glioblastoma cells,

Fig. 25a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 74 hours,

Fig. 25b shows quantification of the band according to Fig. 25a, in which the averages from two values are shown,

Fig. 26a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 48 hours,

Fig. 26b shows quantification of the band according to Fig. 26a, in which the average values from the two values are shown,

Fig. 27 shows a comparative depiction of a transmitted light and fluorescence photomicrograph of a transfection with 175 nM dsRNA (sequence R1 in Table 4).

The double-strand ribonucleic acids dsRNA I and dsRNA II, depicted schematically in Figures 1a and 1b, each have a first end E1 and a second end E2. The first and second ribonucleic acids dsRNA I/dsRNA II have single-strand sections formed from about 1 to 4 unpaired nucleotides on their two ends E1 and E2. Two possible variants are shown (variants 1 and 2), in which variant 2 has a smooth end (E2). The smooth ends, however, can also lie on the other end (E1) in another variant.

A target gene situated on DNA is schematically shown in Fig. 2. The target gene is made recognizable by a black bar. It has a first region B1 and a second region B2.

Each strand of the first dsRNA I (as1) and the second dsRNA II (as2) is complementary to the corresponding region B1 or B2 on the target gene.

Expression of the target gene is then inhibited with particular efficiency, if the dsRNA I/dsRNA II has single strand sections on its ends E1, E2. The single-strand sections can be formed both on

strand as1 or as2 and on the counterstrand (ss1 or ss2) or on strand as1, as2 and on the counterstrand.

The regions B1 and B2, as shown in Fig. 2, can be spaced from each other. However, they can also be adjacent to each other or overlap.

I. Inhibition of Expression of the YFP Gene in Fibroblasts:

Double-strand RNAs (dsRNAs) were prepared from sequences of the yellow fluorescent protein (YFP), a variant of the GFP (green-fluorescent protein) of the alga *Aequoria victoria* and microinjected into fibroblasts, together with a YFP-coding plasmid. Fluorescence reduction was then evaluated relative to cells without dsRNA.

Experimental Protocol:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and ordinary chemical methods, the RNA single strands apparent from the sequence protocols SQ148, 149 and SQ159 and the single strands complementary to them were synthesized. Purification then occurred by HPLC. Hybridization of the single strands to a double-strand occurred by heating the stoichiometric mixture of single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 90°C and subsequent cooling over 6 hours to room temperature. The dsRNAs so obtained were microinjected into the test cell.

The murine fibroblast cell line NIH/3T3, ECACC no. 930615624 (European Collection of Animal Cell Cultures) served as test system for these cell culture experiments. The plasmid pcDNA-YFP was used for microinjections, which contained an 800 bp large Bam HI/Eco RI-YFP fragment in the corresponding restriction cleavage sites of the vector pcDNA3. Expression of YFP was investigated under the influence of simultaneously cotransfected sequence-homologous dsRNA. Evaluation occurred under the fluorescence microscope, at the earliest, 3 hours after injection, with reference to green fluorescence.

Preparation of the Cell Cultures:

Cultivation of the cells occurred in DMEM with 4.5 g/L glucose, 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin/streptomycin (100 IU/100 µg/mL, Biochrom) in an incubator under a 5% CO₂ atmosphere at 37°C. The cells underwent passage every 3 days, in order to keep them in the exponential growth phase. A day before performance of transfection, the cells were trypsinized (10 × trypsin/TEDTA, Biochrom) and inoculated with a cell density of 0.73×10^5 cells into coated petri dishes (CORNING® Cell Culture Dish, 35 mM, Corning Inc., Corning, USA). The petri dishes were incubated with 0.2% gelatin (Biochrom) for at least 30 minutes at 37°C, washed once with PBS and immediately used for seeding of the cells. To permit recovery of individual cells, CELLocate coverslips from the Eppendorf company were used (square size 55 µm).

Microinjection:

To perform microinjection, the petri dishes were removed from the incubator for about 10 minutes. About 50 cells were microinjected per dish and batch (FemtoJet; Mikromanipulator 5171, Eppendorf). Glass capillaries (FemtoTip) from the Eppendorf company with a tip inside diameter of 0.5 µm were used for microinjection. The injection time was 0.8 seconds and the pressure 30 hPa. The microinjections were conducted on an Olympus IX50 microscope with a fluorescence device. 14 mM NaCl, 3 mM KCl, 10 mM KH₂PO₄, pH 7.0, was used as injection buffer, which contains 0.01 µg/mL pcDNA-YFP. To check successful microinjection, 0.08% (w/v) Dextran-70000 coupled Texas-Red (Molecular Probes, Leiden, Netherlands) was added to the injection solution. To investigate inhibition of the YFP expression with specific dsRNA, dsRNAs were added to the injection solution: batch 1: 0.1 µM dsRNA (sequence protocol SQ148/149); batch 2: 0.1 µM dsRNA (sequence protocol SQ148/159); batch 3: without RNA. After microinjection, the cells were incubated for at least three more hours in the incubator. The intracellular YFP fluorescence was then evaluated on the microscope: simultaneously red and green-fluorescent cells: microinjection was successful, no inhibition of YFP expression by dsRNA was observed; or control cells were involved, in which no dsRNA were injected; only red fluorescent cells: microinjection was successful, the dsRNA inhibits YFP expression.

Results:

At a dsRNA concentration of 0.1 μ M, a significantly increased inhibition or expression of the YFP gene in fibroblasts could be observed during use of dsRNA with the protruding single-strand regions (sequence protocol SQ148/159) on both 3' ends by two nucleotides each, in comparison with dsRNA without protruding single-strand ends (Table 1).

The use of short dsRNA molecules, containing 19-25 base pairs with overhangs of a few, preferably 1 to 3, non-base-paired, single-strand nucleotides, therefore permits comparatively stronger inhibition of gene expression in mammal cells than the use of dsRNAs with the same number of base pairs without the corresponding single-strand overhangs at the same RNA concentration.

Batch	Name	Sequence protocol number	0.1 μ M
1	S1A/ S1B	SQ148 SQ149	+
2	S1A/ S4B	SQ148 (protruding end) SQ159	+++
3		without RNA	-

Table 1: The symbols show the relative percentage of non-fluorescent or weakly green fluorescent cells (+++ > 90%; ++ 60-90%; + 30-60%; - < 10%).

II. Inhibition of Gene Expression with Target Gene in Cultivated HELA-S3 Cells and Mouse Fibroblasts by dsRNA:

The efficiency of inhibition of YFP expression after transient transfection of a YFP-coding plasmid based on RNA interference with dsRNAs can be modulated by the configuration of the 3' ends in the length of the base-paired regions.

Practical Example:

To detect the efficiency of dsRNA during specific inhibition of gene expression, transiently transfected NIH/3T3 cells (fibroblasts from NIH Swiss mouse embryo, ECCAC (European Collection of Animal Cell Cultures) no. 93061524) and HELA-S3 (human cervical carcinoma cells, DSMZ (German Collection of Microorganisms and Cell Cultures) no. ACC 161) were used. The plasmid pcDNA-YFP was used for transfection, which contains an 800 bp Bam HI/Eco RI-YFP fragment in the corresponding cleavage sites of the vector pcDNA3. Double-strand RNAs derived from the sequence of the yellow fluorescent protein (YFP) were produced and transiently transfected with the plasmid pcDNA-YFP in the fibroblasts (the employed specific dsRNAs are complementary in their anti-sense strands to the corresponding sections of the gene sequences above YFP and GFP). After 48 hours, the fluorescence reduction was quantified. Cells that were transfected either only with pcDNA-YFP or with pcDNA-YFP and a controlled dsRNA (not derived from the YFP sequence) functioned as controls.

Experimental Protocol:

dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA individual strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred by means of HPLC. The column NucleoPac PA-100, 9 × 250 mM, from the Dionex company was used; 20 mM tris, 10 mM NaClO₄, pH 6.8, 10% acetonitrile as low salt buffer and 20 mM Tris, 400 mM NaClO₄, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

Seeding of the Cells:

All cell culture work was conducted under sterile conditions in a corresponding work bench (HS18, Hera Safe, Kendro, Heraeus). Cultivation of NIH/3T3 cells and HELA-S3 occurred in an incubator (CO₂ incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO₂ and saturated atmospheric humidity in DMEM (Dulbecco's Modified Eagle Medium, Biochrom), for the mouse fibroblasts, and Ham's F12 for the HELA cells with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells underwent passage every 3 days. 24 hours before the forming transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of 1.0×10^4 cells/recess into a 96-well plate (Multiwell dishes 96-well flat bottom, Labor Schubert & Weiss GmbH) in 150 µL growth medium.

Performance of Transient Transfection:

Transfection was conducted with Lipofectamine PlusTM reagent (Life Technologies) according to the information of the manufacturer. 0.15 µg pcDNA-YFP plasmid was introduced per well. The total transfection volume was 60 µL. 3-fold samples were used in each case. Plasmid DNA was first complexed, together with dsRNA. For this purpose, the plasmid DNA and the dsRNA were diluted in a serum-free medium and 1 µL PLUS reagent was used per 0.1 µg plasmid DNA (in a volume of 10 µL) and, after mixing for 15 minutes at room temperature, they were incubated. During incubation, 0.5 µL Lipofectamine was diluted in a total of 10 µL serum-free medium per 0.1 µg plasmid DNA, thoroughly mixed, added to the plasmid/dsRNA/PLUS mixture and incubated for another 15 minutes. During incubation, a medium change was conducted. For this purpose, the cells were washed once with 200 µL serum-free medium and then with 40 µL serum-free medium and then incubated further in the incubator, up to addition of DNA/dsRNA/PLUS/Lipofectamine. After addition of 20 µL DNA/dsRNA/PLUS/Lipofectamine per well, the cells were incubated for 2.5 hours in the incubator. After incubation, the cells were then washed once with 200 µL growth medium and incubated for 24 hours until detection of the fluorescence in 200 µL growth medium in the incubator.

Detection of Fluorescence:

24 hours after the last medium change, the fluorescence of the cells was photographed on the fluorescence microscope (IX50-S8F2, fluorescence unit U-ULS100Hg, burner U-RFL-T200, Olympus) with a USH-I02D mercury lamp (USHIO Inc., Tokyo, Japan), equipped with a WIB fluorescence cube and a digital CCD camera (Orca IIIIm, Hamamatsu and C4742-95 camera controller). Evaluation of the fluorescence recording occurred with the analysis software 3.1 (Soft Imaging System GmbH, Germany). In order to relate the YFP fluorescence to cell density, a cell nucleus staining was carried out (Hoechst staining). For this purpose, the cells were first fixed for 5 in 100 μ L methycarnoy (75% methanol, 25% glacial acetic acid) and then again for 10 minutes in methycarnoy. After air drying, the fixed cells were incubated for 30 minutes in the dark with 100 μ L per well of Hoechst die (75 ng/mL). After washing twice with PBS (PBS Dulbecco w/o Ca^{2+} , M^{2+} , Biochrom), the Hoechst-stained cells were photographed under the fluorescence microscope (Olympus, WU fluorescence cube for Hoechst).

Figures 3 to 9 show the results on inhibition of YFP expression by dsRNA in the cultivated cells:

The effects of YFP-specific dsRNAs and control dsRNAs on YFP expression in NIH/3T3 mouse fibroblasts after transient transfection are summarized in Figures 3, 4, 5 and 6. The experiments were run as described in the experimental protocol. The concentration of dsRNA refers to the concentration in the medium during the transfection reaction. The designations for the dsRNAs can be gathered from Table 2. The relative fluorescence per image section in area percent is shown. 3 different image sections were evaluated per well. The averages are obtained from the 3-fold batches.

The specific inhibition of YFP gene expression by dsRNAs in HELA-S3 cells is shown in Figures 7 and 9. The inhibiting effect of differently configured dsRNA constructs (Table 2) in different concentrations on expression of YFP in HELA cells is shown in Fig. 7. Fig. 8 shows representative fluorescence microscope recordings of NIH/3T3 mouse fibroblasts transiently transfected with YFP without dsRNA and with dsRNA specifically directed against YFP ($\times 100$ magnification).

8A: YFP controls

8B: S1, 10 nM

8C: S4, 10 nM
8D: S7, 10 nM
8E: S7/S11, 1 nM
8F: S7/S12, 1 nM

Fig. 9 shows representative fluorescence microscope recordings of HELA-3S cells transiently transfected with YFP without dsRNA and with dsRNAs specifically directed against YFP ($\times 100$ magnification).

9A: K2-controls, 10 nM
9B: S1, 10 nM
9C: S4, 10 nM
9D: S7, 10 nM
9E: S7/11, 1 nM
9F: S7/12, 1 nM
9G: S1A/S4B, 10 nM
9H: YFP controls

Results:

Fig. 3 shows that YFP expression after transient cotransfection of mouse fibroblasts with the YFP plasmid and dsRNAs specifically directed against the YFP sequence is inhibited with particular efficiency when the 3' ends of the regions containing 22 and 19 base pairs of the dsRNAs have single-strand sections of two nucleotides (nt). Whereas the dsRNA S1 with smooth 3' ends at a concentration of 1 nM (referred to the concentration in the cell culture medium during performance and transfection) exhibits no inhibiting effect on YFP expression, the dsRNAs S7 (19 nucleotide pairs) and S4 (24 nucleotide pairs), each with 2 nt overhangs on both 3' ends, inhibit the YFP expression by 50 or by 70% in comparison with the corresponding control dsRNAs K3 and K2. At a concentration of 10 nM, the dsRNA denoted S1 with smooth ends inhibits YFP expression by about 65%, whereas inhibition of YFP expression by the dsRNA S4 is about 94% (Fig. 4). The inhibiting effects of the dsRNAs denoted S4 and S7 is concentration-dependent (Figures 3 and 4, see also Fig. 7).

Fig. 4 shows that, for efficient suppression of YFP gene expression, the single-strand structure is not necessary on both 3' ends (on the sense and anti-sense strand). To achieve the most effective possible inhibition of YFP expression, only the 2 nt overhang on the 3' end is necessary on the anti-sense strand. Inhibition of YFP expression at a concentration of 1 nM in the two dsRNAs S4 (with 2 nt overhangs on both 3' ends) and S1A/S4B (with the 2 nt overhang on the 3' end of the anti-sense strand) lies at about 70%. On the other hand, if the 2 nt overhang is situated on the 3' end of the sense strand (and the 3' end of the anti-sense strand carries no single-strand region), inhibition of YFP gene expression is only 50%. Similarly, inhibition at higher concentrations is much better, if at least the 3' end of the anti-sense strand carries a 2 nt overhang.

A more distinct inhibition of YFP expression is achieved, if the base-paired region has 21 nucleotide pairs instead of 22 (S1 and S4), 20 (S13 and S13/14) or 19 (S7) (Figures 5, 6 and 7). Inhibition of YFP expression by S1 (22 base pairs with smooth ends) in a concentration of 5 nM is about 40%, whereas inhibition by S7/S12 (21 base pairs with smooth ends), also with 5 nM, lies at about 92%. If the dsRNA with 21 base pairs also has a 2 nt overhang on the anti-sense strand 3' end (S7/S11), inhibition lies at ~ 97% (compared with ~ 73% inhibition with S4 and ~ 70% inhibition with S7).

III. Investigation of Serum Stability of Double-Strand RNA (dsRNA):

The objective is to increase the effectiveness found the cell cultures of inhibition of gene expression of target genes mediated by dsRNA for use in vivo. This is achieved by improved stability of the dsRNAs in serum and by an extended residence time of the molecule in the circulation and the increased effective concentration of the functional molecules related to this, resulting from improved stability.

Practical Example:

The serum stability of dsRNAs that inhibit GFP expression was tested in vivo in murine and human serum.

Experimental Protocol:

Incubation with human or murine serum with the corresponding dsRNA occurred at 37°C. 85 µL serum was incubated with 15 µL 100 µM dsRNA. After specified incubation times (30 minutes, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h), the samples were frozen at -80°C. dsRNA without serum (+ 85 µL ddH₂O) and dsRNA at time 0 were used as control.

For isolation of the dsRNA from the incubation charge, which occurred on ice, 400 µL with 0.1% SDS was added to the charges and these are subjected to phenol extraction: 500 µL phenol:chloroform:isoamyl alcohol (IAA, 25:24:1, Roti®-Phenol, Roth, Karlsruhe) was added per charge and vortexed for 30 seconds at the highest stage (Vortex Genie-2; Scientific Industries). After 10 minutes of incubation on ice, phase separation occurred by centrifuging at 12,000 × g, 4°C for 10 minutes (Sigma 3K30, Rotor 12131-H). The upper aqueous phase (about 200 µL) was taken off and subjected first to DNase I and the proteinase K digestion: addition of 20 µL 10-fold DNase I buffer (100 mM Tris, pH 7.5, 25 mM MgCl₂, 1 mM CaCl₂) and 10 U DNase I (D7291, Sigma-Aldrich), 30 minutes incubation at 37°C, addition of 6 U DNase I again and incubation for another 20 minutes at 37°C, addition of 5 µL proteinase K (20 mg/mL, 04-1075, Peqlab, Germany) and 30 minutes incubation at 37°C. Phenol extraction was then conducted. For this purpose, 500 µL phenol:chloroform:IAA (25:24:1) was added, vortexed at the highest stage for 30 seconds, 10 minutes for 12000 × g, 4°C, centrifuged, the supernatant taken off and mixed in succession with 40 µL 3M Na-Ac (sodium acetate), pH 5.2, and 1 mL 100% EtOH, mixed thoroughly in the meantime and precipitated for at least 1 hour at -80°C. The precipitate was pelletized by centrifuging at 12000 × g for 30 minutes and 4°C, washed with 70% EtOH and recentrifuged (10 minutes, 12000 × g, 4°C). The air dried pellet was taken up in 30 µL RNA gel application buffer (7 M urea, 1 × TBE (0.09 M tris-borate, 0.002 M EDTA

(ethylenediaminetetraacetate), 0.02% (w/v) bromophenol blue, 0.02% (w/v) xylene cyanol) and stored at -20°C until gel application.

For characterization of the dsRNA, an analytical, denaturing polyacrylamide gel electrophoresis (analytical PAGE) was conducted. The urea gels were prepared right before the run: 7 M urea (21 g) was dissolved during agitation in 25 mL 40% aqueous acrylamide/bisacrylamide stock solution (Rotiphoresis gel, A515.1, Roth) and 5 μ L 10 \times TBE (100 g Tris, 55 g boric acid, 9.3 g EDTA per L distilled water) and made up to 50 μ L with distilled water. Right before pouring, 50 μ L TEMED (N,N,N',N'-tetramethylethylenediamine) and 500 μ L 10% APS (ammonium peroxodisulfate) were added. After polymerization, the gel was introduced to a vertical electrophoresis apparatus (Merck, Darmstadt) and a prerun was conducted for 30 minutes at a constant 40 mA current intensity. As run buffer, 1 \times TBE buffer was used. Before application onto the gel, the RNA samples were heated for 5 minutes at 100°C, cooled on ice and centrifuged for 20 seconds in a table-top centrifuge (Eppendorf, minispin). 15 μ L was applied to the gel. The run occurred for about 2 hours at a constant current of 40 mA. After the run, the gel was stained for 30 minutes at RT (room temperature) with Stains all stain solution (20 mL Stains all stock solution dissolved in 200 mL formamide) mixed with 200 mL distilled water and 180 mL formamide) and the background staining eliminated after rinsing in distilled water for 45 minutes. The gels were photographed with the photo documentation system Image Master VDS from Pharmacia.

Figures 10 to 17 show the serum stability of dsRNA after incubation with human and murine serum and subsequent electrophoretic separation in 20% 7 M urea gel.

Fig. 10: Incubation of S2 (0-22-0) in mouse serum

1. at time 0 (without serum)
2. at time 0
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours

7. for 12 hours
8. 2 μL 100 μM S1 without incubation
- S1A) Sense strand S1 (10 μL 20 μM S1A)
- S1B) Anti-sense strand S1 (10 μL 20 μM S1B)

Fig. 11: Incubation of S1 (0-22-0) in human serum

1. 2 μL 100 μM S1 untreated (without incubation)
2. for 30 minutes
3. for 2 hours
4. for 4 hours
5. for 6 hours
6. for 8 hours
7. for 12 hours
8. for 24 hours
- S1A) Sense strand S1 (10 μL 20 μM S1A)
- S1B) Anti-sense strand S1 (10 μL 20 μM S1B)

Fig. 12: Incubation at S7 (2-19-20) in mouse serum

1. at time 0 (without serum)
2. for 30 minutes
3. for 4 hours
4. for 12 hours

Fig. 13: Incubation of S7 (2-19-2) in human serum

1. Sense strand S7 (10 μL 20 μM S7A)
2. Anti-sense strand S7 (10 μL 20 μM S7B)
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours
7. for 6 hours

8. for 12 hours
9. for 24 hours
10. at time 0 (without serum)

Fig. 14: Incubation of K3 (2-19-20) in mouse serum

1. Sense strand K3 (10 μ L 20 μ M K3A)
2. Anti-sense strand K3 (10 L 20 μ M K3B)
3. at time 0 (without serum)
4. at time 0 (with serum)
5. for 30 minutes
6. for 1 hour
7. for 2 hours
8. for 4 hours
9. for 12 hours

Fig. 15: Incubation of PKC1/2 (0-22-2) in mouse serum

1. for 30 minutes
2. for 1 hour
3. for 2 hours
4. for 4 hours
5. for 12 hours
6. 2 μ L 100 μ M PKC1/2 (untreated)

Fig. 16: Incubation of S1A/S4B (0-22-2) in human serum

1. at time 0 (without serum)
2. for 24 hours
3. for 12 hours
4. for 8 hours
5. for 6 hours
6. for 4 hours
7. for 2 hours

8. for 30 minutes
9. Sense strand S1A (10 μ L 20 μ M S1A)
10. Anti-sense strand S4B (10 μ L 20 μ M S4B)

Fig. 17: Incubation of K2 (2-22-2) in human serum

1. Sense strand K2 (10 μ L 20 μ M K2A)
2. Anti-sense strand K2 (10 μ L 20 μ M K2B)
3. at point 0 (without serum)
4. for 30 minutes
5. for 2 hours
6. for 4 hours
7. for 6 hours
8. for 8 hours
9. for 12 hours
10. for 24 hours

Results:

dsRNAs without single-strand regions on the 3' ends are much more stable in both human and murine serum than dsRNAs with single-strand 2nt overhangs on the 3' ends (Figures 10 to 14 and 17). After 12 and 24 hours incubation at S1 in murine or human serum, bands in the original size are almost fully retained. On the other hand, in dsRNAs with 2nt overhangs on both 3' ends, the stability in human and murine serum diminishes significantly. After only 4 hours of incubation of S7 (Figures 12 and 13) or K3 (Fig. 14), no bands can be detected in the original size.

In order to increase the stability of dsRNA in serum, it is sufficient if the dsRNA has a smooth end. In mouse serum after 4 hours incubation (Fig. 15, track 4), the bands in the original size are scarcely broken down in comparison with S7 (after 4 hours complete degradation; Fig. 12, track 3).

As an optimal compromise with respect to biological efficacy of dsRNA, the use of dsRNA with a smooth end and a single-strand region of 2 nucleotides can be considered, in which the single-strand overhang should be situated on the 3' end of the anti-sense strand.

The sequences used here are apparent from the following Table 2 and the sequence protocols SQ148-151 and 153-167.

Name	Sequenz- proto- koll-Nr.	dsRNA-Sequenz	
S1	SQ148 SQ149	(A) 5' - CCACAUGAAGCAGCAGACUUC -3' (B) 3' - GGUGUACUUCGUCGUGCUGAAG -5'	0-22-0
S7	SQ150 SQ151	(A) 5' - CCACAUGAAGCAGCAGACUU -3' (B) 3' - CUGGUGUACUUCGUCGUGCUG -5'	2-19-2
K1	SQ153 SQ154	(A) 5' - ACAGGAUGAGGAUCGUUUCGCA -3' (B) 3' - UGUCCUACUCCUAGCAAAGCGU -5'	0-22-0
K3	SQ155 SQ156	(A) 5' - GAUGAGGAUCGUUUCGCAUGA -3' (B) 3' - UCCUACUCCUAGCAAAGCGUA -5'	2-19-2
K2	SQ157 SQ158	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3' (B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	2-22-2
S1A/ S4B	SQ148 SQ159	(A) 5' - CCACAUGAAGCAGCAGACUUC -3' (B) 3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	0-22-2

PKC 1/2	SQ160	(A)	5' - CUUCUCCGCCUCACACCGCUGCAA -3'	2-22-0
	SQ161	(B)	3' - GAAGAGGCGGAGUGUGGCGACG -5'	
S7/S12	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-0
	SQ162	(B)	3' - GGUGUACUUCGUCGUGCUGAA -5'	
S7/S11	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-2
	SQ163	(B)	3' - CUGGUGUACUUCGUCGUGCUGAA -5'	
S13	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-2
	SQ165	(B)	3' - CUGGUGUACUUCGUCGUGCUGA -5'	
S13/14	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-0
	SQ166	(B)	3' - GGUGUACUUCGUCGUGCUGA -5'	
S4	SQ167	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-2
	SQ159	(B)	3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	
K1A/ K2B	SQ153	(A)	5' - ACAGGAUGAGGAUCGUUUCGCA -3'	0-22-2
	SQ158	(B)	3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	
K1B/ K2A	SQ154	(A)	5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-0
	SQ157	(B)	3' - UGUCCUACUCCUAGCAAAGCGU -5'	
S1B/ S4A	SQ149	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-0
	SQ167	(B)	3' - GGUGUACUUCGUCGUGCUGAAG -5'	

Key to figure: (Headings)

Name

Sequence protocol no.

dsRNA sequence

Table 2

IV. In Vivo Study:

Double-strand RNA (dsRNA) that was derived from the GFP sequence where unspecific dsRNA was injected intravenously into the caudal vein of “GFP laboratory mice” that express the green fluorescent protein (GFP) in all cells that conduct protein biosynthesis. At the end of the experiment, the animals were killed and the GFP expression analyzed in tissue sections and in plasma.

Experimental Protocol:

Synthesis of dsRNA:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA single strands apparent from the sequence protocols and the single strand complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. As columns, NucleoPac PA-100, 9 × 250 mm from the Dionex company were used; 20 mM Tris, 10 mM NaClO₄, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO₄, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

Experimental Animal Keeping and Performance of the Experiment

The transgenic laboratory mouse strain TgN (GFPU) 5Nagy (Jackson Laboratory, Bar Harbor, Maine, USA) was used, which expresses GFP (with a beta-actin promoter and a CMV intermediate early enhancer) in all previously investigated cells (Hadjantonakis AK et al. 1993, Mech. Dev. 76: 79-90; Hadjantonakis AK et al., 1998 Nature Genetics 19: 220-222). GFP-transgenic mice can be clearly distinguished from the corresponding wild types (WT) by means of fluorescence (with a UV hand lamp). For breeding, the corresponding WT was paired with a heterozygous GFP type.

The experiment was performed according to the German Animal Protection Regulations. The animals were kept under controlled environmental conditions in groups of 3-5 animals in type III Makrolon cages from the Ehret company, Emmendingen, at a constant temperature of 22°C and a light-dark rhythm of 12 h. Softwood granulate 8/15 from the Altromin company, Lage, was used as sawdust litter. The animals received tap water and standard feed Altromin 1324 pelletized (Altromin) ad libitum.

To perform the experiment, the heterozygous GFP animals were kept in groups of 3 animals each in cages, as described above. Injections of the dsRNA solution occurred intravenously (IV) into the caudal vein in 12-hour cycles (between 5:30 and 7:00 a.m. and between 5:30 and 7:00 p.m.) over 5 days. The injection volumes were 60 µL for per 10 g of body weight and the dose was 2.5 mg dsRNA and 50 µg per kg of body weight. Division into groups was as follows:

- Group A: PBS (phosphate buffered saline) 60 µL per 10 kg of body weight,
- Group B: 2.5 mg per kg of body weight of a nonspecific control dsRNA (K1 control with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group C: 2.5 mg per kg of body weight of another unspecific control dsRNA (K3 control with 2nt overhangs on both 3' ends and a double-strand region of 19 nucleotide pairs),
- Group D: 2.5 mg per kg of body weight dsRNA (specific against GFP, subsequently referred to as S1, with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group E: 2.5 mg dsRNA per kg of body weight (specific against GFP, subsequently referred to as S7, with 2nt overhangs on the 3' ends of both strands and a double-strand region of 19 nucleotide pairs)
- Group F: 50 µg S1-dsRNA per kg of body weight (i.e., 1/50 of the dose of group D).

After the last injection of a total of 10 injections, the animals were killed after 14-20 h and the organs and blood taken as described.

Organ Removal:

Immediately after killing the animals by CO₂ inhalation, blood and different organs were taken (thymus, lungs, heart, spleen, stomach, intestines, pancreas, brain, kidneys and liver). The organs were rinsed briefly in cold sterile PBS and divided with a sterile scalpel. One part was fixed for immunohistochemical staining in methylcarnoys (MC, 60% methanol, 30% chloroform, 10% glacial acetic acid) for 24 hours, one part was shock frozen for frozen sections and for protein isolation immediately in liquid nitrogen and stored at -80°C, and another smaller part was frozen for RNA isolation in RNAeasy-Protect (Qiagen) at -80°C. The blood was immediately held for 30 minutes on ice after sampling, mixed, centrifuged for 5 minutes at 2000 rpm (Mini spin, Eppendorf), the supernatant removed and stored at -80°C (here referred to as plasma).

Processing of the Biopsies:

After 24 h of fixation of the tissue in MC, the tissue pieces were dehydrated in an increasing alcohol series at RT (room temperature): every 40 minutes 70% methanol, 80% methanol, 2 × 96% methanol and 3 × 100% isopropanol. The tissue was then heated in 100% isopropanol to 60°C in an incubator, then incubated for 1 hour in an isopropanol/paraffin mixture at 60°C and 3 × for 2 hours in paraffin and then imbedded in paraffin. For immunoperoxidase staining, tissue sections with 3 µm section thickness were prepared with a rotary microtome (Leica), mounted on slides (Superfrost, Vogel) and incubated for 30 minutes at 60°C in an incubator.

Immunoperoxidase Staining versus GFP:

The sections were deparaffinized 3 × 5 minutes in xylene, rehydrated in an increasing alcohol series (3 × 3 min 100% ethanol, 2 × 2 min 95% ethanol) and then incubated for 20 minutes in 3% H₂O₂/methanol to block endogenous peroxidases. All incubation steps were conducted subsequently in a moist chamber. After 3 × 3 minutes of washing with PBS, they were incubated

with the first antibody (goat anti-GFP, sc-5384, Santa Cruz, Biotechnology) 1:500 in 1% BSA/PBS overnight at 4°C. Incubation with the biotinylated secondary antibody (donkey anti-goat; Santa Cruz Biotechnology; 1:2000 dilution) occurred for 30 minutes at RT, whereupon they were incubated for 30 minutes with Avidin D Peroxidase (1:2000 dilution, Vector Laboratories). After each antibody incubation, the sections were washed 3 × 3 min in PBS and the buffer residues removed from the sections with wadding. All antibodies were diluted in 1% bovine serum albumin (BSA)/PBS. Staining with 3,3'-diaminobenzidine (DAB) was conducted with the DAB substrate kit (Vector Laboratories) according to the manufacturer's data. As nuclear counterstain, hematoxylin III according to Gill (Merck) was used. After dehydration in a rising alcohol series at 3 × 5 minutes xylene, the sections were covered with Entellan (Merck). Microscopic evaluation of staining occurred with the IX50 microscope from Olympus, equipped with a CCD camera (Hamamatsu).

Protein Isolation from Tissue Pieces:

800 µL isolation buffer (50 mM HEPES, pH 7.5, 150 mM NaCl; 1 mM EDTA; 2.5 mM EGTA; 10% glycerol; 0.1% Tween; 1 mM DTT, 10 mM β-glycerol phosphate; 1 mM NaF; 0.1 mM Na₃VO₄ with a protease inhibitor tablet "Complete" from Roche) were added to the still frozen tissue pieces and homogenized 2 × 30 seconds with an Ultraturrax (DIAX 900, dispersal die 6 G, Heidolph), and cooled in between on ice. After 30 minutes of incubation on ice, they were mixed and centrifuged for 20 minutes at 1000 × g, 4°C (3K30, Sigma). The supernatant was incubated for another 10 minutes on ice, mixed and centrifuged for 20 minutes to 15000 × g, 4°C. A protein determination according to Bradford, 1976, modified after Zor & Selinger, 1996, was conducted with the supernatant with the Roti-Nanoquant system of Roth according to the data of the manufacturer. BSA (bovine serum albumin) in concentrations from 10 to 100 µg/mL was used for the protein calibration line.

SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multigel long electrophoresis chamber from Biometra with a denaturing, discontinuous 15% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 1970). For this purpose, a

separation gel 1.5 mM thick was initially poured: 7.5 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1.5 M tris/HCl, pH 8.4, 150 μ L 10% SDS, 3.3 mL doubly distilled water, 250 μ L ammonium persulfate (10%), 9 μ L TEMED (N,N,N',N'-tetramethylethylenediamine) and coated up to polymerization with 0.1% SDS. The collected gel was then poured: 0.83 μ L acrylamide/bisacrylamide (30%/0.9%), 630 μ L 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50 μ L 10% SDS, 50 μ L 10% ammonium persulfate, 5 μ L TEMED.

Before application of the gel, the proteins were mixed with a corresponding amount of 4-fold sample buffer (200 mM tris, pH 6.8, 4% SDS, 100 mM DTT (dithiotreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes in a heating unit at 100°C, briefly centrifuged after cooling on ice and applied to the gel. The same plasma or protein amounts were used per track (3 μ L plasma and 25 μ g total protein each). Electrophoresis occurred water-cooled at RT and a constant 50 V. The protein gel marker from Bio-Rad (kaleidoscope prestained standard) was used as length standard.

Western Blot and Immune Detection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinyl difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyhse-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.8 mA/cm² for 1.5 h. A Tris/glycine buffer was used as transfer buffer (39 mM glycine, 465 mM Tris, 0.1% SDS and 20% methanol). To check the electrophoretic transfer, both the gels after blotting and the blot membranes after immune detection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid). For saturation of nonspecific bonds, the blot membrane after transfer was incubated in 1% skim milk powder/PBS for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (goat anti-GFP, sc 5384, Santa Cruz Biotechnology) occurred in a dilution of 1:1000 for 1 h at RT. It was then washed 3 \times 5 min and incubated for 1 hour at RT with a secondary antibody (donkey anti-goat IgG horseradish peroxidase labeled, Santa Cruz Biotechnology) in a dilution of 1:1000. Detection occurred with the ECL system from Amersham according to the data of the manufacturer.

Figures 18 to 20 show inhibition of GFP expression after intravenous injection of dsRNA specifically directed against GFP with immunoperoxidase staining relative to GFP on 3 μ m paraffin sections. During the experiment, dsRNA directed against GFP with a double-strand region of 22 nucleotide (nt) pairs without overhangs on the 3' ends (D) and the corresponding unspecific control dsRNA (B), as well as dsRNA directed specifically against GFP with a double-strand region containing 19 nucleotide pairs with 2 nt overhangs on the 3' ends (E) and the corresponding nonspecific control dsRNA (C) were applied in 12-hour cycles over 5 days. (F) received 1/50 of the dose of group D. Animals without dsRNA administration (A) and WT animals were investigated as additional controls. Fig. 18 shows inhibition of GFP expression in kidney sections, Fig. 19 in heart tissue and Fig. 20 in pancreas tissue. Figures 21 to 23 show Western blot analyses of GFP expression in plasma and tissues. Inhibition of GFP expression in plasma is shown in Fig. 21, in the kidneys in Fig. 22 and in the heart in Fig. 23. Total protein isolates from different animals are shown in Fig. 23. The same total protein amounts per track were applied. In the animals, to which unspecific control dsRNA was administered (animals of groups B and C), the GFP expression relative to animals that received no dsRNA is not reduced. Animals that received dsRNA specifically directed against GFP with 2 nt overhangs on the 3' ends of both strands and a double-strand region containing 19 nucleotide pairs exhibited a significantly inhibited GFP expression in the investigated tissues (heart, kidneys, pancreas and blood), compared with the untreated animals (Figures 18 to 23). In the animals of groups D and F, in which dsRNA directed specifically against GFP with smooth ends and double-strand region containing 22 nucleotide pairs was administered, only those animals that received dsRNA in a dose of 50 μ g/kg of body weight per day exhibited a specific inhibition of GFP expression, which, however, was much less pronounced than that of the animals in group E. The summarizing evaluation of GFP inhibition in the tissue sections and in Western blot shows that inhibition of GFP expression in blood and the kidneys is strongest (Figures 18, 21 and 22).

V. Inhibition of Gene Expression of EGF Receptor with dsRNA as a Therapeutic Approach in Forms of Cancer with EGFR Overexpression or EGFR-induced Proliferation:

The epidermal growth factor (EGF) receptor (EGFR) belongs to the receptor tyrosine kinases, transmembrane proteins with an intrinsic tyrosine kinase activity, which participate in the control

of a series of cellular processes, like cell growth, cell differentiation, migratory processes or cell vitality (review in: Van der Geer et al. 1994). The EGFR family consists of 4 members, EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) with a transmembrane domain, a cysteine-rich extracellular domain and an intracellular catalytic domain. The sequence of EGFR, a 170 kDa protein, has been known since 1984 (Ullrich et al., 1984).

EGFR is activated by peptide growth factors, like EGF, TGF α (transforming growth factor), amphiregulin, beta-cellulin, HB-EGF (heparin-binding EGF-like growth factor) and neureguline. Ligand bonding induces formation of homo- or heterodimers with subsequent autophosphorylation of cytoplasmic tyrosine (Ullrich & Schlessinger, 1990; Alroy & Yarden, 1997). The phosphorylated amino acids form the bonding sites for a number of proteins that participate in the proximal steps of signal conduction in a complex network. EGFR participates in a wide variety of tumor diseases and is therefore a suitable target for therapeutic approaches (Huang & Harari, 1999). The mechanisms that lead to an aberrant EGFR activation can be due to overexpression, amplification, constituted activation of mutant receptor forms or autocrine loops (Voldborg et al., 1997). An overexpression of EGFR was described for a number of tumors, like breast cancer (Walker & Dearing, 1999), non-small lung carcinoma (Fontanini et al., 1998), pancreatic carcinomas, colon carcinoma (Salomon et al., 1995) and glioblastomas (Rieske et al., 1998). No efficient and specific therapeutic agents have thus far been available for malignant glioblastomas, in particular.

Practical Example:

To demonstrate the efficacy of dsRNA during specific inhibition of EGFR gene expression, U-87 MG cells (human glioblastoma cells), ECCAC (European Collection of Animal Cell Cultures) no. 89081402 were used, which were transfected with dsRNA directed specifically against the EGF receptor (sequence protocol SQ 51). After about 72 hours' incubation, the cells were harvested, the protein isolated and the EGFR expression investigated in the Western blot method.

Experimental Protocol:

dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and an ordinary chemical method, the RNA single strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. The column NucleoPac PA-100, 9 × 250 mm, from the Dionex company was used; 20 mM Tris, 10 mM NaClO₄, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO₄, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double-strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

Seeding of the Cells:

All cell culture work was conducted under sterile conditions and an appropriate work bench (HS18, Her safe, Kendro, Heraeus). Cultivation of U-87 MG cells occurred in an incubator (CO₂ incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO₂ and saturated atmospheric humidity in DMEM (Dulbecco's modified eagle medium, Biochrom) with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom), 1 mM sodium pyruvate (Biochrom), 1 × NEAA (nonessential amino acids, Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells were subjected to passage every 3 days. 24 hours before application of dsRNA by transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of 5 × 10⁵ cells/well in a 6-well plate (6-well plates, Labor Schubert & Weiss GmbH) in 1.5 mL growth medium.

Application of dsRNA in Cultivated U-87 MG Cells:

Application of dsRNA occurred by transfection with OLIGOFECTAMINETM reagent (Life Technologies) according to the information of the manufacturer. The total transfection volume was 1 mL. The dsRNA was first diluted in serum-free medium: for this purpose, 0.5 µL of a 20

μm stock solution of dsRNA specifically directed against EGFR and 9.5 μL of a 20 μm stock solution of unspecific dsRNA (K1A/K2B) with 175 μL serum-free medium were diluted per well (200 nM dsRNA in transfection charge and 10 nM specific EGFR-dsRNA). The OLIGOFECTAMINETM reagent was also diluted in serum-free mediums: 3 μL with 12 μL medium per well and then incubated for 10 minutes at room temperature. The diluted OLIGOFECTAMINETM reagent was then added to the dsRNAs diluted in medium, mixed and incubated for another 20 minutes at RT. During incubation, a medium change was performed. The cells were washed for this purpose once with 1 mL serum-free medium and incubated further in the incubator with 800 μL serum-free medium, up to addition of dsRNA/OLIGOFECTAMINETM reagent. After addition of 200 μL dsRNA/OLIGOFECTAMINETM reagent per well, the cells were further incubated in the incubator to protein isolation.

Protein Isolation:

About 72 hours after transfection, the cells were harvested and protein isolation carried out. For this purpose, the medium was removed and the cell monolayer washed once with PBS. After addition of 200 μL protein isolation buffer (1 \times protease inhibitor “Complete”, Roche, 50 mM HEPES, pH 7.5, 1509 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 10% glycerol, 0.1% Tween-20, 1 mM DTT, 10 mM β -glycerol phosphate, 1 mM NaF, 0.1 mM Na_3VO_4), the cells were separated by means of a cell scraper, incubated for 10 minutes on ice, transferred to an Eppendorf reaction vessel and stored at -80°C for at least 30 minutes. After thawing, the lysate was homogenized on stage 3 for 10 seconds with a disperser (DIAX 900, dispersing die 6G, Heidolph Instruments GmbH & Co KG, Schwabach), incubated on ice for 10 minutes and centrifuged for 15 minutes at $14000 \times g$, 4°C (3K30, Sigma). A protein determination was conducted with the supernatant according to Bradford with the Roti[®] Nanoquant system from Roth (Roth GmbH & Co., Karlsruhe) according to the information of the manufacturer. For this purpose, 200 μL protein solution in appropriate dilution was mixed with 800 μL 1 \times working solution and the extinction measured in semi-microcells at 450 and 590 nm versus distilled water in a Beckman spectrophotometer (DU 250). The corresponding BSA dilutions were used for the calibration line (beaded BSA, Sigma).

SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multi-gel long electrophoresis chamber from Biometra with a denaturing, discontinuous 7.5% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 1977). For this purpose, a separation gel was initially poured with 1.5 mm thickness: 3.7 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1 M Tris/HCl, pH 8.4, 150 µL 10% SDS, 7.15 mL doubly distilled water, 150 µL ammonium persulfate (10%), 9 µL TEMED (N,N,N',N'-tetramethylethylenediamine) and coated with 0.1% SDS to polymerization. The collection gel was then poured: 0.83 mL acrylamide/bisacrylamide (30%/0.9%), 630 µL 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50 µL 10% SDS, 50 µL 10% ammonium persulfate, 5 µL TEMED.

For application to the gel, the protein samples were mixed 1:3 with 4 × sample buffer (200 mM Tris, pH 6.8, 4% SDS, 100 mM DTT (dithiothreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes at 100°C, briefly centrifuged after cooling on ice and applied to the gel. 35 µg total protein was applied per track. The run occurred water cooled at RT and a constant 50 V. The kaleidoscope protein gel marker (BioRad) was used as length standard.

Western Blot and Immunodetection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinylidene difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyhse-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.5 mA/cm² for 1.5 h. The following were used as transfer buffer: cathode buffer (30 mM Tris, 40 mM glycine, 10% methanol, 0.01% SDS; pH 9.4), anode buffer I (300 mM Tris, pH 10.4, 10% methanol) and anode buffer II (30 mM Tris, pH 10.4, 10% methanol). Before combining the blot stack with 3 mm Whatman paper (Schleicher & Schüll), the gel was incubated in the cathode buffer and the PVDF membrane (30 seconds beforehand in 100% methanol) in anode buffer II (5 min): 2 layers 3 mm paper (anode buffer I), 1 layer 3 mm paper (anode buffer II), PVDF membrane, gel, 3 layers 3 mm paper (cathode buffer). To check electrophoretic transfer, both the gels after blotting and the blot membranes after immunodetection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid).

The blot membrane was incubated after transfer in 1% skim milk powder/ PBS/0.1% Tween-20 for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (human EGFR extracellular domain, specific goat IgG, catalog no. AF231, R&D Systems) occurred on a rocking device for 2 h at RT and a concentration of 1.5 µg/mL. It was then washed 3 × for 6 minutes and incubated for 1 hour at RT with the secondary antibody (donkey anti-goat IgG horseradish peroxidase label, Santa Cruz Biotechnology) (diluted 1:10000). After washing (3 × 3 min in PBS/0.1% Tween-20), detection occurred immediately with ECL reaction (enhanced chemiluminescence): 200 µL solution A (250 mM luminol, Roth, dissolved in DMSO), 89 µL solution B (90 mM p-coumaric acid, Sigma, dissolved in DMSO) and 2 mL 30% H₂O₂ solution were pipetted into 18 mL distilled water. Depending on the membrane size, 4-6 mL was pipetted directly onto the membrane, incubated for 1 minute at RT and then an x-ray film (Biomax MS, Kodak) applied immediately.

The sequences used here are shown in the following Table 3 and in the sequence protocols S!153, 157, 158, 168-173.

ES-7	SQ168	(A) 5' - AACACCGCAGCAUGUCAAGAU -3'	2-19-2
	SQ169	(B) 3' - UUUUGUGGCGUCGUACAGUUC -5'	
ES-8	SQ170	(A) 5' - AAGUUAAAUCCCCGUCGCUAU -3'	2⁵-19-2⁵
	SQ171	(B) 3' - CAAUUJUAAGGGCAGCGAUAGU -5'	
ES2A/ ES5B	SQ172	(A) 5' - AGJGUGAUCCAAGCUGUCCCAA -3'	0-22-2
	SQ173	(B) 3' - UUUCACACUAGGUUCGACAGGGUU -5'	
K2	SQ157	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-2
	SQ158	(B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	

K1A/ K2B	SQ153	(A)	5' - ACAGGAUGAGGAUCGUJUCGCA	-3'	0-22-2
	SQ158	(B)	3' - UCUGUCCVACUCCUAGCAAAGCGU	-5'	

Table 3

Inhibition of EGFR Expression in U-87 MG Glioblastoma Cells:

24 hours after seeding of the cells, they were transfected with 10 nM dsRNA as stated (oligofectamine). After 72 hours, the cells were harvested and the protein isolated. Separation of the proteins occurred in 7.5% SDS-PAGE. 35 µg total protein was applied per track. Fig. 4 shows the corresponding Western blot analysis, from which it follows that the EGFR expression after transfection in U-87 MG cells can be significantly inhibited relative to the corresponding controls with the dsRNA specifically directed against the EGFR gene with a 2 nt overhang on the 3' end of the anti-sense strand. This inhibition of expression of an endogenous gene by specific dsRNA therefore confirms the results stated in the practical example II concerning inhibition of expression of an artificial gene introduced to the cell after transient transfection. The inhibition of EGFR expression mediated by ES-7 and ES-8 is much lower. The dsRNAs used in Fig. 24 can be gathered from Table 3.

VI. Inhibition of Expression of the Multidrug Resistance Gene 1 (MDR1):

Experimental Protocol:

In vitro detection for blocking of MDR1 expression was conducted in the colon carcinoma cell line LS174T (ATCC – American Type Culture Collection, Tom et al., 1976). It is known of this cell line that expression of MDR1 can be induced by addition of rifampicin to the culture medium (Geick et al., 2001). Transfections were conducted with different commercial transfection kits (Lipofectamine, Oligofectamine, both Invitrogen; TransMessenger, Qiagen), in which the TransMessenger transfection kit also proved to be best suited for this cell line.

To run the RNA interference experiments, 4 short double-strand ribonucleic acids R1-R4 were used, whose sequences are shown in Table 4. The ribonucleic acids are homologous with sections of the coding sequence of MDR1 (sequence protocol SQ 30). Sequences R1-R3 consists of a 22-mer sense and a 24-mer anti-sense strand, in which the forming double-strand has a two nucleotide overhang on the 3' end of the anti-sense strand (0-22-2). The sequence R4 corresponds to R1, but consists of a 19-mer double strand with 2 nucleotide overhangs on each 3' end (2-19-2).

<u>Name</u>	<u>Sequenz- proto- koll-Nr.</u>	<u>Sequenz</u>	<u>Position in Daten- bank-# AF016535</u>
Seq R1	SQ141 SQ142	5' - CCA UCU CGA AAA GAA GUU AAG A-3' 3' -UG GGU AGA GCU UUU CUU CAA UUC U-5'	1320-1342 1335-1318
Seq R2	SQ143 SQ152	5' - UAU AGG UUC CAG GCU UGC UGU A-3' 3' -CG AUA UCC AAG GUC CGA ACG ACA U-5'	2599-2621 2621-2597
Seq R3	SQ144 SQ145	5' - CCA GAG AAG GCC GCA CCU GCA U-3' 3' -UC GGU CUC UUC CGG CGU GGA CGU A-5'	3778-3799 3799-3776
Seq R4	SQ146 SQ147	5' - CCA UCU CGA AAA GAA GUU AAG-3' 3' -UG GGU AGA GCU UUU CUU CAA U -5'	1320-1341 1339-1318
			<u>Position in Daten- bank-# AF402779</u>
K1A/ K2B	SQ153 SQ158	5' - ACA GGA UGA GGA UCG UUU CGC A-3' 3' -UC UGU CCU ACU CCU AGC AAA GCG U-5'	2829-2808 2808-2831

Key to figure: (Headings)

Name

Sequence Protocol no.

Sequence

Table 4

The sequences shown in Table 4 are shown again in the sequence protocol as sequences SQ 141-147, 152, 153, 158. The dsRNAs were transfected in a concentration of 175 nM as double charges into the cells, which were seeded the day before in 12-well plates at 3.8×10^5 cells/well. For this purpose, 93.3 μ L EC-R buffer (TransMessenger kit, Qiagen, Hilden) was mixed with 3.2 μ L Enhancer-R per transfection charged, thoroughly mixed and incubated for 5 minutes at room temperature. After addition of 6 μ L TransMessenger transfection reagent, the transfection charges were vigorously mixed for 10 seconds and incubated for 10 minutes at room temperature. In the meantime, the medium was withdrawn from the cells by suction, washed once with PBS (phosphate buffered saline) and 200 μ L fresh medium without FCS per well was added to the cells. After 10 minutes of incubation, 100 μ L FCS-free medium was pipetted into the transfection charged, mixed and the mixture pipetted dropwise into the cells (the dsRNA concentration of 175 μ M refers to 400 μ L of medium total volume). The dsRNA/TransMessenger complexes were incubated for 4 hours at 37°C with the cells in FCS-free medium. A medium change was then conducted, in which the fresh medium contained 10 μ M Rifampicin and 10% FCS. As control, and unspecific dsRNA sequence, having no homology with the MDR1 gene sequence, was used (K) and a MOCK transfection carried out, which contained all reagents, except dsRNA.

The cells were harvested after 24, 48 and 72 hours and a total RNA extracted with the RNeasy-Mini-Kit from Qiagen. 10 μ g total RNA of each sample was separated on a 1% agarose formaldehyde gel electrophoretically, blotted onto a nylon membrane and specific probes, random marked with 5'- α^{32} -P-dCTP, were hybridized exposed first relative to MDR1 and, after stripping of the blot, relative to GAPDH as internal control and exposed on x-ray film.

The x-ray films were digitized (Image Master, VDS Pharmacia) and quantified with the Image-Quant software. Balancing of the MDR1-specific bands with the corresponding GAPDH bands was then carried out.

Results:

Figures 25 and 26 show Northern blots (Figures 25a, 26a) with quantitative evaluation of the MDR1-specific bands after balancing with the corresponding GAPDH values (Figures 25b, 26b). A reduction of MDR1-mRNA by up to 55% could be observed in comparison with MOCK transfection and by up to 45% in comparison with unspecific control transfection. After 48 h, a significant reduction of MDR1-mRNA levels was achieved with the dsRNA constructs designated R1, R2, R3 (Table 4). After 48 hours, no significant reduction relative to the controls was observed with the R4 dsRNA constructs (Figures 26a, 26b). After 72 hours, a much stronger reduction of MDR1-mRNA levels was observed with R1, R2 and R2 relative to the controls, in comparison with the 48-hour values (Figures 25a and 25b).

With R4 at this point a significant reduction of MDR1-mRNA levels could also be achieved. The constructs with a 2 nt overhang on the 3' end of the anti-sense strand and a double-strand region of 22 nucleotide pairs therefore reduced the MDR1-mRNA more efficiently than the constructs of the 2 nt overhangs on the 3' ends of both strands (anti-sense and sense strand) and a double-strand region of 19 nucleotide pairs relatively independently of the sequence region homologous to the MDR1 gene (after 48 hours; Fig. 26b). The results therefore confirm the inhibition of EGFR gene expression described in practical example 4 by specific dsRNAs after transfection in U-87 MG cells.

The transfection efficiency was determined in a separate experiment by means of a Texas-Red-labeled DNA oligonucleotide (TexRed-A (GATC)₅T; also 175 nM transfected) (Figures 27a, 27b; 400-fold magnification, 48 hours after transfection). The amount is about 50% based on the red fluorescent cells, in comparison with the total cell count. If one considers the transfection rate of the cells at about 50%, the observed reduction of MDR1-mRNA level lies at about 45-55% (compared with the controls), with the conclusion that in all cells that could be transfected

successfully with specific dsRNA, the MDR1-mRNA was almost fully broken down and specifically.

Literature:

Alroy I & Yarden Y (1997): The Erb signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Letters 410: 83-86.

Bass, B.L., 2000. Double-stranded RNA as a template for gene silencing. Cell 101, 235-238.

Bosher, J.M. and Labouesse, M., 2000. RNA interference: genetic wand and genetic watchdog. Nature Cell Biology 2, E31-E36.

Bradford MM (1976): Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.

Caplen, N.C., Fleenor, J., Fire, A., and Morgan, R.A., 2000. dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. Gene 252, 95-105.

Clemens, J.C., Worby, C.A., Simonson-Leff, N., Muda, M., Maelhama, T., Hemmings, B.A., and Dixon, J.E., 2000. Use of double-stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. Proc.Natl.Acad.Sci.USA 97, 6499-6503.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Liebermann G & Slamon DJ (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that

has progressed after chemotherapy for metastatic disease.
Journal of Clinical Oncology 17: 2639-2648.

Ding, S.W., 2000. RNA silencing. Curr. Opin. Biotechnol. 11, 152-156.

Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C., 1998. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. Nature 391, 806-811.

Fire, A., 1999. RNA-triggered gene silencing. Trends Genet. 15, 358-363.

Freier, S.M., Kierzek, R., Jaeger, J.A., Sugimoto, N., Caruthers, M.H., Neilson, T., and Turner, D.H., 1986. Improved free-energy parameters for prediction of RNA duplex stability. Proc. Natl. Acad. Sci. USA 83, 9373-9377 .

Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276 (18), 14581-14587.

Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G & Ciardiello F (1998): Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIa non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic factors of survival. Clinical Cancer Research 4: 241-249.

- Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J., 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* 404, 293-296.
- Higgins, C.F. (1995). The ABC of channel regulation. *Cell*, 82, 693-696.
- Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1993): Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech. Dev.* 76: 79-90.
- Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1998): Non-invasive sexing of preimplantation mammalian embryos. *Nature Genetics* 19: 220-222.
- Kyhse-Anderson J (1984): Electrophoretic transfer of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. *J. Biochem. Biophys. Methods* 10: 203-210.
- Lämmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.
- Loc, T.W., and Clarke, D.M. (1999) *Biochem. Cell Biol.* 77, 11-23.
- Huang SM & Harari PM (1999): Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. *Investigational New Drugs* 17: 259-269.
- Limmer, S., Hofmann, H.-P., Ott, G., and Sprinzl, M., 1993. The 3'-terminal end (NCCA) of tRNA determines the structure and

stability of the aminoacyl acceptor stem. Proc. Natl. Acad. Sci. USA 90 , 6199-6202.

Montgomery, M.K. and Fire, A., 1998. Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends Genet. 14, 255-258.

Montgomery, M.K., Xu, S., and Fire, A., 1998. RNA as a target of double-stranded RNA-mediated genetic interference in *Caenorhabditis elegans*. Proc. Natl. Acad. Sci. USA 95, 15502-15507.

Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, Bienhat W & Liberski PP (1998): A comparative study of epidermal growth factor (EGFR) and mdm2 gene amplification and protein immunoreactivity in human glioblastomas. Polish Journal of Pathology 49: 145-149.

Robert, J. (1999). Multidrug resistance in oncology: diagnostic and therapeutic approaches. Europ J Clin Invest 29, 536-545.

Stavrovskaya, A.A. (2000) Biochemistry (Moscow) 65 (1), 95-106.

Salomon DS, Brandt R, Ciardiello F & Normanno N (1995): Epidermal growth factor related peptides and their receptors in human malignancies: Critical Reviews in Oncology and Haematology 19: 183-232.

Tom, B.H., Rutzky, L.P., Jakstys, M.M., Oyasu, R., Kaye, C.I., Kahan, B.D. (1976), In vitro, 12, 180-191.

Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res*, 41, 1967-72.

Ui-Tei, K., Zenno, S., Miyata, Y., and Saigo, K., 2000. Sensitive assay of RNA interference in *Drosophila* and Chinese hamster cultured cells using firefly luciferase gene as target. *FEBS Lett.* 479, 79-82.

Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Liebermann TA, Schlessinger J et al. (1984): Human epidermal growth factor receptor cDNA sequences and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* 309: 418-425.

Ullrich A & Schlessinger J (1990): Signal transduction by receptors with tyrosine kinase activity. *Cell* 61: 203-212.

Van der Geer P, Hunter T & Linberg RA (1994): Receptor protein-tyrosine kinases and their signal transduction pathways. *Annual review in Cell Biology* 10: 251-337.

Voldborg BR, Damstrup L, Spang-Thomsen M & Poulser HS (1997): Epidermal growth factor Receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. *Annals of Oncology* 8: 1197-1206.

Walker RA & Dearing SJ (1999): Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. *Breast Cancer Research Treatment* 53: 167-176.

Zamore, P.D., Tuschl, T., Sharp, P.A., and Bartel, D.P., 2000.
RNAi: double-stranded RNA directs the ATP-dependent cleavage
of mRNA at 21 to 23 nucleotide intervals. *Cell* 101, 25-33.

Zor T & Selinger Z (1996): Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. *Anal. Biochem.* 236: 302-308.

Claims

1. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2) of dsRNA I.

2. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

3. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

4. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

5. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

6. Method according to one of the preceding claims, in which at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which

an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

7. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

8. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) overlap or abut each other in sections.

9. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) are spaced from each other.

10. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

11. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

12. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

13. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a combined dsRNA construct of the sequences SQ141-173 from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

14. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.

15. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
16. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
17. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
18. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
19. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
20. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
21. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
22. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
23. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

24. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
25. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs instead of nucleotides.
26. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.
27. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.
28. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.
29. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
30. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).
31. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
32. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.

33. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.
34. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
35. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
36. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
37. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.
38. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.
39. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.
40. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.
41. Use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

42. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

43. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

44. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

45. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

46. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

47. Use according to one of the Claims 41 to 46, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

48. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

49. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.
50. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.
51. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.
52. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.
53. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
54. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.
55. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
56. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.
57. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

58. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.

59. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.

60. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.

61. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

62. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.

63. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).

64. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.

65. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.

66. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.

67. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.
68. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
69. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
70. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).
71. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
72. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
73. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.
74. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
75. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

76. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

77. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

78. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

79. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

80. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

81. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

82. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

83. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).
84. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).
85. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.
86. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.
87. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.
88. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.
89. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.
90. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

91. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
92. Use according to one of the Claims 81 to 91, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
93. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
94. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
95. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
96. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
97. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
98. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
99. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
100. Use according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

101. Use according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
102. Use according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
103. Use according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
104. Use according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
105. Use according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
106. Use according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
107. Use according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
108. Use according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
109. Use according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

110. Use according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
111. Use according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
112. Use according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
113. Use according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
114. Use according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
115. Use according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
116. Use according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
117. Use according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
118. Use according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.
119. Use according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.

120. Use according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

121. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides on at least one end (E1, E2) of dsRNA I.

122. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

123. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

124. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

125. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

126. Method according to one of the preceding claims, in which at least an additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the

preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and which an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

127. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

128. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

129. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) are spaced from each other.

130. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

131. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

132. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

133. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of the sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

134. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.
135. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
136. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
137. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
138. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
139. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
140. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
141. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
142. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
143. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

144. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
145. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
146. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.
147. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.
148. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.
149. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
150. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).
151. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
152. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.

153. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.

154. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.

155. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

156. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

157. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.

158. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

159. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.

160. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.

161. Use of one of double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

162. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

163. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

164. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

165. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

166. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

167. Use according to one of the Claims 41 to 47, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

168. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

169. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.
170. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.
171. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.
172. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.
173. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
174. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.
175. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
176. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.
177. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

178. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.

179. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.

180. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.

181. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

182. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van-der-Waals or stacking interactions, or by metal ion coordination.

183. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).

184. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.

185. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.

186. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.

187. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.
188. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
189. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
190. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).
191. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
192. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
193. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.
194. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
195. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

196. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

197. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

198. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

199. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

200. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

201. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

202. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

203. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).
204. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).
205. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.
206. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.
207. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.
208. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.
209. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.
210. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

211. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
212. Use according to one of the Claims 81 to 90, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
213. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
214. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
215. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
216. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
217. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
218. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
219. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
220. Medicament according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

221. Medicament according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
222. Medicament according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
223. Medicament according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
224. Medicament according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
225. Medicament according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
226. Medicament according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
227. Medicament according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
228. Medicament according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
229. Medicament according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

230. Medicament according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
231. Medicament according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
232. Medicament according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
233. Medicament according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
234. Medicament according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
235. Medicament according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
236. Medicament according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
237. Medicament according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
238. Medicament according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.

239. Medicament according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.

240. Medicament according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

//Key to Figures//

Relative Fluoreszenz = Relative fluorescence

Maus = mouse

Mensch = human

MOCK Transfektion = MOCK transfection

Hellfeld = bright field

Variante = variant

Zielgen = target gene

SEQUENZPROTOKOLL = SEQUENCE PROTOCOL

<120> Method for Inhibition of Expression of a Target Gene

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R1A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R1B) of a dsRNA strand, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R2A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R3A) of a dsRNA that is homologous to the MDR1 gene

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R3B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R4A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R4B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S1A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S1B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S7A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S7B) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R2B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K1A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K1B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K3A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K3B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K2A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K2B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S4B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (PKC1 A) of a dsRNA that is homologous to the protein kinase C sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (PKC2 B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S12B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S11B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S13B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S14B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-7A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-7B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-8A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-8B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-2A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-5B) of a dsRNA, complementary to the human EGFR sequence

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro



(43) Internationales Veröffentlichungsdatum
18. Juli 2002 (18.07.2002)

PCT

(10) Internationale Veröffentlichungsnummer
WO 02/055693 A2

(51) Internationale Patentklassifikation⁷: C12N 15/11

(21) Internationales Aktenzeichen: PCT/EP02/00152

(22) Internationales Anmeldedatum:
9. Januar 2002 (09.01.2002)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:
101 00 586.5 9. Januar 2001 (09.01.2001) DE
101 55 280.7 26. Oktober 2001 (26.10.2001) DE
101 58 411.3 29. November 2001 (29.11.2001) DE
101 60 151.4 7. Dezember 2001 (07.12.2001) DE

LIMMER, Stephan [DE/DE]; Universitätsstrasse 30,
95447 Bayreuth (DE). ROST, Sylvia [DE/DE]; Univer-
sitätsstrasse 30, 95447 Bayreuth (DE). HADWIGER,
Philipp [DE/DE]; Universitätsstrasse 30, 95447 Bayreuth
(DE).

(74) Anwalt: GASSNER, Wolfgang; Nägelsbachstrasse 49a,
91052 Erlangen (DE).

(81) Bestimmungsstaaten (*national*): AE, AG, AL, AM, AT,
AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZM, ZW.

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von
US): RIBOPHARMA AG [DE/DE]; Universitätsstrasse
30, 95447 Bayreuth (DE).

(72) Erfinder; und


(75) Erfinder/Anmelder (nur für US): KREUTZER, Roland
[DE/DE]; Universitätsstrasse 30, 95447 Bayreuth (DE).

(84) Bestimmungsstaaten (*regional*): ARIPO-Patent (GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), europäisches Patent (AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),
OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

[Fortsetzung auf der nächsten Seite]

(54) Title: METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE

(54) Bezeichnung: VERFAHREN ZUR HEMMUNG DER EXPRESSION EINE ZIELGENS



(57) Abstract: The invention relates to a method for inhibiting the expression of a target gene in a cell, comprising the following steps: introduction of an amount of at least one dual-stranded ribonucleic acid (dsRNA I) which is sufficient to inhibit the expression of the target gene. The dsRNA I has a dual-stranded structure formed by a maximum of 49 successive nucleotide pairs. One strand (as1) or at least one section of the one strand (as1) of the dual-stranded structure is complementary to the sense strand of the target gene. The dsRNA has an overhang on the end (E1) of dsRNA I formed by 1 - 4 nucleotides.

(57) Zusammenfassung: Die Erfindung betrifft ein Verfahren zur Hemmung der Expression eines Zielgens in einer Zelle umfassend die folgenden Schritte: Einführen mindestens einer doppelsträngigen Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausreichenden Menge, wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinanderfolgenden Nukleotidpaaren gebildete Struktur aufweist, und wobei ein Strang (as1) oder zumindest ein Abschnitt des einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Sinn-Strang des Zielgens ist, und wobei die dsRNA am einen Ende (E1) der dsRNA I einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

WO 02/055693 A2



Veröffentlicht:

— ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts

Zur Erklärung der Zweibuchstaben-Codes und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.

Verfahren zur Hemmung der Expression eines Zielgens

Die Erfindung betrifft ein Verfahren, eine Verwendung und ein Medikament zur Hemmung der Expression eines Zielgens.

5

Aus der WQ 99/32619 sowie der WO 00/44895 sind Verfahren zur Hemmung der Expression von medizinisch oder biotechnologisch interessanten Genen mit Hilfe einer doppelsträngigen Ribonukleinsäure (dsRNA) bekannt. Die bekannten Verfahren sind zwar
10 hoch effektiv. Es besteht gleichwohl das Bedürfnis, deren Effizienz weiter zu steigern.

Aufgabe der vorliegenden Erfindung ist es, die Nachteile nach dem Stand der Technik zu beseitigen. Es sollen insbesondere
15 ein Verfahren, eine Verwendung und ein Medikament angegeben werden, mit denen eine noch effizientere Hemmung der Expression eines Zielgens erreichbar ist.

Diese Aufgabe wird durch die Merkmale der Ansprüche 1, 41 und
20 81 gelöst. Vorteilhafte Ausgestaltungen ergeben sich aus den Merkmalen der Ansprüche 2 bis 40, 42 bis 80 und 82 bis 120.

Mit den erfindungsgemäß beanspruchten Merkmalen wird überraschenderweise eine drastische Erhöhung der Effektivität der
25 Hemmung der Expression eines Zielgens in vitro und in vivo erreicht. Durch die besondere Ausbildung der Enden der dsRNA kann sowohl deren Effizienz bei der Vermittlung der hemmenden Wirkung auf die Expression eines Zielgens als auch deren Stabilität gezielt beeinflusst werden. Durch die Vergrößerung der
30 Stabilität wird die wirksame Konzentration in der Zelle erhöht.

Unter einem "Zielgen" im Sinne der Erfindung wird der DNA-Strang der doppelsträngigen DNA in der Zelle verstanden, welcher
35 komplementär zu einem bei der Transkription als Matrize dienenden DNA-Strang einschließlich aller transkribierten Be-

TRANSLATION FROM GERMAN

(12) WORLD ORGANIZATION OF INTELLECTUAL PROPERTY INTERNATIONAL APPLICATION PUBLISHED PURSUANT TO THE PATENT COOPERATION TREATY (PCT)

(19) World Organization for Intellectual Property International Office		
(43) International Publication Date: 18 July 2002	PCT	(10) International Publication Number: WO 02/055693 A2
(51) International Patent Classification ¹ : C12N 15/11		LIMMER, Stephan
(21) International Application Number: PCT/EP02/00152		[GERMANY/GERMANY];
(22) International filing date: 9 January 2002		Universitätsstrasse 30, 95447 Bayreuth (GERMANY).
(25) Submission language German		ROST, Sylvia
(26) Publication language German		[GERMANY/GERMANY];
(30) Priority data:		Universitätsstrasse 30, 95447 Bayreuth (GERMANY).
101 00 586.5 9 January 2001 GERMANY		HADWIGER, Philipp
101 55 280.7 26 October 2001 GERMANY		[GERMANY/GERMANY; Universitätsstrasse 30, 95447 Bayreuth (GERMANY).
101 58 411.3 29 November 2001 GERMANY	(74)	Attorneys: GASSNER, Rolfgang;
101 60 151.4 7 December 2001 GERMANY		Nägelsbachstrasse 49a, 91052 Erlangen (GERMANY).
(71) Applicant: <i>(for all designated states, except US):</i> RIBOPHARMA AG [GERMANY/GERMANY]; Universitätsstrasse 30, 95447 Bayreuth (GERMANY).		(81) Designated states (<i>national</i>): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TRADENAME, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
(72) Inventor and		
(75) Inventor/Applicant <i>(for US only)</i> : KREUTZER, Roland [GERMANY/GERMANY]; Universitätsstrasse 30, 95447 Bayreuth (GERMANY).		

(84) Regional states (*regional*): ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR). OAPI Patent (BR, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


– without International Search Report and republished on receipt of the report

Refer to the "Guidance Notes on Codes and Abbreviations" at the beginning of each regular issue of the PCT Gazette for explanation of the two-letter codes and other abbreviations..

(54) Title: **METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE**

(57) Abstract

The invention relates to a method for inhibiting the expression of a target gene in a cell, comprising the following steps: introduction of an amount of at least one dual-stranded ribonucleic acid (dsRNA I) which is sufficient to inhibit the expression of the target gene. The dsRNA I has a dual-stranded structure formed by a maximum of 49 successive nucleotide pairs. One strand (as1) or at least one section of the one strand (as1) of the dual-stranded structure is complementary to the sense strand of the target gene. The dsRNA has an overhang on the end (E1) of dsRNA I formed by 1 – 4 nucleotides.



Variant 1

Variant 2

METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE

The invention concerns a method, an application and a medicament for inhibition of expression of a target gene.

Methods to inhibit expression of genes of medical or biotechnological interest by means of a double-strand ribonucleic acid (dsRNA) are known from WO 99/32619 and WO 00/44895. The known methods are highly effective. But there is also a requirement to further increase their efficiency.

The task of the present invention is to eliminate the shortcomings according to the prior art. In particular, a method, an application and a medicament are to be offered, with which even more efficient inhibition of expression of the target gene is attainable.

This task is solved by the features of Claims 1, 41 and 81. Advantageous embodiments are apparent from the features of Claims 2 to 40, 42 to 80 and 82 to 120.

With the features claimed according to the invention, a drastic increase in the effectiveness of inhibition of expression of the target gene in vitro and in vivo is surprisingly achieved. By the special design of the ends of the dsRNA, both their efficiency in mediating the inhibiting effect on expression of the target gene and their stability can be deliberately influenced. By increasing the stability, the effective concentration in the cell is increased.

Target gene according to the invention is understood to mean the DNA strand of the double-strand DNA in the cell that is complementary to a DNA strand, including all transcribed regions that serve for transcription as matrix. The target gene is therefore generally the “sense” strand. The one strand or anti-sense strand (as1) can be complementary to an RNA transcript formed during expression of the target gene or its processing product, for example, an mRNA. Insertion is understood to mean uptake in the cell. Uptake can occur by the cell itself; it also can be mediated by auxiliaries or aids. “Overhang” is understood to mean a terminal single-strand overhang that does not have paired nucleotides, according to Watson and Crick. “Double-strand

structure” is understood to mean a structure, in which the nucleotides of the individual strands are essentially paired according to Watson and Crick. A double-strand structure in the context of the present invention can also have individual mismatches.

According to a particularly advantageous embodiment, the dsRNA I has the overhang on the 3' end of one strand or the anti-sense strand as1 and/or on the 3' end of the other end or sense strand ss1. The dsRNA I can also be formed smoothly on one end. In this case, the smooth end is advantageously situated on the side of dsRNA I that has the 5' end of one strand (anti-sense strand; as1). In this form, the dsRNA I, on the one hand, has very good efficiency and, on the other hand, high stability in a living organism. The overall in vivo efficiency is excellent. The overhang is expediently formed from 1 to 4 nucleotides, preferably from 1 or 2 nucleotides.

According to another embodying feature, the efficiency of the method can be further increased if at least one additional dsRNA II, formed according to the dsRNA I according to the invention, is inserted into the cell, in which the one strand or at least a section of one strand of the double-strand structure of dsRNA I is complementary to a first region of the sense strand of the target gene, and in which an additional strand or at least a section of the additional strand of the double-strand structure of the additional dsRNA II is complementary to a second region of sense strand of the target gene. Inhibition of expression of the target gene is significantly increased in this case. The first and second region can overlap in sections, abut each other, or also be spaced from each other.

It has also proven advantageous if the dsRNA I and/or the additional dsRNA II have a length of less than 25 consecutive nucleotide pairs. A length in the range between 19 and 23 nucleotide pairs has proven to be particularly effective. The efficiency can be further increased if single-strand overhangs of 1 to 4 nucleotides are present on the double strands preferably formed from 19 to 23 nucleotide pairs.

The target gene, according to an additional embodying feature, can have the sequences SQ001 to SQ140, given in the enclosed sequence protocol. It can also be chosen from the following groups: oncogene, cytokine gene, id-protein gene, prion gene, genes for expression of

angiogenesis-inducing molecules, adhesion molecules and cell surface receptors. genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules, as well as genes for expression of the EGF receptors. The target gene can be the MDR1 gene, in particular. In this context, one of the existing sequences SQ141-173 or a combined dsRNA I/II from antisense (as) and sense sequences (ss) that go together can be used.

According to an additional advantageous embodying feature, expression is inhibited according to the principle of RNA interference.

The target gene is expediently expressed in pathogenic organisms, preferably in plasmodia. It can be a component of a virus or viroid, especially a human pathogenic virus or viroid. The virus or viroid can also be an animal or plant pathogenic virus or viroid.

According to another embodying feature, it is prescribed that the unpaired nucleotides be substituted by nucleoside thiophosphates.

At least one end of the dsRNA I/II can be modified, in order to counteract degradation in the cell or dissociation in the individual strand. Advantageously, cohesion caused by the complementary nucleotide pairs of the double-strand structure is increased by at least one chemical length. The chemical length can be formed by a covalent or ionic bond, a hydrogen bridge bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal ion coordination. It has also proven expedient and to increase stability if the chemical link is formed in the vicinity of one end. Additional advantageous embodiments with respect to chemical linking can be deduced from the features of Claims 24 to 30, without requiring a further explanation for this.

The dsRNA I/II can be incorporated particularly easily in the cell if it is enclosed in micellar structures, advantageously in liposomes. It has also proven advantageous for transport of dsRNA I/II into the cell that it is bonded to at least a viral sheath protein, originating from a virus, derived from a virus or synthetically produced, associated with the sheath protein or

enclosed by it. The sheath protein can be derived from polyoma virus. The sheath protein can contain, in particular, the virus protein 1 and/or the virus protein 2 of polyoma virus. According to another embodiment, it is prescribed that, during formation of a capsid or capsid-like structure from the sheath protein, one side face the interior of the capsid or capsid-like structure. It is also advantageous that the one strand of dsRNA I/II (as1/2) is complementary to the primary or processed RNA transcript of the target gene. The cell can be a vertebrate cell or a human cell.

It has also been found that the dsRNA I/II can advantageously be administered already in an amount of, at most, 5 mg/kg of body weight per day to a mammal, preferably a human. Even in this low dose, an excellent efficiency is achieved.

It has surprisingly been found that the dsRNA I/II can be taken up in a buffer solution for administration and then administered orally or by injection or infusion intravenously, intratumorally, by inhalation or intraperitoneally.

The use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in the cell is also proposed according to the invention, in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (anti-sense strand; as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of the target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

According to an additional stipulation of the invention, a medicament for inhibiting the expression of a target gene in a cell is proposed, containing a double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of a target gene, in which the dsRNA I has a double-strand structure from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

The preceding comments are referred to for the further advantageous embodiment of dsRNA I/II.

The invention is further explained on an example below, with reference to the drawings and practical examples. In the drawings:

- Fig. 1a, b schematically depicts a first and second double-strand RNA and
- Fig. 2 schematically depicts a target gene,
- Fig. 3 depicts relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (first experiment),
- Fig. 4 shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (second experiment),
- Fig. 5 shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (third experiment),
- Fig. 6 shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (fourth experiment),
- Fig. 7 shows relative YFP fluorescence after application of different dsRNA in HeLa-S3 cells (fifth experiment),
- Fig. 8 shows fluorescence micrographs of NIH/3T3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 9 shows fluorescence micrographs of HeLa-S3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 10 shows gel electrophoretic separation of S1 after incubation in mouse serum,

- Fig. 11 shows gel electrophoretic separation of S1 after incubation in human serum,
- Fig. 12 shows gel electrophoretic separation of S7 after incubation in mouse serum,
- Fig. 13 shows gel electrophoretic separation of S7 after incubation in human serum,
- Fig. 14 shows gel electrophoretic separation of K3 after incubation in mouse serum,
- Fig. 15 shows gel electrophoretic separation of PKC1/2 after incubation in mouse serum,
- Fig. 16 shows gel electrophoretic separation of S1A/S4B after incubation in human serum,
- Fig. 17 shows gel electrophoretic separation of K2 after incubation in human serum and
- Fig. 18 shows GFP-specific immunoperoxidase staining on kidney paraffin sections of transgenic GFP mice,
- Fig. 19 shows GFP-specific immunoperoxidase staining on heart paraffin sections of transgenic GFP mice,
- Fig. 20 shows GFP-specific immunoperoxidase staining on pancreas paraffin sections transgenic GFP mice,
- Fig. 21 shows Western blot analysis of GFP expression in plasma,
- Fig. 22 shows Western blot analysis of GFP expression in the kidneys,
- Fig. 23 shows Western blot analysis of GFP expression in the heart,
- Fig. 24 shows Western blot analysis of EGFR expression in U-87 MG glioblastoma cells,

- Fig. 25a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 74 hours,
- Fig. 25b shows quantification of the band according to Fig. 25a, in which the averages from two values are shown,
- Fig. 26a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 48 hours,
- Fig. 26b shows quantification of the band according to Fig. 26a, in which the average values from the two values are shown,
- Fig. 27 shows a comparative depiction of a transmitted light and fluorescence photomicrograph of a transfection with 175 nM dsRNA (sequence R1 in Table 4).

The double-strand ribonucleic acids dsRNA I and dsRNA II, depicted schematically in Figures 1a and 1b, each have a first end E1 and a second end E2. The first and second ribonucleic acids dsRNA I/dsRNA II have single-strand sections formed from about 1 to 4 unpaired nucleotides on their two ends E1 and E2. Two possible variants are shown (variants 1 and 2), in which variant 2 has a smooth end (E2). The smooth ends, however, can also lie on the other end (E1) in another variant.

A target gene situated on DNA is schematically shown in Fig. 2. The target gene is made recognizable by a black bar. It has a first region B1 and a second region B2.

Each strand of the first dsRNA I (as1) and the second dsRNA II (as2) is complementary to the corresponding region B1 or B2 on the target gene.

Expression of the target gene is then inhibited with particular efficiency, if the dsRNA I/dsRNA II has single strand sections on its ends E1, E2. The single-strand sections can be formed both on

strand as1 or as2 and on the counterstrand (ss1 or ss2) or on strand as1, as2 and on the counterstrand.

The regions B1 and B2, as shown in Fig. 2, can be spaced from each other. However, they can also be adjacent to each other or overlap.

I. Inhibition of Expression of the YFP Gene in Fibroblasts:

Double-strand RNAs (dsRNAs) were prepared from sequences of the yellow fluorescent protein (YFP), a variant of the GFP (green-fluorescent protein) of the alga *Aequoria victoria* and microinjected into fibroblasts, together with a YFP-coding plasmid. Fluorescence reduction was then evaluated relative to cells without dsRNA.

Experimental Protocol:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and ordinary chemical methods, the RNA single strands apparent from the sequence protocols SQ148, 149 and SQ159 and the single strands complementary to them were synthesized. Purification then occurred by HPLC. Hybridization of the single strands to a double-strand occurred by heating the stoichiometric mixture of single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 90°C and subsequent cooling over 6 hours to room temperature. The dsRNAs so obtained were microinjected into the test cell.

The murine fibroblast cell line NIH/3T3, ECACC no. 930615624 (European Collection of Animal Cell Cultures) served as test system for these cell culture experiments. The plasmid pcDNA-YFP was used for microinjections, which contained an 800 bp large Bam HI/Eco RI-YFP fragment in the corresponding restriction cleavage sites of the vector pcDNA3. Expression of YFP was investigated under the influence of simultaneously cotransfected sequence-homologous dsRNA. Evaluation occurred under the fluorescence microscope, at the earliest, 3 hours after injection, with reference to green fluorescence.

Preparation of the Cell Cultures:

Cultivation of the cells occurred in DMEM with 4.5 g/L glucose, 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin/streptomycin (100 IU/100 µg/mL, Biochrom) in an incubator under a 5% CO₂ atmosphere at 37°C. The cells underwent passage every 3 days, in order to keep them in the exponential growth phase. A day before performance of transfection, the cells were trypsinized (10 × trypsin/TEDTA, Biochrom) and inoculated with a cell density of 0.73×10^5 cells into coated petri dishes (CORNING® Cell Culture Dish, 35 mM, Corning Inc., Corning, USA). The petri dishes were incubated with 0.2% gelatin (Biochrom) for at least 30 minutes at 37°C, washed once with PBS and immediately used for seeding of the cells. To permit recovery of individual cells, CELLocate coverslips from the Eppendorf company were used (square size 55 µm).

Microinjection:

To perform microinjection, the petri dishes were removed from the incubator for about 10 minutes. About 50 cells were microinjected per dish and batch (FemtoJet; Mikromanipulator 5171, Eppendorf). Glass capillaries (FemtoTip) from the Eppendorf company with a tip inside diameter of 0.5 µm were used for microinjection. The injection time was 0.8 seconds and the pressure 30 hPa. The microinjections were conducted on an Olympus IX50 microscope with a fluorescence device. 14 mM NaCl, 3 mM KCl, 10 mM KH₂PO₄, pH 7.0, was used as injection buffer, which contains 0.01 µg/mL pcDNA-YFP. To check successful microinjection, 0.08% (w/v) Dextran-70000 coupled Texas-Red (Molecular Probes, Leiden, Netherlands) was added to the injection solution. To investigate inhibition of the YFP expression with specific dsRNA, dsRNAs were added to the injection solution: batch 1: 0.1 µM dsRNA (sequence protocol SQ148/149); batch 2: 0.1 µM dsRNA (sequence protocol SQ148/159); batch 3: without RNA. After microinjection, the cells were incubated for at least three more hours in the incubator. The intracellular YFP fluorescence was then evaluated on the microscope: simultaneously red and green-fluorescent cells: microinjection was successful, no inhibition of YFP expression by dsRNA was observed; or control cells were involved, in which no dsRNA were injected; only red fluorescent cells: microinjection was successful, the dsRNA inhibits YFP expression.

Results:

At a dsRNA concentration of 0.1 μ M, a significantly increased inhibition or expression of the YFP gene in fibroblasts could be observed during use of dsRNA with the protruding single-strand regions (sequence protocol SQ148/159) on both 3' ends by two nucleotides each, in comparison with dsRNA without protruding single-strand ends (Table 1).

The use of short dsRNA molecules, containing 19-25 base pairs with overhangs of a few, preferably 1 to 3, non-base-paired, single-strand nucleotides, therefore permits comparatively stronger inhibition of gene expression in mammal cells than the use of dsRNAs with the same number of base pairs without the corresponding single-strand overhangs at the same RNA concentration.

Batch	Name	Sequence protocol number	0.1 μ M
1	S1A/ S1B	SQ148 SQ149	+
2	S1A/ S4B	SQ148 (protruding end) SQ159	+++
3		without RNA	—

Table 1: The symbols show the relative percentage of non-fluorescent or weakly green fluorescent cells (+++ > 90%; ++ 60-90%; + 30-60%; - < 10%).

II. Inhibition of Gene Expression with Target Gene in Cultivated HELA-S3 Cells and Mouse Fibroblasts by dsRNA:

The efficiency of inhibition of YFP expression after transient transfection of a YFP-coding plasmid based on RNA interference with dsRNAs can be modulated by the configuration of the 3' ends in the length of the base-paired regions.

Practical Example:

To detect the efficiency of dsRNA during specific inhibition of gene expression, transiently transfected NIH/3T3 cells (fibroblasts from NIH Swiss mouse embryo, ECCAC (European Collection of Animal Cell Cultures) no. 93061524) and HELA-S3 (human cervical carcinoma cells, DSMZ (German Collection of Microorganisms and Cell Cultures) no. ACC 161) were used. The plasmid pcDNA-YFP was used for transfection, which contains an 800 bp Bam HI/Eco RI-YFP fragment in the corresponding cleavage sites of the vector pcDNA3. Double-strand RNAs derived from the sequence of the yellow fluorescent protein (YFP) were produced and transiently transfected with the plasmid pcDNA-YFP in the fibroblasts (the employed specific dsRNAs are complementary in their anti-sense strands to the corresponding sections of the gene sequences above YFP and GFP). After 48 hours, the fluorescence reduction was quantified. Cells that were transfected either only with pcDNA-YFP or with pcDNA-YFP and a controlled dsRNA (not derived from the YFP sequence) functioned as controls.

Experimental Protocol:

dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA individual strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred by means of HPLC. The column NucleoPac PA-100, 9×250 mM, from the Dionex company was used; 20 mM tris, 10 mM NaClO₄, pH 6.8, 10% acetonitrile as low salt buffer and 20 mM Tris, 400 mM NaClO₄, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

Seeding of the Cells:

All cell culture work was conducted under sterile conditions in a corresponding work bench (HS18, Hera Safe, Kendro, Heraeus). Cultivation of NIH/3T3 cells and HELA-S3 occurred in an incubator (CO₂ incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO₂ and saturated atmospheric humidity in DMEM (Dulbecco's Modified Eagle Medium, Biochrom), for the mouse fibroblasts, and Ham's F12 for the HELA cells with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells underwent passage every 3 days. 24 hours before the forming transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of 1.0×10^4 cells/recess into a 96-well plate (Multiwell dishes 96-well flat bottom, Labor Schubert & Weiss GmbH) in 150 µL growth medium.

Performance of Transient Transfection:

Transfection was conducted with Lipofectamine PlusTM reagent (Life Technologies) according to the information of the manufacturer. 0.15 µg pcDNA-YFP plasmid was introduced per well. The total transfection volume was 60 µL. 3-fold samples were used in each case. Plasmid DNA was first complexed, together with dsRNA. For this purpose, the plasmid DNA and the dsRNA were diluted in a serum-free medium and 1 µL PLUS reagent was used per 0.1 µg plasmid DNA (in a volume of 10 µL) and, after mixing for 15 minutes at room temperature, they were incubated. During incubation, 0.5 µL Lipofectamine was diluted in a total of 10 µL serum-free medium per 0.1 µg plasmid DNA, thoroughly mixed, added to the plasmid/dsRNA/PLUS mixture and incubated for another 15 minutes. During incubation, a medium change was conducted. For this purpose, the cells were washed once with 200 µL serum-free medium and then with 40 µL serum-free medium and then incubated further in the incubator, up to addition of DNA/dsRNA/PLUS/Lipofectamine. After addition of 20 µL DNA/dsRNA/PLUS/Lipofectamine per well, the cells were incubated for 2.5 hours in the incubator. After incubation, the cells were then washed once with 200 µL growth medium and incubated for 24 hours until detection of the fluorescence in 200 µL growth medium in the incubator.

Detection of Fluorescence:

24 hours after the last medium change, the fluorescence of the cells was photographed on the fluorescence microscope (IX50-S8F2, fluorescence unit U-ULS100Hg, burner U-RFL-T200, Olympus) with a USH-I02D mercury lamp (USHIO Inc., Tokyo, Japan), equipped with a WIB fluorescence cube and a digital CCD camera (Orca IIIIm, Hamamatsu and C4742-95 camera controller). Evaluation of the fluorescence recording occurred with the analysis software 3.1 (Soft Imaging System GmbH, Germany). In order to relate the YFP fluorescence to cell density, a cell nucleus staining was carried out (Hoechst staining). For this purpose, the cells were first fixed for 5 in 100 μ L methycarnoy (75% methanol, 25% glacial acetic acid) and then again for 10 minutes in methycarnoy. After air drying, the fixed cells were incubated for 30 minutes in the dark with 100 μ L per well of Hoechst die (75 ng/mL). After washing twice with PBS (PBS Dulbecco w/o Ca^{2+} , M^{2+} , Biochrom), the Hoechst-stained cells were photographed under the fluorescence microscope (Olympus, WU fluorescence cube for Hoechst).

Figures 3 to 9 show the results on inhibition of YFP expression by dsRNA in the cultivated cells:

The effects of YFP-specific dsRNAs and control dsRNAs on YFP expression in NIH/3T3 mouse fibroblasts after transient transfection are summarized in Figures 3, 4, 5 and 6. The experiments were run as described in the experimental protocol. The concentration of dsRNA refers to the concentration in the medium during the transfection reaction. The designations for the dsRNAs can be gathered from Table 2. The relative fluorescence per image section in area percent is shown. 3 different image sections were evaluated per well. The averages are obtained from the 3-fold batches.

The specific inhibition of YFP gene expression by dsRNAs in HELA-S3 cells is shown in Figures 7 and 9. The inhibiting effect of differently configured dsRNA constructs (Table 2) in different concentrations on expression of YFP in HELA cells is shown in Fig. 7. Fig. 8 shows representative fluorescence microscope recordings of NIH/3T3 mouse fibroblasts transiently transfected with YFP without dsRNA and with dsRNA specifically directed against YFP ($\times 100$ magnification).

8A: YFP controls

8B: S1, 10 nM

- 8C: S4, 10 nM
- 8D: S7, 10 nM
- 8E: S7/S11, 1 nM
- 8F: S7/S12, 1 nM

Fig. 9 shows representative fluorescence microscope recordings of HELA-3S cells transiently transfected with YFP without dsRNA and with dsRNAs specifically directed against YFP ($\times 100$ magnification).

- 9A: K2-controls, 10 nM
- 9B: S1, 10 nM
- 9C: S4, 10 nM
- 9D: S7, 10 nM
- 9E: S7/11, 1 nM
- 9F: S7/12, 1 nM
- 9G: S1A/S4B, 10 nM
- 9H: YFP controls

Results:

Fig. 3 shows that YFP expression after transient cotransfection of mouse fibroblasts with the YFP plasmid and dsRNAs specifically directed against the YFP sequence is inhibited with particular efficiency when the 3' ends of the regions containing 22 and 19 base pairs of the dsRNAs have single-strand sections of two nucleotides (nt). Whereas the dsRNA S1 with smooth 3' ends at a concentration of 1 nM (referred to the concentration in the cell culture medium during performance and transfection) exhibits no inhibiting effect on YFP expression, the dsRNAs S7 (19 nucleotide pairs) and S4 (24 nucleotide pairs), each with 2 nt overhangs on both 3' ends, inhibit the YFP expression by 50 or by 70% in comparison with the corresponding control dsRNAs K3 and K2. At a concentration of 10 nM, the dsRNA denoted S1 with smooth ends inhibits YFP expression by about 65%, whereas inhibition of YFP expression by the dsRNA S4 is about 94% (Fig. 4). The inhibiting effects of the dsRNAs denoted S4 and S7 is concentration-dependent (Figures 3 and 4, see also Fig. 7).

Fig. 4 shows that, for efficient suppression of YFP gene expression, the single-strand structure is not necessary on both 3' ends (on the sense and anti-sense strand). To achieve the most effective possible inhibition of YFP expression, only the 2 nt overhang on the 3' end is necessary on the anti-sense strand. Inhibition of YFP expression at a concentration of 1 nM in the two dsRNAs S4 (with 2 nt overhangs on both 3' ends) and S1A/S4B (with the 2 nt overhang on the 3' end of the anti-sense strand) lies at about 70%. On the other hand, if the 2 nt overhang is situated on the 3' end of the sense strand (and the 3' end of the anti-sense strand carries no single-strand region), inhibition of YFP gene expression is only 50%. Similarly, inhibition at higher concentrations is much better, if at least the 3' end of the anti-sense strand carries a 2 nt overhang.

A more distinct inhibition of YFP expression is achieved, if the base-paired region has 21 nucleotide pairs instead of 22 (S1 and S4), 20 (S13 and S13/14) or 19 (S7) (Figures 5, 6 and 7). Inhibition of YFP expression by S1 (22 base pairs with smooth ends) in a concentration of 5 nM is about 40%, whereas inhibition by S7/S12 (21 base pairs with smooth ends), also with 5 nM, lies at about 92%. If the dsRNA with 21 base pairs also has a 2 nt overhang on the anti-sense strand 3' end (S7/S11), inhibition lies at ~ 97% (compared with ~ 73% inhibition with S4 and ~ 70% inhibition with S7).

III. Investigation of Serum Stability of Double-Strand RNA (dsRNA):

The objective is to increase the effectiveness found the cell cultures of inhibition of gene expression of target genes mediated by dsRNA for use in vivo. This is achieved by improved stability of the dsRNAs in serum and by an extended residence time of the molecule in the circulation and the increased effective concentration of the functional molecules related to this, resulting from improved stability.

Practical Example:

The serum stability of dsRNAs that inhibit GFP expression was tested in vivo in murine and human serum.

Experimental Protocol:

Incubation with human or murine serum with the corresponding dsRNA occurred at 37°C. 85 µL serum was incubated with 15 µL 100 µM dsRNA. After specified incubation times (30 minutes, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h), the samples were frozen at -80°C. dsRNA without serum (+ 85 µL ddH₂O) and dsRNA at time 0 were used as control.

For isolation of the dsRNA from the incubation charge, which occurred on ice, 400 µL with 0.1% SDS was added to the charges and these are subjected to phenol extraction: 500 µL phenol:chloroform:isoamyl alcohol (IAA, 25:24:1, Roti[®]-Phenol, Roth, Karlsruhe) was added per charge and vortexed for 30 seconds at the highest stage (Vortex Genie-2; Scientific Industries). After 10 minutes of incubation on ice, phase separation occurred by centrifuging at 12,000 × g, 4°C for 10 minutes (Sigma 3K30, Rotor 12131-H). The upper aqueous phase (about 200 µL) was taken off and subjected first to DNase I and the proteinase K digestion: addition of 20 µL 10-fold DNase I buffer (100 mM Tris, pH 7.5, 25 mM MgCl₂, 1 mM CaCl₂) and 10 U DNase I (D7291, Sigma-Aldrich), 30 minutes incubation at 37°C, addition of 6 U DNase I again and incubation for another 20 minutes at 37°C, addition of 5 µL proteinase K (20 mg/mL, 04-1075, Peqlab, Germany) and 30 minutes incubation at 37°C. Phenol extraction was then conducted. For this purpose, 500 µL phenol:chloroform:IAA (25:24:1) was added, vortexed at the highest stage for 30 seconds, 10 minutes for 12000 × g, 4°C, centrifuged, the supernatant taken off and mixed in succession with 40 µL 3M Na-Ac (sodium acetate), pH 5.2, and 1 mL 100% EtOH, mixed thoroughly in the meantime and precipitated for at least 1 hour at -80°C. The precipitate was pelletized by centrifuging at 12000 × g for 30 minutes and 4°C, washed with 70% EtOH and recentrifuged (10 minutes, 12000 × g, 4°C). The air dried pellet was taken up in 30 µL RNA gel application buffer (7 M urea, 1 × TBE (0.09 M tris-borate, 0.002 M EDTA

(ethylenediaminetetraacetate), 0.02% (w/v) bromophenol blue, 0.02% (w/v) xylene cyanol) and stored at -20°C until gel application.

For characterization of the dsRNA, an analytical, denaturing polyacrylamide gel electrophoresis (analytical PAGE) was conducted. The urea gels were prepared right before the run: 7 M urea (21 g) was dissolved during agitation in 25 mL 40% aqueous acrylamide/bisacrylamide stock solution (Rotiphoresis gel, A515.1, Roth) and 5 μ L 10 \times TBE (100 g Tris, 55 g boric acid, 9.3 g EDTA per L distilled water) and made up to 50 μ L with distilled water. Right before pouring, 50 μ L TEMED (N,N,N',N'-tetramethylethylenediamine) and 500 μ L 10% APS (ammonium peroxodisulfate) were added. After polymerization, the gel was introduced to a vertical electrophoresis apparatus (Merck, Darmstadt) and a prerun was conducted for 30 minutes at a constant 40 mA current intensity. As run buffer, 1 \times TBE buffer was used. Before application onto the gel, the RNA samples were heated for 5 minutes at 100°C, cooled on ice and centrifuged for 20 seconds in a table-top centrifuge (Eppendorf, minispin). 15 μ L was applied to the gel. The run occurred for about 2 hours at a constant current of 40 mA. After the run, the gel was stained for 30 minutes at RT (room temperature) with Stains all stain solution (20 mL Stains all stock solution dissolved in 200 mL formamide) mixed with 200 mL distilled water and 180 mL formamide) and the background staining eliminated after rinsing in distilled water for 45 minutes. The gels were photographed with the photo documentation system Image Master VDS from Pharmacia.

Figures 10 to 17 show the serum stability of dsRNA after incubation with human and murine serum and subsequent electrophoretic separation in 20% 7 M urea gel.

Fig. 10: Incubation of S2 (0-22-0) in mouse serum

1. at time 0 (without serum)
2. at time 0
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours

7. for 12 hours
8. 2 μL 100 μM S1 without incubation
- S1A) Sense strand S1 (10 μL 20 μM S1A)
- S1B) Anti-sense strand S1 (10 μL 20 μM S1B)

Fig. 11: Incubation of S1 (0-22-0) in human serum

1. 2 μL 100 μM S1 untreated (without incubation)
2. for 30 minutes
3. for 2 hours
4. for 4 hours
5. for 6 hours
6. for 8 hours
7. for 12 hours
8. for 24 hours
- S1A) Sense strand S1 (10 μL 20 μM S1A)
- S1B) Anti-sense strand S1 (10 μL 20 μM S1B)

Fig. 12: Incubation at S7 (2-19-20) in mouse serum

1. at time 0 (without serum)
2. for 30 minutes
3. for 4hours
4. for 12 hours

Fig. 13: Incubation of S7 (2-19-2) in human serum

1. Sense strand S7 (10 μL 20 μM S7A)
2. Anti-sense strand S7 (10 μL 20 μM S7B)
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours
7. for 6 hours

8. for 12 hours
9. for 24 hours
10. at time 0 (without serum)

Fig. 14: Incubation of K3 (2-19-20) in mouse serum

1. Sense strand K3 (10 μ L 20 μ M K3A)
2. Anti-sense strand K3 (10 L 20 μ M K3B)
3. at time 0 (without serum)
4. at time 0 (with serum)
5. for 30 minutes
6. for 1 hour
7. for 2 hours
8. for 4 hours
9. for 12 hours

Fig. 15: Incubation of PKC1/2 (0-22-2) in mouse serum

1. for 30 minutes
2. for 1 hour
3. for 2 hours
4. for 4 hours
5. for 12 hours
6. 2 μ L 100 μ M PKC1/2 (untreated)

Fig. 16: Incubation of S1A/S4B (0-22-2) in human serum

1. at time 0 (without serum)
2. for 24 hours
3. for 12 hours
4. for 8 hours
5. for 6 hours
6. for 4 hours
7. for 2 hours

8. for 30 minutes
9. Sense strand S1A (10 μ L 20 μ M S1A)
10. Anti-sense strand S4B (10 μ L 20 μ M S4B)

Fig. 17: Incubation of K2 (2-22-2) in human serum

1. Sense strand K2 (10 μ L 20 μ M K2A)
2. Anti-sense strand K2 (10 μ L 20 μ M K2B)
3. at point 0 (without serum)
4. for 30 minutes
5. for 2 hours
6. for 4 hours
7. for 6 hours
8. for 8 hours
9. for 12 hours
10. for 24 hours

Results:

dsRNAs without single-strand regions on the 3' ends are much more stable in both human and murine serum than dsRNAs with single-strand 2nt overhangs on the 3' ends (Figures 10 to 14 and 17). After 12 and 24 hours incubation at S1 in murine or human serum, bands in the original size are almost fully retained. On the other hand, in dsRNAs with 2nt overhangs on both 3' ends, the stability in human and murine serum diminishes significantly. After only 4 hours of incubation of S7 (Figures 12 and 13) or K3 (Fig. 14), no bands can be detected in the original size.

In order to increase the stability of dsRNA in serum, it is sufficient if the dsRNA has a smooth end. In mouse serum after 4 hours incubation (Fig. 15, track 4), the bands in the original size are scarcely broken down in comparison with S7 (after 4 hours complete degradation; Fig. 12, track 3).

As an optimal compromise with respect to biological efficacy of dsRNA, the use of dsRNA with a smooth end and a single-strand region of 2 nucleotides can be considered, in which the single-strand overhang should be situated on the 3' end of the anti-sense strand.

The sequences used here are apparent from the following Table 2 and the sequence protocols SQ148-151 and 153-167.

Name	Sequenz- proto- koll-Nr.	dsRNA-Sequenz	
S1	SQ148 SQ149	(A) 5' - CCACAUGAAGCAGCACGACUUC -3' (B) 3' - GGUGUACUUCGUCGUGCUGAAG -5'	0-22-0
S7	SQ150 SQ151	(A) 5' - CCACAUGAAGCAGCACGACUU -3' (B) 3' - CUGGUGUACUUCGUCGUGCUG -5'	2-19-2
K1	SQ153 SQ154	(A) 5' - ACAGGAUGAGGAUCGUUUCGCA -3' (B) 3' - UGUCCUACUCCUAGCAAAGCGU -5'	0-22-0
K3	SQ155 SQ156	(A) 5' - GAUGAGGAUCGUUUCGCAUGA -3' (B) 3' - UCCUACUCCUAGCAAAGCGUA -5'	2-19-2
K2	SQ157 SQ158	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3' (B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	2-22-2
S1A/ S4B	SQ148 SQ159	(A) 5' - CCACAUGAAGCAGCACGACUUC -3' (B) 3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	0-22-2

PKC 1/2	SQ160	(A)	5' - CUUCUCCGCCUCACACCGCUGCAA -3'	2-22-0
	SQ161	(B)	3' - GAAGAGGCGGAGUGUGGCGACG -5'	
S7/S12	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-0
	SQ162	(B)	3' - GGUGUACUUCGUCGUGCUGAA -5'	
S7/S11	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-2
	SQ163	(B)	3' - CUGGUGUACUUCGUCGUGCUGAA -5'	
S13	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-2
	SQ165	(B)	3' - CUGGUGUACUUCGUCGUGCUGA -5'	
S13/14	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-0
	SQ166	(B)	3' - GGUGUACUUCGUCGUGCUGA -5'	
S4	SQ167	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-2
	SQ159	(B)	3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	
K1A/ K2B	SQ153	(A)	5' - ACAGGAUGAGGAUCGUUUCGCA -3'	0-22-2
	SQ158	(B)	3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	
K1B/ K2A	SQ154	(A)	5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-0
	SQ157	(B)	3' - UGUCCUACUCCUAGCAAAGCGU -5'	
S1B/ S4A	SQ149	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-0
	SQ167	(B)	3' - GGUGUACUUCGUCGUGCUGAAG -5'	

Key to figure: (Headings)

Name

Sequence protocol no.

dsRNA sequence

Table 2

IV. In Vivo Study:

Double-strand RNA (dsRNA) that was derived from the GFP sequence where unspecific dsRNA was injected intravenously into the caudal vein of “GFP laboratory mice” that express the green fluorescent protein (GFP) in all cells that conduct protein biosynthesis. At the end of the experiment, the animals were killed and the GFP expression analyzed in tissue sections and in plasma.

Experimental Protocol:

Synthesis of dsRNA:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA single strands apparent from the sequence protocols and the single strand complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. As columns, NucleoPac PA-100, 9 × 250 mm from the Dionex company were used; 20 mM Tris, 10 mM NaClO₄, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO₄, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

Experimental Animal Keeping and Performance of the Experiment

The transgenic laboratory mouse strain TgN (GFPU) 5Nagy (Jackson Laboratory, Bar Harbor, Maine, USA) was used, which expresses GFP (with a beta-actin promoter and a CMV intermediate early enhancer) in all previously investigated cells (Hadjantonakis AK et al. 1993, Mech. Dev. 76: 79-90; Hadjantonakis AK et al., 1998 Nature Genetics 19: 220-222). GFP-transgenic mice can be clearly distinguished from the corresponding wild types (WT) by means of fluorescence (with a UV hand lamp). For breeding, the corresponding WT was paired with a heterozygous GFP type.

The experiment was performed according to the German Animal Protection Regulations. The animals were kept under controlled environmental conditions in groups of 3-5 animals in type III Makrolon cages from the Ehret company, Emmendingen, at a constant temperature of 22°C and a light-dark rhythm of 12 h. Softwood granulate 8/15 from the Altromin company, Lage, was used as sawdust litter. The animals received tap water and standard feed Altromin 1324 pelletized (Altromin) ad libitum.

To perform the experiment, the heterozygous GFP animals were kept in groups of 3 animals each in cages, as described above. Injections of the dsRNA solution occurred intravenously (IV) into the caudal vein in 12-hour cycles (between 5:30 and 7:00 a.m. and between 5:30 and 7:00 p.m.) over 5 days. The injection volumes were 60 µL for per 10 g of body weight and the dose was 2.5 mg dsRNA and 50 µg per kg of body weight. Division into groups was as follows:

- Group A: PBS (phosphate buffered saline) 60 µL per 10 kg of body weight,
- Group B: 2.5 mg per kg of body weight of a nonspecific control dsRNA (K1 control with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group C: 2.5 mg per kg of body weight of another unspecific control dsRNA (K3 control with 2nt overhangs on both 3' ends and a double-strand region of 19 nucleotide pairs),
- Group D: 2.5 mg per kg of body weight dsRNA (specific against GFP, subsequently referred to as S1, with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group E: 2.5 mg dsRNA per kg of body weight (specific against GFP, subsequently referred to as S7, with 2nt overhangs on the 3' ends of both strands and a double-strand region of 19 nucleotide pairs)
- Group F: 50 µg S1-dsRNA per kg of body weight (i.e., 1/50 of the dose of group D).

After the last injection of a total of 10 injections, the animals were killed after 14-20 h and the organs and blood taken as described.

Organ Removal:

Immediately after killing the animals by CO₂ inhalation, blood and different organs were taken (thymus, lungs, heart, spleen, stomach, intestines, pancreas, brain, kidneys and liver). The organs were rinsed briefly in cold sterile PBS and divided with a sterile scalpel. One part was fixed for immunohistochemical staining in methycarnoy's (MC, 60% methanol, 30% chloroform, 10% glacial acetic acid) for 24 hours, one part was shock frozen for frozen sections and for protein isolation immediately in liquid nitrogen and stored at -80°C, and another smaller part was frozen for RNA isolation in RNaseasy-Protect (Qiagen) at -80°C. The blood was immediately held for 30 minutes on ice after sampling, mixed, centrifuged for 5 minutes at 2000 rpm (Mini spin, Eppendorf), the supernatant removed and stored at -80°C (here referred to as plasma).

Processing of the Biopsies:

After 24 h of fixation of the tissue in MC, the tissue pieces were dehydrated in an increasing alcohol series at RT (room temperature): every 40 minutes 70% methanol, 80% methanol, 2 × 96% methanol and 3 × 100% isopropanol. The tissue was then heated in 100% isopropanol to 60°C in an incubator, then incubated for 1 hour in an isopropanol/paraffin mixture at 60°C and 3 × for 2 hours in paraffin and then imbedded in paraffin. For immunoperoxidase staining, tissue sections with 3 µm section thickness were prepared with a rotary microtome (Leica), mounted on slides (Superfrost, Vogel) and incubated for 30 minutes at 60°C in an incubator.

Immunoperoxidase Staining versus GFP:

The sections were deparaffinized 3 × 5 minutes in xylene, rehydrated in an increasing alcohol series (3 × 3 min 100% ethanol, 2 × 2 min 95% ethanol) and then incubated for 20 minutes in 3% H₂O₂/methanol to block endogenous peroxidases. All incubation steps were conducted subsequently in a moist chamber. After 3 × 3 minutes of washing with PBS, they were incubated

with the first antibody (goat anti-GFP, sc-5384, Santa Cruz, Biotechnology) 1:500 in 1% BSA/PBS overnight at 4°C. Incubation with the biotinylated secondary antibody (donkey anti-goat; Santa Cruz Biotechnology; 1:2000 dilution) occurred for 30 minutes at RT, whereupon they were incubated for 30 minutes with Avidin D Peroxidase (1:2000 dilution, Vector Laboratories). After each antibody incubation, the sections were washed 3 × 3 min in PBS and the buffer residues removed from the sections with wadding. All antibodies were diluted in 1% bovine serum albumin (BSA)/PBS. Staining with 3,3'-diaminobenzidine (DAB) was conducted with the DAB substrate kit (Vector Laboratories) according to the manufacturer's data. As nuclear counterstain, hematoxylin III according to Gill (Merck) was used. After dehydration in a rising alcohol series at 3 × 5 minutes xylene, the sections were covered with Entellan (Merck). Microscopic evaluation of staining occurred with the IX50 microscope from Olympus, equipped with a CCD camera (Hamamatsu).

Protein Isolation from Tissue Pieces:

800 µL isolation buffer (50 mM HEPES, pH 7.5, 150 mM NaCl; 1 mM EDTA; 2.5 mM EGTA; 10% glycerol; 0.1% Tween; 1 mM DTT, 10 mM β-glycerol phosphate; 1 mM NaF; 0.1 mM Na₃VO₄ with a protease inhibitor tablet "Complete" from Roche) were added to the still frozen tissue pieces and homogenized 2 × 30 seconds with an Ultraturrax (DIAX 900, dispersal die 6 G, Heidolph), and cooled in between on ice. After 30 minutes of incubation on ice, they were mixed and centrifuged for 20 minutes at 1000 × g, 4°C (3K30, Sigma). The supernatant was incubated for another 10 minutes on ice, mixed and centrifuged for 20 minutes to 15000 × g, 4°C. A protein determination according to Bradford, 1976, modified after Zor & Selinger, 1996, was conducted with the supernatant with the Roti-Nanoquant system of Roth according to the data of the manufacturer. BSA (bovine serum albumin) in concentrations from 10 to 100 µg/mL was used for the protein calibration line.

SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multigel long electrophoresis chamber from Biometra with a denaturing, discontinuous 15% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 1970). For this purpose, a

separation gel 1.5 mM thick was initially poured: 7.5 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1.5 M Tris/HCl, pH 8.4, 150 μ L 10% SDS, 3.3 mL doubly distilled water, 250 μ L ammonium persulfate (10%), 9 μ L TEMED (N,N,N',N'-tetramethylethylenediamine) and coated up to polymerization with 0.1% SDS. The collected gel was then poured: 0.83 μ L acrylamide/bisacrylamide (30%/0.9%), 630 μ L 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50 μ L 10% SDS, 50 μ L 10% ammonium persulfate, 5 μ L TEMED.

Before application of the gel, the proteins were mixed with a corresponding amount of 4-fold sample buffer (200 mM Tris, pH 6.8, 4% SDS, 100 mM DTT (dithiothreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes in a heating unit at 100°C, briefly centrifuged after cooling on ice and applied to the gel. The same plasma or protein amounts were used per track (3 μ L plasma and 25 μ g total protein each). Electrophoresis occurred water-cooled at RT and a constant 50 V. The protein gel marker from Bio-Rad (kaleidoscope prestained standard) was used as length standard.

Western Blot and Immune Detection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinylidene difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyte-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.8 mA/cm² for 1.5 h. A Tris/glycine buffer was used as transfer buffer (39 mM glycine, 465 mM Tris, 0.1% SDS and 20% methanol). To check the electrophoretic transfer, both the gels after blotting and the blot membranes after immune detection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid). For saturation of nonspecific bonds, the blot membrane after transfer was incubated in 1% skim milk powder/PBS for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (goat anti-GFP, sc 5384, Santa Cruz Biotechnology) occurred in a dilution of 1:1000 for 1 h at RT. It was then washed 3 \times 5 min and incubated for 1 hour at RT with a secondary antibody (donkey anti-goat IgG horseradish peroxidase labeled, Santa Cruz Biotechnology) in a dilution of 1:1000. Detection occurred with the ECL system from Amersham according to the data of the manufacturer.

Figures 18 to 20 show inhibition of GFP expression after intravenous injection of dsRNA specifically directed against GFP with immunoperoxidase staining relative to GFP on 3 μ m paraffin sections. During the experiment, dsRNA directed against GFP with a double-strand region of 22 nucleotide (nt) pairs without overhangs on the 3' ends (D) and the corresponding unspecific control dsRNA (B), as well as dsRNA directed specifically against GFP with a double-strand region containing 19 nucleotide pairs with 2 nt overhangs on the 3' ends (E) and the corresponding nonspecific control dsRNA (C) were applied in 12-hour cycles over 5 days. (F) received 1/50 of the dose of group D. Animals without dsRNA administration (A) and WT animals were investigated as additional controls. Fig. 18 shows inhibition of GFP expression in kidney sections, Fig. 19 in heart tissue and Fig. 20 in pancreas tissue. Figures 21 to 23 show Western blot analyses of GFP expression in plasma and tissues. Inhibition of GFP expression in plasma is shown in Fig. 21, in the kidneys in Fig. 22 and in the heart in Fig. 23. Total protein isolates from different animals are shown in Fig. 23. The same total protein amounts per track were applied. In the animals, to which unspecific control dsRNA was administered (animals of groups B and C), the GFP expression relative to animals that received no dsRNA is not reduced. Animals that received dsRNA specifically directed against GFP with 2 nt overhangs on the 3' ends of both strands and a double-strand region containing 19 nucleotide pairs exhibited a significantly inhibited GFP expression in the investigated tissues (heart, kidneys, pancreas and blood), compared with the untreated animals (Figures 18 to 23). In the animals of groups D and F, in which dsRNA directed specifically against GFP with smooth ends and double-strand region containing 22 nucleotide pairs was administered, only those animals that received dsRNA in a dose of 50 μ g/kg of body weight per day exhibited a specific inhibition of GFP expression, which, however, was much less pronounced than that of the animals in group E. The summarizing evaluation of GFP inhibition in the tissue sections and in Western blot shows that inhibition of GFP expression in blood and the kidneys is strongest (Figures 18, 21 and 22).

V. Inhibition of Gene Expression of EGF Receptor with dsRNA as a Therapeutic Approach in Forms of Cancer with EGFR Overexpression or EGFR-induced Proliferation:

The epidermal growth factor (EGF) receptor (EGFR) belongs to the receptor tyrosine kinases, transmembrane proteins with an intrinsic tyrosine kinase activity, which participate in the control

of a series of cellular processes, like cell growth, cell differentiation, migratory processes or cell vitality (review in: Van der Geer et al. 1994). The EGFR family consists of 4 members, EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) with a transmembrane domain, a cysteine-rich extracellular domain and an intracellular catalytic domain. The sequence of EGFR, a 170 kDa protein, has been known since 1984 (Ullrich et al., 1984).

EGFR is activated by peptide growth factors, like EGF, TGF α (transforming growth factor), amphiregulin, beta-cellulin, HB-EGF (heparin-binding EGF-like growth factor) and neuregulin. Ligand bonding induces formation of homo- or heterodimers with subsequent autophosphorylation of cytoplasmic tyrosine (Ullrich & Schlessinger, 1990; Alroy & Yarden, 1997). The phosphorylated amino acids form the bonding sites for a number of proteins that participate in the proximal steps of signal conduction in a complex network. EGFR participates in a wide variety of tumor diseases and is therefore a suitable target for therapeutic approaches (Huang & Harari, 1999). The mechanisms that lead to an aberrant EGFR activation can be due to overexpression, amplification, constituted activation of mutant receptor forms or autocrine loops (Voldborg et al., 1997). An overexpression of EGFR was described for a number of tumors, like breast cancer (Walker & Dearing, 1999), non-small lung carcinoma (Fontanini et al., 1998), pancreatic carcinomas, colon carcinoma (Salomon et al., 1995) and glioblastomas (Rieske et al., 1998). No efficient and specific therapeutic agents have thus far been available for malignant glioblastomas, in particular.

Practical Example:

To demonstrate the efficacy of dsRNA during specific inhibition of EGFR gene expression, U-87 MG cells (human glioblastoma cells), ECCAC (European Collection of Animal Cell Cultures) no. 89081402 were used, which were transfected with dsRNA directed specifically against the EGF receptor (sequence protocol SQ 51). After about 72 hours' incubation, the cells were harvested, the protein isolated and the EGFR expression investigated in the Western blot method.

Experimental Protocol:

dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and an ordinary chemical method, the RNA single strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. The column NucleoPac PA-100, 9 × 250 mm, from the Dionex company was used; 20 mM Tris, 10 mM NaClO₄, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO₄, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double-strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

Seeding of the Cells:

All cell culture work was conducted under sterile conditions and an appropriate work bench (HS18, Her safe, Kendro, Heraeus). Cultivation of U-87 MG cells occurred in an incubator (CO₂ incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO₂ and saturated atmospheric humidity in DMEM (Dulbecco's modified eagle medium, Biochrom) with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom), 1 mM sodium pyruvate (Biochrom), 1 × NEAA (nonessential amino acids, Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells were subjected to passage every 3 days. 24 hours before application of dsRNA by transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of 5 × 10⁵ cells/well in a 6-well plate (6-well plates, Labor Schubert & Weiss GmbH) in 1.5 mL growth medium.

Application of dsRNA in Cultivated U-87 MG Cells:

Application of dsRNA occurred by transfection with OLIGOFECTAMINE™ reagent (Life Technologies) according to the information of the manufacturer. The total transfection volume was 1 mL. The dsRNA was first diluted in serum-free medium: for this purpose, 0.5 µL of a 20

μm stock solution of dsRNA specifically directed against EGFR and 9.5 μL of a 20 μm stock solution of unspecific dsRNA (K1A/K2B) with 175 μL serum-free medium were diluted per well (200 nM dsRNA in transfection charge and 10 nM specific EGFR-dsRNA). The OLIGOFECTAMINETM reagent was also diluted in serum-free mediums: 3 μL with 12 μL medium per well and then incubated for 10 minutes at room temperature. The diluted OLIGOFECTAMINETM reagent was then added to the dsRNAs diluted in medium, mixed and incubated for another 20 minutes at RT. During incubation, a medium change was performed. The cells were washed for this purpose once with 1 mL serum-free medium and incubated further in the incubator with 800 μL serum-free medium, up to addition of dsRNA/OLIGOFECTAMINETM reagent. After addition of 200 μL dsRNA/OLIGOFECTAMINETM reagent per well, the cells were further incubated in the incubator to protein isolation.

Protein Isolation:

About 72 hours after transfection, the cells were harvested and protein isolation carried out. For this purpose, the medium was removed and the cell monolayer washed once with PBS. After addition of 200 μL protein isolation buffer (1 \times protease inhibitor “Complete”, Roche, 50 mM HEPES, pH 7.5, 1509 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 10% glycerol, 0.1% Tween-20, 1 mM DTT, 10 mM β -glycerol phosphate, 1 mM NaF, 0.1 mM Na_3VO_4), the cells were separated by means of a cell scraper, incubated for 10 minutes on ice, transferred to an Eppendorf reaction vessel and stored at -80°C for at least 30 minutes. After thawing, the lysate was homogenized on stage 3 for 10 seconds with a disperser (DIAX 900, dispersing die 6G, Heidolph Instruments GmbH & Co KG, Schwabach), incubated on ice for 10 minutes and centrifuged for 15 minutes at $14000 \times g$, 4°C (3K30, Sigma). A protein determination was conducted with the supernatant according to Bradford with the Roti[®] Nanoquant system from Roth (Roth GmbH & Co., Karlsruhe) according to the information of the manufacturer. For this purpose, 200 μL protein solution in appropriate dilution was mixed with 800 μL 1 \times working solution and the extinction measured in semi-microcells at 450 and 590 nm versus distilled water in a Beckman spectrophotometer (DU 250). The corresponding BSA dilutions were used for the calibration line (beaded BSA, Sigma).

SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multi-gel long electrophoresis chamber from Biometra with a denaturing, discontinuous 7.5% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 197). For this purpose, a separation gel was initially poured with 1.5 mm thickness: 3.7 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1 M Tris/HCl, pH 8.4, 150 µL 10% SDS, 7.15 mL doubly distilled water, 150 µL ammonium persulfate (10%), 9 µL TEMED (N,N,N',N'-tetramethylethylenediamine) and coated with 0.1% SDS to polymerization. The collection gel was then poured: 0.83 mL acrylamide/bisacrylamide (30%/0.9%), 630 µL 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50 µL 10% SDS, 50 µL 10% ammonium persulfate, 5 µL TEMED.

For application to the gel, the protein samples were mixed 1:3 with 4 × sample buffer (200 mM Tris, pH 6.8, 4% SDS, 100 mM DTT (dithiothreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes at 100°C, briefly centrifuged after cooling on ice and applied to the gel. 35 µg total protein was applied per track. The run occurred water cooled at RT and a constant 50 V. The kaleidoscope protein gel marker (BioRad) was used as length standard.

Western Blot and Immunodetection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinylidene difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyte-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.5 mA/cm² for 1.5 h. The following were used as transfer buffer: cathode buffer (30 mM Tris, 40 mM glycine, 10% methanol, 0.01% SDS; pH 9.4), anode buffer I (300 mM Tris, pH 10.4, 10% methanol) and anode buffer II (30 mM Tris, pH 10.4, 10% methanol). Before combining the blot stack with 3 mm Whatman paper (Schleicher & Schüll), the gel was incubated in the cathode buffer and the PVDF membrane (30 seconds beforehand in 100% methanol) in anode buffer II (5 min): 2 layers 3 mm paper (anode buffer I), 1 layer 3 mm paper (anode buffer II), PVDF membrane, gel, 3 layers 3 mm paper (cathode buffer). To check electrophoretic transfer, both the gels after blotting and the blot membranes after immunodetection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid).

The blot membrane was incubated after transfer in 1% skim milk powder/ PBS/0.1% Tween-20 for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (human EGFR extracellular domain, specific goat IgG, catalog no. AF231, R&D Systems) occurred on a rocking device for 2 h at RT and a concentration of 1.5 µg/mL. It was then washed 3 × for 6 minutes and incubated for 1 hour at RT with the secondary antibody (donkey anti-goat IgG horseradish peroxidase label, Santa Cruz Biotechnology) (diluted 1:10000). After washing (3 × 3 min in PBS/0.1% Tween-20), detection occurred immediately with ECL reaction (enhanced chemiluminescence): 200 µL solution A (250 mM luminol, Roth, dissolved in DMSO), 89 µL solution B (90 mM p-coumaric acid, Sigma, dissolved in DMSO) and 2 mL 30% H₂O₂ solution were pipetted into 18 mL distilled water. Depending on the membrane size, 4-6 mL was pipetted directly onto the membrane, incubated for 1 minute at RT and then an x-ray film (Biomax MS, Kodak) applied immediately.

The sequences used here are shown in the following Table 3 and in the sequence protocols S!153, 157, 158, 168-173.

ES-7	SQ168	(A) 5' - AACACCGCAGCAUGUCAAGAU -3'	2-19-2
	SQ169	(B) 3' - UUUUGUGGCGUCGUACAGUUC -5'	
ES-8	SQ170	(A) 5' - AAGUUAAAUCCCCGUCGCUAU -3'	2 ⁵ -19-2 ⁵
	SQ171	(B) 3' - CAAUUUUAAGGGCAGCGAUAGU -5'	
ES2A/ ES5B	SQ172	(A) 5' - AGJGUGAUCCAAGCUGUCCCAA -3'	0-22-2
	SQ173	(B) 3' - UUUCACACUAGGUUCGACAGGGUU -5'	
K2	SQ157	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-2
	SQ158	(B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	

K1A/ K2B	SQ153	(A)	5' - ACAGGAUGAGGAUCGUUUCGCA	-3'	0-22-2
	SQ158	(B)	3' - UCUGUCCUACUCCUAGCAAAGCGU	-5'	

Table 3

Inhibition of EGFR Expression in U-87 MG Glioblastoma Cells:

24 hours after seeding of the cells, they were transfected with 10 nM dsRNA as stated (oligofectamine). After 72 hours, the cells were harvested and the protein isolated. Separation of the proteins occurred in 7.5% SDS-PAGE. 35 µg total protein was applied per track. Fig. 4 shows the corresponding Western blot analysis, from which it follows that the EGFR expression after transfection in U-87 MG cells can be significantly inhibited relative to the corresponding controls with the dsRNA specifically directed against the EGFR gene with a 2 nt overhang on the 3' end of the anti-sense strand. This inhibition of expression of an endogenous gene by specific dsRNA therefore confirms the results stated in the practical example II concerning inhibition of expression of an artificial gene introduced to the cell after transient transfection. The inhibition of EGFR expression mediated by ES-7 and ES-8 is much lower. The dsRNAs used in Fig. 24 can be gathered from Table 3.

VI. Inhibition of Expression of the Multidrug Resistance Gene 1 (MDR1):

Experimental Protocol:

In vitro detection for blocking of MDR1 expression was conducted in the colon carcinoma cell line LS174T (ATCC – American Type Culture Collection, Tom et al., 1976). It is known of this cell line that expression of MDR1 can be induced by addition of rifampicin to the culture medium (Geick et al., 2001). Transfections were conducted with different commercial transfection kits (Lipofectamine, Oligofectamine, both Invitrogen; TransMessenger, Qiagen), in which the TransMessenger transfection kit also proved to be best suited for this cell line.

To run the RNA interference experiments, 4 short double-strand ribonucleic acids R1-R4 were used, whose sequences are shown in Table 4. The ribonucleic acids are homologous with sections of the coding sequence of MDR1 (sequence protocol SQ 30). Sequences R1-R3 consists of a 22-mer sense and a 24-mer anti-sense strand, in which the forming double-strand has a two nucleotide overhang on the 3' end of the anti-sense strand (0-22-2). The sequence R4 corresponds to R1, but consists of a 19-mer double strand with 2 nucleotide overhangs on each 3' end (2-19-2).

<u>Name</u>	<u>Sequenz- proto- koll-Nr.</u>	<u>Sequenz</u>	<u>Position in Daten- bank-# AF016535</u>
Seq R1	SQ141 SQ142	5' - CCA UCU CGA AAA GAA GUU AAG A-3' 3' -UG GGU AGA GCU UUU CUU CAA UUC U-5'	1320-1342 1335-1318
Seq R2	SQ143 SQ152	5' - UAU AGG UUC CAG GCU UGC UGU A-3' 3' -CG AUA UCC AAG GUC CGA ACG ACA U-5'	2599-2621 2621-2597
Seq R3	SQ144 SQ145	5' - CCA GAG AAG GCC GCA CCU GCA U-3' 3' -UC GGU CUC UUC CGG CGU GGA CGU A-5'	3778-3799 3799-3776
Seq R4	SQ146 SQ147	5' - CCA UCU CGA AAA GAA GUU AAG-3' 3' -UG GGU AGA GCU UUU CUU CAA U -5'	1320-1341 1339-1318
			<u>Position in Daten- bank-# AF402779</u>
K1A/ K2B	SQ153 SQ158	5' - ACA GGA UGA GGA UCG UUU CGC A-3' 3' -UC UGU CCU ACU CCU AGC AAA GCG U-5'	2829-2808 2808-2831

Key to figure: (Headings)

Name

Sequence Protocol no.

Sequence

Table 4

The sequences shown in Table 4 are shown again in the sequence protocol as sequences SQ 141-147, 152, 153, 158. The dsRNAs were transfected in a concentration of 175 nM as double charges into the cells, which were seeded the day before in 12-well plates at 3.8×10^5 cells/well. For this purpose, 93.3 μ L EC-R buffer (TransMessenger kit, Qiagen, Hilden) was mixed with 3.2 μ L Enhancer-R per transfection charged, thoroughly mixed and incubated for 5 minutes at room temperature. After addition of 6 μ L TransMessenger transfection reagent, the transfection charges were vigorously mixed for 10 seconds and incubated for 10 minutes at room temperature. In the meantime, the medium was withdrawn from the cells by suction, washed once with PBS (phosphate buffered saline) and 200 μ L fresh medium without FCS per well was added to the cells. After 10 minutes of incubation, 100 μ L FCS-free medium was pipetted into the transfection charged, mixed and the mixture pipetted dropwise into the cells (the dsRNA concentration of 175 μ M refers to 400 μ L of medium total volume). The dsRNA/TransMessenger complexes were incubated for 4 hours at 37°C with the cells in FCS-free medium. A medium change was then conducted, in which the fresh medium contained 10 μ M Rifampicin and 10% FCS. As control, and unspecific dsRNA sequence, having no homology with the MDR1 gene sequence, was used (K) and a MOCK transfection carried out, which contained all reagents, except dsRNA.

The cells were harvested after 24, 48 and 72 hours and a total RNA extracted with the RNeasy-Mini-Kit from Qiagen. 10 μ g total RNA of each sample was separated on a 1% agarose formaldehyde gel electrophoretically, blotted onto a nylon membrane and specific probes, random marked with 5'- α^{32} -P-dCTP, were hybridized exposed first relative to MDR1 and, after stripping of the blot, relative to GAPDH as internal control and exposed on x-ray film.

The x-ray films were digitized (Image Master, VDS Pharmacia) and quantified with the Image-Quant software. Balancing of the MDR1-specific bands with the corresponding GAPDH bands was then carried out.

Results:

Figures 25 and 26 show Northern blots (Figures 25a, 26a) with quantitative evaluation of the MDR1-specific bands after balancing with the corresponding GAPDH values (Figures 25b, 26b). A reduction of MDR1-mRNA by up to 55% could be observed in comparison with MOCK transfection and by up to 45% in comparison with unspecific control transfection. After 48 h, a significant reduction of MDR1-mRNA levels was achieved with the dsRNA constructs designated R1, R2, R3 (Table 4). After 48 hours, no significant reduction relative to the controls was observed with the R4 dsRNA constructs (Figures 26a, 26b). After 72 hours, a much stronger reduction of MDR1-mRNA levels was observed with R1, R2 and R2 relative to the controls, in comparison with the 48-hour values (Figures 25a and 25b).

With R4 at this point a significant reduction of MDR1-mRNA levels could also be achieved. The constructs with a 2 nt overhang on the 3' end of the anti-sense strand and a double-strand region of 22 nucleotide pairs therefore reduced the MDR1-mRNA more efficiently than the constructs of the 2 nt overhangs on the 3' ends of both strands (anti-sense and sense strand) and a double-strand region of 19 nucleotide pairs relatively independently of the sequence region homologous to the MDR1 gene (after 48 hours; Fig. 26b). The results therefore confirm the inhibition of EGFR gene expression described in practical example 4 by specific dsRNAs after transfection in U-87 MG cells.

The transfection efficiency was determined in a separate experiment by means of a Texas-Red-labeled DNA oligonucleotide (TexRed-A (GATC)₅T; also 175 nM transfected) (Figures 27a, 27b; 400-fold magnification, 48 hours after transfection). The amount is about 50% based on the red fluorescent cells, in comparison with the total cell count. If one considers the transfection rate of the cells at about 50%, the observed reduction of MDR1-mRNA level lies at about 45-55% (compared with the controls), with the conclusion that in all cells that could be transfected

successfully with specific dsRNA, the MDR1-mRNA was almost fully broken down and specifically.

Literature:

Airoy I & Yarden Y (1997): The Erb signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Letters 410: 83-86.

Bass,B.L., 2000. Double-stranded RNA as a template for gene silencing. Cell 101, 235-238.

Bosher,J.M. and Labouesse,M., 2000. RNA interference: genetic wand and genetic watchdog. Nature Cell Biology 2, E31-E36.

Bradford MM (1976): Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.

Caplen,N.C., Fleenor,J., Fire,A., and Morgan,R.A., 2000. dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. Gene 252, 95-105.

Clemens,J.C., Worby,C.A., Simonson-Leff,N., Muda,M., Maelhama,T., Hemmings,B.A., and Dixon,J.E., 2000. Use of double-stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. Proc.Natl.Acad.Sci.USA 97, 6499-6503.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Liebermann G & Slamon DJ (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that

has progressed after chemotherapy for metastatic disease.
Journal of Clinical Oncology 17: 2639-2648.

Ding, S.W., 2000. RNA silencing. Curr. Opin. Biotechnol. 11, 152-156.

Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C., 1998. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. Nature 391, 806-811.

Fire, A., 1999. RNA-triggered gene silencing. Trends Genet. 15, 358-363.

Freier, S.M., Kierzek, R., Jaeger, J.A., Sugimoto, N., Caruthers, M.H., Neilson, T., and Turner, D.H., 1986. Improved free-energy parameters for prediction of RNA duplex stability. Proc. Natl. Acad. Sci. USA 83, 9373-9377 .

Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276 (18), 14581-14587.

Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G & Ciardiello F (1998): Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIa non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic factors of survival. Clinical Cancer Research 4: 241-249.

Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J., 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* 404, 293-296.

Higgins, C.F. (1995). The ABC of channel regulation. *Cell*, 82, 693-696.

Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1993): Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech. Dev.* 76: 79-90.

Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1998): Non-invasive sexing of preimplantation mammalian embryos. *Nature Genetics* 19: 220-222.

Kyhse-Anderson J (1984): Electrophotting of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. *J. Biochem. Biophys. Methods* 10: 203-210.

Lämmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.

Loe, T.W., and Clarke, D.M. (1999) *Biochem. Cell Biol.* 77, 11-23.

Huang SM & Harari PM (1999): Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. *Investigational New Drugs* 17: 259-269.

Limmer, S., Hofmann, H.-P., Ott, G., and Sprinzl, M., 1993. The 3'-terminal end (NCCA) of tRNA determines the structure and

stability of the aminoacyl acceptor stem. Proc. Natl. Acad. Sci. USA 90 , 6199-6202.

Montgomery, M.K. and Fire, A., 1998. Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends Genet. 14, 255-258.

Montgomery, M.K., Xu, S., and Fire, A., 1998. RNA as a target of double-stranded RNA-mediated genetic interference in *Caenorhabditis elegans*. Proc. Natl. Acad. Sci. USA 95, 15502-15507.

Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, Bienhat W & Liberski PP (1998): A comparative study of epidermal growth factor (EGFR) and mdm2 gene amplification and protein immunoreactivity in human glioblastomas. Polish Journal of Pathology 49: 145-149.

Robert, J. (1999). Multidrug resistance in oncology: diagnostic and therapeutic approaches. Europ J Clin Invest 29, 536-545.

Stavrovskaya, A.A. (2000) Biochemistry (Moscow) 65 (1), 95-106.

Salomon DS, Brandt R, Ciardiello F & Normanno N (1995): Epidermal growth factor related peptides and their receptors in human malignancies: Critical Reviews in Oncology and Haematology 19: 183-232.

Tom, B.H., Rutzky, L.P., Jakstys, M.M., Oyasu, R., Kaye, C.I., Kahan, B.D. (1976), In vitro, 12, 180-191.

Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. (1981).
Overcoming of vincristine resistance in P388 leukemia in vivo
and in vitro through enhanced cytotoxicity of vincristine and
vinblastine by verapamil. *Cancer Res*, 41, 1967-72.

Ui-Tei, K., Zenno, S., Miyata, Y., and Saigo, K., 2000. Sensitive
assay of RNA interference in *Drosophila* and Chinese hamster
cultured cells using firefly luciferase gene as target. *FEBS
Lett*. 479, 79-82.

Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW,
Lee J, Yarden Y, Liebermann TA, Schlessinger J et al. (1984):
Human epidermal growth factor receptor cDNA sequences and ab-
errant expression of the amplified gene in A431 epidermoid
carcinoma cells. *Nature* 309: 418-425.

Ullrich A & Schlessinger J (1990): Signal transduction by re-
ceptors with tyrosine kinase activity. *Cell* 61: 203-212.

Van der Geer P, Hunter T & Linberg RA (1994): Receptor pro-
tein-tyrosine kinases and their signal transduction pathways.
Annual review in Cell Biology 10: 251-337.

Voldborg BR, Damstrup L, Spang-Thomsen M & Poulser HS
(1997): Epidermal growth factor Receptor (EGFR) and EGFR mu-
tations, function and possible role in clinical trials. *Annu-
als of Oncology* 8: 1197-1206.

Walker RA & Dearing SJ (1999): Expression of epidermal growth
factor receptor mRNA and protein in primary breast carcino-
mas. *Breast Cancer Research Treatment* 53: 167-176.

Zamore, P.D., Tuschl, T., Sharp, P.A., and Bartel, D.P., 2000.
RNAi: double-stranded RNA directs the ATP-dependent cleavage
of mRNA at 21 to 23 nucleotide intervals. *Cell* 101 , 25-33.

Zor T & Selinger Z (1996): Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. *Anal. Biochem.* 236: 302-308.

Claims

1. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2) of dsRNA I.

2. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

3. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

4. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

5. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

6. Method according to one of the preceding claims, in which at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which

an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

7. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

8. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) overlap or abut each other in sections.

9. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) are spaced from each other.

10. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

11. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

12. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

13. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a combined dsRNA construct of the sequences SQ141-173 from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

14. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.

15. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
16. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
17. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
18. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
19. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
20. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
21. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
22. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
23. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

24. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
25. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs instead of nucleotides.
26. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.
27. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.
28. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.
29. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
30. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).
31. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
32. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.

33. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.
34. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
35. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
36. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
37. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.
38. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.
39. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.
40. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.
41. Use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

42. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

43. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

44. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

45. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

46. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

47. Use according to one of the Claims 41 to 46, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

48. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

49. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.
50. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.
51. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.
52. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.
53. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
54. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.
55. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
56. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.
57. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

58. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
59. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
60. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
61. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
62. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
63. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).
64. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
65. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
66. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.

67. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.
68. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
69. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
70. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).
71. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
72. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
73. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.
74. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
75. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

76. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

77. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

78. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

79. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

80. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

81. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

82. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

83. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).
84. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).
85. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.
86. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.
87. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.
88. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.
89. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.
90. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

91. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
92. Use according to one of the Claims 81 to 91, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
93. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
94. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
95. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
96. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
97. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
98. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
99. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
100. Use according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

101. Use according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
102. Use according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
103. Use according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
104. Use according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
105. Use according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
106. Use according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
107. Use according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
108. Use according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
109. Use according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

110. Use according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
111. Use according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
112. Use according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
113. Use according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
114. Use according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
115. Use according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
116. Use according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
117. Use according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
118. Use according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.
119. Use according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.

120. Use according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

121. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides on at least one end (E1, E2) of dsRNA I.

122. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

123. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

124. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

125. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

126. Method according to one of the preceding claims, in which at least an additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the

preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and which an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

127. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

128. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

129. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) are spaced from each other.

130. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

131. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

132. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

133. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of the sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

134. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.
135. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
136. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
137. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
138. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
139. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
140. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
141. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
142. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
143. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

144. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.

145. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.

146. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.

147. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.

148. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.

149. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.

150. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).

151. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.

152. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.

153. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.

154. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.

155. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

156. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

157. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.

158. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

159. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.

160. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.

161. Use of one of double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

162. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

163. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

164. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

165. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

166. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

167. Use according to one of the Claims 41 to 47, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

168. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

169. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.

170. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.

171. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

172. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.

173. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

174. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.

175. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.

176. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.

177. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

178. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
179. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
180. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
181. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
182. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van-der-Waals or stacking interactions, or by metal ion coordination.
183. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).
184. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
185. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
186. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.

187. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.
188. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
189. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
190. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).
191. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
192. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
193. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.
194. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
195. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

196. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

197. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

198. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

199. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

200. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

201. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

202. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

203. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).
204. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).
205. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.
206. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.
207. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.
208. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.
209. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.
210. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

211. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
212. Use according to one of the Claims 81 to 90, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
213. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
214. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
215. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
216. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
217. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
218. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
219. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
220. Medicament according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

221. Medicament according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
222. Medicament according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
223. Medicament according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
224. Medicament according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
225. Medicament according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
226. Medicament according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
227. Medicament according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
228. Medicament according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
229. Medicament according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

230. Medicament according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
231. Medicament according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
232. Medicament according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
233. Medicament according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
234. Medicament according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
235. Medicament according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
236. Medicament according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
237. Medicament according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
238. Medicament according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.

239. Medicament according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.

240. Medicament according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

//Key to Figures//

Relative Fluoreszenz = Relative fluorescence

Maus = mouse

Mensch = human

MOCK Transfektion = MOCK transfection

Hellfeld = bright field

Variante = variant

Zielgen = target gene

SEQUENZPROTOKOLL = SEQUENCE PROTOCOL

<120> Method for Inhibition of Expression of a Target Gene

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R1A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R1B) of a dsRNA strand, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R2A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R3A) of a dsRNA that is homologous to the MDR1 gene

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R3B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R4A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R4B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S1A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S1B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S7A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S7B) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R2B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K1A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K1B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K3A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K3B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K2A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K2B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S4B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (PKC1 A) of a dsRNA that is homologous to the protein kinase C sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (PKC2 B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S12B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S11B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S13B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S14B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-7A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-7B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-8A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-8B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-2A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-5B) of a dsRNA, complementary to the human EGFR sequence

reiche ist. Bei dem "Zielgen" handelt es sich also im allgemeinen um den Sinnstrang. Der eine Strang bzw. Antisinnstrang (as1) kann komplementär zu einem bei der Expression des Zielgens gebildeten RNA-Transkript oder deren Prozessierungsprodukt, z.B. eine mRNA, sein. Unter "Einführen" wird die Aufnahme in die Zelle verstanden. Die Aufnahme kann durch die Zelle selbst erfolgen; sie kann auch durch Hilfsstoffe oder Hilfsmittel vermittelt werden. Unter einem "Überhang" wird ein endständiger einzelsträngiger Überstand verstanden, welcher nicht nach Watson & Crick gepaarte Nukleotide aufweist. Unter einer "doppelsträngigen Struktur" wird eine Struktur verstanden, bei der die Nukleotide der Einzelstränge im Wesentlichen nach Watson & Crick gepaart sind. Im Rahmen der vorliegenden Erfindung kann eine doppelsträngige Struktur auch einzelne Fehlpaarungen ("Mismatches") aufweisen.

Nach einer besonders vorteilhaften Ausgestaltung weist die dsRNA I den Überhang am 3'-Ende des einen Strangs bzw. Antisinnstrangs as1 und/oder am 3'-Ende des anderen Strangs bzw. Sinnstrangs ss1 auf. Die dsRNA I kann auch an einem Ende glatt ausgebildet sein. In diesem Fall befindet sich das glatte Ende vorteilhafterweise auf der Seite der dsRNA I, die das 5'-Ende des einen Strangs (Antisinnstrang; as1). In dieser Ausbildung zeigt die dsRNA I einerseits eine sehr gute Effektivität und andererseits eine hohe Stabilität im lebenden Organismus. Die Effektivität insgesamt in vivo ist hervorragend. Der Überhang ist zweckmäßigerweise aus 1 bis 4 Nukleotiden, vorzugsweise aus 1 oder 2 Nukleotiden, gebildet.

Nach einem weiteren Ausgestaltungsmerkmal kann die Effektivität des Verfahrens weiter erhöht werden, wenn zumindest eine entsprechend der erfindungsgemäßen dsRNA I ausgebildete weitere dsRNA II in die Zelle eingeführt wird, wobei der eine Strang oder zumindest ein Abschnitt des einen Strangs der doppelsträngigen Struktur der dsRNA I komplementär zu einem ersten Bereich des Sinnstrangs des Zielgens ist, und wobei

ein weiterer Strang oder zumindest ein Abschnitt des weiteren Strangs der doppelsträngigen Struktur der weiteren dsRNA II komplementär zu einem zweiten Bereich des Sinnstrangs des Zielgens ist. Die Hemmung der Expression des Zielgens ist in diesem Fall deutlich gesteigert. Der erste und der zweite Bereich können abschnittsweise überlappen, aneinander grenzen oder auch voneinander beabstandet sein.

Es hat sich weiter als vorteilhaft erwiesen, wenn die dsRNA I und/oder die weitere dsRNA II eine Länge von weniger als 25 aufeinander folgenden Nukleotidpaaren aufweisen. Als besonders effektiv hat sich eine Länge im Bereich zwischen 19 und 23 Nukleotidpaaren erwiesen. Die Effizienz kann weiter gesteigert werden, wenn an den vorzugsweise aus 19 bis 23 Nukleotidpaaren gebildeten Doppelsträngen einzelsträngige Überhänge von 1 bis 4 Nukleotiden vorhanden sind.

Das Zielgen kann nach einem weiteren Ausgestaltungsmerkmal eine der in dem anhängenden Sequenzprotokoll wiedergegebenen Sequenzen SQ001 bis SQ140 aufweisen. Es kann auch aus der folgenden Gruppe ausgewählt sein: Onkogen, Cytokin-Gen, Id-Protein-Gen, Prionen, Gene zur Expression von Angiogenese induzierenden Molekülen, von Adhäsions-Molekülen und Zelloberflächenrezeptoren, Gene von Proteinen, die an metastasierenden und/oder invasiven Prozessen beteiligt sind, Gene von Proteinasen sowie Apoptose- und Zellzyklus-regulierende Molekülen sowie Gene zur Expression des EGF-Rezeptors. Beim Zielgen kann es sich insbesondere um das MDR1-Gen handeln. Es kann in diesem Zusammenhang eine der Sequenzen SQ141 - 173 bestehende bzw. ein aus jeweils zusammengehörenden Antisinn (as)- und Sinnsequenzen (ss) kombinierte dsRNA I/II verwendet werden.

Nach einem weiteren vorteilhaften Ausgestaltungsmerkmal wird die Expression nach dem Prinzip der RNA-Interferenz gehemmt.

Das Zielgen wird zweckmäßigerweise in pathogenen Organismen, vorzugsweise in Plasmodien, exprimiert. Es kann Bestandteil eines Virus oder Viroids, insbesondere eines humanpathogenen Virus oder Viroids, sein. Das Virus oder Viroid kann auch ein
5 tier- oder pflanzenpathogenes Virus oder Viroid sein.

Nach einem weiteren Ausgestaltungsmerkmal ist vorgesehen, dass die ungepaarten Nukleotide durch Nukleosidthiophosphate substituiert sind.

10

Zumindest ein Ende der dsRNA I/II kann modifiziert werden, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken. Vorteilhafterweise wird dazu der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt
15 der doppelsträngigen Struktur durch mindestens eine chemische Verknüpfung erhöht. Die chemische Verknüpfung kann durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwirkungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-
20 Ionenkoordination gebildet werden. Es hat sich weiter als zweckmäßig und die Stabilität erhöhend erwiesen, wenn die chemische Verknüpfung in der Nähe des einen Endes gebildet ist. Weitere vorteilhafte Ausgestaltungen hinsichtlich der chemischen Verknüpfung können den Merkmalen der Ansprüche 24
25 bis 30 entnommen werden, ohne dass es dafür einer näheren Erläuterung bedarf.

Die dsRNA I/II kann dann besonders einfach in die Zelle eingeschleust werden, wenn sie in micellare Strukturen, vorteil-
30 hafterweise in Liposomen, eingeschlossen wird. Zum Transport der dsRNA I/II in die Zelle hat es sich auch als vorteilhaft erwiesen, dass diese an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon um-
35 geben werden. Das Hüllprotein kann vom Polyomavirus abgeleitet sein. Das Hüllprotein kann insbesondere das Virus-Protein

1 und/oder das Virus-Protein 2 des Polyomavirus enthalten. Nach einer weiteren Ausgestaltung ist vorgesehen, dass bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kapsidartigen Gebildes gewandt ist. Ferner ist es von Vorteil, dass der eine Strang der dsRNA I/II (as1/2) zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist. Die Zelle kann eine Vertebratenzelle oder eine menschliche Zelle sein.

Weiterhin hat es sich gezeigt, dass die dsRNA I/II vorteilhafterweise bereits in einer Menge von höchstens 5 mg/kg Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht werden kann. Bereits in dieser geringen Dosis wird eine ausgezeichnete Effektivität erzielt.

Überraschenderweise hat sich gezeigt, dass die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen und dann oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verabreicht werden kann.

Erfindungsgemäß ist weiterhin die Verwendung einer doppelsträngigen Ribonukleinsäure (dsRNA I) zur Hemmung der Expression eines Zielgens in einer Zelle vorgesehen, wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinander folgenden Nukleotidpaaren gebildete Struktur aufweist, und wobei ein Strang (Antisinnstrang; as1) oder zumindest ein Abschnitt des einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Sinnstrang des Zielgens ist, und wobei die dsRNA I zumindest an einem Ende einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

Nach weiterer Maßgabe der Erfindung ist ein Medikament zur Hemmung der Expression eines Zielgens in einer Zelle vorgesehen, enthaltend eine doppelsträngige Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausrei-

tung unter dem Fluoreszenzmikroskop erfolgte frühestens 3 Stunden nach Injektion anhand der grünen Fluoreszenz.

Vorbereitung der Zellkulturen:

5 Die Kultivierung der Zellen erfolgte in DMEM mit 4,5 g/l Glucose, 10 % fötalem Kälberserum (FCS), 2 mM L-Glutamin, Penicillin/Streptomycin (100 IE/100 µg/ml, Biochrom) im Brutschrank unter 5 % CO₂-Atmosphäre bei 37°C. Die Zellen wurden alle 3 Tage passagiert, um sie in der exponentiellen Wachstumsphase zu halten. Einen Tag vor der Durchführung der Transfektion wurden die Zellen trypsiniert (10x Trypsin/TEDTA, Biochrom) und mit einer Zelldichte von $0,3 \times 10^5$ Zellen in beschichteten Petrischalen (CORNING® Cell Culture Dish, 35 mm, Corning Inc., Corning, USA) ausgesät. Die Petrischalen wurden mit 0,2 % Gelatine (Biochrom) für mindestens 15 30 Minuten bei 37°C inkubiert, einmal mit PBS gewaschen und sofort für die Aussaat der Zellen verwendet. Um ein Wiederfinden individueller Zellen zu ermöglichen, wurden CELLocate Coverslips der Fa. Eppendorf (Square size 55 µm) verwendet.

20

Mikroinjektion:

Zur Durchführung der Mikroinjektion wurden die Petrischalen ca. 10 Minuten aus dem Brutschrank genommen. Pro Schale und Ansatz wurden ca. 50 Zellen mikroinjiziert (FemtoJet; Mikromanipulator 5171, Eppendorf). Für die Mikroinjektion wurden 25 Glaskapillaren (FemtoTip) der Firma Eppendorf mit einem Spitzeninnendurchmesser von 0,5 µm verwendet. Die Injektionsdauer betrug 0,8 Sekunden und der Druck 30 hPa. Durchgeführt wurden die Mikroinjektionen an einem Olympus IX50 Mikroskop mit 30 Fluoreszenzeinrichtung. Als Injektionspuffer wurde 14 mM NaCl, 3 mM KCl, 10 mM KH₂PO₄, pH 7,0 verwendet, der 0,01 µg/µl pcDNA-YFP enthielt. Zur Überprüfung einer erfolgreichen Mikroinjektion wurde der Injektionslösung jeweils 0,08% (w/v) an Dextran-70000 gekoppeltes Texas-Rot (Molecular Probes, 35 Leiden, Niederlande) zugesetzt. Um die Inhibition der YFP-Expression mit spezifischer dsRNA zu untersuchen, wurden der

Injektionslösung dsRNAs zugegeben: Ansatz 1: 0,1 μ M dsRNA (Sequenzprotokoll SQ148/149); Ansatz 2: 0,1 μ M dsRNA (Sequenzprotokoll SQ148/159); Ansatz 3: ohne RNA. Nach der Mikroinjektion wurden die Zellen für mindestens drei weitere
5 Stunden im Brutschrank inkubiert. Danach wurden die intrazelluläre YFP-Fluoreszenz am Mikroskop ausgewertet:
gleichzeitig rot und grün-fluoreszierende Zellen: Mikroinjektion war erfolgreich, es wird keine Inhibition der YFP-Expression durch dsRNA beobachtet; bzw. es handelt sich um
10 Kontrollzellen, in die keine dsRNA injiziert wurde;
nur rot-fluoreszierende Zellen: Mikroinjektion war erfolgreich, die dsRNA inhibiert YFP-Expression.

Ergebnisse:

15 Bei einer dsRNA-Konzentration von 0,1 μ M konnte beim Einsatz der dsRNA mit den an beiden 3'-Enden um je zwei Nukleotide überstehenden Einzelstrangbereichen (Sequenzprotokoll SQ148/159) eine merklich erhöhte Hemmung der Expression des YFP-Gens in Fibroblasten beobachtet werden im Vergleich zur
20 dsRNA ohne überstehende Einzelstrangenden (Tabelle 1).

Die Verwendung von kurzen, 19-25 Basenpaare enthaltenden, dsRNA-Molekülen mit Überhängen aus wenigen, vorzugsweise 1 bis 3 nicht-basengepaarten, einzelsträngigen Nukleotiden ermöglicht somit eine vergleichsweise stärkere Hemmung der
25 Genexpression in Säugerzellen als die Verwendung von dsRNAs mit derselben Anzahl von Basenpaaren ohne die entsprechenden Einzelstrangüberhänge bei jeweils gleichen RNA-Konzentrationen.

Ansatz	Name	Sequenzprotokoll-Nr.	0.1 μ M
1	S1A/ S1B	SQ148 SQ149	+
2	S1A/ S4B	SQ148 (überstehende Enden) SQ159	+++
3		ohne RNA	-

Tabelle 1: Die Symbole geben den relativen Anteil an nicht oder schwach grün-fluoreszierenden Zellen an (+++ > 90%; ++ 60-90%; + 30-60%; - < 10%).

5

II. Hemmung der Genexpression eines Zielgens in kultivierten HELA-S3-Zellen und Mausfibroblasten durch dsRNA:

- 10 Die Effektivität der Inhibition der YFP-Expression nach transienter Transfektion eines YFP-codierenden Plasmids auf der Basis der RNA-Interferenz mit dsRNAs läßt sich durch Gestaltung der 3'-Enden und der Länge des basengepaarten Bereichs modulieren.

15

Ausführungsbeispiel:

- Zum Wirksamkeitsnachweis der dsRNA bei der spezifischen Inhibition der Genexpression wurden transient transfizierte
- 20 NIH/3T3-Zellen (Fibroblasten aus NIH Swiss Mausembryo, ECCAC (European collection of animal cell culture) Nr. 93061524) und HELA-S3 (humane cervikale Karzinomzellen, DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) Nr. ACC 161) verwendet. Für die Transfektion wurde das Plasmid pcDNA-YFP
- 25 verwendet, das ein 800 bp großes Bam HI /Eco RI-YFP-Fragment in den entsprechenden Schnittstellen des Vektors pcDNA3 enthält. Aus der Sequenz des gelb-fluoreszierenden Proteins (YFP) abgeleitete doppelsträngige RNAs (dsRNAs) wurden herge-

stellt und zusammen mit dem Plasmid pcDNA-YFP transient in die Fibroblasten transfiziert (Die verwendeten spezifischen dsRNAs sind in ihren Antisinn-Strängen komplementär zu entsprechenden Abschnitten der Gensequenzen von sowohl YFP als auch GFP). Nach 48 Stunden wurde die Fluoreszenzabnahme quantifiziert. Als Kontrollen fungierten Zellen, die entweder nur mit pcDNA-YFP oder mit pcDNA-YFP und einer Kontroll-dsRNA (nicht aus der YFP-Sequenz abgeleitet) transfiziert wurden.

10 Versuchsprotokoll:

dsRNA-Synthese:

Mittels eines RNA-Synthesizers (Typ Expedite 8909, Applied Biosystems, Weiterstadt, Deutschland) und herkömmlicher chemischer Verfahren wurden die aus den Sequenzprotokollen ersichtlichen RNA-Einzelstränge und die zu ihnen komplementären Einzelstränge synthetisiert. Anschließend erfolgte die Reinigung der rohen Syntheseprodukte mit Hilfe der HPLC. Verwendet wurde die Säule NucleoPac PA-100, 9x250 mm, der Fa. Dionex; als Niedersalz-Puffer 20 mM Tris, 10 mM NaClO₄, pH 6,8, 10% Acetonitril und als Hochsalz-Puffer 20 mM Tris, 400 mM NaClO₄, pH 6,8, 10% Acetonitril. Der Fluß betrug 3 ml/Minute. Die Hybridisierung der Einzelstränge zum Doppelstrang erfolgte durch Erhitzen des stöchiometrischen Gemischs der Einzelstränge in 10 mM Natriumphosphatpuffer, pH 6,8, 100 mM NaCl, auf 80-90°C und nachfolgendes langsames Abkühlen über 6 Stunden auf Raumtemperatur.

Aussaat der Zellen:

30 Alle Zellkulturarbeiten wurden unter sterilen Bedingungen in einer entsprechenden Werkbank (HS18, Hera Safe, Kendro, Heraeus) durchgeführt. Die Kultivierung der NIH/3T3-Zellen und der HELA-S3 erfolgte im Brutschrank (CO₂-Inkubator T20, Hera cell, Kendro, Heraeus) bei 37°C, 5% CO₂ und gesättigter

Luftfeuchtigkeit in DMEM (Dulbecco's modified eagle medium, Biochrom), für die Mausfibroblasten, und Ham's F12 für die HELA-Zellen mit 10% FCS (fetal calf serum, Biochrom), 2 mM L-Glutamin (Biochrom) und Penicillin/Streptomycin (100 IE/100 µg/ml, Biochrom). Um die Zellen in der exponentiellen Wachstumsphase zu halten, wurden die Zellen alle 3 Tage passagiert. 24 Stunden vor der Durchführung der Transfektion wurden die Zellen trypsiniert (10x Trypsin/EDTA, Biochrom, Deutschland) und mit einer Zelldichte von $1,0 \times 10^4$ Zellen/Vertiefung in einer 96-Loch-Platte (Multiwell Schalen 96-Well Flachboden, Labor Schubert & Weiss GmbH) in 150 µl Wachstumsmedium ausgesät.

15

Durchführung der transienten Transfektion:

Die Transfektion wurde mit Lipofectamine Plus™ Reagent (Life Technologies) gemäß den Angaben des Herstellers durchgeführt. Pro Well wurden 0,15 µg pcDNA-YFP-Plasmid eingesetzt. Das Gesamt-Transfektionsvolumen betrug 60 µl. Es wurden jeweils 3-fach-Proben angesetzt. Die Plasmid-DNA wurde zuerst zusammen mit der dsRNA komplexiert. Dazu wurde die Plasmid-DNA und die dsRNA in serumfreiem Medium verdünnt und pro 0,1 µg Plasmid-DNA 1 µl PLUS Reagent eingesetzt (in einem Volumen von 10 µl) und nach dem Mischen für 15 Minuten bei Raumtemperatur inkubiert. Während der Inkubation wurde pro 0,1 µg Plasmid-DNA 0,5 µl Lipofectamine in insgesamt 10 µl serumfreiem Medium verdünnt, gut gemischt, zu dem Plasmid/dsRNA/PLUS-Gemisch zugegeben und nochmals 15 Minuten inkubiert. Während der Inkubation wurde ein Mediumwechsel durchgeführt. Die Zellen wurden dazu 1 x mit 200 µl serumfreiem Medium gewaschen und danach mit 40 µl serumfreiem Medium bis zur Zugabe von DNA/dsRNA/PLUS/Lipofectamine weiter im Brutschrank inkubiert. Nach der Zugabe von 20 µl DNA/dsRNA/PLUS/Lipofectamine pro

Well wurden die Zellen für 2,5 Stunden im Brutschrank inkubiert. Anschließend wurden die Zellen nach der Inkubation 1 x mit 200 µl Wachstumsmedium gewaschen und für 24 Stunden bis zur Detektion der Fluoreszenz in 200 µl Wachstumsmedium im Brutschrank inkubiert.

Detektion der Fluoreszenz:

24 Stunden nach dem letzten Mediumwechsel wurde die Fluoreszenz der Zellen am Fluoreszenz-Mikroskop (IX50-S8F2, Fluoreszenz-Einheit U-ULS100Hg, Brenner U-RFL-T200, Olympus) mit einer USH-I02D-Quecksilber-Lampe (USHIO Inc., Tokyo, Japan), ausgestattet mit einem WIB-Fluoreszenz-Würfel und einer digitalen CCD-Kamera (Orca IIm, Hamamatsu) und C4742-95 Kamera-Controller) photographiert. Die Auswertung der Fluoreszenzaufnahmen erfolgte mit der analysis-Software 3.1 (Soft Imaging Sytem GmbH, Deutschland). Um die YFP-Fluoreszenz in Relation zur Zelldichte zu setzen, wurde eine Zellkernfärbung (Hoechst-Staining) durchgeführt. Dazu wurden die Zellen in 100 µl Methycarnoy (75% Methanol, 25% Eisessig) zuerst für 5 und danach nochmals für 10 Minuten in Methycarnoy fixiert. Nach dem Lufttrocknen wurden die fixierten Zellen für 30 Minuten im Dunkeln mit 100 µl pro Well Hoechst-Farbstoff (75 ng/ml) inkubiert. Nach 2maligem Waschen mit PBS (PBS Dulbecco w/o Ca²⁺, Mg²⁺, Biochrom) wurden die Hoechst-gefärbten Zellen unter dem Fluoreszenz-Mikroskop (Olympus, WU-Fluoreszenz-Würfel für Hoechst) photographiert.

In den Fig. 3 bis 9 sind die Ergebnisse zur Inhibition der YFP-Expression durch dsRNA in kultivierten Zellen zusammengefasst:

30

In Fig. 3, 4, 5 und 6 sind die Effekte von YFP-spezifischen dsRNAs und von Kontroll-dsRNAs auf die YFP-Expression in NIH/3T3-Mausfibroblasten nach transienter Transfektion zusammengefasst. Die Experimente wurden wie im Versuchsprotokoll

Die Fig. 10 bis 17 zeigen die Serumstabilität der dsRNA nach Inkubation mit humanem bzw. murinem Serum und nachfolgender elektrophoretischer Auftrennung im 20%igem 7M Harnstoffgel.

5 **Fig. 10: Inkubation von S1 (0-22-0) in Maus-Serum**

1. zum Zeitpunkt 0 (ohne Serum)
2. zum Zeitpunkt 0
3. für 30 Minuten
4. für 1 Stunde
- 10 5. für 2 Stunden
6. für 4 Stunden
7. für 12 Stunden
8. 2 μ l 100 μ M S1 ohne Inkubation
- S1A) Sinnstrang S1 (10 μ l 20 μ M S1A)
- 15 S1B) Antisinnstrang S1 (10 μ l 20 μ M S1B)

Fig. 11: Inkubation von S1 (0-22-0) in humanem Serum

1. 2 μ l 100 μ M S1 unbehandelt (ohne Inkubation)
2. für 30 Minuten
3. für 2 Stunden
- 20 4. für 4 Stunden
5. für 6 Stunden
6. für 8 Stunden
7. für 12 Stunden
8. für 24 Stunden
- 25 S1A) Sinnstrang S1 (10 μ l 20 μ M S1A)
- S1B) Antisinnstrang S1 (10 μ l 20 μ M S1B)

Fig. 12: Inkubation von S7 (2-19-2) in Maus-Serum

1. zum Zeitpunkt 0 (ohne Serum)
2. für 30 Minuten
- 30 3. für 4 Stunden
4. für 12 Stunden

Fig. 13: Inkubation von S7 (2-19-2) in humanem Serum

1. Sinnstrang S7 (10 μ l 20 μ M S7A)

2. Antisinnstrang S7 (10 μ l 20 μ M S7B)
3. für 30 Minuten
4. für 1 Stunde
5. für 2 Stunden
- 5 6. für 4 Stunden
7. für 6 Stunden
8. für 12 Stunden
9. für 24 Stunden
10. zum Zeitpunkt 0 (ohne Serum)

10 **Fig. 14: Inkubation von K3 (2-19-2) in Maus-Serum**

1. Sinnstrang K3 (10 μ l 20 μ M K3A)
2. Antisinnstrang K3 (10 μ l 20 μ M K3B)
3. zum Zeitpunkt 0 (ohne Serum)
4. zum Zeitpunkt 0 (mit Serum)
- 15 5. für 30 Minuten
6. für 1 Stunde
7. für 2 Stunden
8. für 4 Stunden
9. für 12 Stunden

20 **Fig. 15: Inkubation von PKC1/2 (0-22-2) in Maus-Serum**

1. für 30 Minuten
2. für 1 Stunde
3. für 2 Stunden
4. für 4 Stunden
- 25 5. für 12 Stunden
6. 2 μ l 100 μ M PKC1/2 (unbehandelt)

Fig. 16: Inkubation von S1A/S4B (0-22-2) in humanem Serum

1. zum Zeitpunkt 0 (ohne Serum)
2. für 24 Stunden
- 30 3. für 12 Stunden
4. für 8 Stunden
5. für 6 Stunden
6. für 4 Stunden

7. für 2 Stunden
8. für 30 Minuten
9. Sinnstrang S1A (10 μ l 20 μ M S1A)
10. Antisinnstrang S4B (10 μ l 20 μ M S4B)

5 **Fig. 17: Inkubation von K2 (2-22-2) in humanem Serum**

1. Sinnstrang K2 (10 μ l 20 μ M K2A)
2. Antisinnstrang K2 (10 μ l 20 μ M K2B)
3. zum Zeitpunkt 0 (ohne Serum)
4. für 30 Minuten
- 10 5. für 2 Stunden
6. für 4 Stunden
7. für 6 Stunden
8. für 8 Stunden
9. für 12 Stunden
- 15 10. für 24 Stunden

Ergebnisse:

dsRNAs ohne einzelsträngige Bereiche an den 3'-Enden sind im
20 Serum sowohl von Mensch und Maus wesentlich stabiler als
dsRNAs mit einzelsträngigen 2nt-Überhängen an den 3'-Enden
(Fig. 10 bis 14 und 17). Nach 12 bzw. 24 Stunden Inkubation
von S1 in murinem bzw. humanem Serum ist noch immer eine Ban-
de in der ursprünglichen Größe fast vollständig erhalten. Da-
25 gegen nimmt bei dsRNAs mit 2nt-Überhängen an beiden 3'-Enden
die Stabilität in humanem als auch im murinen Serum deutlich
ab. Bereits nach 4 Stunden Inkubation von S7 (Fig. 12 und 13)
oder K3 (Fig. 14) ist keine Bande in der Originalgröße mehr
detektierbar.

30

Um die Stabilität von dsRNA im Serum zu erhöhen, ist es aus-
reichend, wenn die dsRNA ein glattes Ende besitzt. Im Maus-
Serum ist nach 4 Stunden Inkubation (Fig. 15, Bahn 4) die

Bande in der Originalgröße kaum abgebaut im Vergleich zu S7 (nach 4 Stunden vollständiger Abbau; Fig. 12, Bahn 3).

- Als optimaler Kompromiß hinsichtlich der biologischen Wirksamkeit von dsRNA kann die Verwendung von dsRNA mit einem glattem Ende und einem einzelsträngigem Bereich von 2 Nukleotiden angesehen werden, wobei sich der einzelsträngige Überhang am 3'-Ende des Antisinn-Stranges befinden sollte.
- 10 Die hier verwendeten Sequenzen sind aus der nachstehenden Tabelle 2 und den Sequenzprotokollen SQ148-151 und 153-167 ersichtlich.

Name	Sequenz- proto- koll-Nr.	dsRNA-Sequenz	
S1	SQ148 SQ149	(A) 5'- CCACAUGAAGCAGCACGACUUC -3' (B) 3'- GGUGUACUUCGUCGUGCUGAAG -5'	0-22-0
S7	SQ150 SQ151	(A) 5'- CCACAUGAAGCAGCACGACUU -3' (B) 3'- CUGGUGUACUUCGUCGUGCUG -5'	2-19-2
K1	SQ153 SQ154	(A) 5'- ACAGGAUGAGGAUCGUUUCGCA -3' (B) 3'- UGUCCUACUCCUAGCAAAGCGU -5'	0-22-0
K3	SQ155 SQ156	(A) 5'-GAUGAGGAUCGUUUCGCAUGA-3' (B) 3'-UCCUACUCCUAGCAAAGCGUA-5'	2-19-2
K2	SQ157 SQ158	(A) 5'- ACAGGAUGAGGAUCGUUUCGCAUG -3' (B) 3'- UCUGUCCUACUCCUAGCAAAGCGU -5'	2-22-2
S1A/ S4B	SQ148 SQ159	(A) 5'- CCACAUGAAGCAGCACGACUUC -3' (B) 3'- CUGGUGUACUUCGUCGUGCUGAAG -5'	0-22-2

PKC 1/2	SQ160	(A)	5'- CUUCUCCGCCUCACACCGCUGCAA -3'	2-22-0
	SQ161	(B)	3'- GAAGAGGCGGAGUGUGGCGACG -5'	
S7/S12	SQ150	(A)	5'- CCACAUGAAGCAGCACGACUU -3'	0-21-0
	SQ162	(B)	3'- GGUGUACUUCGUCGUGCUGAA -5'	
S7/S11	SQ150	(A)	5'- CCACAUGAAGCAGCACGACUU -3'	0-21-2
	SQ163	(B)	3'- CUGGUGUACUUCGUCGUGCUGAA -5'	
S13	SQ164	(A)	5'- CCACAUGAAGCAGCACGACU -3'	0-20-2
	SQ165	(B)	3'- CUGGUGUACUUCGUCGUGCUGA -5'	
S13/14	SQ164	(A)	5'- CCACAUGAAGCAGCACGACU -3'	0-20-0
	SQ166	(B)	3'- GGUGUACUUCGUCGUGCUGA -5'	
S4	SQ167	(A)	5'- CCACAUGAAGCAGCACGACUUCUU -3'	2-22-2
	SQ159	(B)	3'- CUGGUGUACUUCGUCGUGCUGAAG -5'	
K1A/ K2B	SQ153	(A)	5'- ACAGGAUGAGGAUCGUUUCGCA -3'	0-22-2
	SQ158	(B)	3'- UCUGUCCUACUCCUAGCAAAGCGU -5'	
K1B/ K2A	SQ154	(A)	5'- ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-0
	SQ157	(B)	3'- UGUCCUACUCCUAGCAAAGCGU -5'	
S1B/ S4A	SQ149	(A)	5'- CCACAUGAAGCAGCACGACUUCUU -3'	2-22-0
	SQ167	(B)	3'- GGUGUACUUCGUCGUGCUGAAG -5'	

Tabelle 2

IV. In vivo-Studie:

5

Es wurde „GFP-Labormäusen“, die das Grün-fluoreszierende Protein (GFP) in allen Proteinbiosynthese betreibenden Zellen exprimieren, doppelsträngige RNA (dsRNA), die aus der GFP-Sequenz abgeleitet wurde, bzw. unspezifische dsRNA intravenös

10 in die Schwanzvene injiziert. Am Versuchsende wurden die Tie-

SDS überschichtet. Danach wurde das Sammelgel gegossen: 0,83 µl Acrylamid/Bisacrylamid (30%/0,9%), 630 µl 1 M Tris/HCl, pH 6,8, 3,4 ml Aqua bidest., 50 µl 10% SDS, 50 µl 10% Ammoniumpersulfat, 5 µl TEMED.

5

Vor dem Auftrag auf das Gel wurden die Proteine mit einer entsprechenden Menge an 4fach Probenpuffer (200 mM Tris, pH 6,8, 4% SDS, 100 mM DTT (Dithiotreitol), 0,02% Bromphenolblau, 20% Glycerin) versetzt, für 5 min im Heizblock bei 100°C denaturiert, nach dem Abkühlen auf Eis kurz abzentrifugiert und auf das Gel aufgetragen. Pro Bahn wurde die gleichen Plasma- bzw. Proteinmengen eingesetzt (je 3 µl Plasma bzw. 25 µg Gesamtprotein). Die Elektrophorese erfolgte wassergekühlt bei RT und konstant 50 V. Als Längenstandard wurde der Proteingelmarker von Bio-Rad (Kaleidoscope Prestained Standard) verwendet.

Western Blot und Immundetektion:

Der Transfer der Proteine vom SDS-PAGE auf eine PVDF (Polyvinylidendifluorid)-Membran (Hybond-P, Amersham) erfolgte im semidry Verfahren nach Kyhse-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) bei RT und einer konstanten Stromstärke von 0,8 mA/cm² für 1,5 h. Als Transferpuffer wurde ein Tris/Glycin-Puffer eingesetzt (39 mM Glycin, 46 mM Tris, 0,1 % SDS und 20% Methanol). Zum Überprüfen des elektrophoretischen Transfers wurden sowohl die Gele nach dem Blotten als auch die Blotmembranen nach der Immundetektion mit Coomassie gefärbt (0,1% Coomassie G250, 45% Methanol, 10% Eisessig). Zum Absättigen unspezifischer Bindungen wurde die Blotmembran nach dem Transfer in 1% Magermilchpulver/PBS für 1h bei RT inkubiert. Danach wurde je dreimal für 3 min mit 0,1% Tween-20/PBS gewaschen. Alle nachfolgenden Antikörperinkubationen und Waschschritte erfolgten in 0,1% Tween-20/ PBS. Die Inkubation mit dem Primärantikörper (goat anti-GFP, sc-5384, San-

ta Cruz Biotechnology) in einer Verdünnung von 1:1000 erfolgte für 1h bei RT. Danach wurde 3 x 5 min gewaschen und für 1h bei RT mit dem Sekundärantikörper (donkey anti-goat IgG Horseradish Peroxidase gelabelt, Santa Cruz Biotechnology) in einer Verdünnung von 1 : 10.000 inkubiert. Die Detektion erfolgte mit dem ECL-System von Amersham nach den Angaben des Herstellers.

In den Fig. 18 bis 20 ist die Inhibition der GFP-Expression nach intravenöser Injektion von spezifisch gegen GFP gerichteter dsRNA mit Immunperoxidase-Färbungen gegen GFP an 3 µm Paraffinschnitten dargestellt. Im Versuchsverlauf wurde gegen GFP gerichtete dsRNA mit einem doppelsträngigen Bereich von 22 Nukleotid-(nt)paaren ohne Überhänge an den 3'-Enden (D) und die entsprechende unspezifische Kontroll-dsRNA (B) sowie spezifisch gegen GFP gerichtete dsRNA mit einem 19 Nukleotidpaare umfassenden Doppelstrangbereich mit 2nt-Überhängen an den 3'-Enden (E) und die entsprechende unspezifische Kontroll-dsRNA (C) im 12 Stunden-Turnus über 5 Tage hinweg appliziert. (F) erhielt 1/50 der Dosis von Gruppe D. Als weitere Kontrolle wurden Tiere ohne dsRNA-Gabe (A) bzw. WT-Tiere untersucht. Die Fig. 18 zeigt die Inhibition der GFP-Expression in Nierenschnitten, Fig. 19 in Herz- und Fig. 20 in Pankreasgewebe. In den Fig. 21 bis 23 sind Western Blot-Analysen der GFP-Expression in Plasma und Geweben dargestellt. In der Fig. 21 ist die Inhibition der GFP-Expression im Plasma, in Fig. 22 in der Niere und in Fig. 23 in Herz gezeigt. In Fig. 23 sind Gesamtproteinisolate aus verschiedenen Tieren aufgetragen. Es wurden jeweils gleiche Gesamtproteinmengen pro Bahn aufgetragen. In den Tieren, denen unspezifische Kontroll-dsRNA verabreicht wurde (Tiere der Gruppen B und C), ist die GFP-Expression gegenüber Tieren, die keinerlei dsRNA erhielten, nicht reduziert. Tiere, die spezifisch gegen GFP gerichtete dsRNA mit 2nt-Überhängen an den 3'-Enden

beider Stränge und einen 19 Nukleotidpaare umfassenden Doppelstrangbereich erhielten, zeigten eine signifikant inhibierte GFP-Expression in den untersuchten Geweben (Herz, Niere, Pankreas und Blut), verglichen mit unbehandelten Tieren (Fig. 18 bis 23). Bei den Tieren der Gruppen D und F, denen spezifisch gegen GFP gerichtete dsRNA mit glatten Enden und einem 22 Nukleotidpaare umfassenden Doppelstrangbereich appliziert wurde, zeigten nur jene Tiere, die die dsRNA in einer Dosis von 50 µg/kg Körpergewicht pro Tag erhielten, eine spezifische Inhibition der GFP-Expression, die allerdings weniger deutlich ausgeprägt war als die der Tiere in Gruppe E.

Die zusammenfassende Auswertung von GFP-Inhibition in den Gewebeschnitten und im Western Blot ergibt, dass die Inhibition der GFP-Expression im Blut und in der Niere am stärksten ist (Fig. 18, 21 und 22).

V. Hemmung der Genexpression des EGF-Rezeptors mit dsRNA als therapeutischer Ansatz bei Krebsformen mit EGFR-Überexpression oder EGFR-induzierter Proliferation:

Der Epidermal Growth Factor (=EGF)-Rezeptor (=EGFR) gehört zu den Rezeptor-Tyrosinkinasen, transmembranen Proteinen mit einer intrinsischen Tyrosinkinase-Aktivität, die an der Kontrolle einer Reihe von zellulären Prozessen wie Zellwachstum, Zelldifferenzierungen, migratorischen Prozessen oder der Zellvitalität beteiligt sind (Übersicht in: Van der Geer et al. 1994). Die Familie der EGFR besteht aus 4 Mitgliedern, EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) und HER4 (ErbB4) mit einer transmembranen Domäne, einer cysteinreichen extrazellulären Domäne und einer intrazellulären katalytischen Domäne. Die Sequenz des EGFR, einem 170 kDa Protein, ist seit 1984 bekannt (Ullrich et al., 1984).

Aktiviert wird der EGFR durch Peptid-Wachstumsfaktoren wie EGF, TGF α (transforming growth factor), Amphiregulin, Beta-cellulin, HB-EGF (heparin-binding EGF-like growth factor) und Neureguline. Ligandenbindung induziert die Bildung von Homo- oder Heterodimeren mit nachfolgender Autophosphorylierung zytoplasmatischer Tyrosine (Ullrich & Schlessinger, 1990; Alroy & Yarden, 1997). Die phosphorylierten Aminosäuren bilden die Bindungsstellen für eine Vielzahl von Proteinen, die an den proximalen Schritten der Signalweiterleitung in einem komplexen Netzwerk beteiligt sind. Der EGFR ist an den verschiedensten Tumorerkrankungen beteiligt und damit ein geeignetes Target für therapeutische Ansätze (Huang & Harari, 1999). Die Mechanismen, die zu einer aberranten EGFR-Aktivierung führen, können auf Überexpression, Amplifikation, konstitutiver Aktivierung mutanter Rezeptor-Formen oder autokrinen Loops beruhen (Voldborg et al., 1997). Eine Überexpression des EGFR wurde für eine Reihe von Tumoren beschrieben, wie z.B. Brustkrebs (Walker & Dearing, 1999); Nicht-Klein-Lungenkarzinom (Fontanini et al., 1998), Pankreaskarzinom, Kolonkarzinom (Salomon et al., 1995) und Glioblastomen (Rieske et al., 1998). Insbesondere für maligne Glioblastome sind bisher keine effizienten und spezifischen Therapeutika verfügbar.

25 Ausführungsbeispiel:

Zum Nachweis der Wirksamkeit der dsRNA bei der spezifischen Inhibition der EGFR-Genexpression wurden U-87 MG-Zellen (humane Glioblastomzellen), ECCAC (European collection of animal cell culture) Nr. 89081402, verwendet, die mit spezifisch gegen den EGF-Rezeptor (Sequenzprotokoll SQ 51) gerichteten dsRNA transfiziert wurden. Nach ca. 72 Stunden Inkubation wurden die Zellen geerntet, Protein isoliert und im Western Blot Verfahren die EGFR-Expression untersucht.

Versuchsprotokoll:dsRNA-Synthese:

- 5 Mittels eines RNA-Synthesizers (Typ Expedite 8909, Applied Biosystems, Weiterstadt, Deutschland) und herkömmlicher chemischer Verfahren wurden die aus den Sequenzprotokollen ersichtlichen RNA-Einzelstränge und die zu ihnen komplementären Einzelstränge synthetisiert. Anschließend erfolgte die Reinigung der rohen Syntheseprodukte mit Hilfe der HPLC. Verwendet wurde die Säule NucleoPac PA-100, 9x250 mm, der Fa. Dionex; als Niedersalz-Puffer 20 mM Tris, 10 mM NaClO₄, pH 6,8, 10% Acetonitril und als Hochsalz-Puffer 20 mM Tris, 400 mM NaClO₄, pH 6,8, 10% Acetonitril. Der Fluß betrug 3 ml/Minute.
- 10
- 15 Die Hybridisierung der Einzelstränge zum Doppelstrang erfolgte durch Erhitzen des stöchiometrischen Gemischs der Einzelstränge in 10 mM Natriumphosphatpuffer, pH 6,8, 100 mM NaCl, auf 80-90°C und nachfolgendes langsames Abkühlen über 6 Stunden auf Raumtemperatur.

20

Aussaat der Zellen:

- Alle Zellkulturarbeiten wurden unter sterilen Bedingungen in einer entsprechenden Werkbank (HS18, Hera Safe, Kendro, Heraeus) durchgeführt. Die Kultivierung der U-87 MG-Zellen erfolgte im Brutschrank (CO₂-Inkubator T20, Hera cell, Kendro, Heraeus) bei 37°C, 5% CO₂ und gesättigter Luftfeuchtigkeit in DMEM (Dulbecco's modified eagle medium, Biochrom) mit 10% FCS (fetal calf serum, Biochrom), 2 mM L-Glutamin (Biochrom), 1 mM Natrium-Pyruvat (Biochrom), 1xNEAA (Non-essential Aminoacids, Biochrom) und Penicillin/Streptomycin (100 IE/100 µg/ml, Biochrom). Um die Zellen in der exponentiellen Wachstumsphase zu halten, wurden die Zellen alle 3 Tage passagiert. 24 Stunden vor der Applikation der dsRNA mittels Transfektion wurden die Zellen trypsiniert (10x Trypsin/EDTA,
- 25
- 30

Kontrolle wurde eine unspezifische dsRNA-Sequenz, die keinerlei Homologie mit der MDR1-Gensequenz aufweist, eingesetzt (K) und eine MOCK-Transfektion durchgeführt, die alle Reagenzien außer dsRNA enthielt.

5

Die Zellen wurden nach 24, 48 und 72 Stunden geerntet und die Gesamt-RNA mit dem RNeasy-Mini-Kit von Qiagen extrahiert. 10 µg Gesamt-RNA jeder Probe wurden auf einem 1%igen Agarose-Formaldehyd-Gel elektrophoretisch aufgetrennt, auf eine Nylon-Membran geblottet und mit 5'-α³²P-dCTP random-markierten, spezifischen Sonden zuerst gegen MDR1 und nach dem Strippen des Blots gegen GAPDH als interne Kontrolle hybridisiert und auf Röntgenfilmen exponiert.

15 Die Röntgenfilme wurden digitalisiert (Image Master, VDS Pharmacia) und mit der Image-Quant-Software quantifiziert. Dabei wurde ein Abgleich der MDR1-spezifischen Banden mit den entsprechenden GAPDH-Banden durchgeführt.

20 Ergebnisse:

Die Fig. 25 und 26 zeigen Northern-Blots (Fig. 25a, 26a) mit quantitativer Auswertung der MDR1-spezifischen Banden nach Abgleich mit den entsprechenden GAPDH-Werten (Fig. 25b, 26b). Es konnte eine Reduktion der MDR1-mRNA um bis zu 55 % im Vergleich zur MOCK-Transfektion und um bis zu 45 % im Vergleich zur unspezifischen Kontroll-Transfektion beobachtet werden. Nach 48 h ist eine signifikante Reduktion des MDR1-mRNA-Niveaus mit den als R1, R2, R3 (Tabelle 4) bezeichneten dsRNA-Konstrukten erreicht worden. Mit den R4-dsRNA-Konstrukten wurde nach 48 h keine signifikante Reduktion gegenüber den Kontrollen beobachtet (Fig. 26a und 26b). Nach 74 h war eine deutlich stärkere Reduktion des MDR1-mRNA-Levels mit R1, R2 und R3 gegenüber den Kontrollen im Vergleich zu den 48 h-Werten zu beobachten (Fig. 25a und 25b).

Mit R4 konnte zu diesem Zeitpunkt ebenfalls eine signifikante Verringerung des MDR1-mRNA-Niveaus erzielt werden. Somit reduzieren die Konstrukte mit einem 2nt-Überhang am 3'-Ende des Antisinnstrangs und einem doppelsträngigen Bereich aus 22 Nukleotidpaaren, relativ unabhängig von dem jeweiligen zum MDR1-Gen homologen Sequenzbereich (nach 48 h; Fig. 26b) das MDR1-mRNA-Level effizienter als die Konstrukte mit mit 2nt-Überhängen an den 3'-Enden beider Stränge (Antisinn- und Sinnstrang) und einem Doppelstrangbereich von 19 Nukleotidpaaren. Die Ergebnisse bekräftigen damit die in Ausführungsbeispiel IV beschriebene Inhibition der EGFR-Genexpression durch spezifische dsRNAs nach Transfektion in U-87 MG-Zellen.

Die Transfektionseffizienz wurde in einem getrennten Experiment mit Hilfe eines Texas-Red-markierten DNA-Oligonukleotids (TexRed-A(GATC)₅T; ebenfalls 175 nM transfiziert) ermittelt (Fig. 27a, 27b; 400fache Vergrößerung, 48h nach Transfektion). Sie betrug etwa 50% auf der Grundlage der rot fluoreszierenden Zellen im Vergleich zur Gesamtzellzahl. Berücksichtigt man die Transfektionsrate der Zellen von etwa 50%, so liegt die beobachtete Verringerung des MDR1-mRNA-Niveaus um ca. 45-55% liegt (verglichen mit den Kontrollen), den Schluss nahe, dass in allen Zellen, die mit spezifischer dsRNA erfolgreich transfiziert werden konnten, die MDR1-mRNA nahezu vollständig und spezifisch abgebaut wurde.

Literatur:

- Alroy I & Yarden Y (1997): The Erb signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Letters 410: 83-86.
- Bass, B.L., 2000. Double-stranded RNA as a template for gene silencing. Cell 101, 235-238.
- Bosher, J.M. and Labouesse, M., 2000. RNA interference: genetic wand and genetic watchdog. Nature Cell Biology 2, E31-E36.
- Bradford MM (1976): Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
- Caplen, N.J., Fleenor, J., Fire, A., and Morgan, R.A., 2000. dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. Gene 252, 95-105.
- Clemens, J.C., Worby, C.A., Simonson-Leff, N., Muda, M., Maelhama, T., Hemmings, B.A., and Dixon, J.E., 2000. Use of double-stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. Proc. Natl. Acad. Sci. USA 97, 6499-6503.
- Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Liebermann G & Slamon DJ (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that

has progressed after chemotherapy for metastatic disease.
Journal of Clinical Oncology 17: 2639-2648.

Ding, S.W., 2000. RNA silencing. Curr. Opin. Biotechnol. 11,
5 152-156.

Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E.,
and Mello, C.C., 1998. Potent and specific genetic interfer-
ence by double-stranded RNA in *Caenorhabditis elegans*. Nature
10 391, 806-811.

Fire, A., 1999. RNA-triggered gene silencing. Trends Genet.
15, 358-363.

15 Freier, S.M., Kierzek, R., Jaeger, J.A., Sugimoto, N., Caruth-
ers, M.H., Neilson, T., and Turner, D.H., 1986. Improved free-
energy parameters for prediction of RNA duplex stability.
Proc. Natl. Acad. Sci. USA 83, 9373-9377 .

20 Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor
response elements mediate induction of intestinal MDR1 by ri-
fampin. J. Biol. Chem. 276 (18), 14581-14587.

Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M,
25 Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR,
Gullick W, Angeletti CA, Bevilacqua G & Ciardiello F (1998):
Evaluation of epidermal growth factor-related growth factors
and receptors and of neoangiogenesis in completely resected
stage I-IIIa non-small-cell lung cancer: amphiregulin and mi-
30 crovessel count are independent prognostic factors of sur-
vival. Clinical Cancer Research 4: 241-249.

- Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J., 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* 404, 293-296.
- 5 Higgins, C.F. (1995). The ABC of channel regulation. *Cell*, 82, 693-696.
- Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1993): Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech. Dev.* 76: 79-90.
- 10 Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1998): Non-invasive sexing of preimplantation mammalian embryos. *Nature Genetics* 19: 220-222.
- 15 Kyhse-Anderson J (1984): Electroblotting of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. *J. Biochem. Biophys. Methods* 10: 203-210.
- 20 Lämmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.
- 25 Loo, T.W., and Clarke, D.M. (1999) *Biochem. Cell Biol.* 77, 11-23.
- Huang SM & Harari PM (1999): Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. *Investigational New Drugs* 17: 259-269.
- 30 Limmer, S., Hofmann, H.-P., Ott, G., and Sprinzl, M., 1993. The 3'-terminal end (NCCA) of tRNA determines the structure and

47. Verwendung nach einem der Ansprüche 41 bis 47, wobei die dsRNA I und/oder die dsRNA II eine Länge von weniger als 25, vorzugsweise 19 bis 23, aufeinander folgenden Nukleotidpaaren aufweist/en.

48. Verwendung nach einem der Ansprüche 41 bis 47, wobei der erste (B1) und der zweite Bereich (B2) abschnittsweise überlappen oder aneinander grenzen.

49. Verwendung nach einem der Ansprüche 41 bis 48, wobei der erste (B1) und der zweite Bereich (B2) voneinander beabstandet sind.

50. Verwendung nach einem der Ansprüche 41 bis 49, wobei das Zielgen eine der Sequenzen SQ001 bis SQ140 aufweist.

51. Verwendung nach einem der Ansprüche 41 bis 50, wobei das Zielgen aus der folgenden Gruppe ausgewählt ist: Onkogen, Cytokin-Gen, Id-Protein-Gen, Priongen, Gene von Angiogenese induzierenden Molekülen, von Adhäsions-Molekülen und von Zelloberflächenrezeptoren, Gene von Proteinen, die an metastasierenden und/oder invasiven Prozessen beteiligt sind, Gene von Proteinasen sowie von Apoptose- und Zellzyklusregulierenden Molekülen.

52. Verwendung nach einem der Ansprüche 41 bis 51, wobei das Zielgen das MRD1-Gens ist.

53. Verwendung nach einem der Ansprüche 41 bis 52, wobei als dsRNA I/II eine der Sequenzen SQ141 -173 bzw. ein aus zwei jeweils zusammengehörenden Antisinn- (as1/2) und Sinnsequenzen (ss1/2) kombiniertes dsRNA-Konstrukt der Sequenzen SQ141 - 173 verwendet wird.

54. Verwendung nach einem der Ansprüche 41 bis 53, wobei die Expression nach dem Prinzip der RNA-Interferenz gehemmt wird.
- 5 55. Verwendung nach einem der Ansprüche 41 bis 54, wobei das Zielgen in pathogenen Organismen, vorzugsweise in Plasmodien, exprimiert wird.
56. Verwendung nach einem der Ansprüche 41 bis 55, wobei das
10 Zielgen Bestandteil eines Virus oder Viroids ist.
57. Verwendung nach Anspruch 56, wobei das Virus ein humanpathogenes Virus oder Viroid ist.
- 15 58. Verwendung nach Anspruch 56, wobei das Virus oder Viroid ein tier- oder pflanzenpathogenes Virus oder Viroid ist.
59. Verwendung nach einem der Ansprüche 41 bis 58, wobei ungepaarte Nukleotide durch Nukleosidthiophosphate substituiert
20 sind.
60. Verwendung nach einem der Ansprüche 41 bis 59, wobei zumindest ein Ende (E1, E2) der dsRNA modifiziert wird, um einem Abbau in der Zelle oder einer Dissoziation in die Einzel-
25 stränge entgegenzuwirken.
61. Verwendung nach einem der Ansprüche 41 bis 60, wobei der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt der doppelsträngigen Struktur durch mindestens eine chemische
30 Verknüpfung erhöht wird.
62. Verwendung nach einem der Ansprüche 41 bis 61, wobei die chemische Verknüpfung durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwir-

kungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet wird.

63. Verwendung nach einem der Ansprüche 41 bis 62, wobei die
5 chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.

64. Verwendung nach einem der Ansprüche 41 bis 63, wobei die
10 chemische Verknüpfung mittels einer oder mehrerer Verbindungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicoxy-1,3-propandiol)- und/oder Oligoethylenglycol-Ketten sind.

65. Verwendung nach einem der Ansprüche 41 bis 64, wobei die
15 chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet wird.

66. Verwendung nach einem der Ansprüche 41 bis 65, wobei die
20 chemische Verknüpfung durch Purinanaloga gebildet wird.

67. Verwendung nach einem der Ansprüche 41 bis 66, wobei die chemische Verknüpfung durch Azabenzoleinheiten gebildet wird.

68. Verwendung nach einem der Ansprüche 41 bis 67, wobei zur
25 Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.

69. Verwendung nach einem der Ansprüche 41 bis 68, wobei die
30 chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-Gruppen gebildet wird.

70. Verwendung nach einem der Ansprüche 41 bis 69, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt wird.

5 71. Verwendung nach einem der Ansprüche 41 bis 70, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen wird.

72. Verwendung nach einem der Ansprüche 41 bis 71, wobei die
10 dsRNA I/II an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben wird/werden.

15 73. Verwendung nach einem der Ansprüche 41 bis 72, wobei das Hüllprotein vom Polyomavirus abgeleitet ist.

74. Verwendung nach einem der Ansprüche 41 bis 73, wobei das Hüllprotein das Virus-Protein 1 (VP1) und/oder das Virus-
20 Protein 2 (VP2) des Polyomavirus enthält.

75. Verwendung nach einem der Ansprüche 41 bis 74, wobei bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kap-
25 sidartigen Gebildes gewandt ist.

76. Verwendung nach einem der Ansprüche 41 bis 75, wobei der eine Strang (as1, as2) der dsRNA I/II zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist.

30

77. Verwendung nach einem der Ansprüche 41 bis 76, wobei die Zelle eine Vertebratenzelle oder eine menschliche Zelle ist.

78. Verwendung nach einem der Ansprüche 41 bis 77, wobei die dsRNA I/II in einer Menge von höchstens 5 mg je Kilogramm Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht wird.

5

79. Verwendung nach einem der Ansprüche 41 bis 78, wobei die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen ist.

10 80. Verwendung nach einem der Ansprüche 41 bis 79, wobei die dsRNA I/II oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verabreicht wird.

15 81. Medikament zur Hemmung der Expression eines Zielgens in einer Zelle enthaltend eine doppelsträngige Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausreichenden Menge,

20 wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinander folgenden Nukleotidpaaren gebildete Struktur aufweist,

und wobei ein Strang (as1) oder zumindest ein Abschnitt des
25 einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Zielgen ist,

und wobei die dsRNA I zumindest am einen Ende (E1, E2) einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

30

82. Medikament nach Anspruch 81, wobei die dsRNA I den Überhang am 3'-Ende des einen Strangs (as1) und/oder am 3'-Ende des anderen Strangs (ss1) aufweist.

126. Verfahren nach einem der vorhergehenden Ansprüche, wobei
zumindest eine entsprechend der dsRNA I nach einem der vor-
hergehenden Ansprüche ausgebildete weitere doppelsträngige
Ribonukleinsäure (dsRNA II) in die Zelle eingeführt wird,
5 wobei der eine Strang (as1) oder zumindest ein Abschnitt des
einen Strangs (as1) der dsRNA I komplementär zu einem ersten
Bereich (B1) des Zielgens ist, und wobei ein weiterer Strang
(as2) oder zumindest ein Abschnitt des weiteren Strangs (as2)
der dsRNA II komplementär zu einem zweiten Bereich (B2) des
10 Zielgens ist.

127. Verfahren nach einem der vorhergehenden Ansprüche, wobei
die dsRNA I und/oder die dsRNA II eine Länge von weniger als
25, vorzugsweis 19 bis 23, aufeinander folgenden Nukleo-
15 tidpaaren aufweist/en.

128. Verfahren nach einem der vorhergehenden Ansprüche, wobei
der erste (B1) und der zweite Bereich (B2) abschnittsweise
überlappen oder aneinander grenzen.

20

129. Verfahren nach einem der vorhergehenden Ansprüche, wobei
der erste (B1) und der zweite Bereich (B2) voneinander beab-
standet sind.

25 130. Verfahren nach einem der vorhergehenden Ansprüche, wobei
das Zielgen eine der Sequenzen SQ001 bis SQ140 aufweist.

131. Verfahren nach einem der vorhergehenden Ansprüche, wobei
das Zielgen aus der folgenden Gruppe ausgewählt ist: Onkogen,
30 Cytokin-Gen, Id-Protein-Gen, Priongen, Gene von Angiogenese
induzierenden Molekülen, von Adhäsions-Molekülen und von
Zelloberflächenrezeptoren, Gene von Proteinen, die an meta-
stasierenden und/oder invasiven Prozessen beteiligt sind, Ge-

ne von Proteinasen sowie Apoptose- und Zellzyklus-regulierenden Molekülen.

132. Verfahren nach einem der vorhergehenden Ansprüche, wobei
5 das Zielgen das MDR1-Gens ist.

133. Verfahren nach einem der vorhergehenden Ansprüche, wobei
als dsRNA I/II eine der Sequenzen SQ141 -173 bzw. ein aus
zwei jeweils zusammengehörenden Antisinn- (as1/2) und Sinnse-
10 quenzen (ss1/2) kombiniertes dsRNA-Konstrukt der Sequenzen
SQ141 - 173 verwendet wird.

134. Verfahren nach einem der vorhergehenden Ansprüche, wobei
die Expression nach dem Prinzip der RNA-Interferenz gehemmt
15 wird.

135. Verfahren nach einem der vorhergehenden Ansprüche, wobei
das Zielgen in pathogenen Organismen, vorzugsweise in Plasmo-
dien, exprimiert wird.

20

136. Verfahren nach einem der vorhergehenden Ansprüche, wobei
das Zielgen Bestandteil eines Virus oder Viroids ist.

137. Verfahren nach Anspruch 16, wobei das Virus ein humanpa-
25 thogenes Virus oder Viroid ist.

138. Verfahren nach Anspruch 16, wobei das Virus oder Viroid
ein tier- oder pflanzenpathogenes Virus oder Viroid ist.

30 139. Verfahren nach einem der vorhergehenden Ansprüche, wobei
ungepaarte Nukleotide durch Nukleosidthiophosphate substitu-
iert sind.

140. Verfahren nach einem der vorhergehenden Ansprüche, wobei zumindest ein Ende (E1, E2) der dsRNA I/II modifiziert wird, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken.

5

141. Verfahren nach einem der vorhergehenden Ansprüche, wobei der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt der doppelsträngigen Struktur durch mindestens eine chemische Verknüpfung erhöht wird.

10

142. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwirkungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet wird.

15

143. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.

20

144. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung mittels einer oder mehrerer Verbindungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicoxy-1,3-propandiol)- und/oder Oligoethylenglycol-Ketten sind.

25

145. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet wird.

30

146. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch Purinanaloga gebildet wird.

147. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch Azabenzoleinheiten gebildet wird.

5 148. Verfahren nach einem der vorhergehenden Ansprüche, wobei zur Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.
10

149. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-
15 Gruppen gebildet wird.

150. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt wird.
20

151. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen wird.

25 152. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben wird/werden.

30 153. Verfahren nach einem der vorhergehenden Ansprüche, wobei das Hüllprotein vom Polyomavirus abgeleitet ist.

154. Verfahren nach einem der vorhergehenden Ansprüche, wobei das Hüllprotein das Virus-Protein 1 (VP1) und/oder das Virus-Protein 2 (VP2) des Polyomavirus enthält.
- 5 155. Verfahren nach einem der vorhergehenden Ansprüche, wobei bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kapsidartigen Gebildes gewandt ist.
- 10 156. Verfahren nach einem der vorhergehenden Ansprüche, wobei der eine Strang (as1, as2) der dsRNA I/II zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist.
- 15 157. Verfahren nach einem der vorhergehenden Ansprüche, wobei die Zelle eine Vertebratenzelle oder eine menschliche Zelle ist.
158. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II in einer Menge von höchstens 5 mg je Kilogramm
20 Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht wird.
159. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II zur Applikation in eine Pufferlösung aufgenom-
25 men ist.
160. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II oral oder mittels Injektion oder Infusion in-
30 travenös, intratumoral, inhalativ, intraperitoneal verabreicht wird.

198. Verwendung nach einem der Ansprüche 41 bis 77, wobei die dsRNA I/II in einer Menge von höchstens 5 mg je Kilogramm Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht wird.

5

199. Verwendung nach einem der Ansprüche 41 bis 78, wobei die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen ist.

10 200. Verwendung nach einem der Ansprüche 41 bis 79, wobei die dsRNA I/II oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verabreicht wird.

15 201. Medikament zur Hemmung der Expression eines Zielgens in einer Zelle enthaltend eine doppelsträngige Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausreichenden Menge,

20 wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinander folgenden Nukleotidpaaren gebildete Struktur aufweist,

und wobei ein Strang (as1) oder zumindest ein Abschnitt des
25 einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Zielgen ist,

und wobei die dsRNA I zumindest am einen Ende (E1, E2) einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

30

202. Medikament nach Anspruch 81, wobei die dsRNA I den Überhang am 3'-Ende des einen Strangs (as1) und/oder am 3'-Ende des anderen Strangs (ss1) aufweist.

Cytokin-Gen, Id-Protein-Gen, Prionen, Gene von Angiogenese induzierenden Molekülen, von Adhäsions-Molekülen und von Zelloberflächenrezeptoren, Gene von Proteinen, die an metastasierenden und/oder invasiven Prozessen beteiligt sind, Gene von Proteinasen sowie von Apoptose- und Zellzyklusregulierende Molekülen.

211. Medikament nach einem der Ansprüche 81 bis 90, wobei das Zielgen das MRD1-Gen ist.

10

212. Medikament nach einem der Ansprüche 81 bis 91, wobei als dsRNA eine der Sequenzen SQ141 -173 bzw. ein aus zwei jeweils zusammengehörenden Antisinn- (as1/2) und Sinnsequenzen (ss1/2) kombiniertes dsRNA-Konstrukt der Sequenzen SQ141 - 173 verwendet wird.

15

213. Medikament nach einem der Ansprüche 81 bis 92, wobei die Expression nach dem Prinzip der RNA-Interferenz gehemmt wird.

214. Medikament nach einem der Ansprüche 81 bis 93, wobei das Zielgen in pathogenen Organismen, vorzugsweise in Plasmodien, exprimierbar ist.

20

215. Medikament nach einem der Ansprüche 81 bis 94, wobei das Zielgen Bestandteil eines Virus oder Viroids ist.

25

216. Medikament nach Anspruch 95, wobei das Virus ein humanpathogenes Virus oder Viroid ist.

217. Medikament nach Anspruch 95, wobei das Virus oder Viroid ein tier- oder pflanzenpathogenes Virus oder Viroid ist.

30

218. Medikament nach einem der Ansprüche 81 bis 97, wobei ungepaarte Nukleotide durch Nukleosidthiophosphate substituiert sind.
- 5 219. Medikament nach einem der Ansprüche 81 bis 98, wobei zumindest ein Ende (E1, E2) der dsRNA modifiziert ist, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken.
- 10 220. Medikament nach einem der Ansprüche 81 bis 99, wobei der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt der doppelsträngigen Struktur durch mindestens eine chemische Verknüpfung erhöht ist.
- 15 221. Medikament nach einem der Ansprüche 81 bis 100, wobei die chemische Verknüpfung durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwirkungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet
- 20 ist.
222. Medikament nach einem der Ansprüche 81 bis 101, wobei die chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.
- 25 223. Medikament nach einem der Ansprüche 81 bis 102, wobei die chemische Verknüpfung mittels einer oder mehrerer Verbindungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicoxy-1,3-propandiol)- und/oder
- 30 Oligoethylenglycol-Ketten sind.
224. Medikament nach einem der Ansprüche 81 bis 103, wobei die chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet ist.

225. Medikament nach einem der Ansprüche 81 bis 104, wobei die chemische Verknüpfung durch Purinanaloga gebildet ist.
- 5 226. Medikament nach einem der Ansprüche 81 bis 105, wobei die chemische Verknüpfung durch Azabenzoleinheiten gebildet ist.
227. Medikament nach einem der Ansprüche 81 bis 106, wobei
10 zur Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.
- 15 228. Medikament nach einem der Ansprüche 81 bis 107, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-Gruppen gebildet ist.
- 20 229. Medikament nach einem der Ansprüche 81 bis 108, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt ist.
- 25 230. Medikament nach einem der Ansprüche 81 bis 109, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen ist.
231. Medikament nach einem der Ansprüche 81 bis 110, wobei
30 die dsRNA I an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben ist/sind.

232. Medikament nach einem der Ansprüche 81 bis 111, wobei das Hüllprotein vom Polyomavirus abgeleitet ist.

233. Medikament nach einem der Ansprüche 81 bis 112, wobei
5 das Hüllprotein das Virus-Protein 1 (VP1) und/oder das Virus-Protein 2 (VP2) des Polyomavirus enthält.

234. Medikament nach einem der Ansprüche 81 bis 113, wobei
bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem
10 Hüllprotein die eine Seite zum Inneren des Kapsids oder kapsidartigen Gebildes gewandt ist.

235. Medikament nach einem der Ansprüche 81 bis 114, wobei
der eine Strang (as1, as2) der dsRNA I zum primären oder pro-
15 zessierten RNA-Transkript des Zielgens komplementär ist.

236. Medikament nach einem der Ansprüche 81 bis 115, wobei
die Zelle eine Vertebratenzelle oder eine menschliche Zelle
ist.

20

237. Medikament nach einem der Ansprüche 81 bis 116, wobei
der erste (B1) und der zweite Bereich (B2) voneinander beab-
standen sind.

25 238. Medikament nach einem der Ansprüche 81 bis 117, wobei
die dsRNA in einer Menge von höchstens 5 mg pro Verabrei-
chungseinheit enthalten ist.

239. Medikament nach einem der Ansprüche 81 bis 118, wobei
30 die dsRNA in eine Pufferlösung aufgenommen ist.

240. Medikament nach einem der Ansprüche 81 bis 119, wobei
die dsRNA oral oder mittels Injektion oder Infusion intrave-

nös, intratumoral, inhalativ, intraperitoneal verabreichbar
ist.

WO 02/055693

PCT/EP02/00152

7/20




Fig. 10




Fig. 11

8/20




Fig. 12




Fig. 13




Fig. 14

9/20




Fig. 15




Fig. 16

10/20




Fig. 17

11/20




Fig. 18

WO 02/055693

PCT/EP02/00152

20/20




Fig. 27

SEQUENZPROTOKOLL

<110> Ribopharma AG

5 <120> Verfahren zur Hemmung der Expression
eines Zielgens

<130>

10 <140>

<141>

<160> 142

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 2955

<212> DNA

20 <213> Homo sapiens

<300>

<302> Eph A1

<310> NM00532

25

<300>

<302> ephrin A1

<310> NM00532

30 <400> 1

```

atggagcggc gctggcccct ggggctaggg ctggtgctgc tgctctgcgc cccgctgccc 60
ccggggcgcg gcgccaagga agttactctg atggacacaa gcaaggcaca gggagagctg 120
ggctggctgc tggatcccc aaaagatggg tggagtgaac agcaacagat actgaatggg 180
acaccctctt acatgtacca ggactgcca atgcaaggac gcagagacac tgaccactgg 240
35 ctctgctcca attggatcta ccgcggggag gaggtctccc gcgtccacgt ggagctgcag 300
ttcaccgtgc gggactgcaa gaggttccct gggggagccg ggcctctggg ctgcaaggag 360
accttcaacc ttctgtacat ggagagtgc caggatgtgg gcattcagct ccgacggccc 420
ttgttcaga aggtaaccac ggtggctgca gaccagagct tcaccattcg agaccttgcg 480
tctggctccg tgaagctgaa tgtggagcgc tgctctctgg gccgcctgac ccgccgtggc 540
40 ctctacctcg ctttccacaa cccgggtgcc tgtgtggccc tgggtgtctgt ccgggtcttc 600
taccagcgct gtctgagac cctgaatggc ttggcccaat tccagacac tctgcctggc 660
ccgctgggt tgggtgaagt ggcggggcacc tgcttgcccc acgcgcgggc cagccccagg 720
ccctcaggtg caccgcgat gcactgcagc cctgatggcg agtggctggg gcctgtagga 780
cggtgccact gtgagcctgg ctatgaggaa ggtggcagtg gcgaagcatg tgttgccctg 840
45 cctagcggct cctaccggat ggacatggac acaccctatt gtctcacgtg ccccagcag 900
agcactgctg agtctgaggg ggccaccatc tgtacctgtg agagcgcca ttacagagct 960
cccggggagg gccccagggt ggcatgcaca ggtccccct cggcccccg aaacctgagc 1020
ttctctgcct cagggactca gctctccctg cgttgggaac cccagcaga tacgggggga 1080
cgccaggatg tcagatacag tgtgaggtgt tccagtgctc agggcacagc acaggacggg 1140
50 gggccctgcc agcctgttgg ggtgggcgtg cacttctcgc cggggggccc ggcgctcacc 1200
acacctgcag tgcattgcaa tggccttgaa ccttatgcca actacacctt taatgtgga 1260
gccccaaatg gagtgtcagg gctgggcagc tctggccatg ccagcacctc agtcagcatc 1320
agcatggggc atgcagagtc actgtcaggc ctgtctctga gactggtgaa gaaagaaccg 1380
aggcaactag agctgacctg ggcgggggtcc cggccccgaa gccctggggc gaacctgacc 1440
55 tatgagctgc acgtgctgaa ccaggatgaa gaacggtacc agatggttct agaaccagg 1500
gtcttgctga cagagctgca gcctgacacc acatacatcg tcagagtccg aatgctgacc 1560
ccactgggtc ctggcccttt ctccctgat catgagtttc ggaccagccc accagtgtcc 1620
aggggcctga ctggaggaga gattgtagcc gtcattcttg ggctgctgct tgggtgcagc 1680
ttgctgcttg ggattctcgt tttccgggtc aggagagccc agcggcagag gcagcagagg 1740
60 cacgtgaccg cgccaccgat gtggatcgag aggacaagct gtgctgaagc cttatgtgg 1800
acctccaggc atacgaggac cctgcacagg gagccttgga ctttaccggg aggctggtct 1860
aattttcctt cccgggagct tgatccagcg tggctgatgg tggacactgt cataggagaa 1920

```

5 ggagagtttg gggaagtgtg tcgagggacc ctcaggctcc ccagccagga ctgcaagact 1980
 gtggccatta agaccttaaa agacacatcc ccagggtggcc agtgggtggaa cttccttcga 2040
 gaggcaacta tcatgggcca gtttagccac ccgcatattc tgcattctgga aggcgtcgtc 2100
 acaaagcgaa agccgatcat gatcatcaca gaatttatgg agaatgcagc cctggatgcc 2160
 10 ttcctgaggg agcgggagga ccagctggtc cctgggcagc tagtggccat gctgcagggc 2220
 atagcatctg gcatgaacta cctcagtaat cacaattatg tccaccggga cctggctgcc 2280
 agaaacatct tggatgaatca aaacctgtgc tgcaagggtg ctgactttgg cctgactcgc 2340
 ctccctggatg actttgatgg cacatacgaa acccaggag gaaagatccc tatccgttg 2400
 acagcccctg aagccattgc ccatcggaac ttcaccacag ccagcgatgt gtggagcttt 2460
 15 gggattgtga tgtgggaggt gctgagcttt ggggacaagc cttatgggga gatgagcaat 2520
 caggaggtta tgaagagcat tgaggatggg taccggttgc cccctcctgt ggactgccct 2580
 gcccctctgt atgagctcat gaagaactgc tgggcataat accgtgcccg ccggccacac 2640
 ttccagaagc ttcaggcaca tctggagcaa ctgcttgcca acccccactc cctgcggacc 2700
 attgccaaact ttgaccccag ggtgactctt cgcctgccc gacctgagtg ctcatatgg 2760
 20 atcccgtatc gaaccgtctc tgagtggctc gagtccatac gcatgaaacg ctacatcctg 2820
 cacttccact cggctgggct ggacaccatg gagtgtgtgc tggagctgac cgctgaggac 2880
 ctgacgcaga tgggaatcac actgcccggg caccagaagc gcattctttg cagtattcag 2940
 ggattcaagg actga 2955
 25 <210> 2
 <211> 3042
 <212> DNA
 <213> Homo sapiens
 30 <300>
 <302> ephrin A2
 <310> XM002088
 35 <400> 2
 gaagttgcgc gcaggccggc gggcgggagc ggacaccgag gccggcgctgc aggcgtgcgg 60
 gtgtgcccga gccgggctcg gggggatcg accgagagcg agaagcgcg catggagctc 120
 caggcagccc gcgcctgctt cgcctgctg tggggctgtg cgctggccgc ggccgcccgc 180
 40 ggcgagggca aggaagtggg actgctggac tttgctgcag ctggagggga gctcggctgg 240
 ctcacacacc cgtatggcaa aggggtgggac ctgatgcaga acatcatgaa tgacatgccg 300
 atctacatgt actccgtgtg caacgtgatg tctggcgacc aggacaactg gctccgcacc 360
 aactgggtgt accgaggaga ggctgagcgt atcttcattg agctcaagtt tactgtacgt 420
 gactgcaaca gcttccctgg tggcgccagc tctgcaagg agactttcaa cctctactat 480
 gccgagtcgg acctggacta cggcaccaac ttccagaagc gcctgttcac caagattgac 540
 45 accattgcgc ccgatgagat caccgtcagc agcgacttcg aggcacgcca cgtgaagctg 600
 aacgtggagg agcgctccgt gggcgccgct acccgcaaag gcttctacct ggccctccag 660
 gatatacggt cctgtgtggc gctgctctcc gtccgtgtct actacaagaa gtccccgag 720
 ctgctgcagg gcctggccca cttccctgag accatcgccg gctctgatgc acctccctg 780
 gccactgtgg ccggcacctg tgtggaccat gccgtggtgc caccgggggg tgaagagccc 840
 50 cgtatgcact gtgcagtgga tggcgagtgg ctgggtgcca ttgggcagtg cctgtgccag 900
 gcaggctacg agaaggtgga ggatgcctgc caggcctgct cgctggatt ttttaagttt 960
 gaggcattct agagcccctg cttggagtgc cctgagcaca cgctgccatc ccctgagggt 1020
 gccacctcct gcgagtgtga ggaaggcttc ttccgggcac ctcaggacct agcgtcgatg 1080
 ccttgacacac gacccccctc cgcaccacac tacctcacag ccgtgggcat gggtgccaag 1140
 55 gtggagctgc gctggacgcc ccctcaggac agcgggggccc gcgaggacat tgtctacagc 1200
 gtcacctgcg aacagtgtc ggcgaagtgc ggggaatgag ggccagtgta ggccagtgat 1260
 cgctactcgg agcctcctca cggactgacc cgaccagtgc tgacagttag cgacctggag 1320
 cccacatgaa actacacctt caccgtggag gcccgcaatg gcgtctcagg cctggtaacc 1380
 agccgcagct tccgtactgc cagtgtcagc atcaaccaga cagagcccc caaggtgagg 1440
 60 ctggagggccc gcagcaccac ctgccttagc gtctcctgga gcaccccccc gccgcagcag 1500
 agccagtggt ggaagtacga ggtcacttac cgcaagaagg gagactccaa cagctacaat 1560
 gtgcgcccga ccgagggttt ctccgtgacc ctggacgacc tggccccaga caccacctac 1620
 ctggtccagg tgcaggcact gacgcaggag ggccaggggg ccggcagcaa ggtgcacgaa 1680
 ttccagacgc tgtccccgga gggatctggc aacttggcgg tgattggcgg cgtggctgtc 1740
 65 ggtgtggtcc tgcctctggt gctggcagga gttggcttct ttatccaccg caggaggaag 1800
 aaccagcgtg cccgccagtc cccggaggac gtttacttct ccaagtcaga acaactgaag 1860
 cccctgaaga catacgtgga cccccacaca tatgaggacc ccaaccaggc tgtgttgaag 1920

5	ttcactaccg tttggggagg gccatcaaga gccggcatca aaatacaagc cttcggggaga gcagctggca aacatcctcg ctggaggagc accgccccgg ggcatttgtca cacgaggtga tccgccatct ttcgctgaca ctggctgact gtgcccttcc cacttcatgg atcaagagga ggactcaagg	agatccatcc tgtacaaggg cgctgaaagc tggggcagtt ccatgatgat aggatggcga tgaagtacct tcaacagcaa acccccaggc aggccatttc tgtgggaggt tgaaagccat accagctcat tcgtcagcat ttgacccccg gcacgggtgtc cggccgggcta ttgggggtgcg accaggtgaa	atcctgtgtc catgctgaag cggctacaca cagccaccac catcactgag gttcagcgtg ggccaacatg cctgggtctgc cacctacacc ctaccggaaag gatgacctat caatgatggc gatgcagtg cctggacaag cgtgtctatc cgagtggctg cactgccatc gctgccccgc cactgtgggg	actcggcaga acatcctcgg gagaagcagc aacatcatcc tacatggaga ctgcagctgg aactatgtgc aagggtgtctg accagtgggc ttcacctctg ggcgagcggc ttccggctcc tggcagcagg ctcattctgt cggctcccca gagtccatca gagaaggtgg caccagaagc atccccatct	aggtgatcgg ggaagaagga gagtggaact gcctagaggg atggggccct tgggcatgct accgtgacct actttggcct gcaagatccc ccagcgacgt cctactggga ccacacccat agcgtgcccg ccctgactc gcacgagcgg agatgcagca tgcatgatgac gcctcgcccta ga	agcaggagag ggtgccgggtg cctcggcgag cgtcatctcc ggacaagttc gcggggcatc ggctgcccg gtcccgcgtg catccgcttg gtggagcttt gttgtccaac ggactgcccc ccgccccaa ctccaagacc ctcgaggagg gtatacggag caacgacgac cagcctgctg	1980 2040 2100 2160 2220 2280 2340 2400 2460 2520 2580 2640 2700 2760 2820 2880 2940 3000 3042
25	<210> 3 <211> 2953 <212> DNA <213> Homo sapiens						
30	<300> <302> ephrin A3 <310> NM005233						
35	<400> 3 atggattgtc gaactgattc gagctgggct cattacacac tggtcgagaa ttcactctac aacctgtact acaaagattg attctgaagc ttggcatttc aagtgccctc cagtcctctg aggatgtact gctgggctatg ttggatggta tcaatgaact gcttgtacc gttatccttg atcatatgta cgcttctctc gcacatacta ccaccaagac ctgacgatta gaacatccta gaaacaagtt ctcgacacta agccgcaagt caagtgggtca tatgttttga cttcattttg acatatgaag	agctctccat cgcagccttc ggatctctta ccatcaggac caaactgggt gagactgcaa acatggagtc acaccattgc tcaacactga aagatgtttg ttacagtgaa tggaggttag gcagtacaga aagaaagagg atatgaagtg gcaggtgtga gaacctgcac actggagttg aaaaatgtgg ctcgacagtt ctcacactct agtttgctgc agaaagatcg atgggactcat ataccattct tatacgtatt ttgagtttga tgatcgccat ttggggaggt gcaattggga accctaccca agctgttcat	cctcctcctt caatgaagtc tccatcacat ttaccaggtg ccccaggaac tagcattcca tgatgatgat agctgatgaa gattagagaa tgcttgtgtt gaactctggc agggtctgtg aggcgaatgg ttttatgtgc tgctaagtgc gaataattac ttccaacaga gccccctggac gtggaatata tggaactcacc tgagattgat ggtcagcatc gacctccaga attggactac gagggcaaga ccaaatccga aactagtcca ttcagcggca ctgtggctat tttaaacttc agctgttcat	ctcagctgct aatctactgg gggtgggaag tgcaatgtca tcagctcaga catgggggtg agtttcaact gtaggtcctg gccttggtgt atgtttccag gtcaacaatt cttgtacca caagcttgct ccgcctcaca ttccgggcag aatggttatc acaggaggcc aaacagtggt aacaccacgg gccgttaagt acaactaatc aatagcatct gaggtcaaat ggcacaaatg gcccgacaag gactctttct gtagcaatta aagtcaaaa ccaggtctca gagtttgcca	ctgtttctcga attcaaaaac agatcagtg tgaccacag agatttatgt gaacttgcaa aatttcgaga aaatggatct tcaacaagaa ctgtgagagt acaaggctacc ctaaggagga ttggcaagtg gaccagggtt gttctactca acaaagaccc ctaatataaa ggaaagatgt agccatgcag gggtgtcaga agggtgctcc ctttgtcctg actatgaaaa ttaccatcag cccgctcag ccatctctgg ttctcctcac atggggcaga ggacttatgt aggaattgga	cagcttcggg aattcaaggg tgtggatgaa tcaaaacaat ggagctcaag ggagacattc gcatcagttt tggggaccgt gggattttat atacttcaaa catggactcc agatcctcca ttcctgcaat gggattttat atacttcaaa ataggactcc gagctctcca ctacaaggca ggaagatggt tccatccagt cgagacctca taccttcaac cccaaatgtc agaccttctg gcaggacaac tagcctcaag tgggacgaac tgaaagtagc tgttgtcatc tgaaaaaaga tgacccaacat tgccaccaac	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1800 1860

	atattccattg	ataaaattgt	tggagcaggt	gaattttggag	aggtgtgcag	tggctgctta	1920
	aaacttcctt	caaaaaaaga	gatttcagtg	gccattaaaa	ccctgaaagt	tggctacaca	1980
	gaaaagcaga	ggagagactt	cctgggagaa	gcaagcatta	tgggacagtt	tgaccacccc	2040
5	aatatcattc	gactggaagg	agttgttacc	aaaagtaagc	cagttatgat	tgtcacagaa	2100
	tacatggaga	atgggtccct	ggatagtttc	ctacgtaaac	acgatgccca	gtttactgtc	2160
	attcagctag	tgggtagctt	tcgagggata	gcatctggca	tgaagtacct	gtcagacatg	2220
	ggctatgttc	accgaagcct	cgctgctcgg	aacatcttga	tcaacagtaa	cttgggtgtg	2280
	aagggtttctg	atttcggact	ttcgctgtgc	ctggaggatg	accagaagc	tgcttatata	2340
10	acaagaggag	ggaagatccc	aatcaggtgg	acatcaccag	aagctatagc	ctaccgcaag	2400
	ttcacgtcag	ccagcgatgt	atggagttat	gggattgttc	tctgggaggt	gatgtcttat	2460
	ggagagagac	catactggga	gatgtccaat	caggatgtaa	ttaaagctgt	agatgagggc	2520
	tctcgactgc	caccccccat	ggactgcccc	gctgccttgt	atcagctgat	gctggactgc	2580
	tggcagaaag	acaggaacaa	cagacccaag	tttgagcaga	ttgttagtat	tctggacaag	2640
	cttatccgga	atcccggcag	cctgaagatc	atcaccagtg	cagccgcaag	gccatcaaac	2700
15	cttcttcttg	accaaagcaa	tgtggatata	tctaccttcc	gcacaacagg	tgactggctt	2760
	aatgggtgtcc	ggacagcaca	ctgcaaggaa	atcttcacgg	gcgtggagta	cagttcttgt	2820
	gacacaatag	ccaagatttc	cacagatgac	atgaaaaagg	ttgggtgcac	cgtgtcttgg	2880
	ccacagaaga	agatcatcag	tagcattaaa	gctctagaaa	cgcaatcaaa	gaatggccca	2940
20	gttcccgtgt	aaa					2953
	<210>	4					
	<211>	2784					
	<212>	DNA					
25	<213>	Homo sapiens					
	<300>						
	<302>	ephrin A4					
	<310>	XM002578					
30	<400>	4					
	atggatgaaa	aaaatacacc	aatccgaacc	taccaagtgt	gcaatgtgat	ggaaccacgc	60
	cagaataact	ggctacgaac	tgattggatc	acccgagaag	gggctcagag	ggtgtatatt	120
35	gagattaaat	tcaccttgag	ggactgcaat	agtcttccgg	gcgtcatggg	gacttgcaag	180
	gagacgttta	acctgtacta	ctatgaatca	gacaacgaca	aagagcgttt	catcagagag	240
	aaccagtttg	tcaaaattga	caccattgct	gctgatgaga	gcttcaccca	agtggacatt	300
	gggtacagaa	tcatgaagct	gaacaccgag	atccgggatg	tagggccatt	aagcaaaaag	360
	gggtttttacc	tggcttttca	ggatgtgggg	gcctgcatac	ccctgggtatc	agtcogtgtg	420
40	ttctataaaa	agtgctccact	cacagtccgc	aatctggccc	agtttctctga	caccatcaca	480
	ggggctgata	cgtcttccct	ggtggaagtt	cgaggctcct	gtgtcaacaa	ctcagaagag	540
	aaagatgtgc	caaaaatgta	ctgtggggcg	gatggtgaat	ggctgggtacc	cattggcaac	600
	tgcctatgca	acgctgggca	tgaggagcgg	agcggagatg	gccaagcttg	caaaattgga	660
	tattacaagg	ctctctccac	ggatgcccac	tgtgccaaagt	gcccacccca	cagctactct	720
45	gtctgggaag	gagccacctc	gtgcacctgt	gaccgaggct	ttttcagagc	tgacaacgat	780
	gctgcctcta	tgccctgcac	ccgtccacca	tctgctcccc	tgaacttgat	ttcaaatgtc	840
	aacgagacat	ctgtgaactt	ggaatggagt	agccttcaga	atacaggttg	ccgccaggac	900
	atttctcata	atgtggtatg	caagaaatgt	ggagctgggt	accccagcaa	gtgccgaccc	960
	tgtggaagtg	gggtccacta	caccccacag	cagataggct	tgaagaccac	caaagtctcc	1020
	atcactgacc	tcctagctca	taccaattac	acctttgaaa	tctgggctgt	gaatggagtg	1080
50	tccaaatata	accctaacc	agaccaatca	gtttctgtca	ctgtgaccac	caaccaagca	1140
	gcaccatcat	ccattgcttt	ggtccaggct	aaagaagtca	caagatacac	tgtggcactg	1200
	gcttggcttg	aaccagatcg	gcccaatggg	gtaatcctgg	aatatgaagt	caagtattat	1260
	gagaaggatc	agaatgagcg	aagctatcgt	atagttcgga	cagctgccag	gaacacagat	1320
	atcaaaggcc	tgaaccctct	cacttcctat	gttttccacg	tgcgagccag	gacagcagct	1380
55	ggctatggag	acttcagtg	gcccttggag	gttacaacca	acacagtgcc	ttcccggaac	1440
	attggagatg	gggctaactc	cacagctcct	ctggtctctg	tctcgggcag	tgtgggtctg	1500
	atgtctatgt	tgaattggag	tttttctatg	atggtggagc	gagctcaata	gattacagct	1560

<211> 3147
 <212> DNA
 <213> Homo sapiens

5 <300>
 <302> alpha v intergrin
 <310> NM0022210

<400> 12
 10 atggccttttc cgccgcggcg acggctgcgc ctccggctccc ggggcctccc gcttcttctc 60
 tcgggactcc tgctacctct gtgcgcgcgc ttcaacctag acgtggacag tcctgccgag 120
 tactctggcc ccgagggaag ttacttcggc ttccgcgtgg atttcttcgt gcccgccgag 180
 tcttcccggg tgttcttctc cgtgggagct cccaaagcaa acaccacca gcctgggatt 240
 gtggaaggag ggcaggctcct caaatgtgac tggctctcta ccgcccgggt ccagccaatt 300
 15 gaatttgatg caacaggcaa tagagattat gccaggatg atccattgga atttaagtcc 360
 catcagtggg ttggagcatc tgtgaggtcg aaacaggata aaattttggc ctgtgcccc 420
 ttgtaccatt ggagaactga gatgaaacag gaggcgagagc ctggttgaac atgctttctt 480
 caagatggaa caaagactgt tgagtatgct ccatgtagat cacaagatat tgatgctgat 540
 ggacagggat tttgtcaagg aggatccagc attgatttta ctaaagctga cagagtactt 600
 20 cttggtggct ctggtagctt ttattggcaa ggtcagctta ttcggatca agtggcagaa 660
 atcgatatcta aatacgacct caatgtttac agcatcaagt ataataacca attagcaact 720
 cggactgcac aagctatttt tgatgacagc tatttgggtt attctgtggc tgtcggagat 780
 ttcaatgggt atggcataga tgactttggt tcaggagttc caagagcagc aaggactttg 840
 ggaatggttt atatttatga tgggaagaac atgtcctcct tatacaattt tactggcgag 900
 25 cagatggctg catatttcgg attttctgta gctgccactg acattaatgg agatgattat 960
 gcagatgtgt ttattggagc acctctcttc atggatcgtg gctctgatgg caaactccaa 1020
 gaggtggggc aggtctcagt gtctctacag agagcttcag gagacttcca gacgacaaag 1080
 ctgaatggat ttgaggtctt tgcacggttt ggcagtgcca tagctccttt gggagatctg 1140
 gaccaggatg gtttcaatga tattgcaatt gctgctccat atgggggtga agataaaaaa 1200
 30 ggaattgttt atactttcaa tgggaagatca acaggcttga acgcagtcct atctcaaate 1260
 cttgaagggc agtgggctgc tcgaagcatg ccaccaagct ttggctattc aatgaaagga 1320
 gccacagata tagacaaaaa tggatatcca gacttaattg taggagcttt tgggtgtagat 1380
 cgagctatct tatacagggc cagaccagtt atcactgtaa atgctggctt tgaagtgtac 1440
 cctagcattt taaatcaaga caataaaacc tgctcactgc ctggaacagc tctcaaagtt 1500
 35 tctgttttta atgttaggtt ctgcttaag gcagatggca aaggagtact tccaggaa 1560
 cttaatttcc aggtggaact tcttttggat aaactcaagc aaaagggagc aattcgagca 1620
 gcactgtttc tctacagcag gtccccaagt cactccaaga acatgactat ttcaaggggg 1680
 ggactgatgc agtgtgagga attgatagcg tatctgcggg atgaatctga atttagagac 1740
 40 aaactcactc caattactat ttttatggaa tatcggttgg attatagaac agctgctgat 1800
 acaacaggct tgcaacccat tcttaaccag ttcacgcctg ctaacattag tcgacaggct 1860
 cacattctac ttgactgtgg tgaagacaat gctctgtaac ccaagctgga agtttctgta 1920
 gatagtgatc aaaagaagat ctatatgggg gatgacaacc ctctgacatt gattgttaag 1980
 gctcagaatc aaggagaagg tgccctacgaa gctgagctca tcgtttccat tccactgcag 2040
 45 gctgatttca tcgggggtgt ccgaaacaat gaagccttag caagactttc ctgtgcattt 2100
 aagacagaaa accaaactcg ccagggtgta tgtgaccttg gaaacccaat gaaggctgga 2160
 actcaactct tagctggctt tcgtttcagt gtgcaccagc agtcagagat ggatacttct 2220
 gtgaaatttg acttacaat ccaaagctca aatctatttg acaaagtaag cccagttgta 2280
 tctcacaag ttgatcttgc tgttttagct gcagttgaga taagaggagt ctcgagtcct 2340
 50 gatcatatct ttcttccgat tccaaactgg gagcacaagg agaaccctga gactgaagaa 2400
 gatgttgggc cagttgttca gcacatctat gagctgagaa acaatggtcc aagttcattc 2460
 agcaaggcaa tgctccatct ccagtggcct tacaaatata ataataacac tctgttgtat 2520
 atccttcatt atgatattga tggaccaatg aactgcactt cagatatgga gatcaaccct 2580
 ttgagaattt agatctcatc tttgcaaaac actgaaaaga atgacacggt tgccgggcaa 2640
 ggtgagcggg accatctcat cactaagcgg gatcttgccc tcagtgaagg agatattcac 2700
 55 actttgggtt gtggagtgc tcagtgttg aagattgtct gccagttgg gagattagac 2760
 agaggaaaaga gtgcaatctt gtactgaaag tcattactgt ggactgagac ttttatgaat 2820
 aaagaaaatc agaatcttcc ctattctctg aagtcgtctg cttcatttaa tgtcatagag 2880
 tttccttata agaatcttcc aattgaggat atcaccact ccacattggt taccactaat 2940
 gtcacctggg gcattcagcc agcgcctatg cctgtgcttg tgtgggtgat catttttagca 3000
 60 gttctagcag tttgttgct actggctgtt ttggtatttg taatgtacag gatgggcttt 3060
 tttaaacggg tccggccacc tcaagaagaa agcagcttca acctcatgaa 3120
 aatggtgaag gaaactcaga aacttaa 3147

```

5   <210> 13
    <211> 402
    <212> DNA
    <213> Homo sapiens

    <300>
    <302> CaSm (cancer associated SM-like oncogene)
10  <310> AF000177

    <400> 13
    atgaactata tgcctggcac cgccagcctc atcgaggaca ttgacaaaaa gcacttggtt 60
    ctgcttcgag atggaaggac acttataggc tttttaagaa gcattgatca atttgcaaac 120
15  ttagtgtctac atcagactgt ggagcgtatt catgtgggca aaaaatacgg tgatattcct 180
    cgagggattt ttgtggtcag aggagaaaat gtggtcctac taggagaaat agacttggaa 240
    aaggagagtg acacaccctt ccagcaagta tccattgaag aaattctaga agaacaaagg 300
    gtggaacagc agaccaagct ggaagcagag aagttgaaag tgcaggccct gaaggaccga 360
    ggtctttcca ttcctcgagc agatactctt gatgagtact aa 402

20

    <210> 14
    <211> 1923
    <212> DNA
25  <213> Homo sapiens

    <300>
    <302> c-myb
    <310> NM005375
30

    <400> 14
    atggcccga gaccccgga cagcatatat agcagtgcag aggatgatga ggactttgag 60
    atgtgtgacc atgactatga tgggctgctt cccaagtctg gaaagcgtca cttggggaaa 120
    acaagggtga cccgggaaga ggatgaaaaa ctgaagaagc tgggtggaaca gaatggaaca 180
35  gatgactgga aagttattgc caattatctc ccgaatcgaa cagatgtgca gtgccagcac 240
    cgatggcaga aagtactaaa ccctgagctc atcaagggtc cttggaccaa agaagaagat 300
    cagagagtga tagagcttgt acagaaatac ggtccgaaac gttggtctgt tattgccaag 360
    cacttaaagg ggagaattgg aaaacaatgt agggagaggt ggcataacca cttgaatcca 420
    gaagttaaga aaacctcctg gacagaagag gaagacagaa ttatttacca ggcacacaag 480
40  agatggggga acagatgggc agaatcgca aagctactgc ctggacgaac tgataatgct 540
    atcaagaacc actggaattc tacaatgcgt cggaagggtc aacaggaagg ttatctgcag 600
    gagtcttcaa aagccagcca gccagcagtg gccacaagct tccagaagaa cagtcatttg 660
    atgggttttg ctcaggctcc gcctacagct caactccctg ccactggcca gccactgtt 720
    aacaacgact attcctatta ccacatttct gaagcacaaa atgtctccag tcatgttcca 780
45  taccctgtag cgttacatgt aaatatagtc aatgtccctc agccagctgc cgcagccatt 840
    cagagacact ataatgatga agacctgag aaggaaaagc gaataaagga attagaattg 900
    ctctaatgt caaccgagaa tgagctaaaa ggacagcagg tgctaccaac acagaaccac 960
    acatgcagct accccgggtg gcacagcacc accattgccg accacaccag acctcatgga 1020
    cagagtgcac ctggttctctg tttgggagaa caccactcca ctccatctct gccagcggat 1080
50  cctggctccc tacctgaaga aagcgcctcg ccagcaaggt gcatgatcgt ccaccagggc 1140
    accattctgg ataatgttaa gaacctctta gaatttgag aaacactcca atttatagat 1200
    tctttcttaa acacttccag taaccatgaa aactcagact tggaaatgcc ttctttaact 1260
    tccacccccc tcattggtca caaattgact gttacaacac catttcatag agaccagact 1320
    gtgaaaactc aaaaggaaaa tactgttttt agaaccccag ctatcaaaag gtcaatctta 1380
55  gaaagctctc caagaactcc tacaccattc aaacatgcac ttgcagctca agaaattaaa 1440
    tacggtcccc tgaagatgct acctctcatc tagtagaaga tctgcaggat 1500
    gtgatcaaac aggaatctga tgaatctgga tttgttgctg agtttcaaga aaatggacca 1560
    cccttactga agaaaatcaa acaagaggtg gaatctccaa ctgataaatc aggaaacttc 1620
    ttctgtcac accactggga aggggacagt ctgaataccc aactgttcac gcagacctcg 1680
60  cctgtgcgag atgcaccgaa tattcttaca agtccggtt taatggcacc agcatcagaa 1740
    gatgaagaca gtgttctcaa agcatttaca gtacctaaaa acaggtcctt ggcgagcccc 1800
    ttgcagcctt gtagcagtag ctgggaacct gcctcctgtg gaaagatgga ggagcagatg 1860

```

```

acatctttcca gtcaagctcg taaatacgtg aatgcattct cagcccggac gctgggtcatg 1920
tga                                                    1923

5  <210> 15
   <211> 544
   <212> DNA
   <213> Homo sapiens

10 <300>
   <302> c-myc
   <310> J00120

   <400> 15
15 gacccccgag ctgtgctgct cgcggccgcc accgccgggc cccggccgctc cctgggtccc 60
   ctccctgcctc gagaagggca gggctttctca gaggcttggc gggaaaaaga acggagggag 120
   ggatcgcgctc gagtataaaa gccggtttttc ggggctttat ctaactcgct gtagtaattc 180
   cagcgagagg cagagggagc gagcgggcgg cccgctaggg tggagagacc gggcgagcag 240
   agctgcgctg cgggcgtcct gggaagggag atccggagcg aatagggggc ttcgcctctg 300
20 gccagccctc cccgctgac cccagccag cggctccgaa cccttgccgc atccacgaaa 360
   ctttgcccat agcagcgggc gggcactttg cactggaact tacaacacc gagcaaggac 420
   gcgactctcc cgacgcgggg aggtattctt gccatttgg ggacacttcc ccgccgctgc 480
   caggaccgcg ttctctgaaa ggctctcctt gcagctgctt agacgctgga tttttttcgg 540
   gtag                                                    544

   <210> 16
   <211> 618
   <212> DNA
30 <213> Homo sapiens

   <300>
   <302> ephrin-A1
   <310> NM004428

35 <400> 16
   atggagttcc tctgggcccc tctcttgggt ctgtgctgca gtctggccgc tgetgatcgc 60
   cacaccgtct tctggaacag ttcaaattcc aagttccgga atgaggacta caccatacat 120
   gtgcagctga atgactacgt ggacatcatc tgtccgcaat atgaagatca ctctgtggca 180
40 gagctggcca tggagcagta catactgtac ctggtggagc atgaggagta ccagctgtgc 240
   cagccccagt ccaaggacca agtccgctgg cagtgcgaac ggcccagtgc caagcatggc 300
   ccggagaagc tgtctgagaa gttccagcgc ttcacacctt tcaccctggg caaggagtgc 360
   aaagaaggac acagctacta ctacatctcc aaacccatcc accagcatga agaccgctgc 420
   ttgaggttga aggtgactgt cagtggcaaa atcactcaca gtcctcaggc ccatgtcaat 480
45 ccacaggaga agagacttgc agcagatgac ccagagggtc gggttctaca tagcatcggg 540
   cacagtgtctg cccacgcct cttcccactt gcctggactg tgctgctcct tccacttctg 600
   ctgctgcaaa ccccgtag                                                    618

   <210> 17
   <211> 642
   <212> DNA
50 <213> Homo sapiens

   <400> 17
55 atggcgcccg cgcagcgccc getgctcccc ctgctgctcc tgctgttacc gctgccgccc 60
   ccgcccttcg cgcgcgccga ggacgcgcc cgcgccaaact cggaccgcta cgccgtctac 120
   tggaaaccgca gcaaccccag gttccacgca ggcgcggggg acgacggcgg gggctacacg 180
   gtggagggtga gcatcaatga ctacctggac atctactgcc cgcactatgg ggcgcgcgtg 240
60 ccgccggccc agcgcagatga gcactacgtg ctgtacatgg tcaacggcga gggccacgcc 300
   tectgcgacc accgccagcg cggcttcaag cgctgggagt gcaaccggcc cgcggcgccc 360
   gggggggccgc tcaagttctc ggagaagttc cagctcttca cgcccttctc cctgggcttc 420

```

```

gagttccggc cgggccacga gtattactac atctctgcc cgcctcccaa tgctgtggac 480
cggccctgcc tgcgactgaa ggtgtacgtg cgcccgacca acgagaccct gtacgaggct 540
cctgagccca tcttcaccag caataactcg tgtagcagcc cgggcggctg ccgcctcttc 600
ctcagcacca tccccgtgct ctggaccctc ctgggttcct ag 642
5

<210> 18
<211> 717
<212> DNA
10 <213> Homo sapiens

<300>
<302> ephrin-A3
<310> XM001787
15

<400> 18
atggcgggcg ctccgctgct gctgctgctg ctgctcgtgc ccgtgcccgt gctgcccgtg 60
ctggcccaag ggcccgagg ggcgctggga aaccggcatg cgggtgactg gaacagctcc 120
aaccagcacc tgcggcgaga gggctacacc gtgcagggtga acgtgaacga ctatctggat 180
20 attactgcc cgcactacaa cagctcgggg gtgggccccg gggcgggacc gggggccgga 240
ggcggggcag agcagtacgt gctgtacatg gtgagccgca acggctaccg cacctgcaac 300
gccagccagg gcttcaagcg ctgggagtgc aaccggccgc acgcccgcga cagccccatc 360
aagttctcgg agaagttcca gcgtacagc gccttctctc tgggctacga gttccacgcc 420
ggccacgagt actactacat ctccacgccc actcacaacc tgcactggaa gtgtctgagg 480
25 atgaaggtgt tcgtctgctg cgcctccaca tcgcactccg gggagaagcc ggtccccact 540
ctccccagt tcaccatggg ccccaatatg aagatcaacg tgctggaaga ctttgaggga 600
gagaaccctc aggtgcccaa gcttgagaag agcatcagcg ggaccagccc caaacgggaa 660
cacctgcccc tggccgtggg catcgccttc ttctcatga cgttcttggc ctccatg 717
30

<210> 19
<211> 606
<212> DNA
<213> Homo sapiens
35

<300>
<302> ephrin-A3
<310> XM001784

40 <400> 19
atgcgggtgc tgcccctgct gcggactgtc ctctgggccc cgttcctcgg ctccccctctg 60
cgcgggggct ccagcctccg ccacgtagtc tactggaact ccagtaaccc cagggttgctt 120
cgaggagacg ccgtggtgga gctgggcctc aacgattacc tagacattgt ctgccccac 180
45 tacgaaggcc cagggccccc tgagggcccc gagacgtttg ctttgtagat ggtggactgg 240
ccaggctatg agtcctgcca ggcagagggc ccccgggcct acaagcgctg ggtgtgctcc 300
ctgccctttg gccatgttca attctcagag aagattcagc gcttcacacc cttctccctc 360
ggctttgagt tcttacctgg agagacttac tactacatct cggtgcccac tccagagagt 420
tctggccagt gcttgaggct ccagggtgtc gtctgctgca aggagaggaa gtctgagtca 480
gccatcctg ttgggagccc tggagagagt ggcacatcag ggtggcgagg gggggacact 540
50 cccagccccc tctgtctctt gctattactg ctgcttctga ttcttcgtct tctgcgaatt 600
ctgtga 606

<210> 20
<211> 687
<212> DNA
<213> Homo sapiens
55

<300>
<302> ephrin-A5
<310> NM001962
60

```

```

<400> 20
atgttgcacg tggagatggt gacgctgggtg tttctgggtgc tctggatgtg tgtgttcagc 60
caggaccccg gctccaaggc cgtcgccgac cgctacgctg tctactggaa cagcagcaac 120
cccagattcc agaggggtga ctaccatatt gatgtctgta tcaatgacta cctggatgtt 180
5 tctgcccctc actatgagga ctccgtccca gaagataaga ctgagcgcta tgtcctctac 240
atggtgaact ttgatggcta cagtgcctgc gaccacactt ccaaaggggt caagagatgg 300
gaatgtaacc ggccctcactc tccaaatgga ccgctgaagt tctctgaaaa attccagctc 360
ttcactccct tttctctagg atttgaattc aggccaggcc gagaatattt ctacatctcc 420
tctgcaatcc cagataatgg aagaagggtcc tgtctaaagc tcaaagtctt tgtgagacca 480
10 acaaatagtc gtatgaaaac tataggtgtt catgatcgtg ttttcgatgt taacgacaaa 540
gtagaaaatt cattagaacc agcagatgac accgtacatg agtcagccga gccatcccg 600
ggcgagaacg cggcacaaaac accaaggata ccagcccgcc ttttggcaat cctactgttc 660
ctcctggcga tgcttttgac attatag 687

15
<210> 21
<211> 2955
<212> DNA
<213> Homo sapiens

20
<400> 21
atggcccttg attatctact actgctcctc ctggcatccg cagtggctgc gatggaagaa 60
acgttaaatg acaccagaac ggctactgca gagctgggct ggacggccaa tcctgcgtcc 120
gggtgggaag aagtcagtggt ctacgatgaa aacctgaaca ccatccgcac ctaccaggtg 180
25 tgcaatgtct tcgagcccaa ccagaacaat tggctgctca ccaccttcat caaccggcgg 240
ggggcccatc gcatctacac agagatgcgc ttcactgtga gagactgcag cagcctccct 300
aatgtcccag gatcctgcaa ggagaccttc aacttgtatt actatgagac tgactctgtc 360
attgccacca agaagtcagc cttctgggtc gagggccctt acctcaaagt agacaccatt 420
gctgcagatg agagcttctc ccagggtggac tttgggggaa ggctgatgaa ggtaaacaca 480
30 gaagtcagga gctttgggcc tcttactcgg aatgggtttt acctcgcttt tcaggattat 540
ggagcctgta tgtctcttct ttctgtccgt gtcttcttca aaaagtgtcc cagcattgtg 600
caaaattttg cagtgtttcc agagactatg acaggggcag agagcacatc tctggtgatt 660

```

<213> Homo sapiens

<400> 27

```

5 atggggccccc ccattcttgg gccgggggggc gtgcgagtcg gggccctgct gctgctgggg 60
  gttttggggc tgggtgtctgg gctcagcctg gagcctgtct actggaactc ggccaataag 120
  aggttccagg cagagggtgg ttatgtgctg taccctcaga tcggggaccg gctagacctg 180
  ctctgcccc gggcccgccg tcctggccct cactcctctc ctaattatga gttctacaag 240
  ctgtacctgg taggggggtgc tcagggcccg cgctgtgagg caccctctgc cccaaacctc 300
  cttctcactt gtgatcgccc agacctggat ctccgcttca ccatcaagt ccaggagtat 360
10 agccctaata tctggggcca cgagttccgc tcgcaccacg attactacat cattgccaca 420
  tcggatggga cccgggaggg cctggagagc ctgcaggag gtgtgtgcct aaccagaggc 480
  atgaaggtgc ttctccagt gggacaaaagt ccccgaggag gggctgtccc ccgaaaacct 540
  gtgtctgaaa tgcccatgga aagagaccga ggggcagccc acagcctgga gcctgggaag 600
  gagaacctgc caggtgacct caccagcaat gcaacctccc ggggtgctga aggccccctg 660
15 cccctccca gcatgcctgc agtggtcctg ggcagcgggg ggctggcgct gctcttgctg 720
  ggcgtggcag gggctggggg tgccatgtgt tggcgagag ggcgggcca gccttcggag 780
  agtcgccacc ctggtcctgg ctcttcggg aggggagggt ctctgggct ggggggtgga 840
  ggtgggatgg gacctcgga ggctgagcct ggggagctag ggatagctct gcggggtggc 900
  ggggctgcag atccccctt ctgccccac tatgagaagg tgagtggtag ctatgggcat 960
20 cctgtgtata tcgtgcagga tgggcccccc cagagccctc caaacatcta ctacaaggta 1020
  tga 1023

```

<210> 28

25 <211> 3399

<212> DNA

<213> Homo sapiens

<300>

30 <302> telomerase reverse transcriptase

<310> AF015950

<400> 28

```

35 atgccgcgcg ctccccgctg ccgagccgtg cgctccctgc tgcgcagcca ctaccgcgag 60
  gtgctgccgc tggccacgtt cgtgcggcgc ctggggcccc agggctggcg gctgggtgcag 120
  cgcggggacc cggcggttt ccgcgcgtg gtggccaggt gcctgggtgt cgtgccctgg 180
  gacgcacggc cgcccccgcc cgccccctcc ttccgccagg tgcctgcct gaaggagctg 240
  gtggcccgag tgctgcagag gctgtgcgag cgcggcgcga agaactgtct ggcccttcggc 300
  ttccgcgtgc tggacggggc ccgcgggggc ccccccagag ccttcaccac cagcgtgcgc 360
40 agctacctgc ccaacacggt gaccgacgca ctgcggggga gcgggcgctg ggggctgctg 420
  ctgcgcgcgc tgggcgacga cgtgctggtt cactgtctgg cagctgcgc gctctttgtg 480
  ctgggtggctc ccagctgcgc ctaccaggtg tgcgggcgcg cgctgtacca gctcggcgct 540
  gccactcagg cccggccccc gccacacgct agtggacccc gaaggcgtct gggatgcgaa 600
  cgggcctgga accatagcgt cagggaggcc ggggtcccc tgggcctgcc agccccgggt 660
45 gcgaggaggc gcgggggcag tgccagccga agtctgccgt tgcccaagag gcccaggcgt 720
  ggcgtgccc ctgagccgga gcggacgccc gttgggcagg ggtcctgggc ccaccgggc 780
  aggacgcgtg gaccgagtga ccgtggtttc tgtgtggtgt cactgccag acccgccgaa 840
  gaagccacct ctttgagggt tgcgtctctt ggcacgcgcc actcccacc atcgtgggc 900
  cgccagcacc acgcggggcc cccatccaca tcgcggccac cactccctg ggacacgcct 960
50 tgtcccccg tgtacgccga gaccaagcac ttctctact cctcaggcga caaggagcag 1020
  ctgcggccct cttctact cagctctctt aggcaccag tgactggcgc tcggaggctc 1080
  gtggagacca tctttctggg ttccaggccc ggatgccag ggactcccc cagggtgccc 1140
  cgctgcccc agcgtactg gcaaagtgcg cccctgtttc tggagctgct tgggaaccac 1200
  gcgcagtgcc cctacggggt gctcctcaag acgcactgcc cgctgcgagc tgcggtcacc 1260
55 ccagcagccg gtgtctgtgc cggggagaag cccagggct ctgtggcggc ccccgaggag 1320
  gaggacacag acccccgtc cctggtgcag ctgctccgc agcacagcag cccctggcag 1380
  gtgtacggct tcgtgcggc ctgcctgcgc cggctggtgc cccaggcct ctggggctcc 1440
  aggcacaacg aacgcgcctt cctcaggaa accaagaagt tcctctccct ggggaagcat 1500
  gccaaagctc cgctgcagga gctgacgtgg aagatgagc tgccggactg cgcttggtg 1560
60 cgcaggagcc cagggttggt ctgtgttccg gccgcagagc accgtctgcg tgaggagatc 1620
  ctggccaagt tcctgcactg gctgatgagt gtgtacgtc tcgagctgct caggctcttc 1680
  ttttatgtca cggagaccac gtttcaaaag aacaggctct ttttctaccg gaagagtgtc 1740

```

5 tggagcaagt tgcaaagcat tggaaatcaga cagcacttga agaggggtgca gctgcgggag 1800
 ctgtcgggaag cagaggtcag gcagcatcgg gaagccaggc ccgccctgct gacgtccaga 1860
 ctccgcttca tccccaagcc tgacgggctg cggccgattg tgaacatgga ctacgtcgtg 1920
 ggagccagaa cgttccgcag agaaaagagg gccgagcgctc tcacctcgag ggtgaaggca 1980
 ctgttcagcg tgctcaacta cgagcgggcg cggcgccccg gcctcctggg cgctctgtg 2040
 ctgggctcgg acgatatcca cagggcctgg cgcaacctcg tgctgcgtgt gcgggcccag 2100
 gaccgcgcgc ctgagctgta ctttgtcaag gtggatgtga cgggcgcgta cgacaccatc 2160
 ccccaggaca ggctcacgga ggtcatcgcc agcatcatca aaccccagaa cacgtactgc 2220
 gtgcgtcggg atgccgtggg ccagaaggcc gcccatgggc acgtccgcaa ggccttcaag 2280
 10 agccacgtct ctaccttgac agacctccag ccgtacatgc gacagtctgt ggctcacctg 2340
 caggagacca gcccgctgag ggatgcgcgt gtcacgcagc agagctcctc cctgaatgag 2400
 gccagcagtg gcctcttcga cgtcttccca cgttccatgt gccaccacgc cgtgcgcac 2460
 aggggcaagt cctacgtcca gtgccagggg atcccgagg gctccatcct ctccacgtg 2520
 ctctgcagcc tgtgctacgg cgacatggag aacaagctgt ttgcggggat tcggcgggac 2580
 15 gggctgctcc tgcgtttggt ggatgatttc ttgttggtga cacctcacct caccacgcg 2640
 aaaaccttcc tcaggaccct ggtccgaggt gtccctgagt atggctgcgt ggtgaacttg 2700
 cggaagacag tgggtgaactt ccctgtagaa gacgaggccc tgggtggcac ggcttttgt 2760
 cagatgcccg cccacggcct attcccctgg tgcggcctgc tgctggatac ccggaccctg 2820
 gaggtgcaga gcgactactc cagctatgcc cggacctcca tcagagccag tctcaccttc 2880
 20 aaccgcggct tcaaggctgg gaggaacatg cgtcgcaaac tctttggggg ctgcggtg 2940
 aagtgtcaca gcctgtttct ggatttgtag gtgaacagcc tccagacggg gtgcaccaac 3000
 atctacaaga tcctcctgct gcaggcgtag aggtttcacg catgtgtgct gcagctccca 3060
 tttcatcagc aagtttgga gaaacccaca ttttctctgc gcgtcatctc tgacacggcc 3120
 tccctctgct actccatcct gaaagccaag aacgcaggga tgtcgctggg ggccaagggc 3180
 25 gccgcgggcc ctctgccctc cgaggccgtg cagtggctgt gccaccaagc attcctgctc 3240
 aagctgactc gacaccgtgt cactctctgg ccactcctgg ggtcactcag gacagcccag 3300
 acgcagctga gtcggaagct cccggggacg acgctgactg ccctggaggc cgcagccaac 3360
 ccggcactgc cctcagactt caagaccatc ctggactga 3399

30 <210> 29
 <211> 567
 <212> DNA
 <213> Homo sapiens

35 <300>
 <302> K-ras
 <310> M54968

40 <400> 29
 atgactgaat ataaacttgt ggtagttgga gcttgtggcg taggcaagag tgccttgacg 60
 atacagctaa ttcagaatca ttttgtggac gaatatgatc caacaataga ggattcctac 120
 aggaagcaag tagtaattga tggagaaacc tgtctcttgg atattctcga cacagcagg 180
 caagaggagt acagtgaat gaggggaccag tacatgagga ctggggaggg ctttctttgt 240
 45 gtatttgcca taaataatac taaatcattt gaagatattc accattatag agaacaatt 300
 aaaagagtta aggactctga agatgtacct atggctcctag taggaaataa atgtgatttg 360
 ccttctagaa cagtagacac aaaacaggct caggacttag caagaagtta tgggaattcct 420
 tttattgaaa catcagcaaa gacaagacag ggtgttgatg atgccttcta tacattagtt 480
 cgagaaattc gaaaacataa agaaaagatg agcaaagatg gtaaaaaaga gaaaaagaag 540
 50 tcaaagacaa agtgtgtaat tatgtaa 567

<210> 30
 <211> 3840
 55 <212> DNA
 <213> Homo sapiens

<300>
 <302> mdr-1
 60 <310> AF016535

<400> 30

	atggatcttg	aaggggaccg	caatggagga	gcaaagaaga	agaacttttt	taaactgaac	60
	aataaaagt	aaaaagataa	gaaggaaaa	aaaccaactg	tcagtgtatt	ttcaatgttt	120
	cgctattcaa	attggcttga	caagttgtat	atggtggtgg	gaactttggc	tgccatcatc	180
5	catggggctg	gacttcctct	catgatgctg	gtgtttggag	aaatgacaga	tatctttgca	240
	aatgcaggaa	atrtagaaga	tctgatgtca	aacatcacta	atagaagtga	tatcaatgat	300
	acagggttct	tcataaatct	ggaggaagac	atgaccaggt	atgcctatta	ttacagtgga	360
	attgggtgctg	gggtgctggg	tgctgcttac	attcaggttt	cattttgggtg	cctggcagct	420
	ggaagacaaa	tacacaaaat	tagaaaacag	ttttttcatg	ctataatgcg	acaggagata	480
	ggctggtttg	atgtgcacga	tggtggggag	cttaacaccc	gacttacaga	tgatgtctcc	540
10	aagattaatg	aaggaattgg	tgacaaaatt	ggaatgttct	ttcagtcaat	ggcaacattt	600
	ttcactgggt	ttatagtagg	atttacacgt	gggtggaagc	taacccttgt	gattttggcc	660
	atcagtcctg	ttcttggact	gtcagctgct	gtctgggcaa	agatactatc	ttcattttact	720
	gataaagaac	tcttagcgta	tgcaaaagct	ggagcagtag	ctgaagaggt	cttggcagca	780
	attagaactg	tgattgcatt	tggaggacaa	aagaaagaac	ttgaaaggta	caacaaaaat	840
15	ttagaagaag	ctaaaagaat	tgggataaag	aaagctatta	cagccaatat	ttctataggt	900
	gctgctttcc	tgctgatcta	tgcatcttat	gctctggcct	tcgtgtatgg	gaccaccttg	960
	gtcctctcag	gggaatatct	tattggacaa	gtactcactg	tattttctgt	attattttgg	1020
	gcttttagtg	ttggacaggc	atctccaagc	attgaagcat	ttgcaaatgc	aagaggagca	1080
	gcttatgaaa	tcttcaagat	aattgataat	aagccaagta	ttgacagcta	ttcgaagagt	1140
20	gggcacaaac	cagataatat	taagggaaat	ttggaattca	gaaatgttca	cttcagttac	1200
	ccatctcgaa	aagaagttaa	gatcttgaag	ggcttgaacc	tgaaggtgca	gagtggggcag	1260
	acggtggccc	tgggtggaaa	cagtggctgt	gggaagagca	caacagtcga	gctgatgcag	1320
	aggctctatg	acccacacga	ggggatgggc	agtgttgatg	gacaggatat	taggaccata	1380
	aatgtaaggt	ttctacggga	aatcattggg	gtggtgagtc	aggaacctgt	attgtttgcc	1440
25	accacgatag	ctgaaaacat	tcgctatggc	cgtgaaaatg	tcaccatgga	tgagatttgag	1500
	aaagctgtca	aggaagccaa	tgccatgatc	tttatcatga	aactgcctca	taaatgtgac	1560
	accctgggtg	gagagagagg	ggcccagttg	agtgggtggc	agaagcagag	gatcgccatt	1620
	gcacgtgccc	tgggttcgaa	ccccaaagtc	ctcctgctgg	atgaggccac	gtcagccttg	1680
	gacacagaaa	gcgaagcagt	gggttcaggtg	gctctggata	aggccagaaa	aggctcgacc	1740
30	accattgtga	tagctcatcg	tttgtctaca	gttcgtaatg	ctgacgtcat	cgctgggttc	1800
	gatgtggag	tcattgtgga	gaaaggaat	catgatgaac	tcatagaaaga	gaaagccatt	1860
	tacttcaaac	ttgtcacaa	gcagacagca	ggaaatgaag	ttgaattaga	aaatgcagct	1920
	gatgaatcca	aaagtgaat	tgatgccttg	gaaatgtctt	caaatgattc	aagatccagt	1980
	ctaataagaa	aaagatcaac	tcgtaggagt	gtccgtggat	cacaagccca	agacagaaaag	2040
35	cttagtacca	aagaggctct	ggatgaaagt	atacctccag	tttccttttg	gaggattatg	2100
	aagctaaatt	taactgaatg	gccttatttt	gttgttgggt	tattttgtgc	cattataaat	2160
	ggaggcctgc	aaccagcatt	tgcaataata	ttttcaaaga	ttataggggt	ttttacaaga	2220
	attgatgatc	ctgaaacaaa	acgacagaat	agtaacttgt	tttactattt	gtttctagcc	2280
	cttggaaat	tttcttttat	tacatttttt	cttcagggtt	tcacatttgg	caaagctgga	2340
40	gagatcctca	ccaagcggct	ccgatacatg	gttttccgat	ccatgctcag	acaggatgtg	2400
	agttggtttg	atgaccctaa	aaacaccatg	ggagcattga	ctaccaggct	cgccaatgat	2460
	gctgtcgaag	ttaaaggggc	tatagggttc	aggcttgctg	taattaccca	gaatatagca	2520
	aatcttggga	caggaataat	tatatccttc	atctatgggt	ggcaactaac	actgttactc	2580
	ttagcaattg	tacccatcat	tgcaatagca	ggagtgtgtg	aaatgaaaat	gttgtctgga	2640
45	caagcactga	aagataagaa	agaactagaa	ggtgctggga	agatcgctac	tgaagcaata	2700
	gaaaactttc	gaaccgttgt	ttctttgact	caggagcaga	agtttgaaca	tatgtatgct	2760
	cagagtttgc	aggtaccata	cagaaactct	ttgaggaaa	cacacatctt	tgggaattaca	2820
	ttttccttca	cccaggcaat	gatgtatttt	tcctatgctg	gatgtttccg	gtttggagcc	2880
	tacttgggtg	cacataaaact	catgagcttt	gaggatgttc	tgtagtattt	ttcagctgtt	2940
50	gtctttgggtg	ccatggccgt	ggggcaagtc	agttcatttg	ctcctgacta	tgccaaagcc	3000
	aaaataatcag	cagccacatc	catcatgatc	attgaaaaaa	cccctttgat	tgacagctac	3060
	agcacggaag	gcctaattgcc	gaacacattg	gaaggaaatg	tcacatttgg	tgaagttgta	3120
	ttcaactatc	ccaccgacc	ggacatccca	gtgcttcagg	gactgagcct	ggaggtgaag	3180
	aagggccaga	cgctggctct	ggtgggcagc	agtggctgtg	ggaagagcac	agtgggtccag	3240
55	ctcctggagc	ggttctacga	ccccttggca	gggaaagtgc	tgcttgatgg	caaagaaata	3300
	aagcgactga	atgttcagtg	gctccgagca	cacctgggca	tcgtgtccca	ggagcccatc	3360
	ctgtttgact	tgagcattgc	tgagaacatt	gcctatggag	acaacagccg	ggtgggtgtca	3420
	caggaagaga	ttgtgagggc	agcaaaggag	gccaacatac	atgccttcat	cgagtacttg	3480
	cctaataaat	atagcactaa	agtaggagac	aaaggaactc	agctctctgg	tggccagaaa	3540
60	caacgcattg	ccatagctcg	tgcccttgtt	agacagcctc	atattttgct	tttggaatgaa	3600
	gccacgtcag	ctctggatag	agaaagtga	aaggttgttc	aagaagccct	ggacaaagcc	3660
	agagaaggcc	gcacctgcat	tgtgattgct	caccgcctgt	ccaccatcca	gaatgcagac	3720

ttaatagtgg tgtttcagaa tggcagagtc aaggagcatg gcacgcatca gcagctgctg 3780
gcacagaaag gcatctatctt ttcaatggtc agtgtccagg ctggaacaaa ggcgcagtga 3840

5 <210> 31
<211> 1318
<212> DNA
<213> Homo sapiens

10 <300>
<302> UPAR (urokinase-type plasminogen activator receptor)
<310> XM009232

<400> 31
15 atggggtcacc cgccgctgct gccgctgctg ctgctgctcc acacctgctg cccagcctct 60
tggggcctgc ggtgcatgca gtgtaagacc aacggggatt gccgtgtgga agagtgcgcc 120
ctgggacagg acctctgcag gaccacgacg gtgcgcttgt gggagaagagg agaagagctg 180
gagctggtgg agaaaagctg taccactca gagaagacca acaggaccct gagctatcgg 240
actggcttga agatcaccag ccttaccgag gttgtgtgtg ggtagactt gtgcaaccag 300
20 ggcaactctg gccgggctgt cacctattcc cgaagccgtt acctcgaatg catttcctgt 360
ggctcatcag acatgagctg tgagaggggc cggcaccaga gcctgcagtg ccgcagccct 420
gaagaacagt gcctggatgt ggtgaccac tggatccagg aaggtgaaga agggcgctca 480
aaggatgacc gccacctccg tggctgtggc taccttcccg gctgcccggt ctccaatggt 540
ttccacaaca acgacacctt ccacttccctg aaatgctgca acaccacca atgcaacgag 600
25 ggcccaatcc tggagcttga aaatctgccg cagaatggcc gccagtgtta cagctgcaag 660
gggaacagca cccatggatg ctctcttgaa gagactttcc tcattgactg ccgaggcccc 720
atgaatcaat gtctggtagc caccggcact cacgaaccga aaaaccaaag ctatatggtg 780
agaggctgtg caaccgcctc aatgtgccaa catgccacc tgggtgacgc cttcagcatg 840
aaccacatg atgtctcctg ctgtactaaa agtggctgta accaccaga cctggatgtc 900
30 cagtaccgca gtggggctgc tcctcagcct ggccctgccc atctcagcct caccatcacc 960
ctgctaataa ctgccagact gtggggaggc actctcctct ggacctaaac ctgaaatccc 1020
cctctctgcc ctggctggat ccgggggacc cctttgccct tccctcggct cccagcccta 1080
cagacttgct gtgtgacctc aggccagtgt gccgacctct ctgggcctca gttttcccag 1140
ctatgaaaac agctatctca caaagtgtg tgaagcagaa gagaaaagct ggagggaaggc 1200
35 cgtgggccaa tgggagagct cttgttatta ttaatatgtg tgccgctgtt gtgtgtgtgt 1260
tattaattaa tattcatatt atttatttta tacttacata aagattttgt accagtgg 1318

<210> 32
40 <211> 636
<212> DNA
<213> Homo sapiens

<300>
45 <302> Bak
<310> U16811

<400> 32
50 atggcttcgg ggcaaggccc aggtcctccc aggcaggagt gcggagagcc tgccctgccc 60
tctgcttctg aggagcagggt agcccaggac acagaggagg ttttccgcag ctacgttttt 120
taccgccatc agcaggaaca ggaggctgaa ggggtggctg cccctgccga cccagagatg 180
gtcaccttac ctctgcaacc tagcagcacc atggggcagg tgggacggca gctcgccatc 240
atcggggacg acatcaaccg acgctatgac tcagagtctc agaccatgtt gcagcacctg 300
cagcccacgg cagagaatgc ctatgagtac ttcaccaaga ttgccaccag cctgttttag 360
55 agtggcatca attggggccg tgtggtggct cttctgggct tcggctaccg tctggcccta 420
cacgtctacc agcatggcct gactggcttc ctaggccagg tgaccgctt cgtggctgac 480
ttcatgctgc atcactgcat tgcccgggtg attgcacaga ggggtggctg ggtggcagcc 540
ctgaacttgg gcaatggctc catcctgaac gtgctggtgg ttctgggtgt ggttctgttg 600
60 ggccagtttg tggtagaag attcttcaaa tcatga 636

<210> 33

<211> 579
<212> DNA
<213> Homo sapiens

5 <300>
<302> Bax alpha
<310> L22473

<400> 33
10 atggacgggt ccggggagca gcccagaggc ggggggcca ccagctctga gcagatcatg 60
aagacagggg cccttttgct tcagggtttc atccaggatc gagcagggcg aatggggggg 120
gaggcaccgg agctggccct ggacccgggtg cctcaggatg cgtccaccaa gaagctgagc 180
gagtgtctca agcgcacggg ggacgaactg gacagtaaca tggagctgca gaggatgatt 240
gccgcccgtg acacagactc ccccgagag gtctttttcc gagtggcagc tgacatgttt 300
15 tctgacggca acttcaactg gggccgggtt gtcgcccttt tctactttgc cagcaaactg 360
gtgctcaagg ccctgtgcac caagggtgccg gaactgatca gaaccatcat gggctggaca 420
ttggacttcc tccgggagcg gctgttgggc tggatccaag accaggggtg ttgggacggc 480
ctcctctcct actttgggac gcccacgtgg cagaccgtga ccatctttgt ggcgggagtg 540
ctcaccgcct cgctaccat ctggaagaag atgggctga 579

20

<210> 34
<211> 657
<212> DNA
25 <213> Homo sapiens

<300>
<302> Bax beta
<310> L22474

30 <400> 34
atggacgggt ccggggagca gcccagaggc ggggggcca ccagctctga gcagatcatg 60

gaggatgctg aggtccagct ctccttccag ctacagatca atgtccctgt ccgagtgtg 1260
 gagctaagtg agagccaccc tgacagtggg gaacagacag tccgctgtcg tggccggggc 1320
 atgccccagc cgaacatcat ctggtctgcc tgcagagacc tcaaaagggtg tccacgtgag 1380
 ctgccgcccc cgctgctggg gaacagttcc gaagaggaga gccagctgga gactaacgtg 1440
 5 acgtactggg agggaggagca ggagtttgag gtggtgagca cactgctgtc gcagcagctg 1500
 gatcgggccac tgtcgggtgcg ctgcacgctg cgcaacgctg tgggccagga cacgcaggag 1560
 gtcatcgtgg tgccacactc cttgcccttt aagggtggtg tgatctcagc catcctggcc 1620
 ctggtggtgc tcaccatcat ctcccttata atcctcatca tgctttggca gaagaagcca 1680
 cgttacgaga tccgatggaa ggtgattgag tctgtgagct ctgacggcca tgagtacatc 1740
 10 tacgtggacc ccatgcagct gccctatgac tccacgtggg agctgccgag ggaccagctt 1800
 gtgctggggac gcaccctcgg cctctggggcc tttggggcagg tgggtggaggc cacggttcat 1860
 ggctgagacc attttcaagc cccaatgaaa gtggccgtca aaaatgctta a 1911

15 <210> 46
 <211> 1176
 <212> DNA
 <213> Homo sapiens

20 <300>
 <302> TGFbeta1
 <310> NM000660

25 <400> 46
 atgcgcctt ccgggctgcg gctgctgccc ctgctgtctc cgctgctgtg gctactggtg 60
 ctgacgcctg gcccgccggc cgcgggacta tccacctgca agactatcga catggagctg 120
 gtgaagcggg agcgcacatga ggccatccgc ggccagatcc tgtccaagct gcggtctgcc 180
 agccccccga gccaggggga ggtgccgccc ggcccgctgc ccgaggccgt gctcgccttg 240
 tacaacagca ccgcgcgacc ggtggccggg gagagtgcag aaccggagcc cgagctgag 300
 30 gccgactact acgccaagga ggtcaccgcg gtgctaattg tggaaaccca caacgaaatc 360
 tatgacaagt tcaagcagag tacacacagc atatatatgt tcttcaacac atcagagctc 420
 cgagaagcgg tacctgaacc cgtgttgctc tcccgggcag agctgctgtc gctgaggagg 480
 ctcaagttaa aagtggagca gcacgtggag ctgtaccaga aatacagcaa caattcctgg 540
 cgatacctca gcaaccggct gctggcaccg agcgactcgc cagagtgggt atcttttgat 600
 35 gtcaccggag ttgtgctggc gtggttgagc cgtggagggg aaattgaggg ctttcgcctt 660
 agcgccact gctcctgtga cagcagggat aacacactgc aagtggacat caacgggttc 720
 actaccggcc gccgaggtga cctggccacc attcatggca tgaaccggcc tttcctgctt 780
 ctcatggcca ccccgctgga gagggccag catctgcaa gctcccggca ccgccgagcc 840
 ctggacacca actattgctt cagctccacg gagaagaact gctgctgtgc gcagctgtac 900
 40 attgacttcc gcaaggacct cggctggaag tggatccacg agcccaagg ctaccatgcc 960
 aactctctgc tcgggccctg cccctacatt tggagcctgg acacgcagta cagcaaggtc 1020
 ctggccctgt acaaccagca taaccggg gcctcgccg cgccgtgctg cgtgccgcag 1080
 gcgctggagc cgctgcccac cgtgtactac gtgggcccga agcccaagg ggagcagctg 1140
 tccaacatga tcgtgcgctc ctgcaagtg agctga 1176

45 <210> 47
 <211> 1245
 <212> DNA
 50 <213> Homo sapiens

<300>
 <302> TGFbeta2
 <310> NM003238

55 <400> 47
 atgcactact gtgtgctgag cgcttttctg atcctgcata tggtcacggg cgcgctcagc 60
 ctgtctacct gcagcacact cgatatggac cagtcatgc gcaagaggat cgaggcgatc 120
 cgccgggcaga tcctgagcaa gctgaagctc accagtcccc cagaagacta tcctgagccc 180
 60 gaggaagtcc ccccgagggt gatctccatg tacaacagca ccagggactt gctccaggag 240
 aaggcgagcc ggagggcgcc cgctcgagga gcgacgaaga gtactacgcc 300
 aaggagggtt acaaaataga catgccgccc ttcttccct cggaaaatgc catcccgccc 360

```

actttctaca gaccctactt cagaattggt cgatttgacg tctcagcaat ggagaagaat 420
gcttccaatt tgggtgaaagc agagttcaga gtctttcggt tgcagaaccc aaaagccaga 480
gtgcctgaac aacggattga gctatatcag attctcaagt ccaaagattt aacatctcca 540
5 acccagcgct acatcgacag caaagttgtg aaaacaagag cagaaggcga atgggtctctc 600
ttcgatgtaa ctgatgctgt tcatgaatgg cttcaccata aagacaggaa cctgggattt 660
aaaataagct tacactgtcc ctgctgcact tttgtacat ctaataatta catcatcca 720
aataaaaagtg aagaactaga agcaagattt gcaggtattg atggcacctc cacatatacc 780
agtgggtgatc agaaaactat aaagtccact agggaaaaaa acagtgggaa gacccacat 840
ctcctgctaa tgttattgcc ctctacaga cttgagtcac aacagaccaa cggcggaag 900
10 aagcgtgctt tggatgcggc ctattgcttt agaaatgtgc aggataattg ctgcctacgt 960
ccactttaca ttgatttcaa gaggatcta ggggtgaaat ggatacacga acccaaagg 1020
tacaatgcca acttctgtgc tggagcatgc ccgtatttat ggagttcaga cactcagcac 1080
agcaggggtcc tgagcttata taataccata aatccagaag catctgcttc tccttgctgc 1140
gtgtcccaag atttagaacc tctaaccatt ctctactaca ttggcaaaac acccaagatt 1200
15 gaacagcttt ctaatatgat tgtaaagtct tgcaaatgca gctaa 1245

```

```

<210> 48
<211> 1239
20 <212> DNA
    <213> Homo sapiens

```

```

<300>
<302> TGFbeta3
25 <310> XM007417

```

```

<400> 48
atgaagatgc acttgcaaag ggctctggtg gtcttgcccc tgctgaactt tgccacggtc 60
agcctctctc tgtccacttg caccaccttg gacttcggcc acatcaagaa gaagaggggtg 120
30 gaagccatta ggggacagat cttgagcaag ctcaggctca ccagccccc tgagccaacg 180
gtgatgacct acgtccccta tcaggctctg gccctttaca acagcaccgg ggagctgctg 240
gaggagatgc atggggagag ggaggaaggc tgcaccaggg aaacaccga gtcggaatac 300
tatgccaaag aaatccataa attcgacatg atccaggggc tggcggagca caacgaactg 360
gctgtctgcc ctaaaggaat tacctccaag gttttccgct tcaatgtgtc ctcagtggag 420
35 aaaaatagaa ccaacctatt ccgagcagaa ttccgggtct tgccgggtgcc caacccacg 480
tctaagcggg atgagcagag gatcgagctc ttccagatcc ttcggccaga tgagcacatt 540
gccaaacagc gctatatcgg tggcaagaat ctgcccacac ggggcactgc cgagtgggtg 600
tcctttgatg tctactgacac tgtgcgtgag tggctgttga gaagagagtc caacttaggt 660
ctagaaatca gcattcactg tccatgtcac accttcagc ccaatggaga tatcctggaa 720
40 aacattcacg aggtgatgga aatcaaattc aaaggcgtgg acaatgagga tgaccatggc 780
cgtggagatc cccggcgctt caagaagcag aaggatcacc acaaccctca tctaactctc 840
atgatgattc cccacaccg gctcgacaac cggggccagg ggggtcagag gaagaagcgg 900
gctttggaca ccaattactg cttccgcaac ttggaggaga actgctgtgt gcgccccctc 960
tacattgact tccgacagga tctgggctgg aagtgggtcc atgaacctaa gggctactat 1020
45 gccaaacttct gctcaggccc ttgccatac ctccgcagtg cagacacaac ccacagcacg 1080
gtgctgggac tgtacaacac tctgaaccct gaagcatctg cctcgccctg ctgcgtgccc 1140
caggacctgg agcccctgac catcctgtac tatgttggga ggacccccaa agtggagcag 1200
ctctccaaca tgggtggtgaa gtcttgtaaa tgtagctga 1239

```

```

50 <210> 49
    <211> 1704
    <212> DNA
    <213> Homo sapiens

```

```

55 <300>
    <302> TGFbetaR2
    <310> XM003094

```

```

60 <400> 49
atgggtcggg ggctgctcag gggcctgtgg ccgctgcaca tcgtcctgtg gacgcgtatc 60
gccagcacga tcccaccgca cgttcagaag tcggttaata acgacatgat agtcactgac 120

```

```

aacaacggtg cagtcaagtt tccacaactg tgtaaatfff gtgatgtgag attttccacc 180
tgtgacaacc agaaatcctg catgagcaac tgcagcatca cctccatctg tgagaagcca 240
caggaagtct gtgtggctgt atggagaaaag aatgacgaga acataaact agagacagtt 300
tgccatgacc ccaagctccc ctaccatgac tttattctgg aagatgctgc ttctccaaag 360
5   tgcattatga aggaaaaaaa aaagcctggt gagactttct tcatgtgttc ctgtagctct 420
gatgagtgca atgacaacat catcttctca gaagaatata acaccagcaa tctgacttg 480
ttgctagtca tttttcaagt gacaggcatc agcctcctgc caccactggg agttgccata 540
tctgtcatca tcatcttcta ctgctaccgc gtttaaccggc agcagaagct gagttcaacc 600
tgggaaaccg gcaagacgcg gaagctcatg gagttcagcg agcactgtgc catcatcctg 660
10  gaagatgacc gctctgacat cagctccacg tgtgccaaca acatcaacca caacacagag 720
ctgctgcccc ttgagctgga caccctggtg gggaaaaggtc gctttgctga ggtctataag 780
gccaagctga agcagaacac ttcagagcag tttgagacag tggcagtcaa gatctttccc 840
tatgaggagt atgcctcttg gaagacagag aaggacatct tctcagacat caatctgaag 900
catgagaaca tactccagtt cctgacggct gaggagcggg agacggagtt ggggaaacaa 960
15  tactggctga tcaccgcctt ccacgccaag ggcaacctac aggagtacct gacgcggcat 1020
gtcatcagct gggaggacct gcgcaagctg ggcagctccc tcgcccgggg gattgtcac 1080
ctccacagtg atcacactcc atgtgggagg cccaagatgc ccatcgtgca caggacctc 1140
aagagctcca atatcctcgt gaagaacgac ctaacctgct gcctgtgtga ctttgggctt 1200
tccctgcgtc tggaccttac tctgtctgtg gatgacctgg ctaacagtgg gcagggtgga 1260
20  actgcaagat acatggctcc agaagtccta gaatccagga tgaatttgga gaatgttgag 1320
tcttcaagc agaccgatgt ctactccatg gctctggtgc tctgggaaat gacatctcgc 1380
tgtaatgcag tgggagaagt aaaagattat gagcctccat ttggttccaa ggtgcgggag 1440
caccctgtg tcgaaagcat gaaggacaac gtgttgagag atcgagggcg accagaaatt 1500
cccagcttct ggctcaacca ccagggcatc cagatggtgt gtgagacgtt gactgagtgc 1560
25  tgggaccacg acccagaggc cgtctcaca gccagtggtg tggcagaacg cttcagttag 1620
ctggagcatc tggacaggct ctcggggagg agctgctcgg aggagaagat tctggaagac 1680
ggctccctaa acactaccaa atag                                     1704

30  <210> 50
    <211> 609
    <212> DNA
    <213> Homo sapiens

35  <300>
    <302> TGFbeta3
    <310> XM001924

    <400> 50
40  atgtctcatt acaccattat tgagaatatt tgtcctaaag atgaatctgt gaaattctac 60
    agtcccaaga gagtgcactt tcctatcccg caagctgaca tggataagaa gcgattcagc 120
    tttgtcttca agcctgtctt caacacctca ctgctctttc tacagtgtga gctgacgctg 180
    tgtacgaaga tggagaagca cccccagaag ttgcctaagt gtgtgcctcc tgacgaagcc 240
    tgcacctcgc tggacgcctc gataatctgg gccatgatgc agaataagaa gacgttcaact 300
45  aagcccttg ctgtgatcca ccatgaagca gaatctaaag aaaaaggctc aagcatgaag 360
    gaaccaaate caatttctcc accaattttc catggtctgg acaccctaac cgtgatgggc 420
    attgcgtttg cagcctttgt gatcggagca ctctgacgg gggccttgtg gtacatctat 480
    tctcacacag gggagacagc aggaaggcag caagtcccca cctccccgcc agcctcgga 540
    aacagcagtg ctgccacag catcggcagc acgcagagca cgccttgctc cagcagcagc 600
50  acggcctag                                     609

    <210> 51
    <211> 3633
55  <212> DNA
    <213> Homo sapiens

    <300>
    <302> EGFR
60  <310> X00588

    <400> 51

```

	atgcgaccct	ccgggacggc	cggggcagcg	ctcctggcgc	tgctggctgc	gctctgcccg	60
	gcgagtcggg	ctctggagga	aaagaaagt	tgccaaggca	cgagtaacaa	gctcacgcag	120
	ttgggcactt	ttgaagatca	ttttctcagc	ctccagagga	tggtcaataa	ctgtgaggtg	180
	gtccttgagg	atgttgaaat	tacctatgtg	cagaggaatt	atgatctttc	cttcttaaag	240
5	accatccagg	aggtggctgg	ttatgtcctc	attgccctca	acacagtgga	gcgaattcct	300
	ttggaaaacc	tgcatatcat	cagaggaat	atgtactacg	aaaattccta	tgcccttagca	360
	gtcttatcta	actatgatgc	aaataaaaacc	ggactgaagg	agctgcccac	gagaaattta	420
	caggaaatcc	tgcatggcgc	cgtgcgggtc	agcaacaacc	ctgccctgtg	caacgtggag	480
	agcatccagt	ggcgggacat	agtcagcagt	gactttctca	gcaacatgtc	gatggacttc	540
10	cagaaccacc	tgggcagctg	ccaaaagtgt	gatccaagct	gtcccaatgg	gagctgctgg	600
	ggtgcaggag	aggagaactg	ccagaaactg	accaaataca	tctgtgccc	gcagtgtctc	660
	gggcgctgcc	gtggcaagtc	ccccagtgac	tgctgccaca	accagtgctc	tgccaggtgc	720
	acaggccccc	gggagagcga	ctgcctggtc	tgccgcaaat	tccgagacga	agccacgtgc	780
	aaggacacct	gccccccact	catgctctac	aaccccacca	cgtaccagat	ggatgtgaac	840
15	cccaggggca	aatacagctt	tggtgccacc	tgctgaaga	agtgtccccg	taattatgtg	900
	gtgacagatc	acggctcgtg	cgtccgagcc	tgtggggccg	acagctatga	gatggaggaa	960
	gacggcgtcc	gcaagtgtaa	gaagtgcgaa	gggccttgcc	gcaaagtgtg	taacggaata	1020
	ggtattgggtg	aatttaaaga	ctcactctcc	ataaatgcta	cgaatattaa	acacttcaaa	1080
	aactgcacct	ccatcagtg	cgatctccac	atcctgccgg	tggtatttag	gggtgactcc	1140
20	ttcacacata	ctcctcctct	ggatccacag	gaactggata	ttctgaaaac	cgtaaaggaa	1200
	atcacagggt	ttttgtgat	tcaggcttgg	cctgaaaaca	ggacggacct	ccatgccttt	1260
	gagaacctag	aaatcatacg	cggcaggacc	aagcaacatg	gtcagtttcc	tcttgagctc	1320
	gtcagcctga	acataacatc	cttgggatta	cgtccctca	aggagataag	tgatggagat	1380
	gtgataattt	caggaaacaa	aaatttgtgc	tatgcaaata	caataaactg	gaaaaaactg	1440
25	tttgggacct	ccggtcagaa	aacaaaaatt	ataagcaaca	gaggtgaaaa	cagctgcaag	1500
	gccacaggcc	aggtctgcca	tgcttgtg	cccccgagg	gctgctgggg	cccgagccc	1560
	agggactgcg	tctcttgccg	gaatgtcagc	caggcgagg	aatgcgtgga	caagtgcagg	1620
	cttctggagg	gtgagccaag	ggagtttgtg	gagaactctg	agtgcataca	gtgccacca	1680
	gagtgcctgc	ctcaggccat	gaacatcacc	tgacacagg	ggggaccaga	caactgtatc	1740
30	cagtgtgccc	actacattga	cggccccccac	tgctcaaga	cctgcccggc	aggagtcatt	1800
	ggagaaaaca	acaccctggt	ctggaagtac	gcagacgccg	gccatgtgtg	ccacctgtgc	1860
	catccaaaact	gcacctacgg	atgcactggg	ccaggtcttg	aaggctgtcc	aacgaattgg	1920
	cctaagatcc	cgtccatcgc	cactgggatg	gtggggggccc	tcctcttgct	gctggtggtg	1980
	gccctgggga	tcggcctctt	catgcgaagg	cgccacatcg	ttcggaagcg	cacgctgcgg	2040
35	aggctgctgc	aggagaggga	gcttgtggag	cctcttacac	ccagtggaga	agctcccaac	2100
	caagctctct	tgaggatctt	gaaggaaact	gaattcaaaa	agatcaaagt	gctgggctcc	2160
	ggctgcgtcg	gcacgggtga	taagggaact	tggtcccg	aagggtgaga	agttaaaatt	2220
	cccgtcgcta	tcaaggaatt	aagagaagca	acatctccga	aagccaacaa	ggaaatcctc	2280
	gatgaagcct	acgtgatggc	cagcgtggac	aacccccacg	tggtccgcct	gctgggcatc	2340
40	tgccctacct	ccaccgtgca	actcatcagc	cagctcatgc	ccttcggctg	cctcctggac	2400
	tatgtccggg	aacacaaaga	caatattggc	tcccagtacc	tgctcaactg	gtgtgtgcag	2460
	atcgcaaaag	cactgaacta	cttggaggac	cgtcgcttgg	tgaccgcga	cctggcagcc	2520
	aggaaacgtac	tggtgaaaac	accgcagcat	gtcaagatca	cagattttgg	gctggccaaa	2580
	ctgctgggtg	cggaagagaa	agaataccat	gcagaaggag	gcaaagtgcc	tatcaagtgg	2640
45	atggcattgg	aatcaatttt	acacagaatc	tataccacc	agagtgatgt	ctggagctac	2700
	ggggtgaccg	tttgggagtt	gatgaccttt	ggatccaagc	catatgacgg	aatccctgcc	2760
	agcgagatct	cctccatcct	ggagaaaagg	gaacgcctcc	ctcagccacc	catatgtacc	2820
	atcgatgtct	acatgatcat	ggtcaagtgc	tggtgatag	acgcagatag	tcgccccaaag	2880
	ttccgtgagt	tgatcatcga	attctccaaa	atggcccag	acccccagcg	ctacctgtgc	2940
50	attcaggggg	atgaaagaat	gcatttgcca	agtcctacag	actccaactt	ctaccgtgcc	3000
	ctgatgggat	aagaagacat	ggacgacgtg	gtggatgccg	acgagtacct	catcccacag	3060
	cagggtctct	tcagcagccc	ctccacgtca	cggactcccc	tcctgagctc	tctgagtcca	3120
	accagcaaca	attccaccgt	ggcttgcat	gtagaaatg	ggctgcaaag	ctgtcccatc	3180
	aaggaaagaca	gcttcttgca	gcgatacagc	tcagacccca	caggcgccct	gactgaggac	3240
55	agcatagacg	acaccttctc	cccagtgcc	gaatacataa	accagtcctg	tcccaaaagg	3300
	cccgtgggct	ctgtgcagaa	tcctgtctat	cacaatcagc	ctctgaaccc	cgcgcccagc	3360
	agagaccac	actaccagga	ccccacagc	actcagtg	gcaaccccg	gtatctcaac	3420
	actgtccagc	ccacctgtgt	caacagcaca	ttcgacagcc	ctgcccactg	ggcccagaaa	3480
	ggcagccacc	aaattagcct	ggacaaccct	gactaccagc	aggacttctt	tcccaaggaa	3540
60	gccaagccaa	atggcatctt	taagggtccc	acagctgaaa	atgcagaata	cctaagggtc	3600
	gcgccacaaa	gcagtgaatt	tattggagca	tga			3633

```

<210> 52
<211> 3768
<212> DNA
5  <213> Homo sapiens

<300>
<302> ERBB2
<310> NM004448
10
<400> 52
atggagctgg cggccttgtg ccgctggggg ctctctctcg cctctttgcc ccccgaggcc 60
gcgagcacc aagtgtgcac cggcacagac atgaagctgc ggctccctgc cagtcccgag 120
accacactgg acatgtctcg ccacctctac cagggctgcc aggtgggtgca gggaaacctg 180
15 gaactcacct acctgcccac caatgccagc ctgtccttcc tgcaggatat ccaggagggtg 240
cagggctacg tgctcatcgc tcacaaccaa gtgaggcagg tcccactgca gaggtgcgg 300
attgtgcgag gcacccagct ctttgaggac aactatgccc tggccgtgct agacaatgga 360
gacccgctga acaataccac ccctgtcaca ggggcctccc caggaggcct gcgggagctg 420
cagcttcgaa gcctcacaga gatcttgaaa ggaggggtct tgatccagcg gaacccccag 480
20 ctctgctacc aggacacgat tttgtggaag gacatcttcc acaagaacaa ccagctgggt 540
ctcacactga tagacaccaa ccgctctcgg gcctgccacc cctgttctcc gatgtgtaag 600
ggctcccgct gctggggaga gaggttctgag gattgtcaga gcctgacgcg cactgtctgt 660
gccggtggct gtgcccgtg caaggggcca ctgcccactg actgctgcca tgagcagtg 720
gctgccggct gcacgggccc caagcactct gactgcctgg cctgcctcca cttcaaccac 780
25 agtggcatct gtgagctgca ctgcccagcc ctggtcacct acaacacaga cacgtttgag 840
tccatgcccc atcccagggg ccggtataca ttcggcgcca gctgtgtgac tgctgtctcc 900
tacaactacc tttctacgga cgtgggatcc tgcacctctg tctgccccct gcacaaccaa 960
gaggtgacag cagaggatgg aacacagcgg tgtgagaagt gcagcaagcc ctgtgcccga 1020
gtgtgctatg gtctgggcat ggagcacttg cgagaggtga gggcagttac cagtgccaat 1080
30 atccaggagt ttgctggctg caagaagatc tttgggagcc tggcatttct gccggagagc 1140
tttgatgggg acccagcctc caacactgcc ccgctccagc cagagcagct ccaagtgttt 1200
gagactctgg aagagatcac aggttaccta tacatctcag catggccgga cagcctgcct 1260

```

	tacccccggtg	tgccctgtgga	ggaacttttct	aagctgctga	aggaggggtca	ccgcatggac	2160
	aagcccagta	actgcaccaa	cgagctgtac	atgatgatgc	gggactgctg	gcatgcagtg	2220
	ccctcacaga	gacccacctt	caagcagctg	gtggaagacc	tggaccgcat	cgtggccttg	2280
	acctccaacc	aggagtacct	ggacctgtcc	atgcccctgg	accagtactc	ccccagcttt	2340
5	cccgcacccc	ggagctctac	gtgctcctca	ggggaggatt	ccgtcttctc	tcatgagccg	2400
	ctgcccaggg	agccctgcct	gccccgacac	ccagcccagc	ttgccaatgg	cggactcaaa	2460
	cgccgctga						2469
10	<210> 72						
	<211> 2409						
	<212> DNA						
	<213> Homo sapiens						
15	<300>						
	<302> FGFR4						
	<310> XM003910						
	<400> 72						
20	atgcggtgc	tgctggccct	gttgggggtc	ctgctgagtg	tgccctgggcc	tccagtcttg	60
	tccctggagg	cctctgagga	agtggagctt	gagccctgcc	tggctcccag	cctggagcag	120
	caagagcagg	agctgacagt	agcccttggg	cagcctgtgc	ggctgtgctg	tgggcgggct	180
	gagcgtggtg	gccactggta	caaggagggc	agtcgcctgg	cacctgctgg	ccgtgtacgg	240
	ggctggaggg	gccgcctaga	gattgccagc	ttcctacctg	aggatgctgg	ccgctacctc	300
25	tgccctggcac	gaggctccat	gatcgtcctg	cagaatctca	ccttgattac	aggtgactcc	360
	ttgacctcca	gcaacgatga	tgaggacccc	aagtcccata	gggacctctc	gaataggcac	420
	agttaccccc	agcaagcacc	ctactggaca	cacccccagc	gcatggagaa	gaaactgcat	480
	gcagtacctg	cggggaacac	cgtcaagttc	cgtgtgccag	ctgcaggcaa	ccccacgccc	540
	accatccgct	ggcttaagga	tggacaggcc	tttcatgggg	agaaccgcat	tggaggcatt	600
30	cggctgcgcc	atcagcactg	gagtctcgtg	atggagagcg	tgggtgccctc	ggaccgcggc	660
	acatacacct	gcctggtaga	gaacgctgtg	ggcagcatcc	gttataacta	cctgctagat	720
	gtgctggagc	gggtccccga	ccggcccatc	ctgcaggccg	ggctcccggc	caacaccaca	780
	gccgtggtgg	gcagcgacgt	ggagctgctg	tgcaagggtg	acagcgatgc	ccagccccac	840
	atccagtggc	tgaagcacat	cgtcatcaac	ggcagcagct	tccgagccga	cggtttcccc	900
35	tatgtgcaag	tcctaaagac	tgcagacatc	aatagctcag	aggtggagggt	cctgtacctg	960
	cggaaacgtg	cagccgagga	cgcaggcgag	tacacctgcc	tcgcaggcaa	ttccatcggc	1020
	ctctcctacc	agtctgcctg	gctcacggtg	ctgccagagg	aggacccccac	atggaccgca	1080
	gcagcgcccc	aggccaggtg	tacggacatc	atcctgtacg	cgtcgggctc	cctggccttg	1140
	gctgtgctcc	tgctgctggc	caggctgtat	caggggcagg	cgtcccacgg	ccggcacccc	1200
40	cgcccccccc	ccactgtgca	gaagctctcc	cgttccctc	tggcccgcaca	gttctccctg	1260
	gagtcaggct	cttccggcaa	gtcaagctca	tccctggtac	gaggcgctgc	tctctcctcc	1320
	agcggccccg	ccttgctcgc	cggcctcgtg	agtctagatc	tacctctcga	cccactatgg	1380
	gagttccccc	gggacaggct	ggtgcttggg	aagcccctag	gcgagggctg	ctttggccag	1440
	gtagtacgtg	cagaggcctt	tggcatggac	cctgcccggc	ctgaccaagc	cagcactgtg	1500
45	gccgtcaaga	tgctcaaaga	caacgcctct	gacaaggacc	tggccgacct	ggtctcggag	1560
	atggaggtga	tgaagctgat	cggccgacac	aagaacatca	tcaacctgct	tggtgtctgc	1620
	accaggaag	ggccccctgta	cgtgatcgtg	gagtgcgccg	ccaaggga	cctgcgggag	1680
	ttcctgcggg	cccggcgccc	cccaggcccc	gacctcagcc	ccgacgggtcc	tccgagcagt	1740
	gaggggcggc	tctccttccc	agtcctgggt	tcctgcgcct	accaggtggc	ccgaggcatg	1800
50	cagtatctgg	agtcctggaa	gtgtatccac	cgggacctgg	ctgcccgcga	tgtgctggtg	1860
	actgaggaca	attgatgaa	gattgctgac	tttgggctgg	ccgcggcgct	ccaccacatt	1920
	gactactata	agaaaaccag	caacggccgc	ctgcctgtga	agtggatggc	gcccagggcc	1980
	ttgtttgacc	gggtgtacac	acaccagagt	gacgtgtggt	cttttgggat	cctgctatgg	2040
	gagatcttca	ccctcggggg	ctccccgtat	cctggcatcc	cgggtggagga	gctgttctcg	2100
55	ctgctgcggg	agggacatcg	gatggaccga	ccccacact	gccccccaga	gctgtacggg	2160
	ctgatgcgtg	agtgctggca	cgcagcgccc	tcccagaggc	ctaccttcaa	gcagctggtg	2220
	gaggcgctgg	acaaggctct	gctggccgtc	tctgaggagt	acctcgacct	ccgcctgacc	2280
	ttcggaccct	attccccctc	tgggtggggac	gccagcagca	cctgctcctc	cagcgattct	2340
	gtcttcagcc	acgacccccct	gccattggga	tccagctcct	tccccttcgg	gtctgggggtg	2400
60	cagacatga						2409

<210> 73
<211> 1695
<212> DNA
<213> Homo sapiens

5

<300>
<302> MT2MMP
<310> D86331

10

<400> 73
atgaagcggc cccgctgtgg ggtgccagac cagttcgggg tacgagtga agccaacctg 60
cgggcgcgctc ggaagcgcta cgccctcacc gggaggaagt ggaacaacca ccactctgacc 120
tttagcatcc agaactacac ggagaagtgt ggctggtacc actcgatgga ggcggtgcgc 180
agggccttcc gcggtgtggga gcaggccacg cccctggtct tccaggagggt gccctatgag 240
15 gacatccggc tgcggcgaca gaaggaggcc gacatcatgg tactctttgc ctctggcttc 300
cacggcgaca gctcgccgtt tgatggcacc ggtggctttc tggcccacgc ctatttcct 360
ggccccggcc taggcgggga caccatttt gacgcagatg agccctggac cttctccagc 420
actgacctgc atggaacaa cctcttcctg gtggcagtgc atgagctggg ccacgcgtg 480
gggctggagc actccagcaa ccccaatgcc atcatggcg cgttctacca gtggaaggac 540
20 gttgacaact tcaagctgcc cgaggacgat ctccgtggca tccagcagct ctacggtacc 600
ccagacggtc agccacagcc taccagcct ctcccactg tgacgccacg gcggccaggc 660
cggcctgacc accggccgcc cggcctccc cagccaccac cccaggtgg gaagccagag 720
cgcccccaa agccgggccc ccagtcag ccccgagcca cagagcggcc cgaccagtat 780
ggccccaa tctcgacgg ggactttgac acagtggcca tgcttcgagg ggagatgttc 840
25 gtgttcaagg gccgctgggt ctggcgagtc cggcacaacc gcgtcctgga caactatccc 900
atgcccatcg ggcacttctg gcgtggtctg cccggtgaca tcagtgtctg ctacgagcgc 960
caagacggtc gttttgtctt tttcaaagg gaccgtact ggctctttcg agaagcgaac 1020
ctggagcccg gctaccaca gccgctgacc agctatggc tgggcatccc ctatgaccgc 1080
attgacacgg ccactctggtg ggagcccaca ggccacacct tcttcttcca agaggacagg 1140
30 tactggcgct tcaacgagga gacacagcgt ggagaccctg ggtaccccaa gccatcagt 1200
gtctggcagg ggcacttctg ctcccctaaa ggggccttcc tgagcaatga cgcagcctac 1260
acctacttct acaagggcac caaatactgg aaattcgaca atgagcgctt gcggatggag 1320
cccggctacc ccaagtccat cctgcgggac ttcattgggt gccaggagca cgtggagcca 1380
ggccccgat ggccgcagct ggcccgccg ccctcaacc cccacggggg tgagagccc 1440
35 gggcgcgaca gcgcagaggg cgacgtgggg gatggggatg gggacttttg ggccgggggtc 1500
aacaaggaca gggcgagccg cgtgggtgtg cagatggagg aggtggcacg gacggtgaac 1560
gtggtgatgg tgctggtgcc actgctgctg ctgctctgag tcctgggcct cacctacgag 1620
ctggtgcaga tgacgcgcaa ggggtgcgcca cgtgtcctgc tttactgcaa gcgctcgctg 1680
caggagtggg tctga 1695

40

<210> 74
<211> 1824
<212> DNA
<213> Homo sapiens

45

<300>
<302> MT3MMP
<310> D85511

50

<400> 74
atgatcttac tcacattcag cactggaaga cggttggatt tcgtgcatca ttcgggggtg 60
ttttcttgc aaaccttgct ttggatttta tgtgctacag tctgcggaac ggagcagtat 120
ttcaatgtgg aggtttgggt acaaaagtac ggctaccttc caccgactga cccagaaatg 180
55 tcagtgtctg gctctgcaga gacctgcag tctgccctag ctgccatgca gcagtctat 240
ggcatttaaca tgacaggaaa agtgacaga aacacaattg actggatgaa gaagccccga 300
tgcggtgtac ctgaccagac aagaggtagc tccaaatttc atattcgctg aaagcgatat 360
gcattgacag gacagaaatg gcagcacaag cacatcactt acagtataaa gaacgtaact 420
ccaaaagtag gagacctga gactcgtaaa gctattcgcc gtgcctttga tgtgtggcag 480
60 aatgtaactc ctctgacatt tgaagaagt ccctacagt aattagaaaa tggcaaacgt 540
gatgtggata taaccattat ttttgcattt ggtttccatg gggacagctc tccctttgat 600
ggagagggag gatttttggc acatgcctac ttccctggac caggaattgg aggagataacc 660

catttttgact cagatgagcc atggacacta ggaaatccta atcatgatgg aaatgactta 720
 tttctttagtag cagtccatga actgggacat gctctgggat tggagcattc caatgacccc 780
 actgccatca tggctccatt ttaccagtac atggaaacag acaacttcaa actacctaata 840
 gatgatttac agggcatcca gaagatatat ggtccacctg acaagattcc tccacctaca 900
 5 agacctctac cgacagtgcc cccacaccgc tctattcctc cggctgaccc aaggaataat 960
 gacaggccaa aacctcctcg gcctccaacc ggcagaccct cctatcccgg agccaaacc 1020
 aacatctgtg atgggaactt taacactcta gctattcttc gtcgtgagat gtttggtttc 1080
 aaggaccagt ggttttgccg agtgagaaac aacagggtga tggatggata cccaatgcaa 1140
 attacttact tctggcgggg cttgcctcct agtatcgatg cagtttatga aaatagcgac 1200
 10 gggaattttg tgttctttaa aggtaacaaa tattgggtgt tcaaggatac aactcttcaa 1260
 cctggttacc ctcagtactt gataaccctt ggaagtggaa ttccccctca tggattgat 1320
 tcagccattt ggtgggagga cgtcgggaaa acctatttct tcaagggaga cagatattgg 1380
 agatatagtg aagaaatgaa aacaatggac cctggctatc ccaagccaat cacagtctgg 1440
 aaagggatcc ctgaatctcc tcaggggagca tttgtacaca aagaaaatgg ctttacgtat 1500
 15 ttctacaaag gaaaggagta ttggaaattc aacaaccaga tactcaagg agaacctgga 1560
 tatccaagat ccattcctcaa ggattttatg ggctgtgatg gaccaacaga cagagttaaa 1620
 gaaggacaca gccaccaga tgatgtagac attgtcatca aactggacaa cacagccagc 1680
 actgtgaaag ccatagctat tgtcattccc tgcattctgg ccttatgcct ccttgatttg 1740
 gtttacactg tgttccagtt caagaggaaa ggaacacccc gccacatact gtactgtaaa 1800
 20 cgctctatgc aagagtgggt gtga 1824

<210> 75
 <211> 1818
 25 <212> DNA
 <213> Homo sapiens

<300>
 <302> MT4MMP
 30 <310> AB021225

<400> 75
 atgcggcgcc ggcgagcccg gggacccggc cgcgcgcccc cagggcccg actctcgcg 60
 ctgcccgtgc tgccgctgcc gctgctgctg ctgctggcgc tggggaccgc cgggggctgc 120
 35 gccgcgccgg aaccgcgcgc ggcgcgccag gacctcagcc tgggagtgga gtggctaagc 180
 aggttcgggtt acctgcccc ggctgacccc acaacagggc agctgcagac gcaagaggag 240
 ctgtctaaag ccattcacagc catgcagcag tttgggtggc tggaggccac cggcatcctg 300
 gacgaggcca ccctggccct gatgaaaacc ccacgctgct ccctgccaga cctccctgtc 360
 ctgaccaggg ctgcgaggag acgccaggct ccagcccca ccaagtggaa caagaggaaac 420
 40 ctgtcgtgga gggctccggac gttcccacgg gactcaccac tggggcacga cagggtgcgt 480
 gcactcatgt actacgccct caaggctctg agcgacattg cgcccctgaa cttccacgag 540
 gtggcgggca gcaccgccga catccagatc gacttctcca aggccgacca taacgacggc 600
 tacccttctg acgcccggcg gcaccgtgcc cacgccttct tccccggcca ccaccacacc 660
 gccgggtaca cccactttaa cgtatgcagag gcctggacct tccgctcctc ggatgccac 720
 45 gggatggacc tgtttgcagt ggctgtccac gagtttggcc acgccattgg gtttaagccat 780
 gtggccgctg cacactccat catgcggccg tactaccagg gcccggtggg tgaccgctg 840
 cgctacgggc tccccctacga ggacaagggt cgcgtctggc agctgtacgg tgtgcgggag 900
 tctgtgtctc ccacggcgca gcccaggag cctcccctgc tgccggagcc ccagacaac 960
 cggctccagc ccccgccag gaaggacgtg cccacacagat gcagactca ctttgacgcg 1020
 50 gtggccaga tccggggtga agctttcttc ttcaaaggca agtacttctg gcggctgacg 1080
 cgggaccggc acctgtgtc cctgcagcgc gcacagatgc accgcttctg gcggggctgc 1140
 ccgctgcacc tggacagcgt ggacgctgtg tacgagcgca ccagcgacca caagatcgtc 1200
 ttctttaaag gagacaggtg ctgggtgttc aaggacaata acgtagagga aggatacccg 1260
 cgccccgtct ccgacttcag cctcccgcct ggccggcatc acgtgcctt ctcctgggccc 1320
 55 cacaatgaca ggaattattt ctttaaggac cagctgtact ggcgctacga tgaccacagc 1380
 aggcacatgg accccggcta ccccgcctgt ggagggtgtg cccagcacg cccagcacg 1440
 ctggacgacg ccattgcgctg gtccgacggt gcctcctact tcttccgtgg ccaggagtac 1500
 tggaaagtgc tggatggcga gctggaggtg gcacccgggt acccacagtc cacggcccgg 1560
 gactggctgg tgtgtggaga ctacacggcc gatggatctg ttgctgcggg cgtggacgcg 1620
 60 gcagaggggc ccgcgcccc tccaggacaa catgaccaga gccgctcgga ggacggttac 1680
 gaggtctgct cctgcacctc tggggcatcc tctccccgg gggcccgagg cccactggtg 1740
 gctgccacca tgctgctgct gctgcgcca ctgtcaccag gcgcctgtg gacagcggcc 1800

caggccctga cgctatga

1818

5 <210> 76
 <211> 1938
 <212> DNA
 <213> Homo sapiens

10 <300>
 <302> MT5MMP
 <310> AB021227

<400> 76
 15 atgccgagga gccggggcgg ccgcgcgcgc cgggggcgcgc gcgcgcgcgc gccgcgcgcgc 60
 ggccaggccc cgcgctggag ccgctggcgc gtccctgggc ggctgctgct gctgctgctg 120
 cccgcgctct gctgcctccc gggcgccgcgc cggcgccgcgc cggcgccgcgc gggggcaggg 180
 aaccgggcag cgggtggcggg ggcgggtggcg cggcgccgcgc aggcggaggc gcccttcgcc 240
 gggcagaact gggttaaagtc ctatggctat ctgcttcctt atgactcacg ggcattctgcg 300
 ctgcactcag cgaaggcctt gcagtcggca gtctccacta tgcagcagtt ttacgggatac 360
 20 ccggtcaccg gtgtgttgga tcagacaacg atcgagtgga tgaagaaacc ccgatgtggt 420
 gtccctgatc acccccactt aagccgtagg cggagaaaca agcgctatgc cctgactgga 480
 cagaagtgga ggcaaaaaca catcacctac agcattcaca actatacccc aaaagtgggt 540
 gagctagaca cgcggaaagc tattcgccag gctttcgatg tgtggcagaa ggtgacccca 600
 ctgacctttg aagaggtgcc ataccatgag atcaaaagtg accggaagga ggcagacatc 660
 25 atgatctttt ttgcttctgg ttcccatggc gacagctccc catttgatgg agaaggggga 720
 ttccctggccc atgcctactt ccctggccca gggattggag gagacacca ctttgactcc 780
 gatgagccat ggacgctagg aaacgccaac catgacggga acgacctctt cctggtggct 840
 gtgcatgagc tgggcccacgc gctgggactg gagcactcca gcgaccccag cgccatcatg 900
 gcgccttctt accagtacat ggagacgcac aacttcaagc tgccccagga cgatctccag 960
 30 ggcattccaga agatctatgg acccccagcc gagcctctgg agcccacaag gccactcccc 1020
 acactccccg tccgcaggat ccactacca tcggagagga aacacgagcg ccagcccagg 1080
 cccctcggc cgccctcgg ggaccggcca tccacaccag gcaccaaacc caacatctgt 1140
 gacggcaact tcaacacagt ggccctcttc cggggcgaga tgtttgtctt taaggatcgc 1200
 tggttctggc gtctgcgcaa taaccgagtg caggagggct accccatgca gatcgagcag 1260
 35 ttctggaagg gcctgcctgc ccgcctcgac gcagcctatg aaagggccga tgggagattt 1320
 gtcttcttca aaggtagaaa gtattgggtg tttaaggagg tgacgggtga gcctgggtac 1380
 cccacagcc tgggggagct gggcagctgt ttgccccgtg aaggcattga cacagctctg 1440
 cgctgggaac ctgtgggcaa gacctacttt ttcaaaggcg agcgggtactg gcgctacagc 1500
 gaggagcggc gggccacgga ccctggctac cctaagccca tcaccgtgtg gaagggcatc 1560
 40 ccacaggctc cccaaggagc cttcatcagc aaggaaggat attacaccta tttctacaag 1620
 ggcggggact actggaagtt tgacaaccag aaactgagcg tggagccagg ctacccgcgc 1680
 aacatcctgc gtgactggat gggctgcaac cagaaggagg tggagcggcg gaaggagcgg 1740
 cggctgcccc aggacgacgt ggacatcatg gtgaccatca acgatgtgcc gggctccgtg 1800
 aacgccgtgg ccgtggtcat ccctgcacg ctgtccctct gcacctcgtt gctgggtctac 1860
 45 accatcttcc agttcaagaa caagacaggc cctcagcctg tcacctacta taagcggcca 1920
 gtccaggaat ggggtgtga 1938

50 <210> 77
 <211> 1689
 <212> DNA
 <213> Homo sapiens

55 <300>
 <302> MT6MMP
 <310> AJ27137

<400> 77
 60 atgcggctgc ggctccggct tctggcgctg ctgcttctgc tgcctggcacc gccgcgcgcgc 60
 gccccgaagc cctcggcgca ggacgtgagc ctggggcgtg actggctgac tcgctatggt 120
 tacctgccgc caccaccacc tgcccaggcc cagctgcaga gccctgagaa gttgcgcgat 180
 gccatcaaag tcatgcagag gttcgcgggg ctgcccggaga ccggccgcac ggaccaggg 240

```

5  acagtggcca ccatgcgtaa gccccgctgc tccctgcctg acgtgctggg ggtggcgggg 300
   ctggtcaggc ggcgtcgccg gtacgctctg agcggcagcg tgtggaagaa gcgaaccctg 360
   acatggaggg tacgttcctt cccccagagc tcccagctga gccaggagac cgtgcgggtc 420
   ctcattgagct atgccttgat ggcctggggc atggagtcag gcctcacatt tcatgaggtg 480
   gattcccccc agggccagga gcccgcacac ctcattgact ttgcccgcgc cttccaccag 540
   gacagctacc ccttcgacgg gttggggggc accctagccc atgccttctt ccttggggag 600
   caccctatct ccggggacac gatgaggaga cctggacttt tgggtcaaaa 660
   gacggcgagg ggaccgacct gtttgccgtg gctgtccatg agtttgcca cgcctgggc 720
   ctggggccact cctcagcccc caactccatt atgaggccct tctaccaggg tccggtgggc 780
10  gaccctgaca agtaccgcct gtctcaggat gaccgcgatg gcctgcagca actctatggg 840
   aaggcgcccc aaaccccata tgacaagccc acaaggaaac cctggctcc tccgccccag 900
   cccccggcct cgccacaca cagcccatcc ttcccatcc ctgatcgatg tgagggaat 960
   tttgacgcca tcgccaacat ccgaggggaa actttcttct tcaaaggccc ctggttctgg 1020
   cgcctccagc cctccgaca gctggtgtcc ccgcgaccg cacggctgca ccgcttctgg 1080
15  gaggggtgct ccgcccaggt gaggggtgtg caggccgcct atgctcggca ccgagacggc 1140
   cgaatcctcc tctttagcgg gccccagttc tgggtgttcc aggaccgga gctggagggc 1200
   ggggcgcggc cgtcacgga gctggggctg cccccgggag aggaggtgga cgcctgttcc 1260
   tcgtggccac agaacgggaa gacctacctg gtccgcggcc ggcagtactg gcgctacgac 1320
   gaggcggcgg cgcgcccggg ccccggttac cctcgcgacc tgagcctctg ggaaggcgcg 1380
20  cccccctccc ctgacgatgt caccgtcagc aacgcagggt acacctactt cttcaagggc 1440
   gccactact ggcgcttccc caagaacagc atcaagaccg agccggacgc cccccagccc 1500
   atggggccca actggctgga ctgccccgcc ccgagctctg gtccccgcgc cccagggccc 1560
   cccaaagcga ccccggtgtc cgaaacctgc gattgtcagt gcgagctcaa ccaggccgca 1620
   ggacgttggc ctgctcccat ccgctgctc ctcttgcccc tgctggtggg ggggtgtagc 1680
25  tcccgtga

```

<210> 78

<211> 1749

30 <212> DNA

<213> Homo sapiens

gatgatgccacagagaaaga cttttctgat ctggtgtcag agatggagat gatgaagatg 1620
 attgggaaac acaagaatat cataaatctt ctggagcct gcacacagga tgggcctctc 1680
 tatgtcatag ttgagtatgc ctctaaaggc aacctccgag aatacctccg agcccgagg 1740
 ccacccggga tggagtactc ctatgacatt aaccgtgttc ctgaggagca gatgaccttc 1800
 5 aaggacttgg tgtcatgcac ctaccagctg gccagaggca tggagtactt ggcttcccaa 1860
 aaatgtattc atcgagattt agcagccaga aatgttttgg taacagaaaa caatgtgatg 1920
 aaaatagcag actttggact cgccagagat atcaacaata tagactatta caaaaagacc 1980
 accaatgggc ggcttccagt caagtggatg gctccagaag ccctgtttga tagagtatac 2040
 actcatcaga gtgatgtctg gtccttcggg gtgttaatgt gggagatctt cactttaggg 2100
 10 ggctcgccct acccagggat tcccgtaggag gaacttttta agctgctgaa ggaaggacac 2160
 agaatggata agccagccaa ctgcaccaac gaactgtaca tgatgatgag ggactgttgg 2220
 catgcagtgc cctcccagag accaacgttc aagcagttgg tagaagactt ggatcgaatt 2280
 ctactctca caaccaatga ggaatacttg gacctcagcc aacctctcga acagtattca 2340
 cctagttacc ctgacacaag aagttcttgt tcttcaggag atgattctgt tttttctcca 2400
 15 gaccccatgc cttacgaacc atgccttcct cagtatccac acataaacgg cagtgttaaa 2460
 acatga 2466

<210> 86
 20 <211> 2421
 <212> DNA
 <213> Homo sapiens

<300>
 25 <302> FGFR3
 <310> NM000142

<400> 86
 atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggcgc tggccatcgt ggccggcgcc 60
 30 tctctggagt ccttggggac ggagcagcgc gtctggggc gagcggcaga agtcccgggc 120
 ccagagcccg gccagcagga gcagttgggtc ttcggcagcg gggatgctgt ggagctgagc 180
 tgtccccgcg ccgggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctggtgggg cccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 35 ttcagtgtgc ggggtacaga cgctccatcc tccggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
 aacccactc cctccatctc ctggctgaag aacggcaggg agttccgcgg cgagcaccgc 600
 attggaggca tcaagctgcg gcacagcagc tggagcctgg tcatggaaag cgtggtgccc 660
 40 tcggaccgcg gcaactacac ctgcgtcctg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgtcgg acgtgctgga gcgtccctcg caccggccca tctgcaggc ggggctgcgg 780
 gccaaaccaga cggcgggtgct gggcagcgac gtggagttec actgcaagggt gtacagtgc 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggccc 900
 gacggcacac cctacgttac cgtgctcaag acggcggggc ctaacaccac cgacaaggag 960
 45 ctagaggttc tctccttgca caacgtcacc tttgaggacg ccggggagta cacctgcctg 1020
 gcgggcaatt ctattgggtt ttctcatcac tctgcgtggc tgggtgtgct gccagccgag 1080
 gaggagctgg tggaggctga cgaggcgggc agtgtgtatg caggcatcct cagctacggg 1140
 gtgggcttct tctgttcat cctggtggtg gcggctgtga cgctctgccg cctgcgcagc 1200
 cccccaaga aaggcctggg ctccccacc gtgcacaaga tctcccgtt cccgctcaag 1260
 50 cgacagggtg ccttgagtc caacgcgtcc atgagctcca acacaccact ggtgcgcate 1320
 gcaaggctgt cctcagggga gggcccaacg ctggccaatg tctccgagct cgagctgcct 1380
 gccgaccca aatgggagct gtctcgggcc cggtgaccc tgggcaagcc ccttggggag 1440
 ggctgcttcg gccaggtggg catggcggag gccatcggca ttgacaagga ccgggcccgc 1500
 aagcctgtca ccgtagccgt gaagatgctg aaagacgatg ccactgacaa ggacctgtcg 1560
 55 gacctggtgt ctgagatgga gatgatgaag atgatcgga aacacaaaaa catcatcaac 1620
 ctgctggggc cctgcacgca gggcggggcc ctgtactgct tggtaggagta cgcgccaaag 1680
 ggtaacctgc gggagtttct gcgggcgcgg cgcccccg gctggacta ctcttcgac 1740
 acctgcaagc cgcccgagga gcagctcacc ttcaaggacc tgggtgtcctg tgcctaccag 1800
 gtggcccggg gcatggagta cttggcctcc cagaagtgc tccacaggga cctggctgcc 1860
 60 cgcaatgtgc tgggtgacga ggacaacgtg atgaagatcg cagacttcgg gctggcccgg 1920
 gacgtgcaca cctcgacta ctacaagaag gccggtgccc cgtgaagtgg 1980
 atggcgctcg aggccttgtt tgaccgagtc tacactcacc agagtgcgt ctggtccttt 2040

5 ggggtcctgc tctgggagat cttcacgctg gggggctccc cgtaccccg ccatccctgtg 2100
 gaggagctct tcaagctgct gaaggagggc caccgcatgg acaagcccgc caactgcaca 2160
 cacgacctgt acatgatcat gcgggagtg cggcatgccg cgcctccca gaggccacc 2220
 ttcaagcagc tgggtggagga cctggaccgt gtccttaccg tgacgtccac cgacgagtac 2280
 ctggacctgt cggcgccctt cgagcagtac tccccgggtg gccaggacac cccagctcc 2340
 agtcctcag gggacgactc cgtgtttgcc cacgacctgc tgcccccggc cccaccagc 2400
 agtgggggct cgcggacgtg a 2421

10 <210> 87
 <211> 2102
 <212> DNA
 <213> Homo sapiens

15 <300>
 <302> HGF
 <310> E08541

20 <400> 87
 atgcagaggg acaaaggaaa agaagaaata caattcatga attcaaaaaa tcagcaaaga 60
 ctaccctaata caaaatagat ccagcactga agataaaaaa caaaaaagt aatactgcag 120
 accaatgtgc taatagatgt actaggaata aaggacttcc attcacttgc aaggcttttg 180
 tttttgataa agcaagaaaa caatgcctct ggttccccct caatagcatg tcaagtggag 240
 tgaaaaaaga atttggccat gaatttgacc tctatgaaaa caaagactac attagaaact 300
 25 gcatcattgg taaaggacgc agctacaagg gaacagtatc tatcactaag agtggcatca 360
 aatgtcagcc ctggagttcc atgataccac acgaacacag ctttttgcc tgcagctatc 420
 ggggtaaaga cctacaggaa aactactgtc gaaatcctcg aggggaagaa gggggaccct 480
 ggtgtttcac aagcaatcca gaggtacgct acgaagtctg tgacattcct cagtgttcag 540
 aagttgaatg catgacctgc aatggggaga gttatcgagg tctcatggat catacagaat 600
 30 caggcaagat ttgtcagcgc tgggatcatc agacaccaca ccggcacaaa ttcttgccct 660
 aaagatatcc cgacaagggc tttgatgata attattgccg caatcccgat ggccagccga 720
 ggccatggtg ctatactctt gaccctcaca cccgctggga gtactgtgca attaaaacat 780
 gcgctgacaa tactatgaat gacactgatg ttcctttgga aacaactgaa tgcattcaag 840
 gtcaaggaga aggtacagg ggcactgtca ataccatttg gaatggaatt ccatgtcagc 900
 35 gttgggattc tcagtatcct cactgactcc acatgactcc tgaaaatttc aagtgaagg 960
 acctacgaga aaattactgc cgaaatccag atgggtctga atcaccctgg tgttttacca 1020
 ctgatccaaa catccgagtt ggctactgct cccaaattcc aaactgtgat atgtcacatg 1080
 gacaagattg ttatcgtggg aatggcaaaa attatatggg caacttatcc caaacaagat 1140
 ctggactaac atgttcaatg tgggacaaga acatggaaga cttacatcgt catatcttct 1200
 40 ggggaaccaga tgcaagtaag ctgaatgaga attactgccg aaatccagat gatgatgctc 1260
 atggaccctg gtgctacacg ggaaatccac tcattccctg ggattattgc cctatttctc 1320
 gttgtgaagg tgataccaca cctacaatag tcaatttaga ccatcccgta atatcttctg 1380
 ccaaaaggaa acaattgcga gttgtaaatg ggattccaac acgaacaaac ataggatgga 1440
 tggttagttt gagatacaga aataaacata tctgcggagg atcattgata aaggagagtt 1500
 45 gggttcttac tgcacgacag tgtttccctt ctcgagactt gaaagattat gaagcttggc 1560
 ttggaattca tgatgtccac ggaagaggag atgagaaatg caaacagggt ctcaatgttt 1620
 cccagctggg atatggccct gaaggatcag atctggtttt aatgaagctt gccaggcctg 1680
 ctgtcctgga tgattttgtt agtacgattg atttacctaa ttatggatgc acaattcctg 1740
 aaaagaccag ttgcagtgtt tatggctggg gctacactgg attgatcaac tatgatggcc 1800
 50 tattacgagt ggcacatctc tatataatgg gaaatgagaa atgcagccag catcatcgag 1860
 ggaaggtgac tctgaatgag tctgaaatat gtgtggtggc tgaaaagatt ggatcaggac 1920
 catgtgaggg ggattatggt ggccacttgg tttgtgagca acataaaatg agaatgggtc 1980
 ttggtgtcat tgttcctggt cgtggatgtg ccattccaaa tctgcctggt atttttgtcc 2040
 gagtagcata ttatgcaaaa tggatacaca aaattatttt aacatataag gtaccacagt 2100
 55 ca 2102

60 <210> 88
 <211> 360
 <212> DNA
 <213> Homo sapiens

<300>
<302> ID3
<310> XM001539

5 <400> 88
atgaaggcgc tgagcccggt gcgcggctgc tacgaggcgg tgtgctgcct gtcggaacgc 60
agtctggcca tcgcccgggg ccgaggggaag ggcccggcag ctgaggagcc gctgagcttg 120
ctggacgaca tgaaccactg ctactcccgc ctgcgggaac tggtaaccgg agtcccgaga 180
ggcactcagc ttagccagggt ggaaatccta cagcgcgtca tcgactacat tctcgacctg 240
10 caggtagtcc tggccgagcc agcccctgga ccccctgatg gccccacct tcccatccag 300
acagccgagc tcactccgga acttgtcatc tccaacgaca aaaggagctt ttgcccactga 360

<210> 89
15 <211> 743
<212> DNA
<213> Homo sapiens

<300>
20 <302> IGF2
<310> NM000612

<400> 89
25 atgggaaatcc caatggggaa gtcgatgctg gtgcttctca ccttcttggc cttcgcctcg 60
tgctgcattg ctgcttaccg cccagtgag accctgtgcg gcggggagct ggtggacacc 120
ctccagttcg tctgtgggga ccgcggcttc tacttcagca ggcccgaag ccgtgtgagc 180
cgtcgcagcc gtggcatcgt tgaggagtgc tgtttccgca gctgtgacct ggccctcctg 240
gagacgtact gtgctacccc cgccaagtcc gagagggacg tgtcgacccc tccgacctg 300
30 cttccggaca acttccccag ataccctctg ggcaagtctt tccaatatga cacctggaag 360
cagtcacccc agcgctgcg caggggcctg cctgccctcc tgcgtgcccg ccggggtcac 420
gtgctcgcca aggagctcga ggcgttcagg gaggccaaac gtcaccgtcc cctgattgct 480
ctaccacccc aagaccccgc ccacgggggc gcccccccag agatggccag caatcggaag 540
tgagcaaaac tgccgcaagt ctgcagcccg gcgccaccat cctgcagcct cctcctgacc 600
acggacgttt ccatcaggtt ccatcccgaa aatctctcgg ttccacgtcc ccctggggct 660
35 tctcctgacc cagtcctcgt gcccgcctc ccgaaaacag gctactctcc tcggccccct 720
ccatcgggct gaggaagcac agc 743

<210> 90
40 <211> 7476
<212> DNA
<213> Homo sapiens

<300>
45 <302> IGF2R
<310> NM000876

<400> 90
50 atggggggccg ccgcccggccg gagccccac ctggggcccg cggccgcccg ccgcccgcag 60
cgctctctgc tcctgctgca gctgctgctg ctgctgctg ccccggggtc cagcgaggcc 120
caggccgccc cgttccccga gctgtgcagt tatacatggg aagctgttga taccaaaaat 180
aatgtacttt ataaaatcaa catctgtgga agtgtggata ttgtccagtg cgggccatca 240
agtgtctgtt gtatgcacga cttgaagaca cgcactatc attcagtggg tgactctgtt 300
55 ttgagaagtg caaccagatc tctcctggaa ttcaacacaa cagtgcgtg tgaccagcaa 360
ggcacaatc acagagtcca gagcagcatt gccttctgt gtgggaaaac cctgggaact 420
cctgaatttg taactgcaac agaattgtg cactactttg agtggaggac cactgcagcc 480
tgcaagaaag acatatTTaa agcaataaag gaggtgccat gctatgtgtt tgatgaagag 540
ttgaggaagc atgatctcaa tcctctgatc aagcttagtg gtgcctactt ggtggatgac 600
tccgatccgg acacttctct attcatcaat gttttagtag acatagacac actacgagac 660
60 ccaggttcac agctgcgggc ctgtccccc ggactgccg cctgcctggt aagaggacac 720
cagggttttg atgttgccca gcccgggac ggactgaagc tgggtgcgaa ggacaggctt 780
gtcctgagtt acgtgagggg agaggcagga aagctagact tttgtgatgg tcacagccct 840

	gcggtgacta	ttacatttgt	ttgcccgtcg	gagcggagag	agggcaccat	tcccaaactc	900
	acagctaaat	ccaactgccg	ctatgaaatt	gagtggtatta	ctgagtatgc	ctgccacaga	960
	gattacctgg	aaagtaaaac	ttgttctctg	agcggcgagc	agcaggatgt	ctccatagac	1020
	ctcacaccac	ttgccccagag	cggagggttca	tcctatatatt	cagatggaaa	agaatatattg	1080
5	ttttatttga	atgtctgtgg	agaaactgaa	atacagttct	gtaataaaaa	acaagctgca	1140
	gtttgccaaag	tgaaaaagag	cgatacctct	caagtcaaaag	cagcaggaag	ataccacaat	1200
	cagaccctcc	gatattcgga	tggagacctc	accttgatat	atgttgagg	tgatgaatgc	1260
	agctcagggt	ttcagcggat	gagcgtcata	aactttgagt	gcaataaaac	cgcaggtaac	1320
	gatgggaaag	gaactcctgt	attcacaggg	gagggttgact	gcacctactt	cttcacatgg	1380
10	gacacggaat	acgcctgtgt	taaggagaag	gaagacctcc	tctgcggtgc	caccgacggg	1440
	aagaagcgct	tgacctgtc	cgcctgtgtc	cgcatgacag	aaccagagca	gaattgggaa	1500
	gctgtggatg	gcagtcagac	ggaaacagag	aagaagcatt	ttttcattaa	tatttgtcac	1560
	agagtgtctg	aggaaggcaa	ggcacgaggg	tgtcccagg	acgcggcagt	gtgtgcagtg	1620
	gataaaaatg	gaagtaaaaa	tctgggaaaa	tttatttccct	ctcccatgaa	agagaaagga	1680
15	aacattcaac	tctcttattc	agatggtgat	gatttgtgtc	atggcaagaa	aattaaaact	1740
	aatatcacac	ttgtatgcaa	gccagggtgat	ctggaaaagt	caccagtgtt	gagaacttct	1800
	ggggaaggcg	gttgctttta	tgagtttgag	tggcgacacag	ctgcggcctg	tgtgctgtct	1860
	aagacagaag	gggagaactg	cacgggtctt	gactcccagg	cagggttttc	ttttgactta	1920
	tcacctctca	caaagaaaaa	tggtgcctat	aaagttgaga	caaagaagta	tgacttttat	1980
20	ataaatgtgt	gtggcccggg	gtctgtgagc	ccctgtcagc	cagactcagg	agcctgccag	2040
	gtggcaaaat	gtgatgagaa	gacttggaa	ttgggtctga	gtaatgcgaa	gctttcatat	2100
	tatgatggga	tgatccaact	gaactacaga	ggcggcacac	cctataacaa	tgaaagacac	2160
	acaccgagag	ctacgctcat	cacctttctc	tgtgatcgag	acgcgggagt	gggcttccct	2220
	gaatatcagg	aagaggataa	ctccacctac	aacttccggt	ggtacaccag	ctatgcctgc	2280
25	ccggaggagc	ccctggaatg	cgtagtgacc	gacccctcca	cgtggagca	gtacgacctc	2340
	tccagctctg	caaatctga	aggtggcctc	ggaggaactc	ggtatgccat	ggacaactca	2400
	ggggaacatg	tcacgtggag	gaaatactac	attaacgtgt	gtcggcctct	gaatccagt	2460
	ccgggctgca	accgatatgc	atcggttgc	cagatgaagt	atgaaaaaga	tcagggtctc	2520
	ttcactgaag	tggtttccat	cagtaacttg	ggaatggcaa	agaccggccc	ggtggttgag	2580
30	gacagcggca	gcctccttct	ggaatacgtg	aatgggtcgg	cctgcaccac	cagcgatggc	2640
	agacagacca	catataccac	gaggatccat	ctcgtctgct	ccaggggcag	gctgaacagc	2700
	caccccatct	tttctctcaa	ctgggagtgt	gtggtcagtt	tccgttgga	cacagaggct	2760
	gcctgtccca	ttcagacaac	gacggataca	gaccaggctt	gctctataag	ggatcccaac	2820
	agtggatttg	tgtttaattct	taatccgcta	aacagttcgc	aaggatataa	cgtctctggc	2880
35	attgggaaga	tttttatgtt	taatgtctgc	ggcacaatgc	ctgtctgttg	gaccatcctg	2940
	ggaaaacctg	cttctggctg	tgaggcagaa	acccaaactg	aagagctcaa	gaattggaag	3000
	ccagcaaggc	cagtcggaat	tgagaaaagc	ctccagctgt	ccacagagg	cttcactact	3060
	ctgacctaca	aagggcctct	ctctgccaaa	ggtaccgctg	atgcttttat	cgtccgcttt	3120
	gtttgcaatg	atgatgttta	ctcaggggccc	ctcaaattcc	tgcatcaaga	tatcgactct	3180
40	gggcaaggga	tccgaaacac	ttactttgag	tttgaaaccg	cgttggcctg	tgttccctct	3240
	ccagtgagct	gccaaatcac	cgacctggct	ggaaatgagt	acgacctgac	tggcctaaag	3300
	acagtcagga	aaccttggac	ggctgttgac	acctctgtcg	atgggagaaa	gaggactttc	3360
	tatttgagcg	tttgcaatcc	tctcccttac	attcctggat	gccagggcag	cgcagtgggg	3420
	tcttgcttag	tgtcagaagg	caatagctgg	aatctgggtg	tggtgcagat	gagtcctcaa	3480
45	gccgcggcga	atggatcttt	gagcatcatg	tatgtcaacg	gtgacaagt	tgggaaccag	3540
	cgcttctcca	ccaggatcac	gtttgagtgt	gctcagatat	cgggctcacc	agcatttcag	3600
	cttcaggatg	gttgtgagta	cgtgtttatc	tggagaactg	tggaagcctg	tcccggtgtc	3660
	agagtggaa	gggacaactg	tgaggtgaaa	gacccaaggc	atggcaactt	gtatgacctg	3720
	aagccccctg	gcctcaacga	caccatcgtg	agcgtggcg	aatacactta	ttacttccgg	3780
50	gtctgtggga	agctttctct	agacgtctgc	cccacaagt	acaagtccaa	ggtggtctcc	3840
	tcagtccagg	aaaagcggga	accgcaggga	tttcacaaa	tggcaggtct	cctgactcag	3900
	aagctaactt	atgaaaatgg	cttgttaaaa	atgaacttca	cgggggggga	cacttgccat	3960
	aagggtttat	agcgtctcac	agccatcttc	ttctactgtg	accgcggcac	ccagcggcca	4020
	gtatttctaa	aggagacttc	agattgttcc	tacttgtttg	agtggcgaa	gcagtatgcc	4080
55	tgcccacctt	tcgatctgac	tgaatgttca	ttcaaagatg	gggctggcaa	ctccttcgac	4140
	ctctcgtccc	tgtcaaggta	cagtgaacac	tgggaagcca	tcactgggac	gggggacccg	4200
	gagcattacc	tcataatgt	ctgcaagtct	ctggccccgc	aggctggcac	tgagcgtgct	4260
	cctccagaag	cagccgcgtg	tctgctgggt	ggctccaagc	ccgtgaacct	cggcagggta	4320
	agggacggac	ctcagtggag	agatggcata	attgtcctga	aatacgttga	tggcgactta	4380
60	tgtccagatg	ggattcggaa	aaagtcaacc	accatccgat	tcacctgcag	cgagagccaa	4440
	gtgaactcca	ggcccatgtt	catcagcgcc	gtggaggact	gtgagtacac	ctttgcctgg	4500
	cccacagcca	cagcctgtcc	catgaagagc	aacgagcatg	atgactgcca	ggtcaccaac	4560

	ccaagcacag	gacacctggt	tgatctgagc	tccttaagtg	gcagggcggg	attcacagct	4620
	gcttacagcg	agaagggggt	ggtttacatg	agcatctgtg	gggagaatga	aaactgccct	4680
	cctggcgtgg	gggcctgctt	tgacagacc	aggattagcg	tgggcaaggc	caacaagagg	4740
	ctgagatacg	tggaccagggt	cctgcagctg	gtgtacaagg	atgggtcccc	ttgtccctcc	4800
5	aaatccggcc	tgagctataa	gagtgtgatc	agtttcgtgt	gcaggcctga	ggccggggcca	4860
	accaataggc	ccatgctcat	ctccctggac	aagcagacat	gcactctctt	cttctcctgg	4920
	cacacgcgcg	tggcctgcga	gcaagcgacc	gaatgttccg	tgaggaatgg	aagctctatt	4980
	gttgacttgt	ctccccttat	tcatcgcact	ggtggttatg	aggcttatga	tgagagttag	5040
	gatgatgcct	cggataccaa	ccctgatttc	tacatcaata	tttgtcagcc	actaaatccc	5100
10	atgcacgcag	tgccctgtcc	tgccggagcc	gctgtgtgca	aagttcctat	tgatgggtccc	5160
	cccatagata	tcggccgggt	agcaggacca	ccaatactca	atccaatagc	aaatgagatt	5220
	tacttgaatt	ttgaaagcag	tactccttgc	ttagcggaca	agcatttcaa	ctacacctcg	5280
	ctcatcgctg	ttcactgtaa	gagaggtgtg	agcatgggaa	cgcctaagct	gttaaggacc	5340
	agcagtgctg	actttgtgtt	cgaatgggag	actcctgtcg	tctgtcctga	tgaagttagg	5400
15	atggatggct	gtaccctgac	agatgagcag	ctcctctaca	gcttcaactt	gtccagcctt	5460
	tccacgagca	cctttaagggt	gactcgcgac	tcgcgcacct	acagcgttgg	ggtgtgcacc	5520
	tttgagtcg	ggccagaaca	aggaggtgtg	aaggacggag	gagtcctgtc	gctctcaggc	5580
	accaaggggg	catcctttgg	acggctgcaa	tcaatgaaac	tggattacag	gcaccaggat	5640
	gaagcggctg	ttttaagtta	cgtgaatggt	gatcgttgcc	ctccagaaac	cgatgacggc	5700
20	gtcccctgtg	tcttcccctt	catattcaat	gggaagagct	acgaggagtg	catcatagag	5760
	agcagggcga	agctgtggtg	tagcacaact	gcggactacg	acagagacca	cgagtggggc	5820
	ttctgcagac	actcaaacag	ctaccggaca	tccagcatca	tatttaagtg	tgatgaagat	5880
	gaggacattg	ggaggccaca	agtcttcagt	gaagtgcgtg	ggtgtgatgt	gacatttgag	5940
	tggaaaacaa	aagttgtctg	ccctccaaag	aagttggagt	gcaaattcgt	ccagaaacac	6000
25	aaaacctacg	acctgcggct	gctctcctct	ctcaccgggt	cctgggtccct	ggtccacaac	6060
	ggagtctcgt	actatataaa	tctgtgccag	aaaatatata	aagggccctt	gggtgctct	6120
	gaaagggcca	gcatttgcag	aaggaccaca	actggtgacg	tccaggtcct	gggactcgtt	6180
	cacacgcaga	agctgggtgt	cataggtgac	aaagtgtgtg	tcacgtactc	caaaggttat	6240
	cgtgtggtg	gaaataagac	cgcacccctc	gtgatagaat	tgacctgtac	aaagacggtg	6300
30	ggcagacctg	cattcaagag	gtttgatata	gacagctgca	cttactactt	cagctgggac	6360
	tcccgggctg	cctgcgccgt	gaagcctcag	gaggtgcaga	tggtgaatgg	gaccatcacc	6420
	aacctataa	atggcaagag	cttcagcctc	ggagatattt	attttaagct	gttcagagcc	6480

	cctgaagttc	tcgatgattc	cataaatatg	aaacattttg	aatccttcaa	acgtgctgac	1200
	atctatgcaa	tgggcttagt	attctgggaa	attgctcgac	gatgttccat	tgggtggaatt	1260
	catgaagatt	accaactgcc	ttattatgat	cttgtagctt	ctgacccatc	agttgaagaa	1320
	atgagaaaag	ttgtttgtga	acagaagtta	aggccaaata	tcccaaacag	atggcgagagc	1380
5	tgtgaagcct	tgagagtaat	ggctaaaatt	atgagagaat	gttgggtatgc	caatggagca	1440
	gctaggctta	cagcattgcg	gattaagaaa	acattatcgc	aactcagtca	acaggaaggc	1500
	atcaaaatgt	aa					1512
10	<210> 94						
	<211> 4044						
	<212> DNA						
	<213> Homo sapiens						
15	<300>						
	<302> Flk1						
	<310> AF035121						
	<400> 94						
20	atgcagagca	aggtgctgct	ggccgctcgcc	ctgtggctct	gcgtggagac	ccgggcccgc	60
	tctgtgggtt	tgcttagtgt	ttctcttgat	ctgcccaggc	tcagcataca	aaaagacata	120
	cttacaatta	aggctaatac	aactcttcaa	attacttgca	ggggacagag	ggacttggac	180
	tggctttggc	ccaataatca	gagtggcagt	gagcaaagg	tggaggtgac	tgagtgcagc	240
	gatggcctct	tctgtaagac	actcacaatt	ccaaaagtga	tcggaaatga	cactggagcc	300
25	tacaagtgtc	tctaccggga	aactgacttg	gcctcggta	tttatgtcta	tgttcaagat	360
	tacagatctc	cattttattgc	ttctgttagt	gaccaacatg	gagtcgtgta	cattactgag	420
	aacaaaaaca	aaactgtggt	gattccatgt	ctcgggtcca	tttcaaactc	caacgtgtca	480
	ctttgtgcaa	gatacccaga	aaagagattt	gttcctgatg	gtaacagaat	ttcctgggac	540
	agcaagaagg	gctttactat	tcccagctac	atgatcagct	atgctggcat	ggtcttctgt	600
30	gaagcaaaaa	ttaatgatga	aagttaccag	tctattatgt	acatagttgt	cgttgtaggg	660
	tataggattt	atgatgtggt	tctgagtcgg	tctcatggaa	ttgaactatc	tggtggagaa	720
	aagcttgtct	taaattgtac	agcaagaact	gaactaaatg	tggggattga	cttcaactgg	780
	gaataccctt	cttcgaagca	tcagcataag	aaacttgtaa	accgagacct	aaaaacccag	840
	tctgggagtg	agatgaagaa	atTTTTtgagc	accttaacta	tagatgggtg	aacccggagt	900
35	gaccaaggat	tgtacacctg	tgcagcatcc	agtgggctga	tgaccaagaa	gaacagcaca	960
	tttgtcaggg	tccatgaaaa	accttttgg	gcttttggaa	gtggcatgga	atctctgggtg	1020
	gaagccacgg	tgggggagcg	tgtcagaatc	cctgcgaagt	accttgggtta	cccaccccca	1080
	gaaataaaat	ggtataaaaa	tgggaataccc	cttgagtcca	atcacacaat	taaagcgggg	1140
	catgtactga	cgattatgga	agtgagtga	agagacacag	gaaattacac	tgatcatcctt	1200
40	accaatccca	tttcaaagga	gaagcagagc	catgtggtct	ctctggttgt	gtatgtccca	1260
	ccccagattg	gtgagaaatc	tctaactctc	ctgttggatt	cctaccagta	cggcaccact	1320
	caaacgctga	catgtacggt	ctatgccatt	cctccccgc	atcacatcca	ctggtattgg	1380
	cagttggagg	aagagtgcgc	caacgagccc	agccaagctg	tctcagtgc	aaacccatac	1440
	ccttgtgaag	aatggagaag	tgtggaggac	ttccagggag	gaaataaaat	tgaagttaat	1500
45	aaaaatcaat	ttgctcta	tgaaggaaaa	aacaaaactg	taagtaccct	tgttatccaa	1560
	gcggaatg	tgtcagcttt	gtacaaatgt	gaagcgggtc	acaaagtcgg	gagaggagag	1620
	agggtgatct	ccttccacgt	gaccaggggt	cctgaaatta	ctttgcaacc	tgacatgcag	1680
	cccactgagc	aggagagcgt	gtctttgtgg	tgcactgcag	acagatctac	gtttgagaac	1740
	ctcacatggt	acaagcttgg	cccacagcct	ctgccaatcc	atgtgggaga	gttgcccaca	1800
50	cctgttttga	agaacttgg	tactctttgg	aaattgaatg	ccaccatgtt	ctctaatagc	1860
	acaaatgaca	ttttgatcat	ggagcttaag	aatgcatcct	tgcaggacca	aggagactat	1920
	gtctgccttg	ctcaagacag	gaagaccaag	aaaagacatt	gcgtgggtcag	gcagctcaca	1980
	gtcctagagc	gtgtggcacc	cacgatcaca	ggaaacctgg	agaatcagac	gacaagtatt	2040
	ggggaaaagca	tcgaagtctc	atgcacggca	tctgggaatc	cccctccaca	gatcatgtgg	2100
55	tttaaagata	atgagaccct	tgtagaagac	tcaggcattg	tattgaagga	tgggaaccgg	2160
	aacctcacta	tccgcagagt	gaggaaggag	gacgaaggcc	tctacacctg	ccaggcatcg	2220
	agtgttcttg	gctgtgcaaa	agtggaggca	tttttcataa	tagaagggtgc	ccaggaaaag	2280
	acgaacttgg	aaatcattat	tctagtaggc	acggcggtga	ttgccatgtt	cttctggcta	2340
	cttcttgtca	tcatcctacg	gaccgttaag	cggggcaatg	gaggggaact	gaagacaggc	2400
60	tacttgtcca	tcgtcatgga	tccagatgaa	ctcccattgg	atgaacattg	tgaacagctg	2460
	ccttatgatg	ccagcaaatg	ggaattcccc	agagaccggc	tgaagctagg	taagcctctt	2520
	ggccgtgggtg	cctttggcca	agtgattgaa	gcagatgcct	ttggaattga	caagacagca	2580

5 acttcgagga cagtagcagt caaaatgttg aaagaaggag caacacacag tgagcatcga 2640
 gctctcatgt ctgaactcaa gatcctcatt catattgggt accatctcaa tgtgggtcaac 2700
 cttctaggtg cctgtaccaa gccaggaggg ccactcatgg tgattgtgga attctgcaaa 2760
 tttggaaacc tgtccactta cctgaggagc aagagaaatg aatttgtccc ctacaagacc 2820
 aaagggggcac gattccgtca agggaaaagc tacgttggag caatccctgt ggatctgaaa 2880
 cggcgcttgg acagcatcac cagtagccag agctcagcca gctctggatt tgtggaggag 2940
 aagtcctca gtgatgtaga agaagaggaa gctcctgaag atctgtataa ggacttctctg 3000
 accttgagac atctcatctg ttacagcttc caagtggcta agggcatgga gttcttgga 3060
 10 tcgcgaaagt gtatccacag ggacctggcg gcacgaaata tcctcttatc ggagaagaac 3120
 gtgggttaaaa tctgtgactt tggcttggcc cgggatattt ataaagatcc agattatgtc 3180
 agaaaaggag tgctcgctt ccttttgaat tggatggccc cagaaacaat ttttgacaga 3240
 gtgtacacaa tccagagtga cgtctggtct tttgggtgtt tgctgtggga aatattttcc 3300
 ttaggtgctt ctccatatcc tggggtaaag attgatgaag aattttgtag gcgattgaaa 3360
 gaaggaaacta gaatgagggc ccctgattat actacaccag aatgtacca gaccatgctg 3420
 15 gactgctggc acggggagcc cagtcagaga ccacgtttt cagagttggt ggaacatttg 3480
 ggaaatctct tgcaagctaa tgctcagcag gatggcaaag actacattgt tcttccgata 3540
 tcagagactt tgagcatgga agaggattct ggactctctc tgctacctc acctgtttcc 3600
 tgtatggagg agggaggaagt atgtgacccc aaattccatt atgacaacac agcaggaatc 3660
 agtcagtatc tgcagaacag taagcgaag agccggcctg tgagtgtaaa aacatttgaa 3720
 20 gatatcccg tagaagaacc agaagtaaaa gtaatcccag atgacaacca gacggacagt 3780
 ggtatgggtc ttgcctcaga agagctgaaa actttggaag acagaacc aaattatctcca 3840
 tcttttgggtg gaatggtgcc cagcaaaagc agggagtctg tggcatctga aggctcaaac 3900
 cagacaagcg gctaccagtc cggatatcac tccgatgaca cagacaccac cgtgtactcc 3960
 agtgagggaag cagaactttt aaagctgata gagattggag tgcaaacgg tagcacagcc 4020
 25 cagattctcc agcctgactc gggg 4044

<210> 95
 <211> 4017
 30 <212> DNA
 <213> Homo sapiens

<300>
 <302> Flt1
 35 <310> AF063657

<400> 95
 atggtcagct actgggacac cggggtcctg ctgtgcgcgc tgctcagctg tctgcttctc 60
 40 acaggatcta gttcagggtc aaaattaaaa gatcctgaac tgagttaaaa aggcacccag 120
 cacatcatgc aagcaggcca gacactgcat ctccaatgca ggggggaagc agcccataaa 180
 tgggtctttgc ctgaaatggt gagtaaggaa agcgaaaggc tgagcataac taaatctgcc 240
 tgtggaagaa atggcacaac attctgcagt actttaacct tgaacacagc tcaagcaaac 300
 cacactggct tctacagctg caaatatcta gctgtacctt cttcaaagaa gaaggaaaca 360
 45 gaatctgcaa tctatatatt tattagtgat acaggtagac ctttcgtaga gatgtacagt 420
 gaaatccccg aaattataca catgactgaa ggaaggagc tcgtcattcc ctgccgggtt 480
 acgtcaccta acatcactgt tactttaaaa aagtttccac ttgacacttt gatccctgat 540
 ggaaaacgca taatctggga cagtagaaag ggcttcatca tatcaaatgc aacgtacaaa 600
 gaaatagggc ttctgacctg tgaagcaaca gtcaatgggc atttgtataa gacaaactat 660
 50 ctacacatc gacaaacc aaataatcata gatgtccaaa taagcacacc acgcccagtc 720
 aaattactta gaggccatc tctgtcctc aattgtactg ctaccactcc cttgaacagc 780
 agagttcaaa tgacctggag ttacctgat gaaaaaata agagagcttc cgtaaggcga 840
 cgaattgacc aaagcaattc ccatgccaac atattctaca gtgttcttac tattgacaaa 900
 atgcagaaca aagacaaagg actttatact tgtcgtgtaa ggagtggacc atcattcaaa 960
 55 tctgttaaca cctcagtgca tatatatgat aaagcattca tcaactgtga acatcgaaa 1020
 cagcaggtgc ttgaaaccgt agctggcaag cggctctacc ggctctctat gaaagtgaag 1080
 gcatttccct cgccggaagt tgtatggtta aaagatgggt tacctgcgac tgagaaatct 1140
 gctcgtctatt tgactcgtgg ctactcgtta attatcaagg acgtaactga agaggatgca 1200
 gggaaattata caatcttgct gagcataaaa cagtcaaatg tgtttaaaaa cctcactgcc 1260
 60 actctaattg tcaatgtgaa accccagatt tacgaaaagg ccgtgtcatc gtttccagac 1320
 ccggctctct accactggg cagcagacaa atcctgactt gtaccgcata tggatctcc 1380
 caacctcaaa tccaagtgtt ctggcaccct atcaaccata atcattccga agcaagggtg 1440
 gacttttgtt ccaataatga agagtccttt atcctggatg ctgacagcaa catgggaaac 1500

	agaattgaga	gcatcactca	gcgcattggca	ataatagaag	gaaagaataa	gatggctagc	1560
	accttggttg	tggctgactc	tagaatttct	ggaatctaca	tttgcatagc	ttccaataaa	1620
	gttgggactg	tgggaagaaa	cataagcttt	tatatcacag	atgtgccaaa	tgggtttcat	1680
	gttaacttgg	aaaaaatgcc	gacggaagga	gaggacctga	aactgtcttg	cacagttaac	1740
5	aagttcttat	acagagacgt	tacttggatt	ttactgcgga	cagttaataa	cagaacaatg	1800
	cactacagta	ttagcaagca	aaaaatggcc	atcactaagg	agcactccat	cactcttaat	1860
	cttaccatca	tgaatgtttc	cctgcaagat	tcaggcacct	atgcctgcag	agccaggaat	1920
	gtatacacag	gggaagaaat	cctccagaag	aaagaaatta	caatcagaga	tcaggaagca	1980
	ccatacctcc	tgcgaaacct	cagtgtacac	acagtggcca	tcagcagttc	caccacttta	2040
10	gactgtcatg	ctaattggtg	ccccgagcct	cagatcactt	ggtttaaaaa	caaccacaaa	2100
	atacaacaag	agcctggaat	tatttttagga	ccaggaagca	gcacgctgtt	tattgaaaga	2160
	gtcacagaag	aggatgaagg	tgtctatcac	tgcaaaagcca	ccaaccagaa	gggctctgtg	2220
	gaaagttcag	catacctcac	tgttcaagga	acctcggaca	agtctaattct	ggagctgac	2280
	actctaact	gcacctgtgt	ggctgcgact	ctcttctggc	tcctattaac	cctctttatc	2340
15	cgaaaaatga	aaaggtcttc	ttctgaaata	aagactgact	acctatcaat	tataatggac	2400
	ccagatgaag	ttccttttga	tgagcagtg	gagcggctcc	cttatgatgc	cagcaagtgg	2460
	gagtttgc	gggagagact	taaactgggc	aaatcacttg	gaagaggggc	ttttggaaaa	2520
	gtggttcaag	catcagcatt	tggcattaag	aaatcaccta	cgtgccggac	tgtggctgtg	2580
	aaaatgctga	aagagggggc	cacggccagc	gagtacaaag	ctctgatgac	tgagctaaaa	2640
20	atcttgaccc	acattggcca	ccatctgaac	gtgggttaacc	tgctgggagc	ctgcaccaag	2700
	caaggagggc	ctctgatggt	gattgttgaa	tactgcaaat	atggaaatct	ctccaactac	2760
	ctcaagagca	aacgtgactt	atTTTTtctc	aacaaggatg	cagcactaca	catggagcct	2820
	aagaaagaaa	aaatggagcc	aggcctggaa	caaggcaaga	aaccaagact	agatagcgtc	2880
	accagcagcg	aaagctttgc	gagctccggc	tttcaggaag	ataaaagtct	gagtgtatgt	2940
25	gaggaagagg	aggattctga	cggtttctac	aaggagccca	tcactatgga	agatctgatt	3000
	tcttacagtt	ttcaagtggc	cagaggcatg	gagttcctgt	cttccagaaa	gtgcattcat	3060
	cgggacctgg	cagcgagaaa	cattctttta	tctgagaaca	acgtgggtgaa	gatttgtgat	3120
	tttggccttg	cccgggatat	ttataagaac	cccgattatg	tgagaaaagg	agatactcga	3180
	cttctctga	aatggatggc	tcctgaatct	atctttgaca	aaatctacag	caccaagagc	3240
30	gacgtgtggt	cttacggagt	attgctgtgg	gaaatcttct	ccttaggtgg	gtctccatac	3300
	ccaggagtac	aaatggatga	ggacttttgc	agtcgcctga	gggaaggcat	gaggatgaga	3360
	gctcctgagt	actctactcc	tgaaatctat	cagatcatgc	tggactgctg	gcacagagac	3420
	ccaaaagaaa	ggccaagatt	tgcagaactt	gtggaaaaac	taggtgattt	gcttcaagca	3480
	aatgtacaac	aggatggtaa	agactacatc	ccaatcaatg	ccatactgac	aggaaatagt	3540
35	gggtttacat	actcaactcc	tgcccttctc	gaggacttct	tcaaggaaag	tatttcagct	3600
	ccgaagtta	attcaggaag	ctctgatgat	gtcagatatg	taaatgcttt	caagttcatg	3660
	agcctggaaa	gaatcaaaaac	ctttgaagaa	cttttaccga	atgccacctc	catgtttgat	3720
	gactaccagg	gcgacagcag	cactctgttg	gcctctccca	tgctgaagcg	cttcacctgg	3780
	actgacagca	aaccaagggc	ctcgctcaag	attgacttga	gagtaaccag	taaaagtaag	3840
40	gagtcggggc	tgtctgatgt	cagcaggccc	agtttctgcc	attccagctg	tgggcacgtc	3900
	agcgaaggca	agcgcaggtt	cacctacgac	cacgctgagc	tggaaaggaa	aatcgcgtgc	3960
	tgtccccgc	ccccagacta	caactcgggtg	gtcctgtact	ccacccacc	catctag	4017
45	<210> 96						
	<211> 3897						
	<212> DNA						
	<213> Homo sapiens						
50	<300>						
	<302> Flt4						
	<310> XM003852						
	<400> 96						
55	atgcagcggg	gcgcccgcgt	gtgcctgcga	ctgtggctct	gcctgggact	cctggacggc	60
	ctggtgagtg	gctactccat	gacccccccg	accttgaaca	tcacggagga	gtcacacgtc	120
	atcgacaccg	gtgacagcct	gtccatctcc	tgacggggac	agcaccacct	cgagtgggct	180
	tggccaggag	ctcaggaggc	gccagccacc	ggagacaagg	acagcgagga	cacgggggtg	240
	gtgcgagact	gcgagggcac	agacgccagg	ccctactgca	agggtgttgct	gctgcacgag	300
60	gtacatgccca	acgacacagg	cagctacgtc	tgctactaca	agtacatcaa	ggcacgcac	360
	gagggcacca	cggccgccag	ctcctacgtg	ttcgtgagag	actttgagca	gccattcatc	420
	aacaagcctg	acacgctctt	ggtcaacagg	aaggacgcca	tgtgggtgcc	ctgtctggtg	480

5 tccatccccg gcctcaatgt cacgctgcgc tcgcaaagct cgggtgctgtg gccagacggg 540
 caggaggtgg tgtgggatga cgggcggggc atgctcgtgt ccacgccact gctgcacgat 600
 gccctgtacc tgcagtgcga gaccacctgg ggagaccagg acttcctttc caacccttc 660
 ctggtgcaca tcacaggcaa cgagctctat gacatccagc tgttgcccag gaagtgcgtg 720
 gagctgctgg taggggagaa gctggctctg aactgcaccg tgtgggtga gtttaactca 780
 ggtgtcacct ttgactggga ctaccaggg aagcaggcag agcggggtaa gtgggtgcc 840
 gagcgacgct ccacagcagc ccacacagaa ctctccagca tcctgacct ccacaacgtc 900
 agccagcacg acctgggctc gtatgtgtgc aaggccaaca acggcatcca gcgatttcgg 960
 gagagcaccg aggtcattgt gcatgaaaat cccttcatca gcgtcgagt gctcaaagga 1020
 10 cccatcctgg agggcacggc aggagacgag ctggtgaagc tgcccgtga gctggcagcg 1080
 taccctccgc ccgagttcca gtggtacaag gatggaaaag cactgtccgg gcgccacagt 1140
 ccacatgccc tgggtgctcaa ggaggtgaca gaggccagca caggcaccta caccctcgcc 1200
 ctgtggaact ccgctgctgg cctgaggcgc aacatcagcc tggagctggg ggtgaatgtg 1260
 cccccccaga tacatgagaa ggaggcctcc tccccagca tctactcgcg tcacagccgc 1320
 15 caggccctca cctgcacggc ctacgggggtg cccctgcctc tcagcatcca gtggcactgg 1380
 cggccctgga caccctgcaa gatgtttgct cagcgtagtc tccggcggcg gcagcagcaa 1440
 gacctcatgc cacagtgcg tgactggagg gcggtgaccg cgcaggatgc cgtgaacccc 1500
 atcgagagcc tggacacctg gaccgagttt gtggaggga agaataagac tgtgagcaag 1560
 ctggtgatcc agaatgccaa cgtgtctgcc atgtacaagt gtgtggtctc caacaagggtg 1620
 20 ggccaggatg agcggctcat ctacttctat gtgaccacca tccccagcg cttcaccatc 1680
 gaatccaagc ctccgagga gctactagag ggccagccgg tgctcctgag ctgccagcc 1740
 gacagctaca agtacgagca tctgcgctgg taccgcctca acctgtccac gctgcacgat 1800
 ggcacggga acccgcttct gctcgactgc aagaacgtgc atctgttcgc caccctctg 1860
 gccgccagcc tggaggaggt ggcacctggg gcgcgccacg ccacgctcag cctgagtatc 1920
 25 ccccgctcg cgcgcagca cgagggccac tatgtgtgcg aagtgcaga ccggcgagc 1980
 catgacaagc atgccacaa gaagtacctg tcggtgcagg cctgggaagc cctcggtc 2040
 acgcagaact tgaccgacct cctggtgaac gtgagcgact cgctggagat gcagtgcctg 2100
 gtggccggag cgcacgcgc cagcatcgtg tggtaaaaag acgagaggct gctggaggaa 2160
 aagtctggag tcgacttggc ggactccaac cagaagctga gcatccagcg cgtgcgcgag 2220
 30 gaggatgcgg gacgtatct gtgcagcgtg tgcaacgcca agggctgcgt caactcctc 2280
 gccacgtcgg ccgtggaagg ctccgaggt atgggagca tggagatcgt gatcctgtc 2340
 ggtaccggcg tcatcgtgt cttcttctgg gtccctctcc tctcatctt ctgtaacatg 2400
 aggaggccgg cccacgcaga catcaagacg ggctacctgt ccacatcat ggaccccg 2460
 gaggtgcctc tggaggagca atgcgaatac ctgtcctacg atgccagcca gtgggaattc 2520
 35 ccccgagagc ggctgcacct ggggagagtg ctcggtacg gcgccttcgg gaagggtgtg 2580
 gaagcctccg ctttcggcat ccacaaggc agcagctgt acaccgtggc cgtgaaaatg 2640
 ctgaaagagg gcgccagcg cagcgagcag cgcgcgctga tgtcgagct caagatcctc 2700
 attcacatcg gcaaccacct caacgtggtc aacctcctcg gggcgtgcac caagccgcag 2760
 ggccctctca tgggtatcgt ggagtctctg aagtacggca acctctccaa cttcctgcgc 2820
 40 gccaaagcgg acgccttcag cccctgcgcg gagaagtctc ccgagcagcg cggacgcttc 2880
 cgcgcatagg tggagctcgc caggctggat cggaggcgg cggggagcag cgacagggtc 2940
 ctcttcgcgc ggttctcgaa gaccgagggc ggagcgaggc gggcttctcc agaccaagaa 3000
 gctgaggacc tgtggtgag cccgctgacc atggaagatc ttgtctgcta cagcttcag 3060
 gtggccagag ggatggagtt cctggcttcc cgaaagtga tccacagaga cctggctgct 3120
 45 cggaacattc tgctgtcgga aagcgacgtg gtgaagatct gtgactttgg ccttgcccgg 3180
 gacatctaca aagacccga ctacgtccg aagggcagtg cccggctgcc cctgaagtgg 3240
 atggcccttg aaagcatctt cgacaagggtg tacaccacgc agagtgcgt gtggtcctt 3300
 ggggtgcttc tctgggagat cttctctctg ggggcctccc cgtaccctgg ggtgcagatc 3360
 aatgaggagt tctgccagcg gctgagagac ggcacaagga tgaggggccc ggagctggcc 3420
 50 actcccgcga tacgcccat catgctgaac tgctggtccg gagaccccaa ggcgagacct 3480
 gcattctcgg agctggtgga gatcctgggg gactctctcc agggcagggg cctgcaagct 3540
 gaagaggagg tctgcatggc cccgcgcagc tctcagagct cagaagaggg cagcttctcg 3600
 caggtgtcca ccatggccct acacatcgcc caggctgacg ctgaggacag cccgccaaagc 3660
 ctgcagcgcc acagcctggc cgccaggtat tacaactggg tgccttctcc cgggtgcctg 3720
 55 gccagagggg ctgagaccgg tggttcctcc aggatgaaga catttgagga attccccatg 3780
 acccaacga cctacaagg ctctgtggac aaccagacag acagtgggat ggtgtggcc 3840
 tcggaggagt ttgagcagat agagagcagg catagacaag aaagcgctt caggtag 3897

60 <210> 97
 <211> 4071
 <212> DNA

<213> Homo sapiens

<300>

<302> KDR

5 <310> AF063658

<400> 97

	atggagagca	aggtgctgct	ggccgctcgcc	ctgtgggtct	gcgtggagac	ccgggcccgc	60
	tctgtgggtt	tgcctagtgt	ttctcttgat	ctgcccaggc	tcagcataca	aaaagacata	120
10	cttacaatta	aggctaatac	aactcttcaa	attacttgca	ggggacagag	ggacttggac	180
	tggctttggc	ccaataatca	gagtggcagt	gagcaaaggg	tggaggtgac	tgagtgcagc	240
	gatggcctct	tctgtaagac	actcacaatt	ccaaaagtga	tcggaaatga	cactggagcc	300
	tacaagtgtc	tctaccggga	aactgacttg	gcctcggtca	tttatgtcta	tgttcaagat	360
	tacagatctc	catttattgc	ttctgttagt	gaccaacatg	gagtcgtgta	cattactgag	420
15	aacaaaaaca	aaactgtggt	gattccatgt	ctcgggtcca	tttcaaactc	caacgtgtca	480
	ctttgtgcaa	gatacccaga	aaagagattt	gttcctgatg	gtaacagaat	ttcctgggac	540
	agcaagaagg	gctttactat	tcccagctac	atgatcagct	atgctggcat	ggtcttctgt	600
	gaagcaaaaa	ttaatgatga	aagttaccag	tctattatgt	acatagtgtg	cgttgtaggg	660
	tataggattt	atgatgtggt	tctgagtccg	tctcatggaa	ttgaactatc	tgttgagaaa	720
20	aagcttgtct	taaattgtac	agcaagaact	gaactaaatg	tggggattga	cttcaactgg	780
	gaataccctt	cttcgaagca	tcagcataag	aaacttgtaa	accgagacct	aaaaaccag	840
	tctgggagtg	agatgaagaa	atttttgagc	accttaacta	tagatgggtg	aaccggagt	900
	gaccaaggat	tgtacacctg	tgcagcatcc	agtgggctga	tgaccaagaa	gaacagcaca	960
	tttgtcaggg	tccatgaaaa	accttttggt	gcttttgtaa	gtggcatgga	atctctgggtg	1020
25	gaagccacgg	tgggggagcg	tgtcagaatc	cctgcgaagt	accttggtta	cccccccca	1080
	gaaataaaat	ggtataaaaa	tgggaatacc	cttgagtcca	atcacacaat	taaagcgggg	1140
	catgtactga	cgattatgga	agtgagtga	agagacacag	gaaattacac	tgtcatcctt	1200
	accaatccca	tttcaaagga	gaagcagagc	catgtggtct	ctctggttgt	gtatgtccca	1260
	ccccagattg	gtgagaaatc	tctaattctc	cctgtggatt	cctaccagta	cggcaccact	1320
30	caaacgctga	catgtacggt	ctatgccatt	cctccccgc	atcacatcca	ctgggtattgg	1380
	cagttggagg	aagagtgcgc	caacgagccc	agccaagctg	tctcagtgac	aaaccatac	1440
	ccttgtgaag	aatggagaag	tgtggaggac	ttccagggag	gaaataaaat	tgaagttaat	1500

tttgatgatg atgaaacctg gacaagtagt tccaaaggct acaacttggt tcttggtgct 660
 ggcgatgagt tcggccactc cttagggtctt gaccactcca aggaccctgg agcactcatg 720
 ttctctatct acacctacac cggcaaaagc cactttatgc ttcttgatga cgatgtacaa 780
 gggatccagt ctctctatgg tccaggagat gaagacccca accctaaaca tccaaaaacg 840
 5 ccagacaaat gtgacccttc cttatccctt gatgccatta ccagtctccg aggagaaaca 900
 atgatcttta aagacagatt ctctctggcg ctgcacctc agcagggtga tgcggagctg 960
 tttttaacga aatcattttg gccagaactt cccaaccgta ttgatgctgc atatgagcac 1020
 ccttctcatg acctcatctt catcttcaga ggtagaaaat tttgggctct taatggttat 1080
 gacattctgg aagggttatcc caaaaaata tctgaactgg gtcttccaaa agaagttaag 1140
 10 aagataagtg cagctgttca ctttgaggat acaggcaaga ctctcctggt ctcaggaaac 1200
 caggtctgga gatgatga tactaaccat attatggata aagactatcc gagactaata 1260
 gaagaagact tcccaggaat tgggtgataaa gtatgctg tctatgagaa aaatgggtat 1320
 atctattttt tcaacggacc catacagttt gaatacagca tctggagtaa ccgtattggt 1380
 cgctcatgc cagcaaattc cattttgtgg tgtaa 1416
 15
 <210> 103
 <211> 1749
 <212> DNA
 20 <213> Homo sapiens
 <300>
 <302> MMP14
 <310> NM004995
 25
 <400> 103
 atgtctcccg ccccaagacc ccccggttgt ctctgctcc ccctgctcac gctcggcacc 60
 gcgctcgctc ccctcggtc ggcccaaagc agcagcttca gcccgaagc ctggctacag 120
 caatatggct acctgcctcc cggggaccta cgtaccaca cacagcgctc acccagtc 180
 30 ctctcagcgg ccacgctgc catgcagaag catgaggcgc cccgatgtg gtgtccaga caagtctggg 240
 gatgcagaca ccatgaaggc catgaggcgc cccgatgtg gtgtccaga caagtctggg 300
 gctgagatca aggccaatgt tcgaagggaag cgctacgcca tccagggtct caaatggcaa 360
 cataatgaaa tcactttctg catccagaat tacaccccca aggtgggcga gtatgccaca 420
 tacgaggcca ttcgcaaggc gttccgcgtg tgggagagtg ccacaccact gcgtctccgc 480
 35 gaggtgccct atgcctacat ccgtgagggc catgagaagc aggcgcacat catgatcttc 540
 ttggccgagg gcttccatgg cgacagcacg ccttcgatg gtgagggcgg cttcctggcc 600
 catgcctact tcccaggccc caacattgga ggagacaccc actttgactc tggcagcct 660
 tggactgtca ggaatgagga tctgaatgga aatgacatct tctggtggc tgtgcacgag 720
 ctggggccatg ccctggggct cgagcattcc agtgaccct cggccatcat ggacccttt 780
 40 taccagtgga tggacacgga gaattttgtg ctgcccgatg atgaccgcg gggcatccag 840
 caactttatg ggggtgagtc aggggtcccc accaagatgc cccctcaacc caggactacc 900
 tcccggcctt ctgttctga taaacccaaa aacccacct atgggcccac catctgtgac 960
 gggaaactttg acaccgtggc catgctccga ggggagatgt ttgtcttcaa ggagcgctgg 1020
 ttctggcggg tgaggaataa ccaagtgatg gatggatacc caatgcccac tggccagttc 1080
 45 tggcggggcc tgctgcgtc catcaacact gcctacgaga ggaaggatgg caaatctgct 1140
 ttcttcaaag gagacaagca ttgggtgttt gatgaggcgt ccttgaacc tggctacccc 1200
 aagcacatta aggagctggg ccgagggtcg cctaccgaca agattgatgc tgcctctctc 1260
 tggatgccc atggaaagac ctacttcttc cgtggaaca agtactaccg tttcaacgaa 1320
 gagctcaggg cagtggatag cgagtacccc aagaacatca aagtctggga agggatccct 1380
 50 agtctccca gagggctcatt catgggcagc gatgaagtct tcaactactt ctacaagggg 1440
 aacaaatact ggaattcaa caacagaag ctgaaggtag aaccgggcta cccaagtca 1500
 gccctgaggg actggatggg ctgccatcg ggaggccggc cggatgaggg gactgaggag 1560
 gagacggagg tgatcatcat tgagggtggac gaggagggcg gcggggcggt gagcgcggt 1620
 gccgtggtgc tgcccgtgct gctgctgctc ctggtgctgg cgggtgggct tgcatcttc 1680
 55 ttcttcagac gccatgggac ccccaggcga ctgctctact gccagcgctc cctgctggac 1740
 aaggtctga 1749
 <210> 104
 60 <211> 2010
 <212> DNA
 <213> Homo sapiens

<300>
 <302> MMP15
 <310> NM002428

5

<400> 104

atgggcagcg	acccgagcgc	gcccggacgg	ccgggctgga	cgggcagcct	cctcggcgac	60
cgaggaggagg	cggcgcggcc	gcgactgctg	ccgctgctcc	tggtgcttct	gggctgcctg	120
ggccttgggcg	tagcggccga	agacgcggag	gtccatgccg	agaactggct	gcggctttat	180
ggctacctgc	ctcagcccag	ccgccatatg	tccaccatgc	gttccgccc	gatcttggcc	240
tcggcccttg	cagagatgca	gcgcttctac	gggatcccag	tcaccgggtg	gctcgacgaa	300
gagaccaagg	agtggatgaa	gcggccccgc	tgtgggggtg	cagaccagtt	cggggtacga	360
gtgaaagcca	acctgcggcg	gcgtcggaag	cgctacgccc	tcaccgggag	gaagtggaa	420
aaccaccatc	tgacctttag	catccagaac	tacacggaga	agttgggctg	gtaccactcg	480
atggaggcgg	tgcgagggc	cttccgcgtg	tgggagcagg	ccacgcccct	ggtcttccag	540
gaggtgccct	atgaggacat	ccggctgcgg	cgacagaagg	aggccgacat	catgggtact	600
tttgccctctg	gcttccacgg	cgacagctcg	ccgcttgatg	gcaccgggtg	ctttctggcc	660
cacgcctatt	tccctggccc	cggcctaggg	ggggacaccc	attttgacgc	agatgagccc	720
tggaccttct	ccagcactga	cctgcatgga	aacaacctct	tcctgggtgg	agtgcattgag	780
ctggggccacg	cgctggggct	ggagcactcc	agcaacccca	atgccatcat	ggcgccgttc	840
taccagtggg	aggacgttga	caacttcaag	ctgcccagag	acgatctccg	tggcatccag	900
cagctctacg	gtaccccaaga	cggtcagcca	cagcctaccc	agcctctccc	cactgtgacg	960
ccacggcggc	caggccggcc	tgaccaccgg	ccgccccggc	ctccccagcc	accacccccca	1020
ggtgggaagc	cagagcggcc	cccaaagccg	ggccccccag	tccagccccg	agccacagag	1080
cggccccgacc	agtatggccc	caacatctgc	gacggggact	ttgacacagt	ggccatgctt	1140
cgcggggaga	tggttcgtgt	caagggccgc	tggttctggc	gagtccggca	caaccgcgtc	1200
ctggacaact	atcccatgcc	catcgggcac	ttctggcgtg	gtctgcccgg	tgacatcagt	1260
gctgcctacg	agcgccaaga	cggtcgtttt	gtctttttca	aagggtgacc	ctactggctc	1320
tttcgagaag	cgaacctgga	gcccggctac	ccacagccgc	tgaccagcta	tggcctgggc	1380
atccccatg	accgcattga	cacggccatc	tgggtgggag	ccacaggcca	caccttcttc	1440
ttccaagagg	acaggctactg	gcgcttcaac	gaggagacac	agcgtggaga	ccctgggtac	1500
cccaagccca	tcagtgtctg	gcaggggatc	cctgcctccc	ctaaaggggc	cttctctgag	1560
aatgacgcag	cctacacctg	cttctacaag	ggcaccaa	actggaaatt	cgacaattgag	1620
cgctgcgga	tggagcccgg	ctaccccaag	tccatcctgc	gggacttcat	gggctgccag	1680
gagcacgtgg	agccaggccc	ccgatggccc	gacgtggccc	ggccgcctt	caacccccac	1740
gggggtgcag	agcccggggc	ggacagcgca	gagggcgacg	tgggggatgg	ggatggggac	1800
tttggggccg	gggtcaacaa	ggacgggggc	agccgcgtgg	tgggtgcagat	ggaggagggtg	1860
gcacggacgg	tgaacgtggt	gatggtgctg	gtgccactgc	tgctgctgct	ctgcgtcctg	1920
ggcctcacct	acgcgctggt	gcagatgcag	cgcaagggtg	cgccacgtgt	cctgctttac	1980
tgcaagcgct	cgctgcagga	gtgggtctga				2010

<210> 105
 <211> 1824
 <212> DNA
 <213> Homo sapiens

45

<300>
 <302> MMP16
 <310> NM005941

50

<400> 105

atgatcttac	tcacattcag	cactggaaga	cggttggatt	tcgtgcatca	ttcgggggtg	60
tttttcttgc	aaaccttgc	ttggatttta	tgtgctacag	tctgcggaac	ggagcagtat	120
ttcaatgtgg	aggtttgggt	acaaaagtac	ggctaccttc	caccgactga	ccccagaatg	180
tcagtgtcgc	gctctgcaga	gacctgcaga	ctgcccctag	ctgccatgca	gcagttctat	240
ggcattaaca	tgacaggaaa	agtggacaga	aacacaattg	actggatgaa	gaagccccga	300
tgcggtgtac	ctgaccagac	aagaggtagc	tccaaatttc	atattcgtcg	aaagcgatat	360
gcattgacag	gacagaaatg	gcagcacaa	cacatcactt	acagtataaa	gaacgtaact	420
ccaaaagtag	gagaccctga	gactcgtaaa	gctattcgcc	gtgcctttga	tgtgtggcag	480
aatgtaaact	ctctgacatt	tgaagaagtt	ccctacagtg	aattagaaaa	tggcaaacgt	540
gatgtggata	taaccattat	ttttgcatct	ggtttccatg	gggacagctc	tccctttgat	600

5 ggagagggag gatttttggc acatgcctac ttccctggac caggaattgg aggagatacc 660
 cattttgact cagatgagcc atggacacta ggaaatccta atcatgatgg aaatgactta 720
 tttctttag cagtccatga actgggacat gctctgggat tggagcattc caatgacccc 780
 actgccatca tggctccatt ttaccagtac atggaaacag acaacttcaa actacctaata 840
 gatgatttac agggcatcca gaaaatataat ggtccacctg acaagattcc tccacctaca 900
 agacctctac cgacagtgcc cccacaccgc tctattcctc cggctgacct aaggaaaaat 960
 gacaggccaa aacctcctcg gctccaacc ggcagaccct cctatcccgg agccaaaccc 1020
 aacatctgtg atgggaactt taacactcta gctattcttc gtcgtgagat gtttgttttc 1080
 aaggaccagt ggttttggcg agtgagaaac aacaggggtga tggatggata cccaatgcaa 1140
 10 attacttact tctggcgggg cttgcctcct agtatcgatg cagtttatga aaatagcgac 1200
 gggaattttg tgttctttaa aggtaacaaa tattgggtgt tcaaggatac aactcttcaa 1260
 cctggttacc ctcagtactt gataaccctt ggaagtggaa ttccccctca tgggtattgat 1320
 tcagccattt ggtgggagga cgtcgggaaa acctatttct tcaagggaga cagatattgg 1380
 agatatagtg aagaaatgaa aacaatggac cctggctatc ccaagccaat cacagtctgg 1440
 15 aaagggatcc ctgaatctcc tcaggggagca tttgtacaca aagaaaatgg ctttacgtat 1500
 ttctacaaag gaaaggagta ttggaaattc aacaaccaga tactcaaggt agaacttga 1560
 catccaagat ccatcctcaa ggattttatg ggctgtgatg gaccaacaga cagagttaaa 1620
 gaaggacaca gccaccaga tgatgtagac attgtcatca aactggacaa cacagccagc 1680
 actgtgaaag ccatagctat tgtcattccc tgcattctgg ccttatgcct ccttgatttg 1740
 20 gtttacactg tgttccagtt caagaggaaa ggaacacccc gccacatact gtactgtaaa 1800
 cgctctatgc aagagtgggt gtga 1824

25 <210> 106
 <211> 1560
 <212> DNA
 <213> Homo sapiens

30 <300>
 <302> MMP17
 <310> NM004141

35 <400> 106
 atgcagcagt ttggtggcct ggaggccacc ggcacccctg acgaggccac cctggccctg 60
 atgaaaaacc cagctgctc cctgccagac ctccctgtcc tgaccaggc tgcaggaga 120
 cgccaggctc cagcccccac caagtggaaac aagaggaaac tgcgtggag ggtccggagc 180
 ttcccacggg actcaccact ggggcacgac acggtgcgtg cactcatgta ctacgccctc 240
 aaggtctgga gcgacattgc gcccctgaac ttccacgagg tggcgggag caccgcccag 300
 atccagatcg acttctccaa ggccgaccat aacgacggct accccttcga cggccccggc 360
 40 ggcaccgtgg cccacgcctt cttccccggc caccaccaca ccgcccggga caccacttt 420
 gacgatgacg aggcctggac cttccgctcc tcggatgccc acgggatgga cctgtttgca 480
 gtggctgtcc acgagtttgg ccacgccatt ggggttaagc atgtggccgc tgcacactcc 540
 atcatgcggc cgtactacca gggcccgggt ggtgaccgc tgcgctacgg gctcccctac 600
 gaggacaagg tgcgctctg gcagctgtac ggtgtgcggg agtctgtgtc tcccacggcg 660
 45 cagcccagag agcctcccc tctgcccggag cccccagaca accggtccag cggcccggcc 720
 aggaaggacg tgcccacag atgcagcact cactttgacg cgggtggcca gatccggggt 780
 gaagctttct tcttcaaagg caagtacttc tggcggctga cgcgggaccg gcacctggtg 840
 tccctgcagc cggcacagat gcaccgcttc tggcggggcc tgccgctgca cctggacagc 900
 gtggacgccc tgtacgagcg caccagcgac cacaagatcg tcttctttaa aggagacagg 960
 50 tactgggtgt tcaaggacaa taacgtagag gaaggatacc cgcgccccgt ctccgacttc 1020
 agcctcccgc ctggcggcat cgacgtgccc tctcctggg cccacaatga caggacttat 1080
 ttctttaaagg accagctgta ctggcgctac gatgaccaca cgaggcacat ggacccggc 1140
 tacccccgcc agagccccct gtggaggggt gtccccagca cgctggacga cggcatgcgc 1200
 tggctccgac gtgcctccta cttcttccgt ggccaggagt actggaaagt gctggatggc 1260
 55 gagctggagg tggcaccggg gtacccacag tccacggccc gggactggct ggtgtgtgga 1320
 gactcacagg ccgatggatc tgtggctgcg ggcgtggacg cggcagaggg gccccgcgc 1380
 cctccaggac aacatgacca gagccgctcg gaggacggtt acgaggtctg ctcagtgcac 1440
 tctggggcat cctctcccc gggggcccca ggccactgg tggctgccac catgctgctg 1500
 60 ctgctgccc cactgtcacc aggcgcctg tggacagcgg cccaggccct gacgctatga 1560

<210> 107

<211> 1983
<212> DNA
<213> Homo sapiens

5 <300>
<302> MMP2
<310> NM004530

<400> 107

10 atggaggcgc taatggcccg gggcgcgctc acgggtcccc tgagggcgct ctgtctcctg 60
ggctgcctgc tgagccacgc cgccgcccgc ccgtcgccca tcatcaagtt ccccgcgat 120
gtcgccccca aaacggacaa agagttaggca gtgcaatacc tgaacacctt ctatggctgc 180
cccaaggaga gctgcaacct gtttgtgctg aaggacacac taaagaagat gcagaagttc 240
tttggactgc ccagacagg tgatcttgac cagaatacca tcgagaccat gcggaagcca 300
15 cgctgcggca acccagatgt ggccaactac aacttcttcc ctgcgaagcc caagtgggac 360
aagaaccaga tcacatacag gatcattggc tacacacctg atctggacct agagacagtg 420
gatgatgcct ttgctcgtgc cttccaagtc tggagcgatg tgacccact gcggttttct 480
cgaatccatg atggagaggc agacatcatg atcaactttg gccgtggga gcatggcgat 540
ggatacccct ttgacggtaa ggacggactc ctggctcatg ctttcgcccc aggcactggg 600
20 gttgggggag actcccattt tgatgacgat gagctatgga ccttgggaga aggccaagtg 660
gtccgtgtga acgtatggca cgccgatggg gactactgca agttcccctt cttgttcaat 720
ggcaaggagt acaacagctg cactgatact ggccgcagcg atggcttctt ctggtgctcc 780
accacctaca actttgagaa ggatggcaag tacggcttct gtcccatga agccctgttc 840
accatgggcg gcaacgctga aggacagccc tgcaagtttc cattccgctt ccagggcaca 900
25 tcctatgaca gctgcaccac tgagggccgc accgatggct accgctggg cggcaccact 960
gaggactacg accgcgacaa gaagtatggc ttctgcctg agaccgcat gtccactgtt 1020
ggtgggaact cagaaggtgc cccctgtgtc tttcccttca ctttctggg caacaaatat 1080
gagagctgca ccagcgccgg ccgcagtgc ggaaagatgt ggtgtgcgac cacagccaac 1140
tacgatgacg accgcaagtg gggcttctgc cctgaccaag ggtacagcct gttcctcgtg 1200
30 gcagcccacg agtttggcca cgccatgggg ctggagcact cccaagacct tggggccctg 1260
atggcaccca ttacacctt caccaagaac ttccgtctgt ccaggatga catcaagggc 1320
attcaggagc tctatggggc ctctcctgac attgaccttg gcaccggccc cccccaca 1380
ctgggcccctg tcaactcctga gatctgcaaa caggacattg tatttgatgg catcgctcag 1440
atccgtgggtg agatcttctt cttcaaggac cggttcattt ggcggaactgt gacgccacgt 1500
35 gacaagccca tggggcccct gctggtggcc acattctggc ctgagctccc ggaaaagatt 1560
gatgcggtat acgaggcccc acaggaggag aaggctgtgt tctttgcagg gaatgaatac 1620
tggtatctact cagccagcac cctggagcga gggtagccca agccactgac cagcctggga 1680
ctgccccctg atgtccagcg agtggatgcc gcctttaact ggagcaaaaa caagaagaca 1740
tacatctttg ctggagacaa attctggaga tacaatgagg tgaagaagaa aatggatcct 1800
40 ggctttccca agctcatcgc agatgcctgg aatgccatcc ccgataacct ggatgccgtc 1860
gtggagctgc agggcggcgg tcacagctag ttcttcaagg gtgcctatta cctgaagctg 1920
gagaaccaaa gtctgaagag cgtgaagttt ggaagcatca aatccgactg gctaggctgc 1980
tga 1983

45 <210> 108
<211> 1434
<212> DNA
<213> Homo sapiens

50 <300>
<302> MMP2
<310> XM006271

55 <300>
<302> MMP3
<310> XM006271

<400> 108

60 atgaagagtc ttccaatcct actgttgctg tgcgtggcag tttgctcagc ctatccattg 60
gatggagctg caaggggtga ggacaccagc atgaaccttg ttcagaaata tctagaaaac 120
tactacgacc tcgaaaaaga tgtgaaacag tttgttagga gaaaggacag tggctcctgtt 180

```

gttaaaaaaa tccgagaaat gcagaagttc cttggattgg aggtgacggg gaagctggac 240
tccgacactc tggaggtgat gcgcaagccc aggtgtggag ttcctgacgt tggtcacttc 300
agaacctttc ctggcatccc gaagtggagg aaaaccacc ttacatacag gattgtgaat 360
tatacaccag atttgccaaa agatgctgtt gattctgctg ttgagaaagc tctgaaagtc 420
5 tgggaagagg tgactccact cacattctcc aggtctgtat aaggagaggc tgatataatg 480
atctcttttg cagttagaga acatggagac ttttaccctt ttgatggacc tggaaatggt 540
ttggcccatg cctatgcccc tgggccaggg attaatggag atgccactt tgatgatgat 600
gaacaatgga caaaggatac aacagggacc aatttatttc tcgttgctgc tcatgaaatt 660
ggccactccc tgggtctctt tcactcagcc aactgaag ctttgatgta ccactctat 720
10 cactcactca cagacctgac tcggttccgc ctgtctcaag atgatataaa tggcattcag 780
tccctctatg gacctcccc tgactccct gagaccccc tggtagccac ggaacctgtc 840
cctccagaac ctgggacgcc agccaactgt gatcctgctt tgcctttga tgctgtcagc 900
actctgaggg gagaaatcct gatctttaa gacaggcact tttggcgcaa atccctcagg 960
aagcttgaac ctgaattgca tttgatctct tcattttggc catctcttcc ttcaggcgtg 1020
15 gatgccgcat atgaagttac tagcaaggac ctcttttca tttttaagg aaatcaattc 1080
tgggccatca gaggaaatga ggtacgagct ggatacccaa gaggcatacca caccctaggt 1140
ttccctccaa ccgtgaggaa aatcgatgca gccatttctg ataaggaaaa gaacaaaaca 1200
tatttctttg tagaggacaa atactggaga tttgatgaga agagaaattc catggagcca 1260
ggctttccca agcaaatagc tgaagacttt ccagggattg actcaaagat tgatgctgtt 1320
20 tttgaagaat ttgggttctt ttatttcttt actggatctt cacagttgga gtttgacca 1380
aatgcaaaga aagtgcaca cactttgaag agtaacagct ggcttaattg ttga 1434

<210> 109
25 <211> 1404
    <212> DNA
    <213> Homo sapiens

<300>
30 <302> MMP8
    <310> NM002424

```

<213> Homo sapiens

<300>

<302> PKC eta

5 <310> NM006255

<400> 114

```
atgtcgtctg gcaccatgaa gttcaatggc tatttgaggg tccgcacggt tgaggcagtg 60
gggctgcagc ccacccgctg gtccctgctc cactcgtctc tcaagaaggg ccaccagctg 120
10 ctggacccct atctgacggg gagcgtggac caggtgcgct tgggcccagac cagcaccaag 180
cagaagacca acaaaccac gtacaacgag gagttttgct ctaacgtcac cgacggcggc 240
cacctcgagt tggccgtctt ccacgagacc cccctgggct acgacttctg ggccaactgc 300
accctgcagt tccaggagct cgtcggcagc accggcgcct cggacacctt cgagggttgg 360
gtggatctcg agccagaggg gaaagtattt gtggtaataa ccttaccgg gagtttctact 420
15 gaagctactc tccagagaga cggatcttcc aaacatttta ccaggaagcg ccaaagggct 480
atgcgaaggc gaggccacca gatcaatgga cacaagtcca tggccacgta tctgaggcag 540
cccacctact gctctcactg caggaggttt atctggggag tggttgaggaa acaggggttat 600
cagtgccaag tgtgcacctg tgtcgtccat aaacgctgcc atcatctaata tgttacagcc 660
tgtacttgcc aaaacaatat taacaaagtg gattcaaaga tgcagaaca gaggttcggg 720
20 atcaacatcc cacacaagtt cagcatccac aactacaaag tgccaacatt ctgcgatcac 780
tgtggctcac tgcctctggg aataatgcga caaggacttc agtgtaaaat atgtaaaatg 840
aatgtgcata ttcgatgtca agcgaacgtg gccctaact gtggggtaaa tgcgggtgaa 900
cttgccaaga cctggcagg gatgggtctc caaccggaa atatttctcc aacctcgaaa 960
ctcgtttcca gatcgaccct aagacgacag ggaaaggaga gcagcaaaga aggaaatggg 1020
25 attgggggta attcttccaa ccgacttggg atcgacaact ttgagttcat ccgagtgttg 1080
gggaagggga gttttgggaa ggtgatgctt gcaagagtaa aagaaacagg agacctctat 1140
gctgtgaagg tgctgaagaa ggacgtgatt ctgctggatg atgatgtgga atgcaccatg 1200
accgagaaaa ggatcctgtc tctggcccgct aatcaccctc tcctcactca gttgttctgc 1260
tgctttcaga ccccgatcg tctgtttttt gtgatggagt ttgtgaatgg ggggtgacttg 1320
30 atgttccaca ttcagaagtc tgcgtctttt gatgaagcac gagctcgctt ctatgctgca 1380
gaaatcaatt cggctctcat gttcctccat gataaaggaa tcactctatag agatctgaaa 1440
ctggacaatg tctgttgga ccacgagggt cactgtaaac tggcagactt cggaatgtgc 1500
aaggagggga tttgcaatgg tgtcaccacg gccacattct gtggcacgcc agactatatc 1560
gctccagaga tcctccagga aatgctgtac gggcctgcag tagactgggt ggcaatgggc 1620
35 gtgttgctct atgagatgct ctgtggtcac gcgccttttg aggcagagaa tgaagatgac 1680
ctctttgagg ccatactgaa tgatgaggtg gtctacccta cctggctcca tgaagatgac 1740
acagggatcc taaaatcttt catgaccaag aaccccacca tgcgcttggg cagcctgact 1800
cagggaggcg agcacgccat cttgagacat ccttttttta aggaaatcga ctgggcccag 1860
ctgaaccatc gccaaataga accgcctttc agaccagaa tcaaataccc agaagatgtc 1920
40 agtaattttg accctgactt cataaaggaa gagccagttt taactccaat tgatgaggga 1980
catcttccaa tgattaacca ggatgagttt agaaactttt cctatgtgtc tccagaattg 2040
caaccatag 2049
```

45 <210> 115

<211> 948

<212> DNA

<213> Homo sapiens

50 <300>

<302> PKC epsilon

<310> XM002370

<400> 115

```
atgttggcag aactcaaggg caaagatgaa gtatatgctg tgaaggctct aaagaaggac 60
gtcatccttc aggatgatga cgtggactgc acaatgacag agaagaggat tttggctctg 120
55 gcacggaaac accgtacct taccacactc tactgtgctc tccagaccaa ggaccgcctc 180
tttttcgtca tggaaatagt aaatgggtgga gacctcatgt ttcagattca gcgctcccga 240
aaattcgacg agcctcgctc acggttctat gctgcagagg tcacatcggc cctcatgttc 300
60 ctccaccagc atggagtcac ctacagggat ttgaaactgg acaacatcct tctggatgca 360
gaaggtcact gcaagctggc tgacttcggg atgtgcaagg aagggtattc gaatgggtgtg 420
acgaccacca cgttctgtgg gactcctgac tacatagctc ctgagatcct gcaggagttg 480
```

5	gagtatggcc ggacagcctc gacgtgctgt acgaagaatc aagcagcacc ccacccttca acccgggaag gaggaattca	ccttccgtgga cctttgaggc acccagctctg cccacaagcg cattcttcaa aaccacgcat agccggtact aaggtttctc	ctgggtgggcc cgacaatgag gctcagcaag cctgggctgt agagattgac taaaaccaa cacccttgtg ctactttggt	ctgggggtgc gacgacctat gaggtctgtca gtggcatcgc tgggtgtccc agagacgtca gacgaagcaa gaagacctga	tgatgtacga ttgagtccat gcatcttgaa agaatggcga tggagcagaa ataattttga ttgtaaagca tgccctga	gatgatggct cctccatgac agctttcatg ggacgccatc gaagatcaag ccaagacttt gatcaaccag	540 600 660 720 780 840 900 948
10	<210> 116 <211> 1764 <212> DNA <213> Homo sapiens						
15	<300> <302> PKC iota <310> NM002740						
20	<400> 116 atgtcccaca gcctactacc ctttgcaatg tggatagatg tttagacttt ccagaacgtc cgccgctgga aggcgtgctc aagtgcacac tgtggcgggc tctgaccatg gttggtgaag ggtcttcagg ttgggtcgat gttaatgatg tccaatcatc tttggttatg cttcctgaag catgagcgag ggccacatta accagcactt tatggtttca aggctctcat ctcttccaag gcaagtgttc caaacaggat atggagcaaa gacacacttg attgtgagga atgtctgcag	cggtcgcagg gcggggatat agggttcgaga aggaaggaga atgagctaaa ctgggatgcc gaaagcttta actgtgccat actgcaaaact attcctttgcc cacagacagt aaaaagaggc attttgattt taaaaaaac atgaggatat ctttccttgt agtatgtaaa aactgcacag ggataattta aactcactga tctgtggtac gtgttgactg ttgatattgt ttattttgga tgaagagttt ttgctgatat aacagctggt attctcagtt agattgatca aagaatgtgt	cgggcggcagc catgataaca catgtgttct cccgtgtaca caaggattct ttgtccagga ttgtgccaat ctgcacagac cttggttcat acaggaacca aattccatat aatgaacacc gctccgggta agatcgtatt tgattgggta tggtgctcat tgaggagagc attttactct tagagatttg ctacggcatg tcctaattac gtgggctctt tgggagctcc aaaacaaatt tccttaataag tcaggggacac acctcccttt tactaatgaa gtctgaattt	ggggaccatt cattttgaac tttgacaacg gtatcatctc gaactcttga gaagataaat ggccacactt cgaatatggg aagaagtgcc gtgatgccca agggaagtgt ataggaagag tatgcaatga cagacagaga tcttgctttc ctaattgttt gcagaaatca aaactggaca tgtaagggaag attgtctcctg ggagtgtctt gataacctcg cgcataccac gacctaaagg ccgttcttcc aaaccaattt cctgtccagc gaagggtttt	cccaccaggt cttccatctc agttggagtt ttcatgtgtt ccatctaccg tccaagccaa gacttggacg ataaactcgt tggatcagtc gtcatgagag gcaaagcttc gaagtatatg aagtttgtga agcatgtgtt agacagaaaag atatgcagcg gtctagcatt atgtattact gattacggcc aaatttttaag tgtttgagat accagaacac gttctctgtc aacgattggg gaaatgttga ttctgggga tcactccaga agtatatcaa	ccgggtgaaa ctttgagggc caccatgaaa agaagaagcc cccttgtgta tagaggtgca gcgtttcaac ccaaggatat cacaattgaa atccatgcat tttggatcaa atccagtcta caaagtactg aaaagagctt tgagcaggca cagattgttc acaaagaaaa aaattatctt ggactctgaa aggagatata aggagaagat gatggcagga agaggattat tgtaaaaagct ttgtcatcct ttgggatatg atttggtttg tgacgatgac tcctcttttg	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1764
55	<210> 117 <211> 2451 <212> DNA <213> Homo sapiens						
60	<300> <302> PKC mu <310> XM007234 <400> 117						

	atgtatgata	agatcctgct	ttttcgccat	gaccctacct	ctgaaaaacat	ccttcagctg	60					
	gtgaaagcgg	ccagtgatat	ccaggaaggc	gatcttattg	aagtgggtctt	gtcagcttcc	120					
	gccacctttg	aagactttca	gattcgtccc	cacgctctct	ttgttcattc	atacagagct	180					
5	ccagctttct	gtgatcactg	tggagaaatg	ctgtgggggc	tggtacgtca	aggtcttaaa	240					
	tgtgaagggt	gtggtctgaa	ttaccataag	agatgtgcat	ttaaaatacc	caacaattgc	300					
	agcgggtgga	ggcggagaag	gctctcaaac	gtttccctca	ctggggtcag	caccatccgc	360					
	acatcatctg	ctgaactctc	tacaagtgcc	cctgatgagc	cccttctgca	aaaatcacca	420					
	tcagagtctg	ttattggctg	agagaagagg	tcaaattctc	aatcatacat	tggacgacca	480					
10	attcaccttg	acaagattht	gatgtctaaa	gttaaagtgc	cgcacacatt	tgtcatccac	540					
	tcctacaccc	ggcccacagt	gtgccagtac	tgcaagaagc	ttctgaaggg	gcttttcagg	600					
	cagggcttgc	agtgcacaaga	ttgcagattc	aactgccata	aacgttgtgc	accgaaagta	660					
	ccaaaacaact	gccttggcga	agtgaaccatt	aatggagatt	tgcttagccc	tggggcagag	720					
	tctgatgtgg	tcatggaaga	agggagtgat	gacaatgata	gtgaaaggaa	cagtgggctc	780					
	atggatgata	tggagaagac	aatggtccaa	gatgcagaga	tggcaatggc	agagtgccag	840					
15	aacgacagtg	gcgagatgca	agatccagac	ccagaccacg	aggacgcaa	cagaaccatc	900					
	agtcacatcaa	caagcaacaa	tatcccactc	atgagggtag	tgcagtctgt	caaacacacg	960					
	aagaggaaaa	gcagcacagt	catgaaagaa	ggatggatgg	tccactacac	cagcaaggac	1020					
	acgctgcgga	aacggcacta	ttggagattg	gatagcaaat	gtattaccct	ctttcagaat	1080					
	gacacaggaa	gcagggtacta	caaggaaatt	cctttatctg	aaatthttgtc	tctggaacca	1140					
20	gtaaaaactt	cagctthtaat	tcctaattggg	gccaatcctc	attgtttcga	aatcactacg	1200					
	gcaaatgtag	tgtattatgt	gggagaaaa	gtggtcaatc	cttcacagcc	atcaccaaat	1260					
	aacagtgttc	tcaccagtgg	cgttgggtgca	gatgtggcca	ggatgtggga	gatagccatc	1320					
	cagcatgccc	ttatgcccg	cattcccaag	ggctcctccg	tgggtacagg	aaccaacttg	1380					
	cacagagata	tctctgtgag	tatttcagta	tcaaattgcc	agattcaaga	aaatgtggac	1440					
25	atcagcacag	tatatcagat	ttttcctgat	gaagtactgg	gttctggaca	gtttggaatt	1500					
	gtttatggag	gaaaacatcg	taaaacagga	agagatgtag	ctattaaaat	cattgacaaa	1560					
	ttacgatttc	caacaaaaa	agaaagccag	cttcgtaatg	aggttgcaat	tctacagaac	1620					
	cttcacacc	ctggtgttgt	aaatttgag	tgtatgtttg	agacgcctga	aagagtgttt	1680					
	gttggttatg	aaaaactcca	tggagacatg	ctggaaatga	tcttgtcaag	tgaaaagggc	1740					
30	aggttgccag	agcacataac	gaagthttta	attactcaga	tactcgtggc	tttgcggcac	1800					
	cttcattthta	aaaatatcgt	tcactgtgac	ctcaaaccag	aaaatgtgtt	gctagcctca	1860					
	gctgacccct	ttcctcaggt	gaaactthttg	gattthgggt	ttgcccggt	cattggagag	1920					
	aagtctthtc	ggagggtcagt	ggtgggtacc	cccgttacc	tggctcctga	ggtcctaagg	1980					
	aacaagggct	acaatcgctc	tctagacatg	tggctctgtt	gggtcatcat	ctatgtaagc	2040					
35	ctaagcggca	cattcccatt	taatgaagat	gaagacatac	acgaccaa	tcagaatgca	2100					
	gctthcatgt	atccaccaa	tccttggaag	gaaatattctc	atgaagccat	tgatcttata	2160					
	aacaattthtc	tgcaagtaaa	aatgagaaa	cgctacagt	tggataagac	cttgagccac	2220					
	ccttggtctac	aggactatca	gacctgggtta	gattthcgag	agctggaatg	caaaatcggg	2280					
	gagcgctaca	tcacccatga	aagtgatgac	ctgaggtggg	agaagtatgc	aggcgagcag	2340					
40	gggctgcagt	acccacaca	cctgatcaat	ccaagtgtca	gccacagtga	cactcctgag	2400					
	actgaagaaa	cagaaatgaa	agccctcggt	gagcgtgtca	gcacccatg	a	2451					
	<210>	118										
45	<211>	2673										
	<212>	DNA										
	<213>	Homo sapiens										
	<300>											
50	<302>	PKC nu										
	<310>	NM005813										
	<400>	118										
	atgtctgcaa	ataattcccc	tccatcagcc	cagaagtctg	tattaccac	agctattcct	60					
55	gctgtgcttc	cagctgcttc	tccgtgttc	agtcctaaga	cgggactctc	tgcccagctc	120					
	tctaattgaa	gcttcagtgc	accatcactc	accaactcca	gaggctcagt	gcatacagtt	180					
	tcattttctac	tgcaaatthg	cctcacacgg	gagagtgtta	ccattgaagc	ccaggaactg	240					
	tctttatctg	ctgtcaagga	tcttgtgtgc	tccatagtht	atcaaaagtt	tccagagtgt	300					
	ggattcttht	gcatgtatga	caaaattctt	ctctthtcg	atgacatgaa	ctcagaaaa	360					
60	attthtcagc	tgattacctc	agcagatgaa	atacatgaag	gagacctagt	ggaagtgtgt	420					
	ctthtcagct	tagccacagt	agaagacttc	cagattcgtc	cacatactct	ctatgtacat	480					
	tcttacaaag	ctcctactth	ctgtgattac	tgtgggtgaga	tgctgtgggg	attgggtacgt	540					

	caaggactga	aatgtgaagg	ctgtggatta	aattaccata	aacgatgtgc	cttcaagatt	600
	ccaaataact	gtagtggagt	aagaaagaga	cgtctgtcaa	atgtatcttt	accaggaccc	660
	ggcctctcag	ttccaagacc	cctacagcct	gaatatgtag	cccttcccag	tgaagagtca	720
5	catgtccacc	aggaaccaag	taagagaatt	ccttcttgga	gtggtcgccc	aatctggatg	780
	gaaaagatgg	taatgtgcag	agtgaagtt	ccacacacat	ttgctgttca	ctcttacacc	840
	cgtcccacga	tatgtcagta	ctgcaagcgg	ttactgaaag	gcctctttcg	ccaaggaatg	900
	cagtgtaaag	attgcaaatt	caactgccat	aaacgctgtg	catcaaaagt	accaagagac	960
	tgccttggag	aggttacttt	caatggagaa	ccttccagtc	tgggaacaga	tacagatata	1020
10	ccaatggata	ttgacaataa	tgacataaat	agtgatagta	gtcggggttt	ggatgacaca	1080
	gaagagccat	cacccccaga	agataagatg	ttcttcttgg	atccatctga	tctcgatgtg	1140
	gaaagagatg	aagaagccgt	taaaacaatc	agtcctcaa	caagcaataa	tattccgcta	1200
	atgaggggtg	tacaatccat	caagcacaca	aagaggaaga	gcagcacaat	ggtgaaggaa	1260
	gggtggatgg	tccattacac	cagcagggat	aacctgagaa	agaggcatta	ttggagactt	1320
	gacagcaaat	gtctaacatt	atttcagaat	gaatctggat	caaagtatta	taaggaaatt	1380
15	ccactttcag	aaattctccg	catatcttca	ccacgagatt	tcacaaacat	ttcacaaggc	1440
	agcaatccac	actgttttga	aatcattact	gatactatgg	tatacttcgt	tggtgagaac	1500
	aatggggaca	gctctcataa	tcctgttctt	gctgccactg	gagttggact	tgatgtagca	1560
	cagagctggg	aaaaagcaat	tcgccaaagc	ctcatgcctg	ttactcctca	agcaagtgtt	1620
	tgcactttctc	caggggcaagg	gaaagatcac	aaagatttgt	ctacaagtat	ctctgtatct	1680
20	aattgtcaga	ttcaggagaa	tgtggatatc	agtactgttt	accagatctt	tgcagatgag	1740
	gtgcttgggt	caggccagtt	tggcatcggt	tatggaggaa	aacatagaaa	gactgggagg	1800
	gatgtggcta	ttaaagtaat	tgataagatg	agattcccca	caaaacaaga	aagtcaactc	1860
	cgtaatgaag	tggctatttt	acagaatttg	caccatcctg	ggattgtaaa	cctggaatgt	1920
25	atgtttgaaa	ccccagaacg	agtctttgta	gtaatggaaa	agctgcatgg	agatatgttg	1980
	gaaatgattc	tatccagtga	gaaaagtcgg	cttcagaaac	gaattactaa	attcatggtc	2040
	acacagatac	ttgttgcttt	gaggaatctg	cattttaaga	atattgtgca	ctgtgattta	2100
	aagccagaaa	atgtgctgct	tgcacagca	gagccatttc	ctcaggtgaa	gctgtgtgac	2160
	tttggatttg	cacgcatcat	tggtgaaaag	tcattcagga	gatctgtggt	aggaactcca	2220
30	gcatacttag	cccctgaagt	tctccggagc	aaaggttaca	accgttccct	agatatgtgg	2280
	tcagtgggag	ttatcatcta	tgtgagcctc	agtggcacat	ttccttttaa	tgaggatgaa	2340
	gatataaatg	accaaatcca	aaatgctgca	tttatgtacc	caccaaatac	atggagagaa	2400
	atttctgggt	aagcaattga	tctgataaac	aatctgcttc	aagtgaagat	gagaaaacgt	2460
	tacagtgttg	acaaatctct	tagtcatccc	tggctacagg	actatcagac	ttggcttgac	2520
35	cttagagaat	ttgaaactcg	cattggagaa	cgttacatta	cacatgaaag	tgatgatgct	2580
	cgctgggaaa	tacatgcata	cacacataac	cttgataacc	caaagcactt	cattatggct	2640
	cctaataccag	atgatattgga	agaagatcct	taa			2673
40	<210>	119					
	<211>	2121					
	<212>	DNA					
	<213>	Homo sapiens					
45	<300>						
	<302>	PKC tau					
	<310>	NM006257					
	<400>	119					
50	atgtcgccat	ttcttcggat	tggcttgtcc	aactttgact	gcgggtcctg	ccagtcttgt	60
	cagggcgagg	ctgttaaccc	ttactgtgct	gtgctcgtca	aagagtatgt	cgaatcagag	120
	aacgggcaga	tgtatatcca	gaaaagcct	accatgtacc	caccctggga	cagcactttt	180
	gatgcccata	tcaacaaggg	aagagtcatg	cagatcattg	tgaaggcaa	aaacgtggac	240
	ctcatctctg	aaaccaccgt	ggagctctac	tcgctggctg	agaggtgcag	gaagaacaac	300
	gggaagacag	aaatatgggt	agagctgaaa	cctcaaggcc	gaatgctaata	gaatgcaaga	360
55	tactttcttg	aaatgagtga	cacaaaggac	atgaatgaat	ttgagacgga	aggcttcttt	420
	gctttgcata	agcgccgggg	tgccatcaag	caggcaaaag	tccaccacgt	caagtgccac	480
	gagttcactg	ccaccttctt	cccacagccc	acattttgct	ctgtctgcca	cgagtttgtc	540
	tggggcctga	acaaacaggg	ctaccagtgc	cgacaatgca	atgcagcaat	tcacaagaag	600
	tgtattgata	aagttatagc	aaagtgcaca	ggatcagcta	tcaatagccg	agaaacctag	660
60	ttccacaagg	agagattcaa	aattgacatg	ccacacagat	ttaaagtcta	caattacaag	720
	agcccagcct	tctgttaaca	ctgtgggacc	ctgctgtggg	gactggcacg	gcaaggactc	780
	aagtgtgatg	catgtggcat	gaatgtgcat	catagatqcc	agacaaaggt	ggccaacctt	840

```

5   tgtggcataa accagaagct aatggctgaa gcgctggcca tgattgagag cactcaacag 900
    gctcgctgct taagagatac tgaacagatc ttcagagaag gtccggttga aattggtctc 960
    ccatgctcca tcaaaaatga agcaaggccg ccatgtttac cgacaccggg aaaaagagag 1020
    cctcagggca tttcctggga gtctccgttg gatgaggttg ataaaaatgtg ccatcttcca 1080
10  gaacctgaac tgaacaaaga aagaccatct ctgcagatta aactaaaaat tgaggatttt 1140
    atcttgcaac aaatgttggg gaaaggaagt tttggcaagg tcttcctggc agaattcaag 1200
    aaaaccaatc aatttttcgc aataaaggcc ttaaagaaaag atgtggtcct gatggacgat 1260
    gatgttgagt gcacgatggg agagaagaga gttctttcct tggcctggga gcatccgttt 1320
    ctgacgcaca tgttttgtac attccagacc aaggaaaacc tcttttttgt gatggagtac 1380
15  ctcaacggag gggacttaat gtaccacatc caaagctgcc acaagttcga cctttccaga 1440
    gcgacgtttt atgctgctga aatcattctt ggtctgcagt tccttcattc caaaggaata 1500
    gtctacaggg acctgaagct agataacatc ctgttagaca aagatggaca tatcaagatc 1560
    gcggattttt gaatgtgcaa ggagaacatg ttaggagatg ccaagacgaa taccttctgt 1620
    gggacacctg actacatcgc cccagagatc ttgctgggtc agaaatacaa ccactctgtg 1680
20  gactggtggt ccttcggggg tctcctttat gaaatgctga ttggtcagtc gcctttccac 1740
    gggcaggatg aggaggagct cttccactcc atccgcattg acaatccctt ttaccacagg 1800
    tggctggaga aggaagcaaa ggaccttctg gtgaagctct tcgtgcgaga acctgagaag 1860
    aggctgggag tgaggggaga catccgccag caccctttgt ttcgggagat caactgggag 1920
    gaacttgaac ggaaggagat tgaccacccg ttccggccga aagtgaaatc accatttgac 1980
    tgcagcaatt tcgacaaaga attcttaaac gagaagcccc ggctgtcatt tgccgacaga 2040
    gcactgatca acagcatgga ccagaatatg ttcaggaact tttccttcat gaaccccgag 2100
    atggagcggc tgatatcctg a                                     2121

25  <210> 120
    <211> 1779
    <212> DNA
    <213> Homo sapiens

30  <300>
    <302> PKC zeta
    <310> NM2744

```

```

    atggaccggg agatggcagc atcgtgcgga ggcgcgggtt tcgtaggtct gatactcttg 60
    accttgtcac cgcactataa gctgttcctc gctaggctca tatggtggtt acaatatatt 120
    atcaccaggg ccgaggcaca cttgcaagtg tggatcccc ccctcaacgt tcggggggggc 180
    cgcgatgccg tcatcctcct cactgctcgc atccaccag agctaattct taccatcacc 240
5   aaaatcttgc tcgccatact cggctccactc atggtgctcc aggctggtat aaccaaagtg 300
    ccgtacttcg tgcgcgcaca cgggctcatt cgtgcatgca tgctggtgcg gaagggtgct 360
    ggggggtcatt atgtccaaat ggctctcatg aagttggccg cactgacagg tacgtacgtt 420
    tatgaccate tcacccact gcgggactgg gccacgcgg gcctacgaga ccttgccgtg 480
    gcagttgagc ccgtcgtctt ctctgatatg gagaccaagg ttatcacctg gggggcagac 540
10  accgcggcgt gtggggacat catcttgggc ctgccgtct ccgccgcag ggggagggag 600
    atacatctgg gaccggcaga cagccttgaa gggcaggggt ggcgactcct c 651

    <210> 129
15  <211> 161
    <212> DNA
    <213> Hepatitis C virus

    <300>
20  <302> NS4A
    <310> AJ238799

    <400> 129
25  gcacctgggt gctggtaggc ggagtcctag cagctctggc cgcgatttgc ctgacaacag 60
    gcagcgtggg cattgtgggc aggatcatct tgtccggaaa gccggccatc attcccagaca 120
    gggaaagtct ttaccgggag ttcgatgaga tggaagagtg c 161

    <210> 130
30  <211> 783
    <212> DNA
    <213> Hepatitis C virus

    <300>
35  <302> NS4B
    <310> AJ238799

    <400> 130
40  gcctcacacc tcccttacat cgaacaggga atgcagctcg ccgaacaatt caaacagaag 60
    gcaatcgggt tgctgcaaac agccaccaag caagcggagg ctgctgctcc cgtgggtggaa 120
    tccaagtggc ggaccctcga agccttctgg gcgaagcata tgtggaattt catcagcggg 180
    atacaatatt tagcaggctt gtccactctg cctggcaacc ccgcgatagc atcactgatg 240
    gcattcacag cctctatcac cagcccgtc accaccaac ataccctcct gtttaacatc 300
    ctggggggat ggggtggccgc ccaacttgct cctcccagcg ctgcttctgc tttcgtaggc 360
45  gccggcatcg ctggagcggc tgttggcagc ataggccttg ggaaggtgct tgtggatatt 420
    ttggcagggt atggagcagg ggtggcaggc gcgctcgtgg cctttaaggt catgagcggc 480
    gagatgccct ccaccgagga cctggttaac ctactccctg ctatcctctc ccctggcgcc 540
    ctagtctctg gggctcgtgtg cgcagcgata ctgcgtcggc acgtgggccc aggggagggg 600
    gctgtgcagt ggatgaaccg gctgatagcg ttcgcttcgc ggggtaacca cgtctcccc 660
50  acgcactatg tgccctgagag cgacgtgca gcacgtgtca ctcagatcct ctctagtctt 720
    accatcactc agctgctgaa gaggcttcac cagtggatca acgaggactg ctccacgcca 780
    tgc 783

    <210> 131
55  <211> 1341
    <212> DNA
    <213> Hepatitis C virus

    <300>
60  <302> NS5A
    <310> AJ238799

```

<400> 131
 tccggctcgt ggctaagaga tgtttgggat tggatatgca cgggtgttgac tgatttcaag 60
 5 acctggctcc agtccaagct cctgccgcga ttgccgggag tcccccttctt ctcatgtcaa 120
 cgtgggtaca agggagctctg gcggggcgac ggcacatgc aaaccacctg cccatgtgga 180
 gcacagatca ccggacatgt gaaaaacggg tccatgagga tcgtggggcc taggacctgt 240
 agtaacacgt ggcatggaac attccccatt aacgcgtaca ccacggggccc ctgcacgccc 300
 tccccggcgc caaattattc tagggcgctg tggcgggtgg ctgctgagga gtacgtggag 360
 10 gttacgcggg tgggggattt ccactacgtg acgggcatga ccactgacaa cgtaaagtgc 420
 ccgtgtcagg ttccggcccc cgaattcttc acagaagtgg atgggggtgcg gttgcacagg 480
 tacgctccag cgtgcaaacc cctcctacgg gaggaggtca cattcctggt cgggctcaat 540
 caatacctgg ttgggtcaca gctcccatgc gagcccgaa cggacgtagc agtgctcact 600
 tccatgctca ccgacccctc ccacattacg gcggagacgg ctaagcgtag gctggccagg 660
 15 ggatctcccc cctccttggc cagctcatca gctagccagc tgtctgcgcc ttccctgaag 720
 gcaacatgca ctaccctgca tgactccccg gacgctgacc tcatcgaggc caacctcctg 780
 tggcggcagg agatgggcgg gaacatcacc cgcgtggagt cagaaaataa ggtagtaatt 840
 ttggactctt tcgagccgct ccaagcggag gaggatgaga gggaagtatc cgttccggcg 900
 gagatcctgc ggaggtccag gaaattccct cgagcgatgc ccatatgggc acgcccggat 960
 20 tacaaccctc cactgttaga gtccctggaag gacccggact acgtccctcc agtggtacac 1020
 ggggtgtccat tgccgcctgc caaggccccct ccgataccac ctccacggag gaaggaggacg 1080
 gttgtcctgt cagaatctac cgtgtcttct gccttggcgg agctcgccac aaagaccttc 1140
 ggcagctccg aatcgtcggc cgtcgacagc ggcacggcaa cggcctctcc tgaccagccc 1200
 tccgacgacg gcgacgcggg atccgacggt gagtcgtact cctccatgcc ccccttgag 1260
 25 ggggagccgg gggatcccga tctcagcgac ggggtcttgg ctaccgtaag cgaggaggct 1320
 agtgaggacg tcgtctgctg c 1341

<210> 132
 <211> 1772
 30 <212> DNA
 <213> Hepatitis C virus

<300>
 <302> NS5B
 35 <310> AJ238799

<400> 132
 tcgatgtcct acacatggac agggcgcctg atcacgccat gcgctgcgga ggaaaccaag 60
 40 ctgcccacat atgcactgag caactctttg ctccgtcacc acaacttgggt ctatgtctaca 120
 acatctcgcga gcgcaagcct gcggcagaag aaggtcacct ttgacagact gcaggctcctg 180
 gacgacctact accgggacgt gctcaaggag atgaaggcga aggcgtccac agttaaggct 240
 aaacttctat ccgtggagga agcctgtaag ctgacgcccc cacattcggc cagatctaaa 300
 tttggctatg gggcaaagga cgtccggaac ctatccagca aggcgttaa ccacatccgc 360
 45 tccgtgtgga aggacttgct ggaagacact gagacaccaa ttgacaccac catcatggca 420
 aaaaatgagg ttttctgcgt ccaaccagag aagggggggc gcaagccagc tcgccttatc 480
 gtattcccag atttgggggt tcgtgtgtgc gagaaaatgg ccctttacga tgtggtctcc 540
 accctccctc aggcctgat gggctcttca tacggattcc aatactctcc tggacagcgg 600
 gtcgagttcc tgggtgaatgc ctggaaagcg aagaaatgcc ctatgggctt cgcatatgac 660
 50 acccgtgtt ttgactcaac ggtcactgag aatgacatcc gtgttgagga gtcaatctac 720
 caatgtttgtg acttggcccc cgaagccaga caggccataa ggtcgctcac agagcggctt 780
 tacatcgggg gcccccctgac taattctaaa gggcagaact gcggctatcg ccggtgcgcg 840
 gcgagcgggt tactgacgac cagctgcggt aataccctca catgttactt gaaggccgct 900
 gcggcctgtc gagctgcgaa gctccaggac tgcacgatgc tcgtatgcgg agacgacctt 960
 55 gtcgttatct gtgaaagcgc ggggacccaa gaggacgagg cgagcctacg ggccttcacg 1020
 gaggctatga ctagatactc tgccccccct ggggacccgc ccaaaccaga atacgacttg 1080
 gagttgataa catcatgctc tcccaatgtg tcagtgcgc acgatgcac tggcaaaagg 1140
 gtgtactatc tcaccctgta ccccaccacc ccccttgcgc gggctgcgtg ggagacagct 1200
 agacacactc cagtcaattc ctggctaggc aacatcatca tgtatgcgcc caccttgttg 1260
 60 gcaaggatga tcctgatgac tcatttcttc tccatccttc tagctcagga acaacttgaa 1320
 aaagccctag attgtcagat ctacggggcc tggtactcca ttgagccact tgacctacct 1380
 cagatcattc aacgactcca tggccttagc gcattttcac tccatagtta ctctccaggt 1440
 gagatcaata ggggtggcttc atgcctcagg aaacttgggg taccgccctt gcgagctcgg 1500

agacatcggg ccagaagtgt ccgcgctagg ctactgtccc aggggggggag ggctgccact 1560
 tgtggcaagt acctcttcaa ctgggcagta aggaccaagc tcaaactcac tccaatcccc 1620
 gctgcgtccc agttggattt atccagctgg ttctgttctg gttacagcgg gggagacata 1680
 tatcacagcc tgtctcgtgc ccgacccccg tggttcatgt ggtgcctact cctactttct 1740
 5 gtaggggtag gcactctatc actccccaac cg 1772

<210> 133
 <211> 1892
 10 <212> DNA
 <213> Hepatitis C virus

<300>
 <302> NS3
 15 <310> AJ238799

<400> 133
 cgcctattac ggccactacc caacagacgc gaggcctact tggttgcac atcactagcc 60
 tcacaggccg ggacaggaac caggctcgagg gggagggtcca agtggtctcc accgcaacac 120
 20 aatcttttctt ggcgacctgc gtcaatggcg tgtgttgagc tgtctatcat ggtgccggct 180
 caaagacctt tgccggccca aaggggccaa tcacccaaat gtacaccaat gtggaccagg 240
 acctcgctcg ctggcaagcg cccccgggg cgcttcctt gacaccatgc acctgccgca 300
 gctcggacct ttacttggtc acgaggcatg ccgatgtcat tccggtgcgc cggcggggcg 360
 acagcagggg gagcctactc tccccaggc ccgtctccta cttgaagggc tcttcggggc 420
 25 gtccactgct ctgcccctcg gggcacgctg tgggcatctt tccgggtgcc gtgtgcaccc 480
 gaggggttgc gaaggcgggt gactttgtac ccgtcgagtc tatggaaacc actatgcggt 540
 ccccggtctt caccgacaac tcgtcccctc cggccgtacc gcagacattc cagggtggccc 600
 atctacacgc ccctactggt agcggcaaga gcactaaggt gccggctgcg tatgcagccc 660
 aagggtataa ggtgcttctc ctgaacccgt ccgtcgccgc caccctaggt ttcggggcgt 720
 30 atatgtctaa ggcacatggt atcgacccta acatcagaac cggggttaagg accatcacca 780
 cgggtgcccc catcacgtac tccacctatg gcaagtttct tgccgacggt ggttgcctctg 840
 ggggcgccta tgacatcata atatgtgatg agtgccactc aactgactcg accactatcc 900
 tgggcatcgg cacagtcctg gaccaagcgg agacggctgg agcgcgactc gtcgtgctcg 960
 ccaccgctac gcctccggga tcggtcaccg tgccacatcc aaacatcgag gaggtggctc 1020
 35 tgtccagcac tggagaaatc cccttttatg gcaaagccat ccccatcgag accatcaagg 1080
 gggggaggca cctcattttc tgccattcca agaagaaatg tgatgagctc gccgcgaagc 1140
 tgtccggcct cggactcaat gctgtagcat attaccgggg ccttgatgta tccgtcatac 1200
 caactagcgg agacgtcatt gtcgtagcaa cggacgctct aatgacgggc tttaccggcg 1260
 atttcgactc agtgatcgac tgcaatacat gtgtcaccca gacagtcgac ttcagcctgg 1320
 40 acccgacctt caccattgag acgacgaccg tgccacaaga cgcgggtgtca cgtctcgagc 1380
 ggcgaggcag gatggttagg ggcaggatgg gcatttacag gtttgtgact ccaggagaac 1440
 ggccctcggg catgttcgat tcctcggttc ctatgcagcg ggtgtgctt 1500
 ggtacgagct cagccccgcc gagacctcag ttaggttgcg ggcttaccta aacacaccag 1560
 ggttgcccgt ctgccaggac catctggagt tctgggagag cgtctttaca ggctcacc 1620
 45 acatagacgc ccatttcttg tcccagacta agcaggcagg agacaacttc ccctacctgg 1680
 tagcatacca ggctacggtg tgcgccaggg ctcaggctcc acctccatcg tgggaccaa 1740
 tgtggaagtg tctcatacgg ctaaagccta cgctgcacgg gccaacgccc ctgctgtata 1800
 ggctgggagc cgttcaaaac gaggttacta ccacacaccc cataaccaa tacatcatgg 1860
 50 catgcatgtc ggctgacctg gaggtcgtca cg 1892

<210> 134
 <211> 822
 <212> DNA
 55 <213> Homo sapiens

<300>
 <302> stmn cell factor
 <310> M59964

60 <400> 134
 atgaagaaga cacaacttg gattctcact tgcatttatc ttcagctgct cctattta 60

cctctcgtca aaactgaagg gatctgcagg aatcgtgtga ctaataatgt aaaagacgtc 120
 actaaattgg tggcaaattct tccaaaagac tacatgataa ccctcaaata tgtccccggg 180
 atggatgttt tgccaagtca ttgttggata agcgagatgg tagtacaatt gtcagacagc 240
 ttgactgata ttctggacaa gttttcaaat atttctgaag gcttgagtaa ttattccatc 300
 5 atagacaaac ttgtgaatat agtcgatgac cttgtggagt gcgtcaaaga aaactcatct 360
 aaggatctaa aaaaatcatt caagagccca gaaccaggc tctttactcc tgaagaattc 420
 tttagaattt ttaatagatc cattgatgcc ttcaaggact ttgtagtggc atctgaaact 480
 agtgattgtg tggtttcttc aacattaagt cctgagaaag attccagagt cagtgtcaca 540
 aaaccattta tgttaccccc tgttgcagcc agctccctta ggaatgacag cagttagcagt 600
 10 aataggaagg ccaaaaatcc ccctggagac tccagcctac actgggcagc catggcattg 660
 ccagcattgt tttctcttat aattggcttt gcttttggag ccttatactg gaagaagaga 720
 cagccaagtc ttacaagggc agttgaaaat atacaaatta atgaagagga taatgagata 780
 agtatgttgc aagagaaaga gagagagttt caagaagtgt aa 822

15
 <210> 135
 <211> 483
 <212> DNA
 <213> Homo sapiens

20
 <300>
 <302> TGFalpha
 <310> AF123238

25
 <400> 135
 atggtccccct cggtcggaca gctcgccttg ttcgctctgg gtatttgtgt ggctgcgtgc 60
 caggccttgg agaacagcac gtccccgctg agtcagacc cgcccggtgc tgcagcagtg 120
 gtgtcccat ttaatgactg ccagattcc cacactcagt tctgcttcca tggaaacctgc 180
 aggttttttg tgcaggagga caagccagca tgtgtctgcc attctgggta cgttgggtgca 240
 30 cgctgtgagc atgcccagct cctggccgtg gtggtgcca gccagaagaa gcaggccatc 300
 accgccttgg tgggtggtctc catcgtggcc ctggtgtgcc ttatcatcac atgtgtgctg 360
 atactactgt gccaggtccg aaaacactgt gagggtgcc gggccctcat ctgccggcac 420
 gagaagccca gcgccctcct gaagggaaga accgcttgct gccactcaga aacagtggtc 480
 tga 483

35
 <210> 136
 <211> 1071
 <212> DNA
 40 <213> Homo sapiens

<300>
 <302> GD3 synthase
 <310> NM003034

45
 <400> 136
 atgagccccct gcgggcgggc ccggcgacaa acgtccagag gggccatggc tgtactggcg 60
 tggaaagtcc cgcggaacct gctgcccatt ggagccagtg ccctctgtgt cgtggctctc 120
 50 tgttggtctc acatcttccc cgtctaccgg ctgcccacag agaaagagat cgtgcagggg 180
 gtgctgcaac agggcacggc gtggaggagg aaccagaccg cgccagagc gttcaggaaa 240
 caaatggaag actgctgcga ccctgcccct ctctttgcta tgactaaaat gaattcccct 300
 atggggaaga gcatgtggtg tgacggggag tttttatact cattcaccat tgacaattca 360
 acttactctc tcttcccaca ggcaacccca ttccagctgc cattgaagaa atgcgcggtg 420
 gtgggaaatg gtgggattct gaagaagagt ggctgtggcc gtcaaataga tgaagcaaat 480
 55 tttgtcatgc gatgcaatct ccctcctttg tcaagtgaat aactaagga tgttgatcc 540
 aaaagtcagt tagtgacagc taatcccagc ataattcggc aaaggtttca gaaccttctg 600
 tggctccagaa agacatttgt ggacaacatg aaaaatctata accacagtta catctacatg 660
 cctgcctttt ctatgaagac aggaacagag ccatctttga gggtttatta tacactgtca 720
 gatgttggtg ccaatcaaac agtgctgttt gccaacccca actttctgcg tagcattgga 780
 60 aagttctgga aaagtagagg aatccatgcc aagcgcctgt ccacaggact ttttctggtg 840
 agcgcagctc tgggtctctg tgaagaggtg gccatctatg gcttctggcc cttctctgtg 900
 aatatgcatg agcagcccat cagccaccac tactatgaca acgtcttacc cttttctggc 960

ttccatgccca tgcccaggga atttctccaa ctctgggtatc ttcataaaat cgggtgcactg 1020
agaatgcagc tggaccccatg tgaagatacc tcactccagc ccacttccta g 1071

5 <210> 137
<211> 744
<212> DNA
<213> Homo sapiens

10 <300>
<302> FGF14
<310> NM004115

<400> 137
15 atggccgcgg ccatcgctag cggcttgatc cgccagaagc ggcaggcgcg ggagcagcac 60
tgggaccggc cgtctgccag caggaggcgg agcagcccca gcaagaaccg cgggctctgc 120
aacggcaacc tgggtggatat cttctccaaa gtgcgcatct tcggcctcaa gaagcgcagg 180
ttgcggcgcc aagatcccca gctcaagggt atagtgacca gggtatattg caggcaaggc 240
tactacttgc aaatgcaccc cgatggagct ctcgatggaa ccaaggatga cagcactaat 300
20 tctacactct tcaacctcat accagtggga ctacgtgttg ttgccatcca gggagtga aa 360
acagggttgt atatagccat gaatggagaa gggtacctct acccatcaga actttttacc 420
cctgaatgca agtttaaaaga atctgttttt gaaaattatt atgtaatcta ctcatccatg 480
ttgtacagac aacaggaatc tggtagagcc tggtttttgg gattaaataa ggaagggcaa 540
gctatgaaag ggaacagagt aaagaaaacc aaaccagcag ctcattttct acccaagcca 600
25 ttggaagttg ccatgtaccg agaaccatct ttgcatgatg ttggggaaac ggtcccgaag 660
cctgggggtga cgccaagtaa aagcacaagt gcgtctgcaa taatgaatgg aggcaaacca 720
gtcaacaaga gtaagacaac atag 744

30 <210> 138
<211> 1503
<212> DNA

zur YFP- bzw. GFP-Sequenz ist

	<400> 150	
5	ccacaugaag cagcacgacu u	21
	<210> 151	
	<211> 21	
	<212> RNA	
10	<213> Künstliche Sequenz	
	<220>	
15	<223> Beschreibung der künstlichen Sequenz: antisense-Strang (S7B) einer dsRNA, die komplementär zur YFP- bzw. GFP-Sequenz ist	
	<400> 151	
	gucgugcugc uucauguggu c	21
20	<210> 152	
	<211> 24	
	<212> RNA	
25	<213> Künstliche Sequenz	
	<220>	
30	<223> Beschreibung der künstlichen Sequenz: antisense-Strang (R2B) einer dsRNA, die komplementär zur MDR-1-Sequenz ist	
	<400> 152	
	uacagcaagc cuggaaccua uagc	24
35	<210> 153	
	<211> 22	
	<212> RNA	
	<213> Künstliche Sequenz	
40	<220>	
	<223> Beschreibung der künstlichen Sequenz: sense-Strang (K1A) einer dsRNA, die homolog zur 5'-UTR der Neomycin-Sequenz ist	
45	<400> 153	
	acaggaugag gaucguuucg ca	22
50	<210> 154	
	<211> 22	
	<212> RNA	
	<213> Künstliche Sequenz	
55	<220>	
	<223> Beschreibung der künstlichen Sequenz: antisense-Strang (K1B) einer dsRNA, die komplementär zur 5'-UTR der Neomycin-Sequenz ist	
60	<400> 154	
	ugcgaaacga uccucauccu gu	22

5 <210> 155
<211> 21
<212> RNA
<213> Künstliche Sequenz

10 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(K3A) einer dsRNA, die homolog zur 5'-UTR der
Neomycin-Sequenz ist

15 <400> 155
gaugaggauc guuucgcaug a 21

20 <210> 156
<211> 21
<212> RNA
<213> Künstliche Sequenz

25 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (K3B) einer dsRNA, die
komplementär zur 5'-UTR der Neomycin-Sequenz ist

30 <400> 156
augcgaaacg auccucaucc u 21

35 <210> 157
<211> 24
<212> RNA
<213> Künstliche Sequenz

40 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(K2A) einer dsRNA, die homolog zur 5'-UTR der
Neomycin-Sequenz ist

45 <400> 157
acaggaugag gaucguuucg caug 24

50 <210> 158
<211> 24
<212> RNA
<213> Künstliche Sequenz

55 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (K2B) einer dsRNA, die
komplementär zur 5'-UTR der Neomycin-Sequenz ist

60 <400> 158
ugcgaaacga uccucauccu gucu 24

<210> 159
<211> 24
<212> RNA
<213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (S4B) einer dsRNA, die
komplementär zur YFP-bzw. GFP-Sequenz ist

5 <400> 159
gaagucgugc ugcuucaugu gguc 24

<210> 160
10 <211> 24
<212> RNA
<213> Künstliche Sequenz

<220>
15 <223> Beschreibung der künstlichen Sequenz: sense-Strang
(PKC1 A) einer dsRNA, die homolog zur
Proteinkinase C-Sequenz ist

<400> 160
20 cuucuccgcc ucacaccgcu gcaa 24

<210> 161
<211> 22
25 <212> RNA
<213> Künstliche Sequenz

<220>
30 <223> Beschreibung der künstlichen Sequenz:
antisense-Strang (PKC2 B) einer dsRNA, die
komplementär zur Proteinkinase C-Sequenz ist

<400> 161
35 gcagcggugu gaggcggaga ag 22

<210> 162
<211> 21
40 <212> RNA
<213> Künstliche Sequenz

<220>
45 <223> Beschreibung der künstlichen Sequenz:
antisense-Strang (S12B) einer dsRNA, die
komplementär zur YFP- bzw. GFP-Sequenz ist

<400> 162
aagucgugcu gcuucaugug g 21

50 <210> 163
<211> 23
<212> RNA
<213> Künstliche Sequenz

55 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (S11B) einer dsRNA, die
komplementär zur YFP- bzw. GFP-Sequenz ist

60 <400> 163
aagucgugcu gcuucaugug guc 23

```

5      <210> 164
      <211> 20
      <212> RNA
      <213> Künstliche Sequenz

      <220>
      <223> Beschreibung der künstlichen Sequenz: sense-Strang
10      (S13A) einer dsRNA, die homolog zur YFP- bzw.
      GFP-Sequenz ist

      <400> 164
15      ccacaugaag cagcacgacu                                20

      <210> 165
      <211> 22
      <212> RNA
20      <213> Künstliche Sequenz

      <220>
      <223> Beschreibung der künstlichen Sequenz:
25      antisense-Strang (S13B) einer dsRNA, die
      komplementär zur YFP- bzw. GFP-Sequenz ist

      <400> 165
      agucgugcug cuucaugugg uc                                22

30      <210> 166
      <211> 20
      <212> RNA
      <213> Künstliche Sequenz

35      <220>
      <223> Beschreibung der künstlichen Sequenz:
      antisense-Strang (S14B) einer dsRNA, die
      komplementär zur YFP- bzw. GFP-Sequenz ist

40      <400> 166
      agucgugcug cuucaugugg                                20
      ,

45      <210> 167
      <211> 24
      <212> RNA
      <213> Künstliche Sequenz

50      <220>
      <223> Beschreibung der künstlichen Sequenz: sense-Strang
      (S4A) einer dsRNA, die homolog zur YFP- bzw.
      GFP-Sequenz ist

55      <400> 167
      ccacaugaag cagcacgacu ucuu                                24

      <210> 168
60      <211> 21
      <212> RNA
      <213> Künstliche Sequenz

```

<220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(ES-7A) einer dsRNA, die homolog zur humanen
5 EGFR-Sequenz ist

<400> 168
aacaccgcag caugucaaga u 21

10 <210> 169
<211> 21
<212> RNA
<213> Künstliche Sequenz

15 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (ES-7B) einer dsRNA, die
komplementär zur humanen EGFR-Sequenz ist

20 <400> 169
cuugacaugc ugcgguguuu u 21

25 <210> 170
<211> 22
<212> RNA
<213> Künstliche Sequenz

30 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(ES-8A) einer dsRNA, die homolog zur humanen
EGFR-Sequenz ist

35 <400> 170
aaguuaaaaau ucccgcgcgc au 22

40 <210> 171
<211> 22
<212> RNA
<213> Künstliche Sequenz

45 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (ES-8B) einer dsRNA, die
komplementär zur humanen EGFR-Sequenz ist

50 <400> 171
ugauagcgcac gggaauuuua ac 22

55 <210> 172
<211> 22
<212> RNA
<213> Künstliche Sequenz

60 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(ES-2A) einer dsRNA, die homolog zur humanen
EGFR-Sequenz ist

<400> 172
agugugaucc aagcuguccc aa 22

5 <210> 173
<211> 24
<212> RNA
<213> Künstliche Sequenz

10 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (ES-5B) einer dsRNA, die
komplementär zur humanen EGFR-Sequenz ist

15 <400> 173
uugggacagc uuggaucaca cuuu 24

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.